AU2003203805A1 - Succinoylamino lactams as inhibitors of ABeta protein production - Google Patents
Succinoylamino lactams as inhibitors of ABeta protein production Download PDFInfo
- Publication number
- AU2003203805A1 AU2003203805A1 AU2003203805A AU2003203805A AU2003203805A1 AU 2003203805 A1 AU2003203805 A1 AU 2003203805A1 AU 2003203805 A AU2003203805 A AU 2003203805A AU 2003203805 A AU2003203805 A AU 2003203805A AU 2003203805 A1 AU2003203805 A1 AU 2003203805A1
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- oxo
- butanediamide
- substituted
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
P/00/011 Regulation 3.2
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION FOR A DIVISIONAL PATENT
ORIGINAL
TO BE COMPLETED BY APPLICANT Name of Applicant: Actual Inventor(s): Address for Service: Invention Title: DU PONT PHARMACEUTICALS COMPANY Richard E. OLSON, Thomas P. MADUSKUIE and Lorin Andrew
THOMPSON
CALLINAN LAWRIE, 711 High Street, Kew, Victoria 3101, Australia SUCCINOYLAMINO LACTAMS AS INHIBITORS OF AP PROTEIN PRODUCTION The following statement is a full description of this invention, including the best method of performing it known to 23/04103,swl 3348spa,1
TITLE
SUCCINOYLAMINO LACTAMS AS INHIBITORS OF AP PROTEIN PRODUCTION FIELD OF THE INVENTION This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositionsand methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Ap-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to P-amyloid production such as Alzheimer's disease and Down's Syndrome.
BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, temporal and local orientation, cognition, reasoning, judgment and emotional stability. AD is a common cause of progressive dementia in humans and is one of the major causes of death in the United States. AD has been observed in all races and ethnic groups worldwide, and is a major present and future health problem. No treatment that effectively prevents AD or reverses the clinical symptoms and underlying pathophysiology is currently available (for review, Dennis J.
Selkoe; Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease, Annu Rev Cell Biol, 1994, 10: 373-403).
Histopathological examination of brain tissue derived upon autopsy or from neurosurgical specimens in effected individuals revealed the occurrence of amyloid plaques and neurofibrillar tangles in the cerebral cortex of such patients. Similar alterations were observed in patients with Trisomy 21 (Down's syndrome), and hereditary cerebral hemorrhage with amyloidosis of the Dutch-type.
Neurofibrillar tangles are nonmembrane-bound bundles of abnormal proteinaceous filaments and biochemical and immunochemical studies led to the conclusion that their principle protein subunit is an altered phosphorylated form of the tau protein (reviewed in Selkoe, Biochemical and immunological studies revealed that the dominant proteinaceous component of the amyloid plaque is an approximately 4.2 kilodalton (kD) protein of about 39 to 43 amino acids. This protein was designated Ap, P-amyloid peptide, and sometimes P/A4; referred to.herein as AO. .In addition to deposition of Ap in amyloid plaques, AP is also found in the walls of meningeal and parenchymal arterioles, small arteries, capillaries, and sometimes, venules. A was first purified, and a partial amino acid reported, in 1984 (Glenner and Wong, Biochem. Biophys. Res. Commun. 120: 885- 890). The isolation and sequence data for the first 28 .amino acids are described in U.S. Pat. No 4,666,829.
Compelling evidence accumulated during the last decade revealed that A is an internal polypeptide derived from a type 1 integral membrane protein, termed p amyloid precursor protein (APP). p APP is normally produced by many cells both in vivo and in cultured cells, derived from various animals and humans. Ap is derived from cleavage of p APP by as yet unknown enzyme (protease) system(s), collectively termed secretases.
The existence of at least four proteolytic activities has been postulated. They include P secretase(s), generating the N-terminus of Ap, a secretase(s) cleaving around the 16/17 peptide bond in Ap, and y secretases, generating Cterminal Ap fragments ending at position 38, 39, 40, 42, and 43 or generating C-terminal extended precursors which are subsequently truncated to the above polypeptides.
Several lines of evidence suggest that abnormal accumulation of Ap plays a key role in the pathogenesis of AD. Firstly, A is the major protein found in amyloid plaques. Secondly, Ap is neurotoxic and may be causally related to neuronal death observed in AD patients. Thirdly, missense DNA mutations at position 717 in the 770 isoform of SAPP can be found in effected members but not unaffected members of several families with a genetically determined (familiar) form of AD. In addition, several other P APP mutations have been described in familiar forms of AD.
Fourthly, similar neuropathological changes have been observed in transgenic animals overexpressing mutant forms of human P APP. Fifthly, individuals with Down's syndrome have an increased gene dosage of P APP and develop early-onset AD.
Taken together, these observations strongly suggest that Ap depositions may be causally related to the AD.
It is hypothesized that inhibiting the production of Ap will prevent and reduce neurological degeneration, by controlling the formation of amyloid plaques, reducing neurotoxicity and, generally, mediating the pathology associated with Ap production. One method of treatment methods would therefore be based on drugs that inhibit the formation of Ap in vivo.
Methods of treatment could target the formation of AP through the enzymes involved in the proteolytic processing of p amyloid precursor protein. Compounds that inhibit.p or y secretase activity, either directly or indirectly, could control the production of Ap. Advantageously, compounds that specifically target y secretases, could control the production of Ap. Such inhibition of p or ysecretases could thereby reduce production of Ap, which, thereby, could reduce or prevent the neurological disorders associated with A, protein.
PCT publication number WO 96/29313 discloses the general formula: 0 R 2
R
3 0 HO, H, NIR4
N
H
Q
R' 0 covering metalloprotease inhibiting compounds useful for the treatment of diseases associated with excess and/or unwanted matrix metalloprotease activity, particularly collagenase and or stromelysin activity.
Compounds of general formula: A 0 0 R
NR
2
R
5
R
4
R
3 are disclosed in PCT publication number WO 95/22966 relating to matrix metalloprotease inhibitors. The compounds of the invention are useful for the treatment of conditions associated with the destruction of cartilage, including corneal ulceration, osteoporosis, periodontitis and cancer.
European Patent Application number EP 0 6 52009A1 relates to the general formula: H2)i N R
H
and discloses compounds that are protease inhibitors that inhibit AP production.
US Patent Number 5703129 discloses the general formula: NN 0 OH R 3
R
2 which covers 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives that inhibit AP production and are useful in the treatment of Alzheimer's disease.
None of the above references teaches or suggests the compounds of the present invention which are described in detail below.
SUMMARY OF THE INVENTTON Accordingly, it is an object of the present invention to ameliorate at least some of the disadvantages of the prior art.
One aspect of the present invention is to provide novel compounds which are useful as inhibitors of the production of AP protein or pharmaceutically acceptable salts or prodrugs thereof It is another aspect of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another aspect of the present invention to provide a method for treating degenerative neurological disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof These and other aspects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of Formula
SR
5
R
5 a 6.
R
3
R
3 na O
(I)
or pharmaceutically acceptable salt or prodrug forms thereof, wherein R 3
R
3 a, R 5
R
5 a,
R
6 Q, B, W, X, Y, and Z are defined below, are effective inhibitors of the production of Ap.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Thus, in a first embodiment, the present invention provides a novel compound of Formula
R
5
R
5 1 6
R
3 R 3a 0
(I)
or a pharmaceutically acceptable salt or prodrug thereof, wherein: Q is -OR 1 or -NP 1
R
2
R
1 at each occurrence, is independently selected from:
H;
C
1
-C
6 alkyl. substituted with 0-3 Ria;
C
2
-C
6 alkenyl substituted with 0-3 Ria;
C
3
-C
10 carbocycle substituted with 0-3 Rlb;-
C
6
-C
1 0 aryl substituted with 0-3 Rib; and to 10 mnembered heterocycle substitu-ted with 0-3 Rib; Ria, at each occurrence, is independently selected from H,
CI-C
6 alkyl, OR 1 4 Cl, F, Br, I, CN, NO 2
NR
1 5
R
1 6
CF
3
C
3
-CI
0 carbocycle substituted with 0-3 Rib;
C
6
-CI
0 aryl substituted with 0-3 Rib; and 5 to 6 membered heterocycle substituted with 0-3 Rib; Rib, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
1 5
RI
6
CF
3 Cl-C 6 alkyl, Cl-C 4 alkoxy, Cl-C 4 haloalkyl, and CI-C 4 haloalkoxy;
R
2 is independently selected from H, NH 2 OH, Cl-C 6 alkyl, Cj-
C
6 alkoxy, phenoxy, benzylox-y, C 3
-CI
0 carbocycle, C 6
-C
10 aryl and 5 to 10 membered heterocycle;
R
3 is (CR 7
R
7 a )n-R 4
(CR
7
R
7 a) n S (CR 7
R
7 a) rnR 4
(CR
7
R
7 a) n-O- (CR 7
R
7 a) m-R 4
(CR
7
R
7 a -N (R 7 b) (CR 7
R
7 a) m-R 4
(CR
7
R
7 a n-S (CR 7
R
7 a) m-R 4
(CR
7
R
7 a) n-S 2
-(CR
7
R
7 a) m-R4,
(CR
7
R
7 a nC (CR 7
R
7 a) m-R 4
(CR
7
R
7 a N (R 7 b)
(CR
7
R
7 a) mR 4
(CR
7
R
7 a) -C N(R 7 b) (CR 7
R
7 a) -R 4
P
-(C7R~ -N R'b S=0)-(C7R~~m-4,or
-(CR
7 Ra n -S =0) 2 N (R- 7 b) -(CR7R 7 a) .7R 4 n is 0, 1, 2, or 3; mn is 0, 1, 2, or 3; R~a is H, OH, Cl-C 4 alkyl, Cj-C 4 alkoxy, or-.C 2
-C
4 alkenyloxy; R4 is H, OH; OR14a, CI-CG alkyl substituted with 0-3 R 4 aF
C
2
-C
6 alkenyl substituted with 0-3 R 4 a,
C
2
-C
6 alkynyl substituted with 0-3 R 4 a,
C
3 -C1O carbocycle substituted with 0-3 R4b,
C
6 -Cj 0 aryl substituted with 0-3 R 4 b, or to 10 membered heterocycle substituted with 0-3 R4b; R~,at each occurrence, is independently selected from is H, F, Cl, Br, I, CF 3
C
3
-C
10 carbocycle substituted with 0-3 R4b,
C
6 -CjO aryl. substituted with 0-3 R4b, or to 10 membered heterocycle substituted with 0-3 R4b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
15
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 Cl-C 6 alkyl, Cj-!C 4 alkoxy, Cl-C 4 haloalkyl, CI-C 4 haloalkoxy, and Cl-C 4 halothioalkoxy;
R
5 is H, OR 14 Cl-C 6 alkyl substituted with 0-3" Cl-C 6 alkoxy substituted with 0-3
C
2
-C
6 alkenyl substituted with 0-3
C
2 -C6 alkynyl substituted with 0-3 R~b;
C
3
-C
10 carbocycle substituted with 0-3 RSc;
C
6 -Cj 0 aryl substituted with 0-3 RSc; or to 10 membered heterocycle substituted with 0-30~c; R~a is H, OH, C 1
-C
4 alkyl, C 1
-C
4 alkoxy, C 2
-C
4 alkenyl, or C 2
C
4 alkenyloxy; R~b, at each occurrence, is independently selected f rom: H, Cl-C 6 alkyl, CF 3
OR
1 4 6i, F, Br, I, CN, NO 2
NR
15
R
16
C
3
-CI
0 carbocycle substituted with 0-3 R 5 c;
C
6 -CIO aryl substituted with 0-3 RSc; or to 10 membered heterocycle substituted with 0-3 RSc;
R
5 c, at each occurrence, is' independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
1 5
R
1 6
-CF
3 -acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3
CI-C
6 alkyl, Cl-C 4 alkoxy, C 1
-C
4 haloalkyl, CI-C 4 haloalkoxy, and C 1
-C
4 halothioalkoxy;
R
6 is H; Ci-C 6 alkyl substituted with 0-3 R 6 a;
C
3
-C
1 0 carbocycle substituted with 0-3 R6b; or
C
6
-C
10 aryl substituted with 0-3R 6 b; R~,at each occurrence, is independently selected from H, Cj-C 6 alkyl, OR 1 4 Cl, F, Br, I, CN, NO 2
NR
15
R
1 6 phenyl or CF 3
R
6 b, at each occurrence, is independently se lected from H, OH, Cl, F, Br, 1, CN, NO 2
NR
15
R
16
-CF
3 Ci-C 6 alkyj.,-
C-C
4 alkoxy, C-C 4 haloalkyl, and C'-C 4 haloalkoxy;
R
7 at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
CF
3 and Cl-C 4 alkyl;
R
7 a, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
CF
3 aryl and Cl-C 4 alkyl;
R
7 b is independently selected from H and Cj-C4 alkyl; W is -8p is 0, 1, 2, 3, or 4;
R
8 and R 8 a, at each occurrence, are independently selected from H, F, Cl-C 4 alkyl, C 2
-C
4 alkenyl, C 2
-C
4 alkynyl and
C
3
-C
8 cycloalkyl; X is a bond;
C
6 -CjO aryl substituted with 0-3 Rx;
C
3
-C
10 carbocycle substituted with 0-3 -Rxb; or 5 to 10 memnbered heterocycle substitutd-- with 0-2 RXb;4 Rxb at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
1 5
R
1 6
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 Cl-C 6 alkyl, CI-C 4 alkoxy, CI-C 4 haloalkyl, C 1
-C
4 haloalkoxy, and Cl-C4halothioalkoxy;, Y is a bond or -(CR 9
R
9 a)t-V-(CR 9
R
9 a)u-; t is 0, 1, 2, or 3; u is 0, 1, 2, or 3;
R
9 and R 9 a, at each occurrence, are independen tly selected from H, F, CI-C 6 alkyl or C 3
-C
8 cycloalkyl; V is a bond, 2 -N(Rl 9 -C(=0)NRl 9 -NR1 9 R19bS(=).. 1S=) 2 9 b-, NR19bS(=O).., -S(=O)NR1 9 or -OC(0O)-; Z is C.I-C 4 alkyl substituted with 0-3 R12b; Cl-C 3 alkyl substituted with 1-2 Ri 2
C
6 -Cj 0 aryl substituted with 0-4 R12b;
C
3 -CIO carbocycle substituted with 0-4 Ri2b; or to 10 memibered heterocycle substituted with 0-3- R12b;
R
12 is C 6 -Cj 0 aryl. subst ituted with 0-4 R 12 b';
C
3 -CIO carbocycle substituted with 0-4 R12b; or to 10 memnbered heterocycle substituted with 0-3 R12b; Rl 2 b, at each occurrence, is independently selected from H, OH;, Cl, F, Br, I, CN, NO 2
NR
1 5
R
16
CF
3 acetyl,
SCH
3
S(=O)CH
3
S(=O)
2
CH
3
C
1
-C
6 alkyl, Cj-C 4 alkoxy,
C
1
-C
4 haloalkyl,
CI-C
4 haloalkoxy, and' C 1
-C
4 halothioa.koxy; B is a 5 to 10 memnbered lactam, wherein the lactan is saturated, partially saturated or unsaturated; wherein each additional lactarn carbon is substituted with 0-2 R1 1 and, optionally, the lactan contains a heteroatom selected from 2 and'-N(R1O)'- RIO is H, C(=O)R 1 7 C(=O)0R 1 7 C(=O)NRlBR1 9
S(=O)
2 NR18Rl 9 S 2
R
1 7 Cl-C 6 alkyl. substituted with 0-2 Rl0a;
C
6
-C
10 aryl substituted with 0-4 -RIOb;
C
3
-C
1 0 carbocycle substituted with 0-3 Ri0b; or 5 to 10 memnbered heterocycle optionally substituted with 0-3 Ri0b; R0,at each occurrence, is independently selected from H,
CI-C
6 alkyl,
OR
1 4 Cl, F, Br, I, CN, NO 2
NR
15
R
1 6
CF
3 or aryl substituted with 0-4. RIOb; Ri0b, at each occurrence, is independently selected. from Hj O H, C 1
-C
6 alkyl,
C
1
-C
4 alkoxy, Cl, F, Br,- 1, CN,* NO 2
NR
1 5
R
16
CF
3 acetyl,
SCH
3
S(=O)CH
3
S(=O)
2
CH
3
CI-C
6 alkyl,
CI-C
4 alkoxy,
C
1
-C
4 haloalkyl,
C
1
-C
4 haloalkoxy, and Cl-C 4 halothioalkoxy;
R
1 1 at each occurrence,- is independently selected from
C
1
-C
4 alkoxy, C1, F, Br,' I, CN, NO 2
NRI
8
RI
9 C(=O)Rl 7 C(=O)0R 1 7
C(=O)NR
1 8
R
1 9
S(=O)
2 NR1 8 Rl9,
CF
3
C
1
-C
6 alkyl substituted with 0-1 R 1 1a_
C
6
-CI
0 aryl substituted with 0-3 R11b;
C
3
-C
1 0 carbocycle substituted with 0-3 R11b; or to 10 membered heterocycle substituted with 0-3 R11b; alternatively, two RI 1 substituents on the same or adjacent carbon atoms may be combined to form a C 3
-C
6 carbocycle or a benzo fused radical; Rila, at each occurrence, is- independently selected from H, Ci-C 6 alkyl, OR' 4 Cl, F, Br,, I, CN, NO 2
NR
1 5
R
1 6
CF
3 or phenyl substituted with- 0-3 -Ru1b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 NR1 5
RI
6
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 Cl-C 6 alkyl, Cl-C 4 alkoxy, Cl-C 4 haloalkyl, Cj-C 4 haloalkoxy, and C 1
-C
4 halothioalkoxy;
R
1 4 at each occurrence, is independently selected from H, phenyl, benzyl, Cl-C 6 alkyl, or C 2
-C
6 alkoxyalkyl;
R
14 a is H, phenyl, benzyl, or Cl-C 4 alkyl; RIS, at each occurrence, is independently selected from H, Cl-C6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 (Cl-C 6 alkyl);
R
16 at each occurrence, is independently. selected from H, OH, Cl-C 6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl);
R
1 7 is H, aryl, aryl-CH 2
C
1
L-C
6 alkyl, or C 2
-C
6 alkoxyalkyl;
R
18 at each occurrence, is independently selected from H4, Cl-C 6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl); and
R
1 9 at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, phenyl, benzyl, phenethyl,
C
6 alkyl) and 2 -(Cl-C6 alkyl); and -1-1- R19b is H, C 1
-C
6 alkyl, C 3
-C
8 cycloalkyl, phenyl, benzyl or phenethyl.
2) in a preferred emibodiment the present provides Q is -NR 1
R
2
R
1 at each occurrence, is independently selected from:
H;
Cl-Cs alkyl substituted with. 0-3 Ria;-
C
2
-C
6 alkenyl substituted with 10-3 Ria; Ria, at each occurrence, is independently selected f ror H,
OR
1 4 F, NR 1 5
R
1 6
CF
3
C
3
-C
6 cycloalkyl substituted with 0-3 Rib; phenyl substituted with 0-3 Rib; and to 6 memnbered heterocycle substituted with 0-3 Rib.
Rib, at each occurrence, is independently selected from H, OH, C1, F, Br, I. CN, NO 2
NR
1 5
R
1 6
CF
3 Cl-C 4 alkyl,
CI-C
4 alkoxy, Cl-C 4 haloalkyl, and Cl-C 4 haloalkoxy;
R
2 is independently selected from H, NH 2 OH, Cl-Cs alkyl, Cj-
C
6 alkoxy, phenoxy, and benzyloxy;
R
3 is -(CR 7
R
7 a),-R 4
(CR
7
R
7 a (CR 7
R
7 a) m-R 4
(CR
7
R
7 a) n-0- (CR 7
R
7 a) m-R 4
(CR
7
R
7 a -N (R 7 b) (CR 7
R
7 a) m-R 4
(CR
7
R
7 a nS (CR 7
R
7 a) m-R 4
(CR
7
R
7 a -S 2
(CR
7
R
7 a) m-R 4
(CR
7
R
7 a nC (CR 7
R
7 a) m-R 4
(CR
7
R
7 a nNHC (CR 7
R
7 a) m-R 4
(CR
7
R
7 a) NH -(CR7R7a) m-R4,
(CR
7
R
7 a)n-NHS (CR 7
R
7 a)m-R" 4 'or
(CR
7
R
7 a) n-S 2 NH- (CR 7
R
7 a) mR 4 -12n is 0, 1, 2, or 3; m is 0, 1, 2, or 3;
R
3 a is H, OH, Cl-C 4 alkyl, Cl-C 4 alkoxy, or C 2
-C
4 alkenyloxy;
R
4 is H, OH, OR 1 4 a, Cl-C 6 alkyl substituted with 0-3 R 4 a,
C
2
-C
6 alkenyl substituted with 0-3 R~a
C
2
-C
6 alkynyl substituted with 0-3 RU,
C
3
-C
10 carbocycle substituted with 0-3 R4b,
C
6
-CI
0 aryl substituted with 0.-3 R 4 b, or to 10 membered heterocycle substituted with 0-3 R4b-
R
4 a, at each occurrence, is independently selected from is H, F, Cl, Br, 1, CF 3
C
3
-C
10 carbocycle substituted with 0-3 R4b,
C
6
-C
1 0 aryl substituted with 0-3 R 4 b, or to 10 membered heterocycle substituted with 0-3 R4b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, NO 2
NR
1 5
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3 S(=0) 2
C-
3
CI-C
6 alkyl, Cl-C 4 alkoxy, CI-C 4 haloalkyl, and Cl-C 4 haloalkoxy; is H, OR 14 Cl-C 6 alkyl substituted with 0-3 R~b; Cl-C 6 alkoxy substituted with 0-3
C
2
-C
6 alkenyl substituted with 0-3 R~b;
C
2
-C
6 alkynyl substituted with 0-3
C
3
-C
10 carbocycle substituted with 0-3 RSc;
C
6
-CI
0 aryl substituted with 0-3 R~c; or to 10 membered heterocycle substituted with 0-30Sc;
R
5 a is H, OH, CI-C 4 alkyl, Cj-C4 alkoxy, C 2
-C
4 alkenyl, or C 2
C
4 alkenyloxy; at each occurrence, is independently selected from: -13- H, C 1
-C
6 alkyl, CF 3
OR
14 Cl, F, Br, I, CN, NO 2 NR1 5
R
16
C
3
-C
10 carbocycle substituted with 0-3- R 5 c;
C
6 -Cj 0 aryl substituted with 0-3 RSc; or 5 to 10 membered heterocycle substituted with 0-3 RSc;
R
5 c, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
1 5
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 Cl-C 6 alkyl, C 1
-C
4 alkoxy, C 1
-C
4 haloalkyl, and Cj-C 4 haloalkoxy;-
R
6 is H;
CI-C
6 alkyl substituted with 0-3 R 6 a-
C
3
-C
6 carbocycle substituted with 0-3 R~b; or C6-Cja aryl substituted with .0-3R 6 b; RGB, at each occurrence, is independently selected from H, Cl-C 6 alkyl, OR 14 Cl, F, Br, I, CN, NO 2
NR
15
R
16 phenyl or CF 3 R6b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
15
R
1 6
CF
3
C
1
-C
6 alkyl, Cl-C 4 alkoxy, CI-C 4 haloalkyl, and C 1
-C
4 haloalkoxy;
R
7 at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
CF
3 and Cl-C 4 alkyl; RQa, at each occurrence, is independently selected from H;, OH, Cl, F, Br, I, CN, NO 2
CF
3 aryl and Cl-C 4 alkyl; R7b is independently selected from H and Cl-C 4 alkyl; W is -(CR8RBap-; p is 0, 1, 2, 3, or 4; -14-
R
8 and R 8 a, at each occurrence, are independently selected from H, F, CI-C 4 alkyl, C 2
-C
4 alkenyl, C 2
-C
4 alkynyl and
C
3 -C8 cycloalkyl; X is abond;
C
6 -CIO aryl substituted with.0-3 Rxb
C
3 -C1O carbocycle substituted with 0-3 Rxb; or to 10 miembered heterocycle substituted with 0-2 Rxb; Rxb, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, *NO 2
NR
15
R
16
CF
3 acetyl, SCH 3 S(0)CH3, S(=O)2CH3, Ci-C 6 axlkyl-, Cli-C 4 alkoxyr; Cf-C 4 haloalkyl, and Cl-C 4 haloalkoxy; Y is a bond or -(CR 9
R
9 a)t-V-(CR 9
R
9 a)u-; t is 0, 1, 2, or 3; u is 0, 1, 2, or 3;
R
9 and R 9 a, at each occurrence, are independently selected from H, F, Cl-C 6 alkyl or C 3
-C
8 cycloalkyl; V is a bond, -C -S -S (=W 2 R9 -C -N19bC -NRI9bS 2- -S 2 NR9b-., -N1b(O- -S(=O)NRl 9 or -OC(0O)-; Z is CI-C 3 alkyl. substituted with 1-2R1 2
C
6 -Cj 0 aryl substituted with 0-4 R1 2 b;
C
3
-C
1 O carbocycle substituted with 0-4 Rl2b; or to 10 memnbered heterocycle substituted with 0-3 R12b;
R
1 2 is C 6 -CjO aryl substituted with 0-4 R1 2 b;
C
3
-C
1 O carbocycle substituted with 0-4 R12b; or 5 to 10 membered heterocycle* substituted with 0-3 Rl2b; Rl2b, at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, N02, NR 15
R
1 6
CF
3 acetyl, SCH 3
S(=O)CH
3 S(=0 2CH 3
C
1
-C
6 alkyl, Ca-C 4 alkoxy, C 1
-C
4 haloalkyl, and CI-C 4 haloalkoxy; B is a 6, 7, or 8 memibered lactam, wherein the lactam. is saturated, partially saturated or unsaturated;wherein each additional lactan carbon is substituted with 0-2 R 11 and, optionally, the lactamn contains a heteroatom selected from 2 and -N(RIO)-; RIO is H, C(=O)Rl 7 C(=O)0R 1 7
C(=O)NR
1 8
R
1 9 S(=O)2NR 1 8 Rl 9 S(=0) 2 Rl 7
;I
CI-C
6 alkyl. substituted with 0-1 Rl0a;
C
6 -CjO aryl substituted with 0-4 Ri0b;
C
3
-C
1 0 carbocycle substituted with 0-3 Ri0b; or to 10 mnembered heterocycle optionally substituted with 0-3 Ri0b;
R
10 a, at each occurrence, is independently selected from H,
C
1
-C
6 alkyl, OR 1 4 Cl, F, Br, I, CN, NO 2
NR
15
RI
6
CF
3 or phenyl substituted with 0-4 Ri0b; Ri0,b, at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, C 1
-C
4 alkoxy, Cl, F, Br, I, CN, NO 2
NRI
5
R
1 6 or CF 3
R
1 1 at each occurrence, is independently selected from
C
1
-C
4 alkoxy, Cl, F, Br, I, ON, N0 2
NR
1 8
R
19 C(=O)Rl 7 C(=O)0R 1
L
7 C(=O)NRl 8
R
1 9
S(=O)
2 NR1 8 Rl 9
CF
3 Cl-C 6 alkyl substituted with 0-1 Rila;
C
6 -Cl 0 aryl. substituted with 0-3 R11b;
C
3 -Cl 0 carbocycle substituted with 0-3 R11b; or 5 to 10 membered heterocycle substituted with 0-3 R11b; -16alternatively, two R 1 1 substituents on the same or adjacent carbon atoms may be combined to form a C3-C6 carbocycle or a benzo fused radical;
R
1 1 a, at each occurrence, is independently selected from H,
CI-C
6 alkyl, OR 1 4 Cl, F, Br, I, CN, N0 2
NR
1 5
R
16
CF
3 or phenyl substituted with 0-3 R11b; R1b, at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, N02, NR3- 5
R
1 6 CF3, Cf-C 6 alkyl, Cl-C 4 alkoxy, C 1
-C
4 haloalkyl, -and C 1
J-C
4 7 haloalkoxy;
R
14 is H, phenyl, benzyl, Ci-C6 alkyl, Or C 2
-C
6 alkoxyalkyl;
R
15 at each occurrence, is independently-selected from H, CJ-C6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl);
R
1 6 at each occurrence, is independently selected from H, OH, C 1
-C
6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl);
R
1 7 is H, aryl, (arylCH 2 Ci-C 6 alkyl, or C 2 -C6 alkoxyalkyl;
R
1 8 at each occurrence, is independently -selected f rom H, Cl-C 6 alkyl, -benzyl, phenethyl, 6 alkyl) 'and 2 -(Cl-C6 alkyl); and
R
1 9 at each occurrence, is independently selected f rom H, OH, Cl-C 6 alkyl, phenyl, benzyl, phenethyl, C6 alkyl) and 2 -(Cl-C 6 alkyl); and R19b is H, C 1
-C
6 alkyl, C3-C8 Cycloalkyl, phenyl, benzyl or phenethyl.
In a further preferred- embodiment the present invention privides; -17- (Ia) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R
3 is (CR 7
R
7 a )n-R4,
-(CR
7
R
7 a) n-S- (CR 7
R
7 a) M-R 4
~(CR
7
R
7
(CR
7
R
7 a)m-R 4 or
(CR
7
R
7 a -(CR 7
R
7 a)m-R 4 n is 0, 1, or 2; m is 0, 1, or 2;
R
3 a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, or butoxy;
R
4 is H, OH, ORl4a, Cl-C 4 alkyl substituted with 0-2 R 4 a,
C
2
-C
4 alkenyl substituted with- 0-2 R 4 a,.
C
2
-C
4 alkynyl substituted with 0-2 R 4 a,
C
3
-C
6 cycloalkyl substituted with 0-3 R 4 b,
C
6 -CIO aryl substituted with 0-3 R4b, or to 10 membered heterocycle substituted with 0-3 R4b;
R
4 a, at each occurrence, is independently selected from is H, F, Cl, Br, I CF 3
C
3 -CIO carbocycle substituted with 0-3 R 4 b,
C
6
-C
10 aryl substituted with 0-3 R4b, or to 10 membered heterocycle substituted with 0-3 R 4 b; R4b, at each occurrence, is independently selected f rom H, OH, Cl, F, Br, I, CN, N0 2
NR
15
R
16
CF
3 acetyl, SCH 3 -18-
SC=O)CH-
3 S(=O)2CH3, Cl-C6 alkyl, C.I-C 4 alkoxy, k.l-L:4 haloalkyl, and Cl-C 4 haloalkoxy;
R
5 is H, OR 1 4 Cl-C 6 alkyl substituted with 0-3 R~b;I
C
2 -C6 alkenyl substituted with 0-3
C
2 -Cr, alkynyl substituted with 0-3 R-9b; C3-ClO carbocycle substituted with 0-3 RSc; aryl substituted with 0-3 R 5 c; or 5 to 10 memnbered heterocycle substituted -with 0-3RSc;- RS&_ is H, OH, Cl-C 4 alkyl, Cj-C 4 alkoxy, C 2
-C
4 alkenyl, or 'C 2
C
4 alkenyloxy; R~b, at each occurrence, is independently selected from: H, Cj-C6 alkyl, CF3, OR 14 Cl, F, Br, I, CN, N02, NRlSpR 6
C
3 -ClO carbocycle substituted with 0-3 RSc;
C
6 -Cj 0 aryl substituted with 0-3 RSc; or 5 to 10 membered heterocycle substitu ted with 0-3 R 5 c; -~RSc, at each occurrence, is independently'selected from H, OH, Cl, F, Br, 1, CN, N02, NR 15
R
16 CF3, acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3
C
1
-C
6 alkyl, C 1
-C
4 alkoxy, CI-C 4 haloalkyl, and C 1 -C4 haloalkoxy;
R
6 is H, methyl, or ethyl;
R
7 at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, N0 2
CF
3 and Cl-C 4 alkyl;
R
7 at each occurrence, is independently -selected from H, OH, Cl, F, Br, I, CN, N02, CF3, phenyl and Cl-C 4 alkyl;
R
7 b is independently selected from H, methyl, ethyl, propyl, and butyl; W is -(CRBa)p-; -19- P is 0, 1, or 2;
R
8 and R 8 a, at each occurrence, are independently selected from H, F, Cl-C3 alkyl, C 2
-C
3 alkenyl, C 2
-C
3 alkynyl and
C
3
-C
6 cycloalkyl; X is a bond;
C
6
-CI
0 aryl substituted with 0-3 Rxb;
C
3 -ClO carbocycle substituted with 0-2 RXb; -or to 10 membered heterocycle substituted with 0-2 Rxb; Rxb at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, NO 2
NR
1 5
R
1 6
CF
3 acetyl, SCH 3
S(=O)CH
3 S4=O) 2
CH
3
CI-C
6 alkyl, C 1
-C
4 alkoxy, Cl-C 4 haloalkyl, an-d C 1
-C
4 haloalkoxy; Y is a bond or -(CR 9
R
9 a)t-V-(CR 9
R
9 a)u-; t is 0, 1, or 2; u is 0, 1, or 2;
R
9 and R 9 a, at each occurrence, are- idependently. seliectedfrom H, F, Cj-C 4 alkyl or C 3
-C
6 cycloalkyl; V is a bond, 2
-N(R
1 9 -C (Q)N19b-,. -NR19bC(=O)-, _NRl9bS.(=) 2 S(=0) 2
NR
9 -NR1bS(=)-,or -S(=O)NRl 9 b-; Z is Cl-C 3 alkyl substituted with 1-2 R1 2
C
6 -C1O aryl substituted with 0-4 Rl2b;
C
3 -Cl 0 carbocycle substituted with 0-4 R1 2 b; or to 10 memibered heterocycle substituted with 0-3 R12b;
R
12 is C 6 -Cj 0 aryl substituted with 0-4 Rlzb;
C
3 -Cl 0 carbocycle substituted with 0-4 Rl2b; or to 10 membered heterocycle substituted with 0-3 R1 2 b; Rl 2 b, at each occurrence,--is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
1 5
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 Cl-C 6 alkyl, Cj-C 4 alkoxy, Cl-C 4 haloalkyl, and Ci-C 4 haloalkoxy; B is a seven membered lactan, wherein the lactam, is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 Ri 1 and, optionally, the lactam contains a heteroatom selected from S(=0) 2 and -NCR 10
R
10 is H, C(=O)Rl 7 C(=O)0R 1 7
C(=O)NR
1 8
R
1 9 S 2
NR
1 8
R
1 9 Cj-C 6 alkyl substituted with 0-1 R 10 a;
C
6 -CIO aryl substituted with 0-4 Ri0b;
C
3
-C
1 0 carbocycle substituted with'0-3 Ri0b; or 5 to 10 membered heterocycle optionally substituted with 0-3 Ri0b; Rica, at each occurrence, is independently selected from-H,
C
1
-C
6 alkyl, OR 14 Cl, F, Br, I, CN, N0 2
NR
1 5
R
16
CF
3 or phenyl substituted with 0-4 Ri0b; Ri0b, at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, Cl.-C 4 alkoxy, Cl, F, Br, I, CN, NO 2 NRi5R16, or CF 3
R
11 at each occurrence, is independently selected from- Ci-C 4 alkoxy, Cl, F, NiR8R 9 C(=O)Rl 7 C(=O)ORi 7 C(=0)NRlBR 1 9
S(=O)
2
NR
1 8
RI
9
CF
3 Cl-C 6 alkyl substituted with 0-1 Rila;
C
6 -Cj 0 aryl substituted with 0-3 R11b;
C
3 -Cl 0 carbocycle substituted with -0-3 Ru1b; or to 10 membered heterocycle substituted with 0-3 R11b; -21alternatively, two R 1 1 substituents on the same or adjacent carbon atoms may be combined to form a C 3
-C
6 carbocycle or a benzo fused radical;
R-
1 a, at each occurrence, is independently selected from H, Cl-C 6 alkyl, OR 1 4 Cl, F, Br, I, CN, NO 2
NR
15
R
1 6
CF
3 or phenyl substituted with 0-3 R11b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, N0 2
NR
1 5
R
1 6
CF
3 Cl-C 6 alkyl,.
Cl-C 4 alkoxy, Cl-C 4 haloalkyl, and CI-C 4 haloalkoxy;
R
1 4 is H, phenyl, benzyl, Cl-C 6 alkyl, -or C 2
-C
6 alkoxyalkyl; R15, at each occurrence, is independently selected from H,
CI-C
6 alkyl, benzyl, phenethyl, 1
-C
6 alkyl) and 2 (Cl-C 6 alkyl); R16, at each occurrence, is independently selected from H, OH, C 1
-C
6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl);- R1" is H, aryl,. (aryl)CH2-, Cl-C 6 alkyl, or C 2
-C
6 alkoxyalkyl; R18, at each occurrence, is independently selected from H, Cl-C 6 alkyl, benzyl, phenethyl, -C(=O)-(Cl-C6'alkyl) and 2 -(Cl-C 6 alkyl); and
R
19 at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, phenyl, benzyl, phenethyl,
C
6 alkyl) and 2 -(Cl-C 6 alkyl) and R19b is H, Cl-C 6 alkyl, C 3
-C
8 cycloalkyl, phenyl, benzyl or phenethyl.
In a further pref erred embodiment the present invention provides -22-
R
3 is (CR 7
R
7 a) -R 4
(CR
7
R
7
(CR
7 R8)mR 4 (C7~ nO(C7~~-4 or
-(CR
7
R
7 a n-N(R 7 b) -(CR 7 R7a) m-R4;n is 0 or 1 Mn is 0 or 1
R
3 a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, or butoxy;
R
4 is H, OH,
C
1
-C
4 alkyl substituted with' 0'-2 R 4 a,
C
2
-C
4 alkenyl substituted with 0-2 R 4 a,
C
2
-C
4 alkynyl substituted with 0-1 R 4 a,
C
3 -c 6 cycloalkyl substituted with 0-3 R 4 b,
C
6 -Cj 0 aryl substituted with 0-3 R4b, or to 10 memibered heterocycle substituted with 0-3 R4b; R~,at each occurrence, is independently selected from is H, F, Cl, CF 3
C
3
-C
6 cycloalkyl substituted with 0-3 R 4 b, phenyl substituted with 0-3 R 4 b, or 5 to 6 membered heterocycle substituted with 0-3 R4b; Rdb, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NR
1 5 R1 6
CF
3 acetyl, SCH 3
S(=O)CH
3 S(=O)2CH 3
CI-C
4 alkyl, CI-C 3 alkoxy, Cl-C 2 haloalkyl, and C 1
-C
2 haloalkoxy;
R
5 is H, OR1 4
C
1
-C
4 alkyl substituted with 0-3 R~b;
C
2
-C
4 alkenyl substituted with 0-2 R5b; or
C
2
-C
4 alkynyl substituted with 0-2 R~b; R~a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, or allyl; -23- R~b, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, buty-1, CF 3
OR
1 4
C
3
-C
6 cycloalkyl substituted with 0-2 RSc; phenyl substituted with 0-3 RSc; or to 6 membered heterocycle substituted with 0-2 RSc;
R
5 C, at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, N02, NR 1 5
R
1 6
CF
3 acetyl, SCH 3
S(=O)CH
3 S(=0) 2
CH
3 Cl-C 4 alkyl, Ca-C3 alkoxy, C 1
-C
2 haloalkyl, and Cl-C2-hAloalkoxy;
R
6 is H; R7, at each occurrence, is independentlyselected from H, F,
CF
3 methyl, and ethyl;
R
7 8, at each occurrence, is independently selected from H, F,
CF
3 methyl, and ethyl; .R7b is independently selected from H, methyl, and ethyl; W is a bond, -CH 2
-CH(CH
3
-CH
2
CH
2 or -CH(CH 3
)CH
2 X is a bond; phenyl. substituted with 0-2 Rxb; C3-C6 cycloalkyl substituted with 0-2 kx' or to 6 membered heterocycle substituted with 0-2 Rxb; Rxb, at each occurrence, is independently selected from H, OH, Cl, F, 'NR 15
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 Cl-C 4 alkyl, Cl-C 3 alkoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; Y is a bond, -CH 2 or H- V is a bond, 2
-NH-,
-N(CH
3 or -N(CH 2
CH
3 -24- Z is C 1
-C
2 alkyl substituted with 1-2 R 12
C
6 -Co aryl substituted with 0-4 R 1 2 b;
C
3 -C6 carbocycle substituted with 0-3 R1 2 b;-or 5 to 10 membered heterocycle substituted with 0-3 R 12 b;
R
12 is C 6 -Co 0 aryl substituted with 0-4 R 1 2b;
C
3
-C
6 carbocycle substituted with 0-3 R 1 2b; or to 10 membered heterocycle substituted with 0-3 R1 2 b;
R
1 2b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
1 6
CF
3 acetyl, SCH3, S(=O)CH 3 S(=0)2CH3, C 1
-C
4 alkyl, Ci-C 3 alkoxy, C 1
-C
2 haloalkyl, and C 1
-C
2 haloalkoxy; B is a seven membered lactam, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R 1 1 and, optionally, the lactam contains a heteroatom selected from 2 and -N(R 1 0
R
10 is H, C(=O)R 1 7
C(=O)OR
17
CI-C
4 alkyl substituted with 0-1 R 1 0 a; phenyl substituted with 0-4
C
3
-C
6 carbocycle substituted with 0-3 R 1 0 b; or to 6 membered heterocycle optionally substituted with 0-3 R 1 0 b;
R
1 0a at each occurrence, is independently selected from H,
C
1
-C
4 alkyl, OR 14 Cl, F, Br, I, CN, NO 2
NR
15
R
16
CF
3 or phenyl substituted with 0-4
R
10b at each occurrence, is independently selected from H, OH, C 1
-C
4 alkyl, CI-C 3 alkoxy, Cl, F, Br, I, CN, NO 2
NR
1 5
R
1 6 or CF3;
R
11 at each occurrence, is independently selected from
C
1
-C
4 alkoxy, Cl, F, NR 18
R
19 C(=0)R 7 C(=O)0R 17
CF
3
C
1
-C
4 alkyl substituted with Rila; phenyl substituted with 0-3 R11b;
C
3
-C
6 carbocycle substituted with 0-3 R11b; or to 6 memnbered heterocycle substituted with 0-3 RIub; alternatively, two R 11 substituents on the same or adjacent carbon atoms may be combined to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a benzo fused radical;
R
11 a, at each occurrence, is independently selected from H, Cl-C 4 alkyl, OR 1 4 F, NR 1 5
R
1 6
CF
3 or phenyl substituted with 0-3 R11b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
16
CE'
3 Cl-C 4 alkyl, Cl-C3 alkoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
14 is H, phenyl, benzyl, C 1
L-C
4 alkyl, or C 2
-C
4 alkoxyalkyl;
R
15 at each occurrence, is independently selected from H, Cl-C 4 alkyl, benzyl, phenethyl, 4 alkyl) and 2 -(Cl-C 4 alkyl);
R
16 at each occurrence., is independently selected from H, OH, Ca-C 4 alkyl, benzyl, phenethyl, 4 alk-yl) and 2
-(C
1
-C
4 alkyl);
R
17 is H, phenyl, 4-fluorophenyl, 4-chiorophenyl, 4methylphenyl, 4 -trifluorophenyl, fluorophenyl) methyl, (4-chlorophenyl )methyl, (4-methyiphenyl) methyl, (4trifluorophenyl)methyl, methyl, ethyl, propyl, butyl, methoxymethyl, methyoxyethyl, ethoxymethyl, or ethoxyethyl; -26-
R
1 8 at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and
R
1 9 at each occurrence, is independently selected from H, methyl, and ethyl.
(51 In a more preferred embodi-ment, the present invention provides
H-
H
2 N )Z R 3 0B (Ib) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R
3 is -CH 3
-CH
2
CH
3
-CH
2 CH2CH3, -CH2CH2CH2CH3, -CH2(C113)2, -CH(CH 3
)CH
2
CH
3
-CH
2
CH(CH
3 2
-CH
2
C(CH
3 3
-CF
3
-CH
2
CF
3
-CH
2
CH
2
CF
3
-CH
2
CH
2
CH
2
CF
3 -CH=tH 2 -CH2CH=CH 2
-CH
2
C(CH
3
)=CH
2
-CH
2 CH=C (CH 3 2
-CH
2
CH
2
CH=CH
2
-CH
2
CH
2 C (CH 3
=CH
2
-CH
2
CH
2 CH=C (CH 3 2 cIs-CH 2 CH=CH (CH3), cis-CH 2
CH
2
CH=CH(CH
3 trans-
CH
2 CH=CH (CH 3 trans -CH 2
CH
2 CH=CH (CH 3 -CMCH, -CH 2 C=-CH, -CH 2
C--C(CH
3 cyclopropyl-CH 2 cyclobutyl-CH 2 cyclopentyl -CH 2 cyclohexyl-CH 2 cyclopropyl-CH2CH2 cytclobutyl-
CH
2
CH
2 cyclopentyl-CH2CH 2 cyclohexyl-CH2CH2-, phenyl-CH 2 (2-F-phenyl)CH2-, (3-F-phenyl)CH2-, (4-F-phenyl)CH2-, (2-Cl-phenyl)CH2-, (3-Cl-phenyl)CH2-, (4-Clphenyl) CH 2 (2,3-diF-phenyl)CH 2 (2,4-diF-phenyl)CH2-, 2 6-diF-phenyl)CH 2 4-diF-phenyl)CH 2 5-diF-phenyl)CH 2 (2,3-diCl-phenyl)CH 2 (2,4-diCl-phenyl)CH 2 -27- (2,5-diCl-phenyl)CH2-. (2,6-diCl-phenyl)CH2-, (3,4-diCl-phenyl)CH 2 (3,5-diCl-phenyl)CH2-, (3-F-4-C1-phenyl)CH2-, (3-F-5-C1-phenyl)CH2-, (3-C1-4-F-phenyl )CHi 2 phenyl-CH2CH2-, (2-F-phenyl)CH 2
CH
2 (3-F-phenyl)CH2CH2-, (4-F-phenyl)CH2CH2-, (2-C1-phenyl)CH2CH2-, (3-C1-phenyl)CH 2
CH
2 (4-C1-phenyl)CH2CH 2 (2,3-diF-phenyl)CH2CH2-, (2,4-diF-phenyl)CH2CH2-, 5-diF-phenyl)CH 2
CH
2 6-diF-phenyl)CH2CH2-, 4-diF-phenyl) CH 2
CH
2 5-diF-.phenyl)PH 2
CH
2 3-diCl-phenyl)CH 2 CH2-, 4-diCl-phenyl),CH 2
CH
2 5-diCl-phenyl)CH 2
CH
2 6-diCl-phenyl)CH2CH 2 4-djCl-phenyl)CH2CH2-, (3 ,5-diCi-phenyl)CH2'CH 2 (3-F-4-C1-phenyl)CM 2
CH
2 (3-F-5-C1-phenyl)CH2CH 2 or
R
5 is-CH3, -CH 2
CH
3
-CH
2
CH
2
CH
3
-CH
2 (CH3)2, -CH 2 CH2CH2CH3, -CH(C113) cH 2
CH
3 -CI-i 2 CH(CH3) 2. -CH- 2 C (CH 3 3,
-CH
2
CH
2
CH
2
CH
2 CHi 3
-CH(CH
3
CH
2
CH
2
CH
3
-CH
2
CH(CH
3
CH
2
CH
3
-CH
2
CH
2 CH(CH3)2, -CH(CH2CH3)2, -CF -CH 2
CF
3
-CH
2
CH
2
CF
3
-CH
2
CH
2
CH
2 CF3, -CH 2
CH
2
CH
2
CH
2 CF3, -CH=CH 2
-CH
2
CH=CH
2
-CH=CHCH
3 cis-CH 2 CH=CH (CH 3 trans-CH 2 CH=CH (CH 3 tranls-CH 2 CH=CH (C6H5) -CH 2 CHzC (CH 3 ci;s-CH 2
*CHCHCH
2
CH
3 trans -CH 2
CH=CHCH
2
CH
3 cis-CH 2 CH2CH*CH (CH 3 trans-
CH
2 CH2CH=CH (CH3), tranlsCH2CH=CHCH2 (C 6
H
5 -CE-CH, -CHf 2 CaCH, -CH 2 C=-C(CH3), -CH 2 C=-C=(C6Hs)
-CH
2
CH
2 CE-CH, -CH2.CH2C-C (CH3), -qH 2
CH
2 CE=C (C 6
H
5
-CH
2
CH
2
CH
2 C=-CH, -CH 2
CH
2
CH
2 CE-C(CH3), -CH 2
CH
2
CH
2 CEC (C6HS) cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-, cyclohexyl-C1 2 (27CH 3 -cyclopropy1)CH2-, (3-CHi 3 -cyclobutyl) CM 2 cyclopropyl-CH2CH 2 cyclobutyl-CH 2 CH2-, cyclopentyl-H2CH 2 cyclohexyl-CH2CH2-, (2-CH3-cyclopropyl) CH 2 CH2-, (3-CH 3 -cyclobutyl) CH 2 CH2-, phenyl-CH 2 (2-F-phenyl)CH2-, (3-F-phenyl)CH 2 (4-F-phenyl )CH 2 furanyl-CH2-, thi.enyl-CH2-, pyridyl-CH 2 1-imidazolyl-CH2-, oxazolyl-CH 2 isxaollC2, -28- WO 00107995 phenyl-CH 2 CH2-, (2-F-pherlyl)CH 2 CH2-, (3-F-phenyl)CH 2
CH
2 (4-F-phenyl)CH2CH 2 turanyl-CH 2 CH2-, thienyl-CH 2
CH
2 pyr idyl -CH 2 CH2 1- imidazolyl -CH 2 CH2-. oxazo lyl-CH 2
CH
2 isoxazolyl-CH2CH 2 wA is a bond, -CH 2 or -CH(CH 3 X is a bond;
N
or Y is a bond, -CH 2 or -V-CH 2 V is a bond, 2 or -N (CH 3 Z is phenyl. 2-F-phenyl, 3-F-phenyl,-4-F-phenyl, 2-Ci-phenyl, 3-Ci-phenyl, 4-Ci-phenyl, 2, 3-diF-phenyl, 2 .4-diF-phenyl, 2, 5-diF-phenyl, .2.,6-diF-phenyl, 3, 4-diF-phenyl, 3, 5-diF-phenyl,..2, 3-diCl-phenyl,.
2, 4-diCi-phenyl, 2, 5-diCi-phenyl, 2, 6-diCi-phenyl, 3, 4-diCi-phenyl, 3, 5-diCi-phenyl, 3-F-4-C1-phenyl, 3-F-5-C1-phenyl, 3 -C1--4-F-phenyl, 2-MeO-phenyl, 3-MeO--phenyl, 4-MeO-phenyl, 2 -Me-phenyl, 3 -Me-phenyl, 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl, 2-CF 3 0-phenyl, 3 -CF 3 O-phenyl, 4-CF 3 O-phenyl, furanyl, thienyl, pyridyl, 2-Me-pyridyl, 3-Mepyridyl, 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl, 1-benz imidazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, inorpholino, N-piperinyl, phenyl-CH2-, (2-F-phenyl) CH 2 (3 -F-phenyl )CH 2 -29- (4-F-phenyl)CH 2 (2-C1-phenyl)CH 2 (3-C1-phenyl)CH 2 (4-C1-phenyl)CH 2 (2,3-diF-phenyl)CH 2 (2,4-diF-phenyl)CH 2 (2,5-diF-phenyl)CH 2 6-diF-phenyl)CH 2 4-diF-phenyl)CH 2 5-diF-phenyl)CH 2 3-diCl-phenyl)CH 2 4-diCl-phenyl)CH 2 (2,5-diCl-phenyl)CH 2 (2,6-diCl-phenyl)CH 2 (3,4-diCl-phenyl)CH 2 5-diCl-phenyl)CH 2 (3-F-4-C1-phenyl)CH 2 2 (3-C1-4-F-phenyl)CH 2 (2-MeO-phenyl) CH 2 (3 -Meo-phenyl) CH 2 (4-MeO-phenyl) CH 2 .(2-Me-phenyl) CH 2 (3-Me-phenyl)CH 2 (4-Me-phenyl)CH 2 (2-MeS-phenyl)CH 2 (3-MeS-phenyl)
CH
2 4-MeS-phenyl)C11 2 (2-CF3Q'-phenyl)CH 2 (3 -CF 3 O-phenyl) CH 2 (4-CF3O-phenyl) CH 2 (furanyl)CH 2 (thienyl)CH 2 (pyridyl)CH2-, (2-Me-pyridyl)CH 2 (3-Me-pyridyl) CH 2 (4-Me-pyridyl)CH 2 (1-imidazolyl) CH 2 (oxazolyl)C1 2 (isoxazoly.)CH 2 3 (1-benzimidazolyl)
CH
2 (cyclopropyl)CH 2 (cyclobutyl)CH 2 (cyclopentyl) CH 2 (cyclohexyl )CH 2 (morpholino) CH 2 (N-pipridinyl).CH 2 phenyl-CH 2
CH
2 (phenyl) 2
CHCH
2 (2 -F-phenyl )CH 2
CH
2 (3-F-phenyl)CH 2
CH
2 (4-F-phenyl)
CH
2 CH2-, (2-C1-phenyl)CH2CH 2 (3-C1-phenyi)CH 2 cH 2 (4-C1-phenyl)CH 2
CH
2 3-diF-phenyl)CH 2
CH
2 4-diF-phenyl)CH 2
CH
2 (2,5-diF-phenyl)CH 2
CH
2 6-diF-phenyl) CH 2
CH
2 4-diF-phenyl) CH 2
CH
2 5-diF-phenyl )CH 2
CH
2 3-diCl-phenyl)CH 2
CH
2 (2,4-diCl-phenyl)CH 2
CH
2 5-diCl-phenyl)CH 2
CH
2 6-diCl-phenyl)CH 2
CH
2 4-diCl-phenyl)CH 2
CH
2 5-diCl-phenyl)CH 2
C
2 (3-F-4-C1-phenyl)CH 2 cH 2 (3-F-5-C1-phenyl)CH 2
CH
2 (3-Ci-4-F-phenyl)CH 2
CH
2 (2 -MeO-phenyl )CH 2
CH
2 (3-MeO-phenyl) CH2CH2-, (4 -MeO-phenyl) CH 2
CH
2 (2-Me-phenyl) CH 2
CH
2 (3 -Me-phenyl )CH 2
CH
2 (4-Me-phenyl )CH2CH 2 (2-MeS-phenyl) CH2CH 2 (3-MeS-phenyl)CH 2
CH
2 (4--MeS-phenyl)CH 2
CH-
2 (2-CF3O-phenyl)CH 2
CH
2 (3-CF3O-phenyl)CH 2
CH
2 (4-CF3O-phenyl)CH 2
CH
2 (furanyl)CH 2
CH
2 (thienyl )CH 2 CHi 2 -(pyridyl) CH 2
CH
2 (2-Me-pyridyl)CH 2
CH
2 Q3-Me -pyr idyl) CH2CH 2 (4-Me-pyridyl)CH 2
CH
2 (imidazolyl)CH 2
CH
2 (oxazolyl)CH 2
CH
2 (isoxazolyl) CH2CH 2 (benzimidazolyl
)CH
2
CH
2 (cyclopropyl
)CH
2
CH
2 (cyclobutyl) CH 2
CH
2 (cyclopentyl) CH2CH2 (cyclohexyl)CH 2 CHi 2 (norpholino)CH 2
CH
2 (N-pipridinyl)
CH
2
CH
2 B is a seven memnbered lactam, wherein the lactamn is saturated-, partially saturated or unsaturated; wherein each additional lactan carbon is substituted with 0-2 R 1 1 and, optionally, the lactam contains a heteroatom selected from 2 and -N(RIO)-;
R
10 is H, methyl, ethyl, phenyl, benzyl, phenethyl, 4-Fphenyl, (4-F-phenyl)CH 2 (47F-phenyl)CH 2
CH
2 4-Clphenyl, (4-Cl-phenyl)CH 2 (4-Cl-phenyl)CH 2
CH-
2 4-CH 3 phenyl, (4-CH3-phenyl
)CH
2 (4 -CH 3 -phenyl) CH 2 CfI 2 4 -CF3phenyl, (4-CF3-phenyl)CH 2 or (4-CF 3 -phenyl) CH 2
CH
2
R
11 at each occurrence, is independently selected from H,.
methyl, ethyl, phenyl, benzyl, phenethyl, 4-Fphenyl, (4-F-phenyrl)CH 2 (4-F-phbnyl)CH 2
CH
2 4-Clphenyl, (4-Cl-phenyl)CH 2 -(4-Cl-phenyl)CH 2
CH
2 4-CIA 3 phenyl, (4-CHj--phenyl)CH 2 (4-CH 3 -phenyl) CH 2
CH
2 4-CF 3 phenyl, (4-CF3-phenyl)
CH
2 or (4-CF3-phenyl)
CH
2
CH
2 and alternatively, two R 11 substituents on the sanme or adjacent carbon atoms may be combined to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a benzo fused radical.
-31- In a futher more preferred embodiment the present invention provides B is0 0
N
{N
0R 0
N
0
N
X,
R
0
{N
R1o In an even more preferred embodiment the present invention provides -32- 0 R 5 H 0
H
2 N NN"- X -IZ
R
3 0- (Ic) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R
3 is R 4
R
4 is Cl-C 4 alkyl substituted with 0-2 R 4 a,
C
2
-C
4 alkenyl substituted with 0-2 Rwa,
C
2
-C
4 alkynyl substituted with 0-2 R 4 a,
R
4 a, at each occurrence, is independently selected from is H, F, CF 3
C
3
-C
6 cycloalkyl1 substituted with 0-3 R 4 b, phenyl substituted with 0-3 R 4 b, or to 6 memnbered heterocycle substituted with 0-3 R4b;
R
4 b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
1 6
CF
3 acetyl,.
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -0 2 haloalkyl, and C 1
-C
2 haloalkoxy;
R
5 is C 1
-C
4 alkyl substituted with 0-3
C
2
-C
4 alkenyl substituted with 0-2 R~b; or-
C
2
-C
4 alkynyl substituted with 0-2 at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF 3
OR
14 =0;
C
3 -C6 cycloalkyl substituted with 0-2 RSc; phenyl substituted with 0-3 RSc;. or to 6 membered heterocycle substituted with 0-2 R 5 c; -33- RSc, at each occurrence, is independently selected from H, OH, Cl, F, N~R 15
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl,; butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkox,; W is -CH2-, or -CH(CH 3 X is a bond; phenyl substituted with
C
3
-C
6 cycloalkyl substituted with 0-2 Rn'; or to 6 membered heterocycle substituted with 0-2 Rxb; Rxb, at each occurrence, is independently selected- from H, OH, Cl, F, NR 15
RI
6
CF
3 acetyl, SCH 3
S(=O)CH
3 S(=O)2CH 3 methyl, -ethyl,' propyl, butyl, ruethoxy, ethoxy, propoxy, Ci-C 2 haloalkyl, and CI-C 2 haloalkoxy; Y is a bond, -CH 2 or -V-CH 2 VJ is a bond, 2
-NH-,
-N(CH
3 or -N(CH 2
CH
3 Z is C 1
-C
2 alkyl. substituted with 1-2 Ri 2 C6-Cj 0 aryl substituted with 0-4 Rl2b;
C
3
-C
6 carbocycle substituted with' 0-3 R1 2 b; or to 10 membered heterocycle substituted with 0-3 Rl 2 b-
R
12 is C6-Cj 0 aryl substituted with 0-4 Rl2b;
C
3
-C
6 carbocycle substituted with 0-3 R12b; or 5 to 10 membered heterocycle substituted with 0-3 Rl2b; R12b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1
-SR
1 6
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1
_C
2 haloalkyl, and CI-C 2 haloalkoxy;
R
11 is methoxy, ethoxy, propoxy, butoxy, Cl, F, NR 18
R
19
CF
3 -34-
C
1
-C
4 alkyl substituted with 0-1 R 11 a; phenyl substituted with 0-3 R 11 b; C3-C 6 carbocycle substituted with 0-3 R 11 b; or to 6 membered heterocycle substituted with 0-3 R 11 b; alternatively, two R 11 substituents on the same or adjacent carbon atoms may be combined to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a benzo fused radical;
R
11a at each occurrence, is independently selected from H,
C
1
-C
4 alkyl, OR 14 F, NR 15
R
1 6
CF
3 or phenyl substituted with 0-3 R 11 b
R
11b at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
16
CF
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C 2 haloalkyl, and C 1
-C
2 haloalkoxy;
R
14 is H, phenyl, benzyl, methyl, ethyl, propyl, butyl;
R
15 at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
R
16 at each occurrence, is independently selected from H, OH, C 1
-C
4 alkyl, benzyl, phenethyl, 1
-C
4 alkyl) and 2
-(C
1
-C
4 alkyl);
R
18 at each occurrence, is independently selected from H, methyl, ethyl, propyl. butyl, phenyl, benzyl, and phenethyl; and
R
19 at each occurrence, is independently selected from H, methyl, and ethyl.
In another even more preferred embodiment the present invention provides R o
N
(Id) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R
3 is R 4
R
4 is Cl-C 4 alkyl substituted with 0-2 R 4 a,
C
2
-C
4 alkenyl substituted with 0-2 R 4 a,
C
2
-C
4 alkynyl substituted with 0-2 R 4
R
4 a, at each occurrence, is independently selected from is H, F, CF 3
C
3
-C
6 cycloalkyl substituted with 0-3 RQb, phenyl substituted with 0-3 R4b, or to 6 memb~ered heterocycle substituted with 0-3 R4b;
R
4 b, at each occurrence, is independently selected from H, OH, Cl, F, NRlSRlr-, CF 3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl,' butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
5 is C 1
-C
4 alkyl substituted with 0-3 R~b;
C
2
-C
4 alkenyl substituted with 0-2 R5b; or
C
2
-C
4 alkynyl substituted with 0-2 R~b; RSb, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF 3
OR
1 4
C
3 -C6 cycloalkyl substituted with 0-2 RSc; phenyl substituted with 0-3 RSc; or to 6 membered heterocycle substituted with 0-2 RSc; -36- RSc, at each occurrence, is independently selected f rom H, OH, Cl, F, NR 15
R
1 6
CF
3 acetyl, SCH 3 S CH 3 S(=O)2CH 3 methyl, ethyl, propyl, -butyl, methoxy,ethoxy, propoxy, CI-C 2 haloalkyl, and Cl-C 2 haloalkoxcy; W is -CH 2 or -CH(CH 3 X is a bond; phenyl substituted with 0-2 Rxb;
C
3
-C
6 cycloalkyl substituted with 0-2 Rxb'; or to 6 membered heterocycle substituted with 0-2 R)U2; Rxb at each occurrence, is independently selected from H, OH, Cl, F, NR 15
R
16
CF
3 acetyl, SCH 3
S.(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, rnethoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; Y is a bond, -CH 2 or -V-CH 2 V is a bond, 2 -NlH-,
-N(CH
3 or -N(CH 2
CH
3 Z is Cl-C2 alkyl substituted with1 1-2 R1 2
C
6
-C
1 O aryl substituted with 0-4 R1 2 b;
C
3
-C
6 carbocycle substituted with 0-3 Rl2b; or S to 10 membered heterocycle substituted with 0-3 Rl~b;
R
1 2 is C 6
-CI
0 aryl substituted with 0-4 Rl2b;
C
3
-C
6 carbocycle substituted with 0-3 R12b; or 5 to 10 memnbered heterocycle substituted with 0-3 Rl2b; Rl 2 b, at each occurrence, is independently selected f rom H, OH, Cl, F, NR 15
R
16
CF
3 acetyl, SCH 3 S CH 3 S 2CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C 2 haloalkyl, and CI-C 2 haloalkoxy;
R
1 0 is H, C(0O)RI 7 C(0)0R 1 7 Cl-C 4 alkyl substituted with 0-1 Rl0a; -37phenyl substituted with 0-4 Ri0b;
C
3
-C
6 carbocycle substituted with 0-3 RI0b; or to 6 membered heterocycle optionally substituted with 0-3 Ri0b; Raat each occurrence, is independently selected from H, Cl-C 4 alkyl, OR 1 4 Cl, F, Br, I, CN, NO 2
NR
15
R
16
CF
3 or phenyl substituted with 0-4 Ri0b; R10b, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl, F, Br, 1, CN, N0 2
NR
15
R
16 or CF 3
R'
14 is H, phenyl, benzyl, methyl, ethyl, propyl, 'butyl;
R
15 at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
R
16 at each occurrence, is independently selected from H, OH, C 1
-C
4 alkyl, benzyl, phenethyl, 4 alkyl) and 2
-(CI-C
4 alkyl); and
R
17 is H, phenyl, 4-f luorophenyl, 4-chiorophenyl, 4methylphenyl, 4 -trif luorophenyl, (4-f luorophenyi )methyl, 29 ~(4-chlorophenyl)methyl, (4-methylphenyl)methyl,' (4trifluorophenyl)methyl, methyl, ethyl, propyl, butyl, methoxymethyl, mnethyoxyethyl, ethoxymethyl, or ethoxyethyl.
In another even more preferred embodiment the present invention provides -38- (Ie) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R
3 is R 4
R
4 is CI-C 4 alkyl substituted with 0-2 R 4
O,
C
2
-C
4 alkenyl substituted with 0-2 R 4 a,
C
2
-C
4 alkynyl substituted with 0-2 -R 4 a, R~a, at each occurrence, is independently selected from is- Hf, F. CF 3
C
3
-C
6 cycloalkyl substituted with 0-3 R4b, phenyl substituted with 0-3 R 4 b, or to 6 memnbered heterocycle substituted with 0-3 R4b;
R
4 b, at each occurrence, is independently selected from H, OH, Cl, F, NRI 5
R
1 6 CF3, acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
5 is Cl-C 4 alkyl substituted with 0-3 R~b;
C
2
-C
4 alkenyl substituted with 0-2 R~kb; or
C
2
-C
4 alkynyl substituted with 0-2 R~b; at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CFj, OR 14 =0;
C
3
-C
6 cycloalkyl substituted with 0-2 R 5 c; phenyl substituted with 0-3 R 5 c; or to 6 membered heterocycle substituted with 0-2 RSc; RSc, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2 CH3, methyl;' ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; W is -CH2-, or -CH(CH 3 -39- X is a bond; phenyl substituted with 0-2 Rxb%
C
3
-C
6 cycloalkyl substituted with 0-2 Rxb; or 5 to 6 membered Iheterocycle substituted with 0-2 R~b; R~b at each occurrence, is independently selected from H, OH, Cl, F, NR 15
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxcy, ethoxy, propoxy,' CI-C 2 haloalkyl, and C 1
-C
2 haloalkoxy; Y is a bond, -CH 2 or -V-CH- 2 V is a bond, 2
-NH-,
-N(CH
3 or -N(CH 2
CH
3 Z is C 1
-C
2 alkyl substituted with 1-2 R 12
C
6
-C.
10 aryl substituted with 0-4 R-12b;
C
3 -c 6 carbocycle substituted with 0-3 R3l 2 b; or 5 to 10 membered heterocycle substituted with 0-3 R12b;
R
12 is C 6 -Cj 0 aryl substituted with 0-4 Rl 2 b;
C
3
-C
6 carbocycle substituted with 0-3 Rl 2 b; or to 10 membered heterocycle substituted with 0-3 Rl2b; R22b, at each occurrence, is independently'selected from H, OH, Cl, F, NR1 5
R
1 6
CF
3 acetyl*, SCH 3 3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1
-C
2 haloalkyl, and Cl-C 2 haloalkoxy;-
R
11 is methoxy, ethoxy, propoxy, butoxy, Cl, F, NR 18
R
19
CF
3 Cl-C 4 alkyl substituted with 0-1 RIla; phenyl substituted with 0-3 R11b;
C
3
-C
6 carbocycle substituted with 0-3 R11b; or to 6 miembered heterocycle substituted with 0-3 R11b; Rlla, at each occurrence, is independently selected from H,
C
1 -C4 alkyl, OR 1 4 F, NR 1 5
R
1 6 CF3, or phenyl substituted with 0-3 R 11 b;
R
1 l b at each occurrence, is independently selected from H, OH, Cl, F, NR15R 16
CF
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C2 haloalkyl, and C 1
-C
2 haloalkoxy;
R
14 is H, phenyl, benzyl, methyl, ethyl, propyl, butyl;
R
1 5 at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
R
16 at each occurrence, is independently selected from H, OH, Ci-C 4 alkyl, benzyl, phenethyl, 4 alkyl) and 2
-(C
1
-C
4 alkyl);
R
18 at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and R19, at each occurrence, is independently selected from H, methyl, and ethyl.
In another even more preferred embodiment the present invention provides
H
2
NHNN
R3 O (If) or a pharmaceutically acceptable salt or prodrug thereof, wherein: -41-
R
3 is R 4
R
4 is Cl-C 4 alkyl substituted with 0-2 R 4 a,
C
2
-C
4 alkenyl substituted with -0-2 Rj 4 a'"
C
2
-C
4 alkynyl substituted with 0-1 Rl",
R
4 a, at each occurrence, is independently selected from is H, F, CF 3
C
3
-C
6 cycloalkyl substituted with 0-3 R4b, phenyl substituted with 0-3 R 4 orto 6 membered heterocycle substituted with 0-3 R 4 b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
1 6 1
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxcy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
5 is Cl-C 4 alkyl substituted with 0-3
C
2
-C
4 alkenyl substituted with 0-2 R5b; or
C
2
-C
4 alkynyl substituted with 0-2 R~b, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF3, 0R 1 4
C
3
-C
6 cycloalkyl substituted with 0-2 RSc; phenyl substituted with 0-3 RSc; or to 6 memnbered heterocycle substituted with 0-2 RSC; RSc, at each occurrence, is independently selected from H, OH, Cl, F, NR 15
R
1 6
CF
3 acetyl, SCH 3
S(=O)CH
3 S(=Q)2CH3, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; is -CH2-, or -CH(CH 3 X is a bond; phenyl substituted with 0-2 Rxcb;
C
3
-C
6 cycloalkyl substituted with 0-2 Rxb; or -42to 6 memnbered heterocycle substituted with 0-2 Rxat each occurrence, is independently selected f rom H, OH, Cl, F, NR 1 5
R
1 6
CF
3 acetyl, SCH3, S(=O)CH 3
S(=O)
2 CH3, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; Y is a bond, -CH 2 or -V-CH2-; V is a bond, 2
-NH-,
or -N(CH 2
CH
3 Z is Cl-C2 alkyl substituted with 1-2 -R 12 c 6 -Cj 0 aryl substituted with 0-4 R12b;
C
3
-C
6 carbocycle substituted With 0-3 Rl2b; or to 10 membered heterocycle substituted with 0-3 R12b;
R
12 is C6-CjO aryl substituted with 0-4 R1 2 b;
C
3
-C
6 carbocycle substituted with 0-3 R1 2 b; or 5 to 10 membered heterocycle substituted with 0-3 Rl2b; R12b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
RI
6 Cl' 3 acetyl, SCH 3
S(=O)CH
3 S(=O)2CH3, methyl, ethyl, propyl-, butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
1 4 is H, phenyl, benzyl, methyl, ethyl, propyl, butyl;
R
15 at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl; and
R
16 at each occurrence, is independently selected from H, OH, C 1
-C
4 alkyl, benzyl, phenethyl, 4 alkyl) and 2 -(Cl-C 4 alkyl).
[11] In another preferred embodiment the present invention provides -43- HO, N' VVI (Iha) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R
3 is -(CR 7
R
7 a )n-R 4
(CR
7
R
7 a (CR 7
R
7 a) m--R 4
-(CR
7
R
7 a n-0-(CR 7
R
7 a) m-R4, or
(CR
7
R
7 a n-N (R 7 b) (CR 7 R~a) -R 4 n is 0, 1, or 2; m is 0, 1, or 2; R~a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, or butoxy;
R
4 is H, OH, OR 14 a,
C
1
-C
4 alkyl substituted with 0-2 R 4 a,
C
2
-C
4 alkenyl substituted with 0-2 'R4a,
C
2
-C
4 alkynyl substituted with 0-2 R 4 a,
C
3
-C
6 cycloalkyl substituted with 0-3 R 4 b,
C
6 -Cj 0 aryl substituted with 0-3 Rdb, or.
5 to 10 membered heterocycle substituted with 0-3 Rdb;
R
4 a, at each occurrence, is independently selected from is H, F, Cl, Br, I CF 3
C
3 -CIO carbocycle substituted with 0-3 R4b,
C
6 -Cj 0 aryl substituted with 0-3 R4b, or to 10 membered heterocycle substituted with 0-3 R4b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
NRISR
16
CF
3 acetyl, SCH3, -44- S(0)CH3, S(=O)2CH3, Cl-C6 alkyl, Cl-C 4 alkoxy, C 1
-C
4 hialoalkyl, and Cl-C 4 haloalkoxy;
R
5 is H, OR 1 4 ;0 cl-c 6 alkyl substituted''with 0-3
C
2
-C
6 alkenyl substituted with 0-3 R~b;
C
2
-C
6 alkynyl substituted with 0-3
C
3
-C
10 carbocycle substituted with 0-3 RSc;
C
6
-C
10 aryl substituted with 0-3 R 5 c; or 5 to 10 memnbered heterocycle substituted with 0-30Sc; RSa is H, OH, Cl-C 4 alkyl, Cl-C 4 alkoxy, C 2
-C
4 alkenyl, or-C 2 04 alkenyloxy; R5b, at each occurrence, is independently -selecte *d from: H, Ci-C6 alkyl, CF 3
OR
1 4 Cl, F, Br, I. CN, NO 2
NR
15
R
1 6
C
3
-C
10 carbocycle substituted with 0-3 RSc;
C
6 -Cj 0 aryl substituted with 0-3 RSc; or 5 to 10 mnembered heterocycle substituted with 0-3 RSc; RSc, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, ON, NO 2
NR
15
R
1 6 0F3, acetyl, SCH 3
S(=O)CH
3 S(=O)2CH 3 Cl-0 6 alkyl, Cl-C 4 alkoxy, CI-C 4 haloalkyl, and Cl-C4 haloalkoxy;
R
6 is H, methyl, or ethyl;
R
7 at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2
CF
3 and C 1 4 alkyl,
R
7 a, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, ON, NO 2
OF
3 phenyl and CI-C 4 alkyl;
R
7 b is independently selected from- H, methyl, ethyl, propyl, and butyl; W is -(CR 8 RBa)p-; p is 0, 1, or 2;
R
8 and R 8 a, at each occurrence, are independently -sekected..
from H, F, CI-C 3 alkyl, C 2
-C
3 alkenyl, C 2
-C
3 alkynyl arnd
C
3
-C
6 *cycloalkyl; X is a bond;
C
6 -CIO aryl substituted with .0-3 Rxb;
C
3 -C1o carbocycle.. substituted with 0-2 Rxb; or to 10 membered heterocycle substituted with 0-2.Rxb;.
Rxb at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N0 2
NR
15
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2 CH3, Cj.-C6 alkyl. Cl-C 4 alkoxy, C 1
-C
4 haloalkyl, and Cl-C 4 haloalkoxy; Y is a bond or -(CR 9
R
9 a)t-V-(CR 9
R
9 a)u-; t is 0, 1, or 2; .u is 0, 1, or 2;
R
9 and R 9 a, at each occurrence, are independently selected from H, F, Cl-C 4 alkyl or C 3
-C
6 cycibalkyl; V is a bond, 2
-N(R
19 -C NRl 9
-NR
9 -NR19bS(=0) 2 2 NRi 9 b-, -NR1bS(=)-,or -S(=O)NR1 9 b-; Z is C 1 -C3 alkyl substituted with 1-2 Ri1 2
C
6 -CIO aryl substituted with 0-4 Rl2b;
C
3
-C
10 carbocycle substituted with 0-4 R12b; or to 10 memibered heterocycle substituted with 0-3 R12b;
R
12 is C6-CJIo aryl substituted with 0-4 Rl2b;
C
3
-C
10 carbocycle substituted with 0-4 R12b; or to 10 memibered heterocycle substituted with 0-3 Ri 2 b-I -46- Rl 2 b, at each occurrence, is independently selected- from H, OH, Cl, F, Br, I, CN, NO 2
NR
1 5
R
16
CF
3 acetyl, SCH3,
S(=O)CH
3
S(=O)
2 CH3, CI-C 6 alkyl, Cl-C 4 alkoxy, Cl-C 4 haloalkyl, and Cl-C 4 haloalkoxy; B is a seven membered lactan, wherein the lactam. is saturated, partially saturated or unsaturated; wherein each additional lactam, carbon is-,substituted.
with 0-2 R 1 1 and, optionally, the lactan contains a heteroatom selected from 2 and -N(Rl 0
R
10 is H, C(=O)Rl7, C(=O)0R 1 7
C(=O)NR
1 8
R
1 9
S(=O)
2 NRl 8
R
19 S(=0) 2 Rl 7 Cl-C 6 alkyl substituted with 0-1
C
6
-CI
0 aryl substituted with 0-4
C
3 -Cl 0 carbocycle substituted with 0-3 Ri0b; or 5 to 10 membered heterocycle optionally substituted with 0-3
R
10 a, at each occurrence, is independently selected from H,
C
1
-C
6 alkyl, OR 1 4 Cl, F, Br, I, CN, N0 2 NR3 15
R
16 2S CF 3 or phenyl substituted with..0-4- Ri0b; Ri0b, at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, Cl-C 4 alkoxy, Cl, F, Br, I, CN, NO 2 rNR 15
R
16 or CF 3 RII, at each occurrence, is independently selected from Cl-C 4 alkoxy, Cl, F, NR 18
R
19 C(=O)Rl 7 C(=O)0R 1 7 C(0)NR 1 8 Rl 9 S(=0) 2
NR
1 8 Rl 9
CF
3 Cl-C 6 alkyl substituted with 0-1 Rila;
C
6 -Cj 0 aryl substituted with 0-3 R11b;
C
3 -ClO carbocycle substituted with 0-3 R11b; or to 10 membered heterocycle substituted with 0-3 R11b; -47alternatively, two R 11 substituents on the same or adjacent.
carbon atoms may be combined to formi a C 3
-C
6 carbocycle or a benzo fused radical;
R
11 a, at each occurrence, is independently selected from H, Cl-C 6 alkyl, OR 14 Cl, F, Br, CN, N02, NR 15
R
16
CF
3 or phenyl substituted with 0-3 R1ub; R11b, at each occurrence, is -independently selected from H, OH, Cl, F, Br, I, CN, N02, NR 1
SR
16
CF
3 Cl-C 6 alkyl, Cl-C 4 alkoxy, Cl-C 4 haloalkyl', -and' Cl-C 4 haloalkoxy;
R
1 4 is H, phenyl, benzyl, Ci-C 6 alkyl, 'or C 2
-C
6 alkoxyalkyl;
R
15 at each occurrence, is independently selected from H,
CI-C
6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C6 alkyl);
R
16 at each occurrence, is independently selected from H, OH, Ci-C6 alkyl, benzyl. phenethyl, 6 alkyl.) and 2 -(CI-Cr, alkyl.);
R
1 '7 is H, aryl, (a-ryl)CH 2
C
1
-C
6 alkyl, or C 2
-C
6 alkoxyalkyl;
R
1 8 at each occurrence, is independently -selectL-d from H.- Ci-C 6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 (Cl-C 6 alkyl); and.
R
19 at each occurrence, is independently selected from H, OH, Cu-C 6 alkyl, phenyl, benzyl, phenethyl,
C
6 alkyl) and -S 2 (Cl-C 6 alkyl) and Rl9b is H, Cl-C 6 alkyl, C 3
-C
8 cycloalky., phenyl, benzyl. or phenethyl.
(12] In a more preferred embodiment the present invention provides -48-
HONI
Cub) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R
3 is R4, n is 0 or 1; m is 0 or 1;
R
4 is H, OH, Cj-C 4 alkyl substituted with 0-2 R 4 a,
C
2
-C
4 alkenyl substituted with 0-2 R 4 a,
C
2
-C
4 alkynyl substituted with 0-1 R 4 a,
C
3
-C
6 cycloalkyl substituted with 0-3 R4b,
C
6
-C
1 O aryl substituted with 0-3 R 4 b, or to 10 membered heterocycle substituted with 0-3 O~b.
R
4 a, at each occurrence, is independently selected from is H F, Cl, CF 3
C
3
-C
6 cycloalkyl substituted with 0-3 phenyl substituted with 0-3 Rdb, or 5 to 6 memibered heterocycle substituted with 0-3 R4b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N0i 2
NR
15
RI
6
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 Cl-C 4 alkyl, C 1
-C
3 alkoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
5 is H, OR 14
;I
Cl-C 4 alkyl substituted with 0-3 R~b;
C
2
-C
4 alkenyl substituted with 0-2 R~b; or
C
2
-C
4 alkynyl substituted with 0-2 -49-
R
5 b, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF 3
OR
14
C
3
-C
6 cycloalkyl substituted with 0-2 RS; phenyl substituted with 0-3 RSC; or to 6 membered heterocycle substituted with 0-2 RSC;
R
5 c, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO2, NR 1 5
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3 S(=0) 2
CH
3
C
1
-C
4 alkyl, Ci-C 3 alkoxy, C 1
-C
2 haloalkyl, and Ci-C 2 haloalkoxy; o W is a bond, -CH 2
-CH(CH
3
-CH
2
CH
2 or -CH(CH 3
)CH
2 X is a bond; phenyl substituted with 0-2 RXb;
C
3
-C
6 cycloalkyl substituted with 0-2 Rxb; or to 6 membered heterocycle substituted with 0-2 RXb;
R
x b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
1 6 CF3, acetyl, SCH 3
S(=O)CH
3 S(=0) 2
CH
3
C
1
-C
4 alkyl, C 1
-C
3 alkoxy, C 1
-C
2 haloalkyl, and C 1
-C
2 haloalkoxy; Y is a bond, -CH 2 or -V-CH 2 V is a bond, 2
-NH-,
-N(CH
3 or -N(CH 2
CH
3 Z is Ci-C 2 alkyl substituted with 1-2 R 12
C
6
-C
1 0 aryl substituted with 0-4 R12b;.
C
3
-C
6 carbocycle substituted with 0-3 R 12 b; or to 10 membered heterocycle substituted with 0-3 R 1 2b;
R
12 is C 6 -C10 aryl substituted with 0-4 R 1 2b;
C
3
-C
6 carbocycle substituted with 0-3 R 1 2b; or to 10 membered heterocycle substituted with 0-3 R 1 2b; R1 2 b. at each occurrence, is independently selected from H.
OH, el, F, NR 15
RI
6
CF
3 acetyl, SCH 3 S(=O)CH3, S(=O)2CH3, CI-C 4 alkyl, Cl-C 3 alkoxy, C 1 -C2 haloalky., and Cl.-C 2 haloalkoxy; B is a seven membered lactam, wherein the lactam is saturated, partially saturated or unisatura ted; wherein each ddditional lactam carbon is substituted with 0-2 R 11 and, optionally, the lactai contains a heteroatom selected from and '-N(Rl 0 RIO is H, C(0)RI 7 C(=O)0R 1 7 Cl-C 4 alkyl substituted with 0-1 Rloa; phenyl substituted with 0-4
C
3 -C6 carbocycle substituted with 0-3 R10b; or to 6 miembered heterocycle optionally substituted with 0-3
R
10 a, at each occurrence, is independently selected from H,
CI-C
4 alkyl, OR 14 Cl, F, Br, I, CN, N0 2
NR
1 5
R
16 CF3, or phenyl substituted with 0-4 Ri0b; Ri-0b, at each occurrence, is independently selected. from H, OH, C 1
-C
4 alkyl, C 1
-C
3 alkoxcy, Cl, Br, CN, .N02,.
N1SR1 6 or CF3;
R
11 at each occurrence, is independently selected from
CI-C
4 aJlkoxy, Cl, F, NR 18
R
19 C(=O)Rl 7 C(=O)0R 17
CF
3
C
1
-C
4 alkyl substituted with 0-1 Rila; phenyl. substituted with 0-3 R11b;
C
3
-C
6 carbocycle substituted with 0-3 R11b; or 5 to 6 memnbered heterocycle substituted with 0-3 R11b; alternatively, two R 11 substituents on the same or -adjacent carbon atoms may be combined to form a cyclopropyl, -51cyclobutyl. cyclopentyl, cyclohexyl, or a benzo f used radical;
R
11 a, at each occurrence, is independently selected f rom' H, Cl-C 4 alkyl, OR 14 F, NR1 5
R
1 6
CF
3 or phenyl substituted with 0-.3 R11b;- R11b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5
R
16 CF3, Cl 7 C4 alkyl, C 1
-C
3 alkoxy, CI-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
14 is H, phenyl, benzyl, Cl-C 4 alkyl, or C 2
-C
4 alkoxyalkyl;
R
1 5 at each occurrence, is independently selected from H, Cl-C 4 alkyl, benzyl, phenethyl, 4 alkyl) and 2 -(Cl-C 4 alkyl);
R
16 at each occurrence, is independently selected from H, OH, Cl-C 4 alkyl, benzyl, phenethyl, 1
-C
4 alkyl) and 2
-(C
1
L-C
4 alkyl):
R
17 is H, phenyl, 4-f luorophenyl, 4-chiorophenyl, 4methyiphenyl, 4-trifluorophtnyl, (4-f luorophenyl) methyl, (4-chlorophenyl) methyl, (4-rnethylphenyl )methyl, (4trifluorophenyl)methyl, methyl,, ethyl, propyl, butyl,methoxymethyl, methyoxyethyl,.ethoxymethyl, or ethoxyethyl;
R
1 8 at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and
R
19 at each occurrence, is independently selected from H, methyl, and ethyl.
[131 In an even more preferred embodiment the present invention provides -52- B is 0
N
R
10 0 N4 0
N
R)
S\R1 0
NA
(14] In another even more preferred embodiment the present invention provides compounds of Formula selected from: (2R,3S) Nl-[(3S)-hexahydro-l-(3-phenoxybenzyl)-2-oxo-1Hazepin- 3 -yl] -2 (2 -methyipropyl) -3 (propyl) butanediamide; (2R,3S) Nl-[( 3 S)-hexahydro-l-(3-(4-methoxyphenyl)benzyl)- 2-oxo-1H-azepin-3-yll1 (2-methyipropyl) (propyl) butanediamide; -53 (2R,3S) N1-((3S)-hexahydro-1-(3-(4trif luoromethylphenyl benzyl) -2-oxo-1H-azepin-3-ylJ -2- (2 -methyipropyl) (propyl) -butanediamide (2R,3S) N1-[ (3S)-hexahydro--(3-(4-methyl .phyenzl)byl)2oxo-1H-azepin-3-yl]-.2- (2-methylpropyl) -3-i-propiyl)'butanediamide; (2R,3S) Nl1((3S)-hexahydro-1-(3-(2,4dichlorophenyl)benzyl) -2-oxo-1H-azepin-3-ylI (2methylpropyl) (propyl) -butanediamide; (2R,3S) N1-((3S)-hexahydlro-1-(3-(3--chloro-4-...........
f luorophenyl)benzyl) -2-oxo-1H-azepin-3-yl] (2methyipropyl) (propyl) -butanedianide;-.
(2R, 3S) N1-( (3S)-hexahydro-l- (benzophenon-3-yl) -2-oxo-1Hazepin-3-yl] (2-methyipropyl) -3-.(propyl) butanediarmide;.
(2R,3S) Nl1U3S)-hexahydro-l-(3-(2-naphthyl)benzyl)-2-oxo- 1H-azepin-3-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) N-(3S)-hexahydro--(3-(3-fluorophenyl)benzyl)-2oxo-1H-azepin-3-yl]-2- (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-[ (3S)-hexahydro-1-(-3-(3-methoxyphenyl)benzyl)- 2-oxo-lH-azepin-3-yl] (2-methylpropyl) (propyl) butanediainide; (2R,3S) N1-((3S)-hexahydro-1-(3-(2-methoxyphenyl)benzyl)- 2-oxo-1H-azepin-3-yl] (2-niethy]lpropyl).-3- (propyl)butanediamide; (2R,3S) Nl-[(3S)-hexahydro-1-(3-(4-methoxyphenyl)pyrid-5ylmethyl) -2-oxo-LH-azepin-3-ylJ (2-methyipropyl) -3- (propyl) -butanediaxnide; (2R,3S) N1-[(3S)-hexahydro-l-(3-(4trifluoromethyiphenyl )pyrid-5-ylmethyl) -2-oxo-lH-azepin- 3 -yl] -2 (2 -methyipropyl) -3 (propyl) -butanediamide; (2R,3S) N1-((3S)-hexahydro-l-(3-(3-chloro-4fluorophenyl)pyrid-5-ylnethyl) -2-oxo-1lH-azepin-3-yl] -2- (2 -zethylpropyl) -3 (propyl) -butanediaride; -54- (2R,3S) Ni-[ (3S)-hexahydro-1-(4-(4trifluoromethylpheny)beizyl) -2-oxo-1H-azepin-3-yiJ -2- (2 -rethylpropyl) (propyl) -butanedianide; (2S, 3R) Ni- -hexahydro-i- tetrazolylphenyl)benzyi) -2-oxo-1H-azepiri-3-ylI -2- (propyl) (2-methyipropyl) -butanediamide; (2S,3R) N1-[ (3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1Hazepin-3-yl] (propyl) (2-methyipropyl) butanediamide; (2R,3S) Nl-f(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1Hazepin-3-yl]1 (2-methyipropyl) (ailyl) -butaiiediamide; (2R,3S) N1-( (35) -hexahydro-1-(benzophenon-'3-yl) -2-ox'o'-ipazepin-3-ylJ (2-methyipropyl) (allyl) -butanediamide; (2R) N1-( (3S) -hexahydro-1- (3-phenoxybenzyl) -2-oxo-iHazepin-3 (2-nethyipropyl) -butanediamide; (2R,3S) N1-( (3S)-hexahydro-1-(3-(4-methoxyphenyi)benzyl)- 2-oxo-1H-azepiri-3-ylj-2- (2-methyipropyl) (allyl) butanediamide; (2R,3S) Ni-! (3S)-hexahydro-1-(3-(4trifluoromethylphenyl)benzyl) -2-oxo-1H-azepin-3-yl] -2- (2-methyipropyl) (allyl) -butanediamide; (2R,3S) N1-[ (3S)-hexahydro-1-(3-(4-methylphenyl)benzyi)--2oxo- 1H-azepin-3 -yl]1 -2 (2 -methyipropyl) (al lyl) butanediamide; (2R, 3S) Ni- -hexahydro-i- (2.4dichlorophenyl)benzyl) -2-oxo-iH-azepin-3-yi]-2--(2methyipropyl) (allyl) -butanediamide;.
(2R,3S) Ni-( (3S)-hexahydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-1H-azepin-3-ylI (2inethyipropyl) (allyl) -butanediamide; (2R,3S) N1-[(3S)-hexahydro-1-(3-(2-naphthyl)benzyl)-2-oxo- 1H-azepin-3-yl]-2- (2-methyipropyl) -3-(aiiyl) butanediamide; (2R,3S) N1-( (35) -hexahydro-i-(3-phenoxybenzyl) -2-oxo-iHazepin-3-yl) (2-niethyipropyl) (butyl) -butanediainide; (2R,3S) N1-( (3S)-hexahydro-i-(3-(4-methoxyphenyl)benzyl)- 2-oxo-1H-azepin-3-ylJ (2-methyipropyl) (butyl) butanediamide; (2R, 3S) Ni- -hexahydro-l- (4trifluorornethylphenl)befl~) -2-oxo-1H-azepin-3-yi 1-2- (2-methyipropyl) (butyl) -butanediaiide; (2R,3S) N1-[(3S)-hexahydro-1-(3-(4-methylphenli)benzy1)-2oxo-lH-azepin-3-yl] (2-methyipropyl) -3-(butyl) butanediamide; (2R,3S) Nl-[(3S)-hexahydro-1-(3-( 2 4 dichlorophenyl) bezyi) -2 -oxo-iH-azepin-3 -yl)-2 (2 methyipropyl) (butyl) -butanediamide; (2R.3S) Nl-[(3S)-hexahydro-1(3-(3-chloro- 4 fluorophenyl)benzyl) -2*-oxo-1 H-azepin-3-yl] (2ruethyipropyl) -3 (butyl) -butanediamide; (2R,3S) Ni-( (3S) -hexahydro-1- (benzophenon-3-yl) -2-oxo-1Hazepin-3 -yl]1 (2 -methyipropyl) -3 (butyl) -butanedianide; (2R,3S) Ni-((3S)-hexahydro-1-(3-(2flaphthyi)benzl)i2-oxo- 1H-azepin-3-y1] (2-methyipropyl) (butyl) butanediamide; (2R,3S) Ni1- E(3S) -hexahydro-1-( 3-phenoxybelzyi) -2-oxo-1Hazepin- 3-yl -2 (cyclopropylmethyl) 3- (propyl) butanediamide; (2R,3S) N1-((3S)-hexahydro-l-(3-(4-ethoxyphelyl)befzl)l 2-oxo-1H-azepin-3-ylP 2 (cyclopropylmethyl) (propyl) butanedianide; (2R,3S) N1-[(3S)-hexahydro-143- 4 trifluororuethyiphelyl)belzyl) -2-oxo-1H-azepin-3-ylJ -2- (cyclopropylmethyl) (propyl) -butanediamide; (2R,3S) N1-[(3S)-hxahydro--(3-(4-ethy1phel)bel~)- 2 oxo-1H-azepiri-3-yl] (cyclopropylmethyl) (propyl) butanediauide; (2R,3S) N1-((3S)-hexahydro---(3-( 2 ,4dichloropheny)beizyl) -2-oxo-1H-azepin-3-y11 -2- (cyclopropylmethyl) -3 (propyl) -butanedianiide; (2R,3S) Ni-1(3S)-hexahydro-1-(3'-(3-chloro- 4 fluorophenyl)benzyl) -2-oxo-iH-azePil-3-Y1J -2- (cycJlopropyirnethyl) -3 (propyl) -butanediamide; (2R,3S) Ni- -hexahyclro-1- (benzophenon-3-y1) -2-oxo-1Hazepin-3-yll (cyciopropylmlethyl) (propyl) butanediamide; -56- (2R,3S) Nl[3)hxhdol(-2-ahhlbny)2oo 1H-azepin-3-yl] (cyciopropylmfethyi) (propyl) but anediamide; (2R.3S) Ni-C (3S)-hexahydro-l-(3-phefloxybefzl~)- 2 -oxo -1Hazepin-3-yll (cyciopropylinethYl) (ailyl) butanediamide; (2R,3S) Ni-C (3S)-hexahydro-1-(3-(4-nethoxyphenli)belzyl)- 2-oxo-lH-azepil-3-y1] (cyclopropylmfethyi) (allyl) butanediamide; (2R,3S) Ni-C (3S)-hexahydro-i-(3-( 4 trifluoromethylphenyl)belzyl) -2-oxo-1H-azepil-3-y.J-2- (cyclopropyimethyl) (allyl) -butanediamide;' (2R,3S) Ni-C (3S)-hexahydro-i-(3-(4-methyipheli)benzyl)- 2 oxo-IH-azepifl-3-Y1] (cyclopropylmTethyi) (allyl) butanediamide; (2R,3S) Ni-C (3S)-hexahydro-1-(3-(2, 4 dichlorophenyl)benzyi) -2-oxo-1H-azepifl-3-y1] -2- (cyclopropylniethYl) (ailyl) -butanediamide; (2R.,3S) Ni-IA3S)-hexahydro-i-(3-(3-chloro- 4 fluorophenyl )benzyi) -2-oxo-1H-azepin-3-yi] -2- (cyclopropylmethyl) (ailyl) -butanediamide; (2R,3S) Ni-C (3S)-hexahydro-i-Cbeflzopheflof--l3)- 2 -oxolIHazepin-3-yi] (cyclopropylnethyl) (allyl) butanediamide; (2R,3S) Ni-C (3S)-hexahydro-i(3-(2flaphthy1)benzylih 2 -oxo- IH-azepin-3-yi] (cyclopropyimethyl) (ailyl) butanediamide; (2R,3S) Ni-C (3S)-hexahydro-l-(3-phenoxybefzlZY)- 2 -oxo-lHazepin-3-yil (cyciopropylmethyl) (butyl) butanediamide; (2R,3S) Nl(3)hxhdol(-4mtoyhnlbny) 2-oxo-iH-azepin-3-yi] (cyclopropyitnethYl) (butyl) butanediamide; (2R,3S) Ni-[(3S)-hexahydro-i-(3-(4trifluoromethyipheny)bel~) -2-oxo-iHl-azepin-3-YiJ -2- (cyciopropylmethyl) (butyl) -butanediamide; -S7l- (2R,3S) Nl-((3S)-hexahydro--(3-(4-methy1phel)benzlZ~)-2oxo-1H-azepin-3-yl] (cyciopropylmethyl)'-3-(b'utyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1l-(3-'(2,4dichlorophenyl)benzyl) -2-oxo-1H-azepin-3.-ylj -2- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(3-chioro-4fluorophenyl)benzyl) -2-oxo-1H-azepin-3-yl] -2- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) Ni-f (3S) -hexahydro-'- (benzophenon-3-yl)-2.-oco-1Hazepin-3-yi] (cyciopropylmethyl) (butyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(2-naphthyl)benzyl)-2-oxo- 1H-azepin-3-yl] (cyclopropylmethyl) (butyl) butanediauide; O2R, 3S) Ni-f( (3S) -hexahycdro-1- (3-phenoxybenzyl) -2-oxo-lHazepin-3-ylJ (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) Ni-f (3S) -hexahydro-1- (4-methoxyphenyl)benzyl) 2-oxo-1H-azepin-3-ylI (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(4trifluoromethylphenyl)benzyl) -2-oxo-iH-azepin-3-yi) -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-l-(3-(4-nethy1phefl)befzl~y)-2oxo-1H-azepin-3 -yl 1 -2 (cyclobutyimethyl) -3 (propyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-l-(3-(2,4dichiorophenyl) benzyl) -2-oxo-1H-azepin-3-yl] -2- (cyclobutylmethyl) -3 (propyl) -butanediamnide; (2R,3S) N1-I(3S)-hexahydro-i-(3-(3-chioro-4fluorophenyl )benzyl) -2 -oxo- 1H-azepin- 3-yl] -2- (cyciobutylinethyl) (propyl) -butanediamide; (2R,3S) Ni-f (3S) -hexahydro-1- (benzophenon-3-yl) -2-oxo-1Hazepin-3-ylJ (cyciobutylmethyl) (propyl) butanedianide; -58- (2R.3S) Ni-f(3S)-hexahydro--(3-(2-iaphthyl)benzy)-2-oxo.
IH-azepin-3-yi] (cyciobutylinethyl) (propyl) butanediaiide; (2R,3S) Nl-[(3S)-hexahydro-1-(3-phenoxybenzyl).-2-oxo-1Hazepin-3-ylJ-2-(cyciobutylmethyl)-.3-.(aliyl)butanedianide; (2R,3S) Ni-[ (3S)-hexahydro-i-(3-(4-niethoxyphenyl)benzyl)- 2-oxo-iH-azepin-3-yi] (cyciobutyi-methyl) (ailyl) butanediamide; (2R. 3S) Ni-f (3S) -hexahydro---(3- (4trifiuoromethylphenyl)'benzyi) -2-oxo-1H-azepin-3-ylJ -2- (cyclobutyimethyl) (allyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-i-(3-(4-methyrlphenyl)benzyl)-2oxo-1H-azepin-3-yiJ -(cyciobutyimethyl) (allyl) is butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-1- (2,4dichiorophenyl )benzyi) -2 -oxo-1H-azepin-3 -yl] -2- (cyclobutyimethyl) (allyl) -butanediaiide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(3-choro-4fiuorophenyl)benzyl) -2-oxo-1H-azepin-3-ylJ -2- (cyclobutylmethyl) (ailyl) -butanedianide; (2R,3S) Ni-f (3S)-hexahydro-1-(be-nzophenon-3'-Yl)-2-oxo-l1Hazepin-3-yl] (cyciobutylmethyl) (ailyl) bu tanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(2-naphthyi)benzyl)-2-oxo- 1H-azepin-3-yi] (cyclobutylmnethyl) -3-(ailyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-phenoxybenzyl) -2-oxo-1Hazepin-3-yll (cyclobutyimethyi) (butyl) butanediaxnide; (2R,3S) Ni-f (3S)-hexahydro-i-(3-(4-methoxyphenyi)benzyl)- 2-oxo-1H-azepii-3-yi] (cyciobutyniethyl) (butyl) butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-1- (4trifiuoronethyiphenyl) benzyi) -2-oxo-iH-azepin-3-yil -2- (cyciobutyirnethyl) (butyl) -butanedianiide; -59- (2 R,3 S) N -hexahydro- 1- (3 -(4-methylphenyl) benzyl) -2 oxo -1H- azepin-3 -yl -2 (cyc lobutyrnethyl) 3- (bu tyl) butanediamide; (2R,3S) Nl-[ (3S)-hexahydro-1-(3-(2,4dichlorophenyl)benzyl) -2-oxo-I-H-azepin-3-yl] -2- (cyclobutylmethyl) (butyl) -butanediaiide; (2R,3S) Nl-f (3S)-hexahydro-l-(3-(3-chloro-4f luorophenyl) benzyl) 2 -xo- 1H-azepin-3 -ylJ1 -2 (cyclobutylmethyl) (butyl) -butanedanide; (2R,3S) Ni-f (3S)-hexahydro-1-(benzophenon-3-yl)-2-oxo-1Hazepin-3-yl (cyclobutylmethyl) (butyl)butanediamide; (2R,3S) Nl1(3S)-hexahydro-l-(3-(2-naphthyl)benzyl)-2'-oxo- 1H-azepin-3-ylJ (cyclobutylmethyl) (butyl) butanediamide;- (2R,3S) Ni-( (3S) -hexahydro-1- (3-phenoxybenzyl) -2-oxo-1Hazepin-3-yl] (cyclopentylmethyl) (propyl) butanediamide; (2R,3S) Nl-( (3S) -hexahydro-l-(3-(4-methoxyphenyl)benzyl)- 2-oxo-1H-azepin-3-yl] (cyclopentylmethyl) (propyl) butanediamide; (2R,35) Ni-f (3S)-hexahydro-1 trifluoromethylphenyl)benzyl) -2-oxo-1H-azepin-3-yl) -2- (cyclopentylmethyl) (propyl) 7butanediamide; (2R,3S) N1-[ (3S)-hexahydro-1-(3-(4-methylphenyl)benzyl)-2oxo-lH-azepin-3-yl] (cyclopentylmethyl)-3- (propyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-l-(3-(2,4dichlorophenyl)benzyl) -2-oxo-1H-azepin-3-ylJ -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(3-chioro-4fluorophenyl)benzyl) -2-oxo-1H-azepin-1-y1-2- (cyclopentylmethyl) 3- (propyl) -butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-1- (benzophenon-3-yi) -2'-oxo-lHazepin-3 -ylJ) -2 (cyclopentylmethyl) -3 (propyl) butanediamide; (2R,3S) Ni-I(3S)-hexahydro1l(3-(2-naphthyl)benzyl)- 2 oxo- 1H-azepifl- 3 -YlI (cyclopentylmlethyl) (propyl) butanediamide; (2R,3S) Nl-((3S)-hexahydro--(3-phefloxybenzyl)- 2 -oxo-lHazepin-3-yl] (cyclopentylfethyl) (Allyl) butanediamide; (2R,3S) Nl-((3S)-hexahydro1I-3-4metho~ypheny)benzyl)- 2-oxo-1H-azepil-3-Y'l] (cyclopent:ylmethyi) (a1lyl) but anediamide; (2R, 3S) Ni- f (3S) -hexahydro-i- (4trifluoromethylpheyl)'belzyl) -2-oxo-lH-azepil-3-yl] -2- (cyclopentylmethYl) (ailyl) -butanediaiide; (2R.,3S) Nl[3)hxhdol(-4-ehlhnlbny)2 ox-Haei- y 2 cco-'tlehl -3 -(allyl) butanediamide; (2R, 3S) Ni-I (3S) -hexahydro-1- (2,4dichioropheflyl benzyl) -2 -oxo-1H-azePifl-3 -Yl] -2- (cyclopentylmethyl) -3 (ally1) -butanedianide; (2R,3S) Nl-( (3S)-hexahydro-1-(3-(3-chloro- 4 fluorophenyl)belzyl) -2-oxo-1H-azepin-3-yl)- 2 (cyc Iopen tylme thyl) -3 (allyl) -butanediaiide; (2R,3S) N1-((3S)-hexahydro-1-(benzophenon 3 yl)- 2 -oxo-lHazepin- 3 -yl] (cyclopentyllnethyl) (allyl) butanediamide; (2R,3S) Nl-I(3S)-hexahydro-1(3-(2-naphthyl)benzyl)- 2 -oxoiH-azepin-3-yl] (cyclopentYlmethyl) (allyl) butanediamide; (2R,3S) Ni-I (3S) -hexah ydro-l-(3-pheloxybel~) -2-oxo-1Hazepin-3-yl] (cyclopentylmfethyl) (butyl) butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-1- (4-methoxypheiyl)befzl~) 2-oxo-1H-azepin- 3 (cyclopentYlmethY-) (butyl) butanediamide; (2R,3S) N1-[(3S)-hexahydro-l-( 3 4 trifluoroniethylpheflyl)benzyl) -2-oxo-lH-azepin-3-yll -2- (cyclopentylmethyl) (butyl) -butanediamide; -61- (2R,3S) N1-[(3S)-hexahydro-1-(3-(4-methyphel)bezl~y)-2oxo-1H-azepin-3-ylJ (cyclopentylmethyl) (butyl) butanediamide; (2R,3S) Ni-[(3S)-hexahydro-1-(3-(2,4dichlorophenyi)benzyl) -2-oxo-1H-azepin-3-yl] (cyclopentyixnethyl) (butyl) -butanediamide; (2R, 3S) Ni-I (35) -hexahydro-1- (3-chioro-4fluorophenyl) benzyl) -2-oxo-1H-azepi-n-3 -yl] -2- (cyclopentyimethyl) (butyl) -butanediamide; (2R,3S) Ni-[(3S)-hexahydro-1-(benzophenon-3-y).-2-oxo-1Hazepin-3-yl] (cyclopentylmethyl) (butyl) butanediamide; and (2R,3S) N-[(3S)-hexahydro-i-(3-(2-naphthyl)benzyi)-2-oxoiH-azepin-3-yl] (cyclopentyimethyl) 3- (butyl) butanediamide; (2R. 35) Ni-C (35) -hexahydro-1- (benzyl)-2-oxo-iH-azepin-3yl] (2-methyipropyl) (propyl) -butanediamide; (2R, 35) Ni-i (35) -hexahydro-i- (phenethyl) -2-oxo-lH-azepin- 3-yl] (2-methyipropyl) (propyl) -butanediamide; (2R,3S) Ni-[(3S)-hexahydro-1-((4-fluorophenyl)methyl)-2oxo-1H-azepin-3-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni-I (3S)-hexahydro-1- (cyclopropyimethyl) -2-oxo-1Hazepin-3-yl] (2-methyipropyl) (propyl) butanedianide; (2R,3S) Ni-[ (35) -hexahydro-1- (cyclobutylmethyl) -2-oxo.-1H-.
azepin-3-yl] (2-methyipropyl) (propyl) butanediamide; (2R, 35) Ni- -hexahydro-1- (cyclopentyimethyl) -2-oxo-Iazepin-3-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni-I (3S)-hexahydro-i- (cyclohexyimethyl) -2-oxo-llazepin-3-yiJ (2-methyipropyl) (propyl) butariediamide; (2R,3S) Ni- -hexahydro-l- (cyclopropylethyl) -2-oxo-1Hazepin-3-ylJ (2-nethyipropyl) (propyl) butanediamide;.
-62- (2R,3S) Ni-f (3S)-hexahydro--(cycobutyl~thy-2OxoiH.
azepin-3-yl) (2-methyipropyl) (propyl) butanedanide; (2R,3S) Ni-f (3S) -hexahydro-i-<(cyclopentyiethyl) -2-oxo-IH- azepin-3-yi] (2-methyipropyl) -3-'(propyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(cyclohexyiethyl) -2-oxo-1Hazepin-3-yl].-2- (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni-[(3S)-hexahydro--(benzy)-2-oxoiHazepin3yiI1 -2 (2 -nethyipropyl)'-3 (aiiyl-)-buitari.ediami-de; (2R, 3S) Ni-[l(3S) -hexahydro-1- (phenethyl) 2 -oxo-1H-azepin- 3 -yl 1 -2 (2 -nethyipropyl) -3 -butanediamide; (2R,3S) N1-t(3S)-hexahylro-i-( (4-fluorophenyi)methyi)-2oxo-1H-azepin-3-yl] (2-miethyipropyl) (ailyl) butanediamide; (2R. 3S) Ni-f (3S) -hexahydro-i-(cyciopropylmethyl) -2-oxo-1Hazepin-3-yi]1 (2-methyipropyl) (allyl) -butanediamide; (2R,3S) Ni-f (3S) -hexahydro--(cycobutymethy)-2oxoIH.
azepin-3 -yi]1 -2 (2 -methyipropyl) -3 (allyl) -butanediamide; (2R,3S) Ni-f (3S) -hexahydro--(cycopentymethyl)2oxIH..
azepin-3 -yi] (2 -nethyipropyl) (ailyl )-butanediamide; (2R,3S) Ni-[(3S)-hexahydro--(cyclohextyletyl)2oxo.iH azepin-3 -yi) (2 -methyipropyl) -3 (ailyl) -butanediamide; (2R,3S) Ni-((3S)-hexaydro--(cycopropyethy)2-oxoH azepin-3-yl) (2-methyipropyl) (ailyl) -butanediamide; (2R,3S) Ni-f (3S) -hexahydro-i- (cyclobutylethyl) -2-oxo-iHazepin-3-yi] (2-methyipropyl) (ailyl) -butanediamide; (2R,3S) NI-f (3QS) -hexahydro-1-(cyc openty ethyl.) -2 -oxo- 1Hazepin-3-yl] (2-niethyipropyl) (ailyl) -butanedianide; (2R,3S) Ni-f (3S) -hexahydro-i- (cyciohexylethyl) -2-oxo-1Hazepin-3 -yl]1 (2 -methyipropyl) -3 (allyl) -butanedianide; (2R,3S) Ni-I (3S) -hexahydro-i- (benzyl) -2-oxo-iH-azepin-3ylJ1 -2 (2 -methyipropyl) 3- (butyl) -butanediamide; (2R,3S) Ni-I (3S) -hexahydro-i-(pheethy)-2-oxoHazepin- 3 -yiJ1 -2 (2 -rethylpropyi) -3 (butyl) -butanediamide; -63- (2R,3S) Nl-((3S)-hexahydro--((4-fluorophenyl)methyl).2oxo-1H-azepin-3-yl] (2-methyipropyl) (butyl) butanediamide; (2R,3S) Ni-i (3S) -hexahydro-l-(cyclopropy-lmethy)-2-oxo-H.
azepin-3-yl] (2-methyipropyl) (butyl) -butanediaiide; (2R,3S) Ni-i (3S) -hexahydro-1-(cyciobutylmeth-yl) -2-ox'o-Hazepin-3 -yi]1 -2 (2 -methyipropyl) 3 (bultyl) -butanediamid'e; (2R,3S) Ni-i (3S)-hexahydro-l-(cyclopentymethy)-2-oxo-H.
azepin-3-yi] (2-methyipropyl) (butyl) -butanediamide; (2R,3S) N1-i(3S)-hexahydro--(cycohex-yfmethy)-2-oxo4H.
azepin- 3-ylI] 2- (2 -methyilpropyl) 3 (butyll-butanediamide; (2R,3S) Ni-i (3S) -hexahydro-l-(cyclopropylethyl)-2-oxoiH.
azepin-3-yl] (2-methyipropyl) (butyl -butanediamide; (2R,3S) Nl-[ (3S)-hexahydro-l- (cyclobutylethyl) -2-oxo-iHazepin-3-yi] (2-methyipropyl) (butyl) -butanediamide; (2R, 3S) Ni-i (3S) -hexahydro-l- (cyclopentylethyl) -2-oxo-1Hazepin-3-ylJ (2-methyipropyl) (butyl) -butanediamide; and (2R,3S) Ni-i (3S)-hexahydro-i- (cyclohexylethyl) -2-oxo-lHazepin-3-yl] (2-methyipropyl) (butyl) -butanediamide.
In another even more preferred embodiment the present invention provides compounds of Formula selected from: (2R,3S) Ni-[i.3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5-- (phenyl) -2H-i, 4-benzodiazepin-3 -yl 1-2- (2-methyipropyl) 3- (ailyl) -butanediamide; (2R,3S) Ni-ii,3-dlihydro-i-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-i, 4-benzodiazepin-3-yi] -2.-(2-methyipropyl) 3-(propyi)-butanediamide; (2R,3S) Ni-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- -2H-1, 4-benzodiazepin-3-yiJ (2methyipropyl) (propyl) -butanediamide; (2R,3S) N1-il,3-dihydro-l-(3-(4trifiuoromethyiphenyi)benzyi) -2-oxo-5- (phenyl-)-2H-i, 4benzodiazepin-3-yi]-2- (2-methyipropyl) (propyl) butanediamide; -64- (2R,3S) Nl[,-iyr--3(-ehlhnlbny)2 (phenyl) -2H-1, 4-benzodiazepil-3-yl] (2methyipropyl) (propyl) -butanediamide; (2R,3,S) Nl-[1,3-dihydro-i3-2,4dichorophny)benzyl)methyipropyl) (propyl) -butanediamide; fluorophenyl)belzyl) -2-oxo-5- (phenyl) -2H-1, 4benzodiazePil- 3 -yl] (2-methyipropYl) (propyl) butanediamide; (2W. 3S) Nl-[1,3-dihydro-i-bezophelofl- 3 -yl)- 2 (phenyl) -2H-1, 4-benzodiazepil- 3 -yfl (2-methyipropyl) 3- (propyl) -butanediamide; (2R,3S) Nl[,-iyr--3(-ahhlbny)2oo5 (phenyl.) -2H-1, 4-benzodiazepil- 3 -yl -2 (2 -methyipropyl) 3- (propyl) -butanediamide; (2R,3S) Nl[,-iyr--3(-mtoyhnlbny)2 (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2methyipropyl) (allyl) -butanediamide; (2R,3S) NI-j1,3-dihydro-1-(3-( 4 tri fluoromethyphelyl) benzyl) 2-oxo -5 (phenyl) 2H-1, 4 4benzodiazepin- 3 -yl) (2-methyipropyl) (aJllyl) butanediamide; (2R,3S) NI1,-iyr--3(-ehlhnlbny)2 oxo-5- (phenyl) -2H-1, 4-benzodiazepifl-3-yl] 2 (2methyipropyl) (allyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1(3-(2,4-dichlorophenyl)benzyl)- (pheriyl) -2H-1, 4-benzodiazepifl-3-y 1 (2methyipropyl) (aJllyl) -butanediamide; (2R,.3S) Nl1113-dihydro-1-(3-3-chloro- 4 f luorophenyl)belzyl) -2-oxo-5- (phenyl) -2H-1, 4benzodiazepil- 3 -yl (2 -me thyipropyl) 3- (al lyl)butanediamide; (2R,3S) Nl(,-iyr--3(-ahhlbny)2oo5 (phenyl) -2H-1, 4-benzodiazepin- 3 -yl] (2-nethylpropyl) 3- (allyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-phen~oxybenzyl)-2-oxo-5- (phenyl) -2H-1,4-benzodiazepil-3-y1I (2-methyipropyl) 3- (butyl) -butanediamnide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)'-2oxo-5-(phenyl)-2H-1,4-belzodiazepifl-3-yI]-2-(2methyipropyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4trifluoromethylphenyl)belzyl) -2-oxo-5- (phenyl) -2H-1. 4benzodiazepin-3-yl] (2-methyipropyl) (butyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3(4-methylphenyl)befzyl)72 (phenyl) -2H-1, 4-benzodiazepin-3-ylI (2rnethylpropyl) (butyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- 2-oxo-5- (phenyl)-2H-1,4-benzodiazepin-3-y1]-2- (2methyipropyl) (butyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-l. 4benzodiazepin-3-yl) (2-iethyipropyl) (butyl) butanediamide; (2R,3S) Mi-Cl, 3-dihydlro-1-(benzophenon-3-yl) (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methipropyl) 3- (butyl) -butanediamide; (2R,3S) Nl-I1,3-dihydro-1-(3-(2-naphthyl)beflzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ (2-methyipropyl) 3- (butyl) -butanedianide; (2R,3S) NI-[l,3-dihydro-1-(3-pheloxybenzyl) (phenyl) -2H-1,4-benzodiazepin-3-yl) -2- (cyclopropylmethyl) (propyl)-bultanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- (phenyl)-2H-1,4-benzodiazepin-3-yl] -2- (cyclopropylinethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4trifluoromethyiphenyl )benzyl) -2-Qoxo-S- (phenyl) -2H-1, 4benzodiazepin-3 -yll (cyclopropylmethyl) (propyl) butanediamide; -66- (2R..3S) Nl-[l,3-dihydro-1-(3-(4-methylphenyl)benzyl)- 2 (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (propyl) -butanediamide; (2R,3S) Ni-(1,3-dihydro-l-(3-(2,4-dichlorophenyl)benzyl) 2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyciopropylrnethyl) -3 (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro--(3-(3-chloro-4.
fluorophenyl )benzyl) -2-oxo-5- (phenyl) -2H-1, 4benzodiazepin-3-yl]1 (cyclopropylmethyi) (propyl) butanedianide; (2R,3S) Ni- (1,3-dihydro-i- (benzophenon-3-yl) (phenyl) -21-1. 4-benzodiazepin-3-yl] -2- (cyclopropylxnethyl) (propyl) -butanediamide; (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2cyclopropyimethyl) (propyl) -butanediamide; (2R,3S) Ni- (1,3-dihydro-l- (3-phenoxybenzy)-2-oxo.s.
(phenyl) -2H-1, 4-benzodiazepin-3-yl) -2cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) Nl-(lI 3 -dihydro-1-(3-(4-methoxyphenyl)benzyl)- 2 (phenyl) -2H-1, 4-benzodiazepin-3-yl) -2- (cyclopropyimethyl) (ailyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-l-(3-(4trifluoromethylphenyi)benzyl) -2-oxo-5-(phenyi) -2H1-1, 4benzodiazepin-3-yl] (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) Ni- [l1 3 -dihydro-l-(3-(4-methylphenyl)benzyl).2oxo-S- (phenyl) -2H1-1, 4-benzodiazepin-3-yl] -2- (cyclopropyirnethyl) (allyl) -butaneliaxnide; (2R,3S) Nl-(l, 3 -dihydro--(3(2,4dichorophy)enzy1).....) (phenyl 4-benzodiazepin-3-.ylJ -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) N1I1,3-dihydo--(-(3-(3chloro4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1,4benzodiazepin-3-yl] (cyclopropylmethyi) (allyl) butanediamide; -67- (2R,3S) Nl-(1,3-dihydro-l-(benzophenon--3-yl)-2-oxo-5- (pheriyl) -2H-l, 4-benzodiazepiri-3-yl] -2- (cyc lopropylnethyl) 3- (al lyl) -butanediaiide.; (2R,3S) N1-(1,3-dihydro-1-(3-(2-naphthyl)beizyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) Nl-[l,3-dihydro-l-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3 -yl (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-l-(3,--(4-niethoxyphe3-nyl)benzyl)- 2- (phenyl) -2H-1. 4-benzodiazepin-3-ylJ (cyclopropylmethyl) (butyl) -butanediamide;- (2R,3S) N1-(1,3-dihydro-1-(3-(4trifluorornethylphenyl)benzyl) -2-oxo-5- (pheiiyl) -2H-'1,4benzodiazepin-3-yl)-2- (cyclopropylmethyl) (butyl) butanediadide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- (pheriyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -2- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1,4benzodiazepin-3-yl] (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) N1-(1,3-dihydro-1-(benzophenon-3-yl)-2-oxo-5-- (phenyl) -2H-l, 4-benzodiazepin-3-yl 1-2- (cyclopropylmethy))-3- (butyl) -butanediamide; (2R,3S) N1-(l,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-l, 4-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-l-(3-phenoxcybenzyl)-2-oxo-5- (phenyl) -2H-l, 4-benzodiazepin-3-yll -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R,3S) Nl-[1,3-dihydlro-1-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -28-1, 4-benzodiazepin-3-ylJ -2- (cyclobutylmethyl) (propyl) -butanedianide; -68- (2R,3S) N1-fl,3-dihydro-1-(3-(4trifluoromethylpheny1)bel) -2-oxo-5- (phenyl) -2H1-1, 4benzodiazepin-3-yl]1 (cyclobutyimethyl) -3-.(propyl) butanediaiide; (2R,3S) N1-(1,3-dihydro--(3-(4-mlethylphenyl)belzyl)--2- (phenyl) -211-1, 4-benzodiazepin-3-yl].-2- (cyclobutylmethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichlorophelyl)belzyl)- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(3-chlcrofluorophenyl)benzyl) -2-oxo-5- (ph~enyl)-2H-., 4benzodiazepin-3-yl] (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) Nl-t1,*3-dihydro-1-(benzophenon-3-y1)-2-oko-5- (phenyl) -211-1, 4-benzodiazepin-3-ylI -2- (cyclobutyJlmethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydo--(3-(2-laphthyl)befzl)l2-oxo-5- (phenyl) -211-1, 4-berizodiazepin-3-yll -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro--(3-pheloxybelzy--)-2--oxo-S--- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ (cyclobutylinethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-l-(3-(4-methoxyphelyl)beflzYl)-2oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (allyl) -butanediamide; (2R,3S) N1-(1,3-dihydiro-1-(3-(4trifluoromethyiphenyl )benz~1) -2-oxo-5- (phenyl) -2H-1, 4benzodiazepin-3 -ylI1 -2 (cyclobutylmethyl) -3 (al lyl) butanediamide; (2R,3S) N-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (allyl) -butanediamide; (2R,3S) N1-(1.3-dihydro-1-(3-(2,4-dich.orophe1yl)befzlZY)- 2-oxo-5- (phenyl) -211-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (allyl) -butanedialnide; (2R,3S) Nl-(1,3-dihydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-S- (phenyl) -211-1,4- -69benzodiazepin-3-yl]-2- (cyclobutylmethyl) (allyl) butariediamide; (2R,3S) N1-[1,3-dihydro-l-(benzophenon-3-yl)-2-oxo-5- (phenyl) -2H-1,4-benzodiazepin-3-yl] (cyclobutylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (allyl) -butanedianide; (2R,3S) N1-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (cyclobutylmethyl) (butyl) -butanediamide;- (2R,35) N1-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -2H-1,4-benzodiazepin-3-yl] -2cyclobutylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4trifluoromethyiphenyl )benzyl) -2-oxo-5- (phenyl) -2H-1, 4benzodiazepin-3-yl] (cyclobutylmethyl) (butyl) butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (butyl) -butanediaiide; (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- (phenyl) -2H-1. 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (butyl) -butanpediamide; (2R,3S) N1-[1,3-dihydro-l-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4benzodiazepin-3-yl]-2- (cyclobutylmethyl) (butyl) but anediamide; (2R,3S) N1-[1,3-dihydro-1- (benzophenon-3-yl) (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -2- (cyclobutylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (butyli -butanediamide; (2R,3S) N'l-1,3-dihydro--(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -2- (cyclopentyrnethyl) (propyl) -butanediaiide; (2R,3S) N1-(1,3-dihydro.-1-(3-(4-methocyphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(4trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1. 4benzodiazepin-3-yl]-2- (cyclopentylmethyl) (propyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -2- (cycJlopentylmethyl) (propyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- (pheriyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R.3S) N1-[1,3-dihydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo---(phenyl) -2H-1, 4benzodiazepin-3-yl] (cyclopentylmethyl) (propyl) butanediamide; (2R,3S) N-[1.3-dihydro-1-(benzophenon-3-yl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1- (3-(2-naphthyl)benzyl) (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide.; (2R,3S) 14-1,3-dihydro-1-(3-(4trifluoronethyiphenyl) benzyl) -2-*oxo-5- (phenyl) -2H-1, 4benzodiazepin-3-yl] (cyclopentylmrethyl) (allyl) butanediamide; (2R,3S) N-[1,3-dihydro-l-(3-(4-nethylphenyl)benzyl)-2oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide; -71- (2R,3S) Nl-[1,3-dihydro-1-(3-(2,4-dichlorophelyl)benzyl)- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cycl1open tylmethyl -3 (allyl) -buta-nediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(3-chloro- 4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -21-1.4benzodiazepin-3 -yl 1 -2 (cyclopentylmethyl) -3 (allyl) butanediarnide; (2R,3S) N1-[1,3-dihydro-l-(benzophenon-3-yl)-2-oxo-5- (phenyl) -2H1-1, 4 -benzodiazepin- 3-yll I2 (cyclopentylmethyl) (allyl)-'butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl]1 -2- (cyclopentylmethyl) (allyl) -butanediamide; (2R,3S) Nl-(1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H1-1, 4-benzodiazepin-3-yl]1 -2- (cyclopentylmethyl) (butyl) -butanediamide; (2R,3S) Nl-(1,3-dihydro-l-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -2H1-1, 4-benzodiazepin-3-ylJ -2- (cyclopentylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4trif luoromethylphenyl) benzyl)- -2-oxo-5- (phenyl) -2H-1. 4benzodiazepin-3 -yl -2 (cyclop entylmethyl) -3--(butyl) butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3--(4-methyliphernyl')beiz-yl)-'2oxo-5- (phenyl) -2H1-1, 4-benzodiazepin-3=yl] (cyclopentylmethyl) (butyl) -butanediamide; (2R,3S) Nl-[1.3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- (phenyl) -2H1-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (butyl) -butanedianide; (2R..3S) Nl-(1,3-dihydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -211-1,4benzodiazepin-3 -yl]1 -2 (cyclopentylmethyl) -3 (butyl) butanediamide; (2R.3S) Nl-[1,3-dihydro-l-(benzophenon-3-yl)-2-oxo-5- (phenyl) -211-1, 4-benzodiazepin-3-ylJ -2- (cyclopentyirnethyl) (butyl) -butanediamide; and -72- (2R,3S) N1-[1,3-dihydro--(3-(2-naphthyl)benzy)-2-o...5- (phenyl) -2H-1. 4-benzodiazepin-3-yl] -2- (cycl1open tylmethyl) -3 (butyl) -butanediamide.; (2R,3S) Nl-(1,3-dihydro--(benzy)-2oxo5(pheny)2H-.
1, 4-benzodiazepin-3-yl] (2-methipropyl) (propyl) butanediamide; (2R,3S) N1-[1,3-dihydro--(phenethy)-2-oxo5(pheny)2H.
1, 4-benzodiazepin-3-yll (2-methyipropyl) (propyl) butanedianide; (2R,3S) N1-(1,3-dihydro-1-( (4-fluor'opheny1)m .thyl)-2-oxo- (phenyl) -2H-1, 4-benzodia'zepin-3-yl] methyipropyl) (propyl) -butanediamide;- (2R,3S) N1-(1,3-dihydro-1- (cyclopropylmethyl) (pheriyl) -211-1.4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanedianide; (2R,3S) Nl11,3-dihydro-lcobutylmethyl)..ooxo-5-..
(pheriyl) -2H-1, 4 -benzodiazepin-3 -ylJ1 -2 (2 -methyipropyl) 3- (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1- (cyclopentylmethyl) (phenyl) -2H- 1, 4 -benzodiazepin-3 -yl -2 (2 -nethylpropyl) 3- (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro--(cycohexlmethy...2oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ (2-methyipropyl) 3- (propyl) -butanediamide; (2R, 3S) N1-[1,3-dihydro-l-(cyclopropylethyl) (phenyl) -2H-1, 4-benzodiazepin-3-yl) (2-methyipropyl) 3- (propyl) -butanediamide; (2R,3S) N-[1,3-dihydro-1-(cyclobutylethyl) (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanediamide; (2R,3S) Ni- (l,3-dihydro--(cycopentylet1)2... (pheny.) -2H-1, 4-benzodiazepin-3-yl] (2-xethylpropyi) 3- (propyl) -butanediamide; (2R,3S) Ni- (l,3-dihydro--(cycohexyethy)2oxo5- (phenyl) -2H-1, 4 -benzodiazepin-3-yiJ (2-nethyipropyl) 3- (propyl) -butanedianiide; -73- (2R,3S) N1-I113-dihydro--(benzyl)-2-oxo-5-(phenyl)2H- 1, 4-benzodiazepin-3-yl] (2-methyipropyl) (allyl) butanediamide; (2R,3S) Ni-[1,3-dihydro-1-(phenethyl)-2-oxo-5- (phenyl)-2H- 1, 4-benzodiazepin-3-yll (2-methyipropyl) (aiiyl) butanediamide; (2R,3S) N1-[1,3-dihydro-l-((4-fluorophenyl)ethyl)2-oxo (phenyl) -2H-1, 4-benzodiazepin-3-y'I] (2methylpropy.) -3 (allyl) -butanediamide; (2R,3S) N1-f1,3-dihydro-1-(cyclopropylmethyl)-2oxo.5.
(phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-Iethylpropyl) 3- (alJlyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (allyl) -butanediamide; (2R,3S) Ni- [1,3-dihydro-1- (cyclopentylmethyl) -2-oxo-S- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (allyl) -butanedianide; (2R,3S) N1-(1,3-dihydro-1- (pheniyl) -2H-1, 4-benzodiazepin-3 -yl]1 (2-methyipropyl) 3- (allyl) -butanediamide; (2R,3S) Ni- (1,3-dihydro-1- (cyclopropylethyl) (phenyl) -2H-1, 4 -benzodiazepin-3 -ylJI 2- (2 -methyipropyl) 3- (allyl) -butanedianide; (2R,3S) N1-(1,3-dihydro-l-(cyclobutylethyl)-2-oxo-5-.
(phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-iethylpropyl) 3- (allyl) -butanediamide; (2R,3S) Ni- L1,3-dihydro-1-(cycloperltylethyi) (phenyl) -2H-1, 4-benzodiazepin-3 -yl]1 -2 (2 -methyipropyl) 3- (allyl)-butanedianide; (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (allyl) -butanedianide; (2R,3S) N1[1,3-dihydlro-1-(benzyl)-2-oxo-5-(phenyl)-2...
1,4-benzodiazepin-3-yl]-2- (2-methyipropyl) -3-(butyl) butanediamide; -74- (2R,3S) Ni- (1,3-dihydro-1- (phenethyl) -2-oxo-5- (phenyi)-2Hi,4-benzodiazepin-3-yl] -2-(2-methyipropyi) -3-Cbutyl) butanediamide; (2R.3S) Ni-f1,3-dihydro-1-((4-fluorophenyi)methyl)-2-oxo- 5- (phenyl) -2H-1, 4-benzodiazepin-3-ylj methyipropyl) (butyl) -butanedianide; (2R, 3S) Ni- f1,3-dihydro-l- (cyciopropylmethyl) (phenyl) -2H-1, 4-benzodiazepin-3-ylI (2-methyipropyl) 3- (butyl) -butzinedianide; (2R,3S) Ni-f 1,3-dihydro-l-(cyciobutylmethyi)-2-oxo-5- (phenyl) -2H1-1, 4-benzoaiazepin-3-yl] (2-methyipropyl) 3- (butyl) -butanedianide; (2R,3S) -Nl-(l,3-dihydro-1- (cyciopentyimethyl) -2-ox6o-5- (phenyl) -211-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) Ni-fl, 3-dihydro-1- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) Ni-f l,3-dihydro-1- (phenyl) -211-1, 4-benzodiazepin-3-yi] (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro--(cyclobutylethyl).-2-oxo-5- (phenyl) -211-1, 4-benzodiazepin-3-yiJ (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) Ni-(1,3-dihydro-1-(cyclopientyiethyl-)-2-OXo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyliropyl) 3- (butyl) -butanediamide; and (2R,3S) Ni-fl, 3-dihydro-1- (phenyl) -2H1, 4-benzodiazepin-3-yi] (2-methyipropyl) 3- (butyl) -butanediamide.
f 16] In another even more preferred embodiment the present invention provides compounds of Formula selected from: (2R,3S) Ni-f6,7-dihydro-5-(3-phenoxybenzyl)-6-oxo-5Hdibenz (b~d]azepin-7-yi] (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3--(4-methoxyphenyl)benzyl)-6oxo-5H-dibenz(b,d~azepin-7-y1J-2- (2-methylpropyl)-3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4trifluoromethyiphenyl )benzyl) -6-oxo-SHdibenz~b,dlazepin-7-ylJ-2-( 2-methylpropyl) (propyl) butanediamide; (2R,3S) Nl-[6.7-dihydro-5-(3-(4-methylphenyl)-benzyl)-6oxo-SH--dibenz lb, d]azepin-7-yl] (2-methylpropyl)-3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2,4-dichloropheryl)benzyl)- 6-oxo-SH-dibenz [b,d]azepin-7-ylI (2-methylpropyl).-3-, (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(3--chloro-4fluorophenyl) benzyl) -6-oxo-5H-dibenz azepin-7-yl 1-2- (2-methyipropyl) (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(benzophenon-3-yl) -6-oxo-51dibenz (b,djazepin-7-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Nl-(6,7-dihydro-5-(3-(2-naphthyl)benzyl)-6-oxo-5Hdibenz tb,d)azepin-7-ylJ (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-[6.7-dihydro-5-(3-phenoxybenzyl)-6-oxo-5Hdibenz azepin-7-yl] (2'methylpropy1)t-3- (allyl) butanediamide; (2R,3S) N1-[6,7-dihyclro-5-(3-(4-methoxyphenyl)benzyl)-6oxo-5H-dibenz(b,djazepin-7-yll (2-rnethylpropyl) T 3 (allyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4trifluoromethyiphenyl) benzyl) dibenz[b,dlazepin-7-yl] (2-methyipropyl) (allyl) butanediamide; (2R,3S) Nl-(6,7-dihydro-5-(3-(4-methylphenyl)benzyl)-6oxo-5H-dibenz~b,dlazepin-7-yl] (2-methyipropyl) -3- (allyl) -butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(2,4-dichlorophenyl)benzyl)- 6-oxo-5H-dibenz(b,dlazepin-7-ylJ (2-methyipropyl) -3- (allyl) -butanediamide; -76- (2R,3S) Nl-[6,7-dihydro-5-(3-(3-chloro-4fluorophenyl)benzyl) -6-oxo-5H-dibenz(b,dlazepin-7-yi) -2- (2 -methyipropyl) (ally)-butanediamide; (2R,3S) Nl-[6,7-dihydro-5-(3-(2-naphthyl)belzyl)-6-oxo-5idibenz d] azepin-7-yl]-2- (2-methyipropyl) (.alli) butanediamide; (2R, 3S) Ni- [6,7-dihydro-5- (3-phenoxybenzyl) -6-oxo-SHdibenz(b,d]azepin-7-yl]-2- (2-xethylpropyl)-3- (butyl) butanediamide; (2R,3S-) Nl-[6,7-dihydro-5-(3-(4-nethoxyphenl)belzyl)-6b,dJazepin-7-ylJ (2-methyipropyl) -3- (butyl) -butanedianide; (2R,3S) Nl-(6,7-dihydro-5-(3-(4trifluoromethyiphenyl) benzyl) dibenz(b,d~azepin-7-yl)-2-(2-methylpropyl)-3-(butyl) butanediamide; (2R,3S) Nl-[6,7-dihydro-5-(3-(4-methylphelyl)beflzyl)-6oxo-SH-dibenz dlazepin-7-yl) (2-methyipropyl) -3- (butyl) -butanediamide; (2R,3S) Nl-(6,7-dihydro-5-(3-(2,4-dichlorophenyl)benzyi)d] azepin-7-yl] (2-methyipropyl) -3- (butyl) -butanediamide; (2R,3S) Nl-(6,7-dihydro-5-(3-(3-chloro-4fluorophenyl) benzyl) -6-oxo-5H-dibenz (b,d]azepin-7-ylI-2- (2 -iethyipropyl) (butyl) -butanediamide; (2R, 3S) Ni- 7-dihydro-5- (benzophenon-3-yl) dibenz dlazepin-7 -yl] (2 -rethyipropyl)-3- (butyl).butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2-laphthyl)beflzyl)-G-oxo-5Hdibenz~b,dlazepin-7-yl]-2-(2-methylpropyl) -3-(butyl) butanediamide; (2R,3S) Ni-[6,7-dihydro-5-(3-phenoxybelzyl)-6-oxo-5Hdibenz azepin-7-yll (cyclopropyliethyl) -3- (propyl) -butanediamide; (2R,3S) Nl-f6,7-dihydro-5-(3-(4-methoxyphenyl)benzyi)-6oxo-SH-dibenz dlazepin-7-yl] (cyclopropylniethyl) -3- (propyl) -butanedianide; -77- (2R,3S) N1-16,7-dihydro-5-(3-(4trifluoromethylphenyl) benzyl) -6-oxo-51dibenz dlazepin-7-yl] (cyclopropylmethyl) -3- (propyl) -butanedianide; (2R,3S) N1-(6, 7 -dihydro--(3-(4-ethypheny)enzy..6dl azepin-7-yl] (cyclopropylmethyl) -3- (propyl) -butanedianide; (2R,3S) N1-(6, 7 -dihydro-5-(3-(2,4-dicilorophenyl)benzyl).
(b,djazepin-7-yl] (cyclopropylmethyl) 3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4-.
fluorophenyl)benzyl) -6-oxo-SH-dibenz (b,dlazepin-7-yl] -2- (cyclopropylinethyl) (propyl-).butanediamide.;.
(2R,3S) N1-(6,7-dihydro-5-(benzophenon-3-yl)-6-oxo..Hdibenz[b~dlazepin-7-yl]-2-(cyclopropylmethyl) -3- (propyl) -butanediamide; (2R,3S) Nl-(6,7-dihydro--(3-(2-naphthy)benzy)6-oxo-Hdibenz dlazepin-7-yl] (cyclopropylmethyl) -3- (propyl) -butanedianide; (2R,3S) Nl-(6,7-dihydro-5-(3-phoenzxbyl)6-oo....5H dibenz [b,dlazepin-7-yl] (cyclopropylnethyl) (allyl) butanedianide; (2R,3S) Nl-[6,7-dihydro--(3-(4-methox-yphenyl)ezyl).6.
azepin-7-yl] (cyclopropylrnethyl) -3- (allyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4trifluoromethylphenyl)benzyl) dibenz (b~dlazepin-7-yl] (cyclopropylmethyl) (allyl) but anediamide; (2R,3S) N1-t6,7-dihydro5-(3-(4-methylphenyl)benzyl)6..
diazepin-7-yl] (cyclopropylniethyl) -3- (allyl) -butanediamide; (2R,3S) Nl-[6, 7 -dihydro-5-(3-(2,4-dichlorophenyl)benzyl).
6-oxo-SH-dibenz dlazepin-7-yl] (cyclopropylnmethy1) 3-(allyl)-butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4fluorophenyl)benzyl) -6-oxo-5H-dibenz fb,d~azepin-7-ylJ (cyclopropylmethyl) (allyl) -butanediauide; -78- (2R,3S) Nl.(6,7-dihydro-5-(benzophenon-3..yl)-6oxoSHdibenz[b,dlazepin-7-yl] (cyclopropylmethyl) (allyl) butanediaznide; (2R,3S) Nl-[6, 7 -dihydro-5-(3-(2-.naphthy.)benzy)6oxo5Hdibenz[b5,djazepin-7-yl] (cyciopropylmethyl) (allyl) butanedianide; (2R,3S) Ni.- 7-dihydlro-5- (3-phenoxybenzyi) -6-oxo-SHdibenzlb. djazepin-7-yl] (cyclopropylmethyl) (butyl) butanedianide; (2R,3S) Nl-( 6 7 -dihydro-5-(3-(4-.methoxypheny)benzyl)- 6 [b,djazepin-7-yl]- (cyc6lopropyieth~l)3 (butyl) -butanediamide; (2R, 3S) N1- 7-dihydro-5- (4 tri fluoromethyiphenyl) benzyl) -6 diberz[b,dlazepin-7-ylI 2 -(cyclopropylnethyl) -3-(butyl) butanediamide; (2R,3S) Nl-[Es 7 -dihydro-5-(3-(4-methylphenyl)benzyl)- 6 (bdlazepin-7-yl] (cyclopropylmethyl) -3- (butyl) -butanediamide; (2R,3S) Nl([ 6 7 -dihydro-5S.(3-(2 4-dichlorophenyl)benzyl)- (b,dlazepin-7-yl -2-(cyclopropylmethyl) 3- (butyl) -butanediamide; (2R,3S) N1-[6,7-aihydro-5-(3-(3choro-4fluorophenyl)benzyl) 6 -oxo--SH-dibenz azepin-7-yl] -2- (cyclopropylmethyl) (butyl) -butanediamide;-* (2R,3S) Nl-[6,7-dihydro-5- (benzophenon-3-yl)-6-oxoSH.
diberlz[b,dlazepin-7-yl] (cyclopropylmethyl) -3-(butyl) butanediamide; (2R,3S) Nl-(S, 7 -dihydro-5-(3-(2naphthy)benzy)6oxo5Hdibenzfb,dlazepin-7-yl- (cyclopropylmethyl) -3-(butyl) butanediamide; (2R,3S) Nl-[S.
7 -dihydro-5-(3...phenobenzy)6oxo5Hdibenz[b,dlazepin-7-yl] (cyclobutylmethyl) (propyl) butanediamide; C2R,3S) Nl[,-iyr--3(-mtoyhnlbny)6 azepin-7-yl] (cyclobutyimethyl) -3- (propyl) -butanediamide; -79- (2R,3S) N1-[6,7-dihydro-5-(3-(4trifluoromethylphenyl.) benzyl) dibenz[b,d]azepin7y..
2 (cyclobutylmfethyl) (propyl) butanediamide; (2R,3S) Nl[,-iyr--3(-ehlhnlbny)6 oxo-SH-dibenz (b,dlazepin-7-yl] (cyclobutylniethyl) -3- (propyl) -butanediamide; (2R,3S) Nl(,-iyr--3(,-ihoohnlbny) 6 -oxo-SH--dibenz dl azepin-7-yl) (cyclobutylnlethyl) -3- (propyl) -butanedianiide; (2R,3S) Nl-[6, 7 -dihydro5(3(3choro4 fluorophenyl)benzyl) -6-oxo-5H-dibenz'[b,d) azepin-7-y1] -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R, 3S) N1-[6, 7-dihydro-5- (benzophenon-3-yl) dibenz [b,dlazepin-7-yl] (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) Nl-[6, 7 -dihydro5.(3(2-naphthbny)enzyl)ES dibenz [b,dlazepin-7-yl] (cyclobutylnmethyl) (propyl) butanediamide; (2R,3S) Nl[,-iyr--3peoyezl--x-H dibenz [b,dlazepin-7-yl] (cyclobutylmethyl) (allyl) butanediamide; (2R,3S) Nl[,-iyr--3(-mtoyhnlbny)6 [b,djazepin-7-ylI (cyclobu tylmethyl) -3- (allyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5(3.(4 trifluoromethyiphenyl )benzyl) dibenz [b~dlazepin-7-yl] (cyclobutylmethyl) (allyl) butanediamide; (2R,3S) Nl-[6, 7 -dihydro-5-(3-.(4rethypheny1benzl)- 6 oxo-SH-dibenz d]azepin.7-yl) 2 (cyclobutylmethyl) -3 (allyl) -butanediamide; (2R,3S) Nl[,-iyr--3(,-ihoohnlbny) 6 -oxo-SH-dibenz (b,d~azepin-7-yl] (cyclobutylmethyl) -3- (allyl) -butanediamide; fluorophenyl)benzyl) 6-oxo-5H-djbenz [b,djazepin-7.zyl]p2- (cyclobutylmethyl) (allyl) -butanediamide; (2R,3S) Ni-(6,7-dihydro-5-(benzophenon-3-y)-6oxo5Hdibenz(b,dlazepin-7-y.] -2-(cyciobutyliethyl) -3I-(aiiyl)butanedianiide; (2R. 3S) Ni-(6, 7-dihydro-5- (2-naphthy)benzy)--6-oo-H.
dibenz[b,dlazepin-7-yl] (cyclobutyrnethyl) -3-(allyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-phenoybenzy)6ox...5Hdibenz azepii-7-yl] -2-(cyclobutylmethyl) (bultyl) butanediaznide; (2R,3S) N1-(6,7-dihydro-5-(3-(4-methoxpheny)benzyl..6azepin-7-yl] (cyclobutylmethyl) -3- (butyl) -butanedianide; (2R,3S) N-[6,7-dihydro-5-(3-(4trifluoromethylphenyl) benzyl) dibenz~b,d]azepin-7-y1]-2-(cyclobutylmethyl) (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-methylphenyl)benzyl)6.
(b,d]azepin-7-yl] (cyclobutylmethyl) -3- (butyl) -butanedianide; (2R,3S) Nl-(6,7-dihydro-5-(3-(2,4-dichlorophenyl)bezy) lb.d]azepin-7--yl] (cyclobutyrnethyl) -3- (butyl) -buta-nediamide; (2R,3S) N1-(6,7-dihyciro-5-(3-(3-chloro-4fluorophenyl)benzyl) -6-oxo-5H-dibeiz [b,d)azepin-7-ylJ -2- (cyclobutylmethyl) (butyl) -butanedianide; (2R,3S) Ni-[6,7-dihydro-5-(benzophenon-3-yl) dibenz dl azepin-7-yl] (cyclobutylmethyl) (butyl) butanediamide; (2R,3S) Ni-(6,7-dihydro-5-(3-(2-naphthyl)benzy. dibenz~b~d~azepin-7-yl]-2-(cyclobutylmethyl) (butyl)butanediaxnide; (2R, 3S) Ni- 7-dihydro-5- (3-phenoxybenzyi) dibenz (b,djazepin-7-yl] (cyclopentylniethyl) -3- (propyl) -butanedianide; (2R,3S) Nl-(6, 7 -dihydro-5-(3-(4-methoxyphenyl )benzyl).6oxo-SH-dibenz lb. d]azepin-7-yl] (cyclopentyirnethyl) -3- (propyl) -butanediamide; -81- (2R,3S) Nl-(6,7-dihydro-S-(3-C4trifluorocnethylpheflyl )benzyl) -6-oxo-Sidibenz lb,d] azepin-7-ylJ (cyclopentylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-nethylpheflyl)benzyl)-6- [b,d~azepin-7-yl] (cyclopentylmethyl) -3- (propyl) -butanedianide; (2R,3S) Nl-16,7-dihydro-5-(3-(2,4-dichlorophenyi)benzyl)- 6-oxo-5H-dibenzfb,djazepin-7-yl (cyclopentylniethyl) 3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4fluorophenyl)benzyl) -6-oxo-5H-dibeiz b,d] azepin-7-ylJ -2- (cyclopentylmethyl) (propyl) -butanediamide;- (2R,3S) N1-[6,7-dihydro-5- (benzophenon-3-yl) dibenz azepin-7-yl] -2-(cyclopentylmethyl) -3- (propyl) -butanediamide;- (2R,3S) N1-(6,7-dihydro-5-(3-(2-flaphthyl)beflzyl)-6-0x0-5Hdibenz dl azepin-7-yl] (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) Ni- (6,7-dihydro-5- (3-phenoxybenzyl) -6-oxo-SHdibenz [b,d]azepin-7-yi] -2-(cyclopentylmethyl) (ailyl) butanediamide; (2R,3S) N1-[6,7-dihydlro-5-(3-(4-xnethoxyphenYl)benzyl)-6d) azepin-7 -yl] 2- (c-yclopentylmethyl') -3 (ailyl) -butanediamide; (2R,3S) N-[6,7-dihydro-5-(3-(4trif luoromethyiphenyl) benzyi) -6 dibenz (bdlazepin-7-yll -2-(cyclopentylmethyl) (allyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-methbylphenyl)benzyi)-6- [b,dJ azepin-7-yl] (cyclopentylmethyl) -3- (ailyl) -butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(2,4-dichlorophenyl)belzyl)- (b,d)azepin-7-yl] (cyclopentylmethyl) 3- (allyl) -butanedianide; (2R,3S) Nl-[6,7-dihydro-5-(3-(3-chloro-4fluorophenyl)benzyl) -6-oxo-5H-dibenz Eb,dlazepin-7-yiJ -2- (cyclopentyimethyl) -3 (alilyl) -butanediamide; -82- (2R,3S) Nl-[6,7-dihydro-5-(benzophenon-3-yl)-6-oxo-5Hdibenz azepin-7-yl] (cyclopentylmethyl) (allyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(2-naphth-yl)benzyly--6--oxo-5Hdibenz(b,djazepin-7-yl] (icyctloperitylinethyl) (allyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-phenoxybenzyl)-6-oxo-5Hdibenz fb,dJ azepin-7-yl] (cyclopentylmethyl) (butyl) butanediamide; (2R,3S) Nl-(6,7-dihydro-5-(3-(4-nlethoxyphenyl)benzyl)-6- (b,d~azep~in-7-yl] (cyclopentylmethyl) -3- (butyl) -butanediainide; (2R,3S) Nl-[6,7-dihydro-5-(3-(4--' trifluoromethylphenyl)benzyl) dibenz dlazepin-7 -yl 1 -2 (cyclopentylmethyl) -3 (butyl) butanediamide; (2R,3S) Nl-[(6.7-dihydro-5-(3-(4-methylphenyl)benzyl)-6oxo-SH-dibenz (b,dJ azepiri-7-yl] (cyclopentylmethyl) -3- (butyl) -butanediamnide; (2R,3S) N1-(6,7-dihydro-5-(3-(2,4-dichlorophenyl)benzyl)lb.dl azepin-7-yl] (cyclopentylmethyl) 3- (butyl) -butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(3-chloro-4fluorophenyl)benzyl) -6-oxo-5H-dibenzlb. d].azepin-7-yl] -2- (cyclopentylmethyl) (butyl) -butanediamnide; (2R,3S) N1-[6,7-dih~ydro-5-(benzophenon-3-yl) -6-oxo-SHdibenz~b,dlazepin-7-yl] (cyclopentylmethyl) (butyl) butanedianide; and (2R,3S) N1-[6,7--dihydro-5-(3-(2-naphthyl)benzyl)-6-oxo-5Hdibenz (b,dlazepin-7-yl] (cyclopentylmethyl) (butyl) butanediamide.
(2R,3S) N1-[6,7-dihydro-5-(benzyl) dibenz (b,djazepin-7-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Nl-[6,7-dihydro-S-(phenethyl)-6-oxo-5Hdibenz azepin-7-yl] (2-methyipropyl) (propyl) butanediamide; -83- (2R,3S) N1-(6,7-dihydro-5-( (4-fluorophenyl)methyl)-6-oxo- 5H-dibenz(b,diazepin-7-y1]-2- (2-methyipropyl) -3- (propyl) -butanediaiide; (2R, 3S) Ni- (6,7-dihydro-5-(cyclopropylmethy1)-6-oxo-5Hdibenz(b,dlazepin-7-yi]-2-(2-methyipropyi)-3-(propyl)butanediamide; C2R, 3S) Ni- (6,7-dihydro-S-(cyciobutyimethyi) dibenz(b~dlazepin-7-yl-2-(2-methyipropyi) (propyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5-(cyclopentylmethyl)-6-oxo-5Hdibenz d]azepin-7-yi] (2-methyipropyl) (propyl) butanediamide; (2Rg3S) Ni- (6,7-dihydro-5-(cycJlohexylmethyl) dibenz(b,dlazepin-7-yl] -2-(2-methyipropyl)-3- (propyl) butanediamide; (2R,3S) Ni C[6, 7-dihydro- 5- (cycilopropyi ethyl) -6 dibenz (b,dlazepin-7-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni- (6,7-dihydro-5-(cyclobutylethyl)-6-oxo-5Hdibenz~b,dlazepin-7-yi] -2-(2-methylpropyi) -3-(propyi) butanediamide; (2R,3S) N1-(6,7-dihydro-5-(cyclopentyiethyl)-6-oxo-5Hdibenz dlazepin-7-yl] (2-methyipropyl) (propyl) butanediamide; (2R, 3S) Ni- 7-dihydro-5- dibenz d] azepin-7-yi) (2-methyipropyl) (propyl) butanedianide; (2R, 3S) Ni- 16.7-dihydro-5- (benzyl) dibenz d] azepin-7-y] (2-mfethylpropyi) (aiiyi) butanediamide; (2R,3S) Ni-(6,7-dihydro-5-(phenethyi)-6-oxo-5Hdibenz d]azepin-7-yl] (2-methylpropyi) -3 (aillyl) butanediamide; (2R,3S) Ni-(6,7-dihydro-5-((4-fiuorophenyi)methyl)-6-oxo- 5H-dibenz [b,djazepin-7-yl] (2-methyipropyl) (allyl) butanedianide; -84- (2R,3S) N1-[6,7-dihydro-5-cyclopropylmethyl)-6-oxo-5H.
dibenz(b,djazepin-7-yl] (2-methyipropyl-)-3- (allyl) butanediamide; (2R,3S) Nl-rE,7-dihydro-5-(cyclobutylmethyl)-6-oxoSH dibenz[b,dlazepin-7-yl]-2-(2-methylpropyl)-3-(allyl)butanediamide; (2R,3S) Nl-[6,7-dihydro-5-(cyclopentylmethyl)-6-oxoSHdibenz (b~djazepin-7-yl] (2-me thyipropyl) (allyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(cyc6hexymethy)-6-oxo.sHdibenz dJazepin-7-ylj (2-methyipropyl)-3- (allyl) butanediamide; (2R,3S) Nl-(6, 7-dihydro-5-(cyclopropylethyl) -6-oxco-Hdibenz(b,dlazepin-7-yl] -2-(2-methylpropyl) (allyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5- (cyclobutylethyl) dibenz [b,dlazepin-7-yl] (2-inethyipropyl) (allyl) butanediamide; (2R,3S) Nl-(6,7-dihydro-5--(cyclopentylethyl) dibenz~b~d~azepin-7-yl] (2-methyipropyl) (allyl) butanediamide; (2R,3S) Nl-[6,7-dihydro-5-(cycoheyethy)--oxo-Hdibenz (b,d~azepin-7-yl] (2-methyipropyl) (allyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5-(benzyl)-6-oxo-5Hdibenz(b,d~azepin-7-yl] (2-methyipropyl) (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(phenethyl)-6-oxo-5Hdibenz d] azepin-7-ylJ (2-methyipropyl) (butyl) butanediamide; (2R,3S) N1-I6,7-dihydro-5-( (4-fluorophenyl)rnethyl)-6-oxo- 5H-dibenz~b,dlazepin-7-yl]-2- (2-methyipropyl) -3-(butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(cyclopropylmethyl) dibenz(b,d]azepin-7-yl-2- (2-methylpropyl.3-(butyl) butanedianide; (2R,3S) N1-(6,7-dihydro-5-(cyclobutylmethyl)-6-oxo-5Hdibenz[b,dlazepin-7-yll (2-methylpropyl)-3- (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro--5-(cyclopentylmethyl)-6-oxo-SH- 5dibenz[b,dlazepin-7-ylj-2-(2-nethylpropyl)-3-(butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-S-(cyclohexylmethyl)-6-oxo-5Hdibenz(b,d]azepin-7-ylI (2-inethyipropyl) (butyl) butariediamide; (2R,3S) Nl-[6, 7-dihydro-5- (cyclopropylethyl) -6-oxo-SHdibenz (b,da]azepin-7-yI] (2 -methyi1propyl)-3- (butyl,)but anediamide; (2R,3S) N1-(6,7-dihydro-5-(cyclobutylethy1)-6-oxo-5Hdibenz[b,djazepin-7-yl] (2-methyipropyl) (butyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5- (cyclopentylethyl) dibenz (b,dlazepin-7-yl] (2-methyipropyl) (butyl) butanediamide; and (2R, 3S) Ni- 7-dihydro-5- (cyclohexylethyl) dibenzfb,d]azepin-7-yl] -2-(2-methylpropyl)-3-(butyl) butanediamide.
(17] In -another even more preferred embodiment the present invention provides compounds of Formula selected from: (2R,3S) !fl-[l3,4,5-tetrahydro-l-(3-phenoxybenzyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) (propyl) -butanediaiide; (2R,3S) N1-f1,3,4,S-tetrahydro-1-(3-(4methoxyphenyl)benzyl) -2-oxo-5-(phenyl) -2H-1, benzodiazepin-3-yl] (2-methyipropyl) (propyl) butanedianide; (2R,3S) Nl-(l,3,4,5-tetrahydro-l-(3-(4trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yll-2- (2-methyipropyl) (propyli butanediamide; (2R,3S) N1-El,3,4..5-tetrahydro-l-(3-(4- Methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, -86benzodiazepin-3-yl] (2-methylpropy1) (propyl) bu tanediamide; dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -yl]1 -2 (2 -methyipropyl) (propyl)butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(3-chloro-4fluorophenyl) benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -yl]1 -2 (2 -methyipropyl) -3 (propy.) butanediamide; (2R,3S) N1-(1,.3,4,5-tetrahydro-1- -(benzophenon-3-yl-)-2--oxo- (phenyl) -2H-1. 5-benzodiazepin-3-yl] (2inethyipropyl) (propyl) -butanedianide; oxo-S- (phenyl)-2H-1,5-benzodiazepin-3-yl] (2methyipropyl) (propyl) -butanedianide; (2R,3S) N1-[1,3,4, 5-tetrahydro-1- (3-phenoxybenzyl) -2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) (allyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -211-1,5benzodiazepiri-3-yl] (2-methyipropyl) (allyl) butanediainide; (2R,3S) N-(1,3,4,5-tetrahydro-1-(3-(4trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-ylJ (2-methyipropyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-methylpropyl) -3-.(allyl) butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-(3-(2,4dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-methyipropyl) (allyl) butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(3-(3-chloro-4fluoropheriyl)benzyl) -2-oxo-S- (phenyl) -2H-1, -87benzodiazepin-3-yl]1 (2-methyipropyl) (allyl) but anediamide; (2R,3S) Nl-(1,3,4,5-tetrahydro-1-(3-(2-naphthyl)belzyl)-2- (pheriyl) -2H-1,5-benzodiazepin-3-yl] (2iethyipropyl) 3- (al lyl), -butanediamide; (2R,3S) N1-[1,3,4, 5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo.- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) 3- (butyl) butanediamide; methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -2 (2 -methylpropyl)--3- (butyl) butanediamide; (2R,3S) N1-[2,3,4,5-tetrahydro-1-(3-(4trifluoroniethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-methylpropy.) (butyl)butanediamide; (2R,3S) N-[1,3,4,5-tetrahydro-l-(3-(4methylphenyl) benzyl) -2-oxo-5- (pheniyl) -2H-1, benzodiazepin-3 -yl]1 -2 (2 -methyipropyl) -3 (butyl) butanediamide; dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-methyipropyl) (butyl) butanediamide; (2R,3S) Nl-(1,3..4,5-tetrahydro-1-(3-(3-chloro-4f luorophenyl) benzy-) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-methylpropyl).-3- (butyl) butanediamide; (2R,3S) NI-(1.3,4,5-tetrahydro-1-(benzophenon-3-yl)-2-oxo- 5- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) -3 (butyl) -butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-l-(3-(2-naphthyl)benzyl)-2- -2H-l,5-benzodiazepin-3-yl] methyipropyl) -3 (butyl) -butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-l-(3-pheloxybenzyl)- 2 -oxo- (phenyl) -2H-1, 5-benzodiazepin-3-ylI -2- (cyclopropylmethyl) -3 (propyl) -butanediamide; -88- (2R,3S) Ni-[1,3,4.,5-tetrahydro-1-(3-(4methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -yl]1 -2 (cyciopropylmethyl) (propyl) butanedianide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(.3-(4trifluorornethylphenyl)benzyl) -2-oxo-5-(phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (propyl) butanediamide; C2R,3S) N1-(1,3,4,5-tetrahydro-1-(3-(4methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (propyl) butanediamide; (2R,3S) Nl-[1,3,4,S-tetrahydro-1I-(3-(2,4dichlorophenyl)beizyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (propyl) butanediaiide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) -3 (propyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(benzophelof-3-yl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopropylnethyl) (propyl) -butanedianide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-(3-(2-naphthyl)belzyl)-2oxo-5- (phenyl) -2H-1, 5-benzodiazepin-3-y1) -2- (cyclopropylmethyl) (propyl) -butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-1--(3-pheloxybeflzyl)-2-OXO- (phenyl) -2H-1. 5-benzodiazepin-.3-ylJ (cyclopropylmethyl) (allyl) -butanedianide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4methoxyphenyl)benzyl) -2-oxo-5-(phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (allyl) butanediamide; (2R, 3S) Ni- 5-tetrahydro-1- (4trifluoromethylphenyl)benzyl)-2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-ylJ (cyclopropylmethyl) (allyl) butanediamide; -89- (2R,3S) N1-(1.3, 4.5-tetrahydro-1-(3-(4zethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) Nl11,3,4,5-tetrahydro-1-(3-(2,4dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyc]lopropylmethyl) (allyl) butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] -2-'(cyclopropylmethyl) (allyl) butanediamide; (2R,3S) Nl-(1,3,4,5-tetrahydro-1-(benzophenon-3-yl)-2-oxo- (phenyl) -2H-l, 5-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) N1-13,4,5-tetrahydro-1-(3-(2-naphthyl)benzyl)-2- (phenyl) 5-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-l-(3-phenoxybenzyl)-2-oxo- 5- (phenyl) -211-1, 5-benzodiazepin-3-yl) -2- (cyclopropyrnethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,,4,5-tetrahydro-l-(3-(4methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(47 trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1. benzodiazepin-3-yl] (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) N1-'[1,3,4,5-tetrahydro-l-(3-(4methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1,5benzodiazepin-3-yli (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-(3-(2,4dichlorophenyl)benzyl) -2-oxo-5- (phenyl)-2H-1, benzodiazepin-3-ylJ (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) Nl-(1,3,4,5-tetrahydXo-l-(3-(3-chloro- 4 fluorophenyl)belzyl) -2-oxo-5- (phenyl) -2H-1,5benzodiazepin-3-yl] (cyclopropylniethyl)-3.-(butyl) butanediamide; (2R,3S) Nl-(1,3,45-tetrahydro--(belzopheflof-3-y1)-2-oxo- (phenyl) -2H-1, 5-benzodiazepii-3-ylJ -2- (cyclopropylmethyl) (butyl) -butanedianide; '(2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2-laphthyl)beflzyl)-2- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (butyl) -butanedianide; (2R,3S) N1-(1,3,4,5-tetrahydro-17(3-pheloxybefzl.)-2-oxo- (phenyl) -2H-1, 5-benzodiazepil-3-yl] -2- (cyclobutylinethyl) (propyl.) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-l-(3-(4methoxyphenyl)belzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl 1-2- (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) N-(13,4,5-tetrahydro-l-(3-(4trifluoromethylphenyl)belzyl) -2-oxo-5- (phenyl) -2H-1. benzodiazepil-3-y11 (cyclobutylinethyl) (propyl) but anediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4methylphenyl)benzyl) -2-oxo-5- (phenyl) benzodiazepin-3-y1] (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) Nl-(1, 3.4, 5-tetrahydro-l-(3-(2,4dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-ylJ (cyclobutylmethyl) (propyl) but anediamide; (2R,3S) NlT-(1,3,4,5-tetrahydro--(3-(3-chloro-4fluorophenyJ.)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-ylI (cyclobutylmethyl) (propyl) butanediainide; (2R,3S) N1-(1, 3,4, 5-tetrahydro-l- (benzophenon-3-yl) -2-oxo- 5-(phenyl) -2H-1. 5-benzodiazepil-3-ylJ -2- (cyclobutylmethyl) (propyl) -butariediaxnide; -91- (2R.3S) Nl-(1,3,4,5-tetrahydro-1-(3-(2-naphthyl)belzyl)-2- -211-1, 5-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydxro-1l-(3-plhenoxybenzyl)-2-oxo- 5 (phenyl) -2H- 1, 5-benzodiazepin-3 -yl 1 -2 (cyclobutylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahkdro-1-(3-(4me thoxyphenyl) ben zyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-y1] (cyclobutylmethyl) (ally.) butanediamide; trif luoromethylphenyl)benzyl) -2-oxo-5- (phenyl) berizodiazepin-3-ylJ (cycl'obutylmnethyl) (alflyl) butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(3-(4methylphenyl)benzyli) -2-oxo-5- (phenylI) -2H-1, benzodiazepin-3-yl) (cyclobutylinethyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2,4dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl]1 (cyclobutylmethyl) -3 (allyl) butanediamide; (2R,3S) N-[1,3,4,5-tetrahydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclobutylmethyl)'-3- (alJlyl) butanediamide; (2R,3S) N-(1,3,4,5-tetrahydro-1-(benzophenon-3-yl)-2-oxo- (phenyl) -2H1-1, 5-benzodiazepin-3-ylJ -2- (cyclobutylmethyl) (allyl) -butanediarnide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2-naphthyl)benzyl)-2- (phenyl) -2H-1, 5-benzodiazepin-3-ylJ -2- (cyclobutylmethyl) (allyl) -butanedianide; (2R,3S) Nl-(1.3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl]1 -2- (cyclobutylmethyl) (butyl) -butanediamide; (2R,3S) N1-(1,3,4,S-tetrahydro-1-(3-(4methoxyphenyl)benzyl) -2-oxo-5-(phenyl) -2H-1,5- -92benzodiazepifl- 3 -y 1 1 (cyclobutylmlethyi) (butyl) butanediahide; (2R,3S) N1-(1,3,4,5-tetrahydro1l-( 3 4 trif luoromethylphenli)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepil- 3 -yl) (cyclobutylmfethYl) (butyl) butanediamTide; (2R,3S) Ni-E1,3,4,5-tetrahydro-l-( 3 4 methylpheny)belzyl) -2-oxo-5- (phenyl) -2H-1. benzodiazepifl- 3 -yiI-2- (cyciobutYlmethYl) (butyl) butanediamide; dichloropheli)bezl~) -2-oxo-5- (phenyl) -2H-1. benzodiazepil- 3 -yl -2 (cyciobutylfethyl) -3-7 (butyl) butanediamide; (2R,3S) Ni-(1,3,4,5tetrahydro1l(3(3chloro- 4 fiuorophelyl)bel~) -2-oxo-5-(phelYl) -2H-1, benzodiazepil- 3 -yl -2 (cyclobutylmfethYl) -3 (butyl) butanediamide; (2R, 3S) Nl-f1,3,4,5-tetrhyro-l- (benzophenof-3-y)- 2 0oxo 5- (phenyl) -21-1. 5-benzodiazepil- 3 -yiI -2- (cyclobutylmfethyi) (butyl) -butanediamide; 2
R,
3 S) Nl-(i,3,4,-tetrahyro1l(3(2naphthyl)benzyl)- 2 (phenyl) -2H-1. 5-benzodiazepil- 3 -yi) -2- (cycilobutyirnethYl) 3- (butyl) -butanediamide; (2R, 3S) Ni- 5-tetrahydro-l- (3-phenoxybelzyl) -2-oxo- (phenyl) -2H-1. 5-benzodiazepin- 3 -yiI -2- (cyciopentYlmfethyl) (propyl) -butanedianide; (2R,3S) Ni-(i,3,4,5-tetrahydro1l( 3 4 methoxypheli)belzyl) -2-oxo-S- (phenyl) -2H-i, benzodiazepil- 3 -yl) (cyciopentylmlethyi) (propyl) butanedia'ide; (2R,3S) N1l-f1,34,5-tetrahydro-l( 3 4 trifluoromethylphelYl)belzyl) -2-oxo-5- (phenyl) -211-1,5benzodiazepinfl 3 -yiJ (cyciopentylmethYl) (propyl) butanediamide; methylphenyl)bel) -2-oxo-5- (phenyl) -2H1-1, -93berizodiazepin-3-yl]1 (cyclopentylmnethyl) (propyl) butanediamide; (2R,3S) N1-[1,3,4. 5-tetrahydro-1-(3-(2,4d ic hlo ropheny1) ben z yl -2 -oxo 5- (phenyl1) 21H- benzodiazepin-3 -yl]1 -2 (cyclopentylmethyl) -3 (propyl) butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-l-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl benzodiazepin-3-yl] (cyclopentylmethyl) -37 (propyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahyro--(benzophelof-3-Yl)-2-oxo- (phenyl) 5-benzodiazepin-3-ylJ (cyclopentylmethyl) -3 (propyl) -butanediamide; (2R,3S) Nl-(1,3,4,5-tetrahydro-1-(3-(2-naphthyl)benzyl)-2oxo-5- (phenyl) -2H1-1, 5-benzodiazepin-3-yll -2- (cyclopentylmethyl) -3 (propyl) -butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro--(3-phenoxybelzyl)-2-oxo- (phenyl) -2H1-1, 5-benzodiazepin-3-yl]1 -2- (cyclopentylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4rethoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethy l)-3 (allyl)butanedianide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4rnethylpheriyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (allyl) butanediamide; (2R,3S) Nl-(1,3,4,5-tetrahydro-1-(3-(2,4dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2-1,5benzodiazepin-3-yl (cyclopenqtylmethyl)-3- (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(3-chloro-4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -211-1,5- -94benzodiazepin-3-yl 1 (cyclopentylmethyl) -3 (allyl) butanediainide; (2R..3S) NI1,,,-erayr- bnopein3y)2oxo- (phenyl) -2H-1, S-berizodiazepin-3-ylJ -2- (cyclopentylmethyl) -3 (allyl) -butanedianide; (2R,3s) Nl-(l.
3 4 ,5-tetrahydro-l-(3-(2-.naphthy1)benzyl)- 2 (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopentylznethyl) -3 (allyl) -butanediamide; (2R,3S) Nl[,,,-erhdol(-hnxbny)2oo 5- (phenyl) -2H-1, S-benzodiazepin-3-yl -2- (cyclopentylznethyl) (butyl) -butarlediamide; (2R,3S) Ni-f1,3,4,5-tetrahyd-1(...(4..
methoxyphenyl)benzyl) -2-oxo-S- (phenyl) -2H-1, benzodiazepin-3-yl] (cyci1open tylme thyl) -3 (butyl) butanediazuide; (2R,3S) N-(1,3,4,5-tetrahydro...(3-.(4..
trifluoromethyiphenyl )benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (Cciopentylmethyl) (butyl) butanediamide; (2R,3S) N-[1,3,4,5-tetrahydro-..(3-(4-.
methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (butyl) butanediamide; dichlorophenyl)benzyl) -2-oxo-5- (phenyl1)-2H-1, benzodiazepin-3 -yl]1 -2 (cyciopentylmethyl) -3 (butyl) butanediamide; (2R,3S) Nl-(l, 3 4 ,5-tetrahydro-1(3(3choro.4fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H4-1, benzodiazepin-3 -yl 1 -2 (cyclopentylmethyl) -3 (butyl) butanediamide; (2R,3S) 5-tetrahydro-l- (benzophenon-3-y)-2-oxo- (phenyl) -2H-1, 5-benzodia'zepin-3-yl] -2- (cyclopentylniethyl) -3 (butyl) -butanediarnide; and (2R,3S) Nl-(i.
3 4 ,5-tetrahydro1.(3-(2-.naphthyl)benzy1)- 2 (phenyl) -2H-1, 5-benzodiazepin '-3-ylJ -2- (cyclopentylmethyl) -3 (butyl) -butanedianide; (phenyl) -2H-1, 5-benzodiazepin-3-ylJ (2-methyipropyl) 3- (propyl) -butanediamide; (2R,3S) Nl-[l.
3 4 ,S-tetrahydo.1..(phenethy)-2-oxo-5S (pheriyl) -2H-1, 5-benzodiazepin-3-yl] 2 -(2-methylpropyl).
3 -(propyl)-butanediamide; (2R,3S) Nl-[lI 3 4 ,5-tetrahydro-l1((4.fluorophenyl)methyl)- (phenyl) -2H-1, 5-benzodiazepin-3-y1I (2methyipropyl) (propyl) -butanediamide; (2R,3S) Nl-[l, 3 4 ,5-tetrahydro.l1..(cycopropymethy)- 2 (phenyl) -2H-1, S-benzodiazepin-3-ylI (2methyipropyl) (propyl) -butanediamide; (2R,3S) Nl-(1,3,4, S-tetrahydro-l- (cyclobutylmethyl) -2-oxo- (phenyl) -2H-1. 5-benzodiazepin-3-y1I (2methyipropyl) (propyl) -butanedjamide; (2R,3S) Nl[,,,-erhdol(ylpnymty)2 (phenyl) -2H-1, 5-benzodiazepin-3-yl) (2methyipropyl) (propyl) -butanediamide; (2R,3S) Nl-[l.
3 4 ,5-tetrahydro..l.(cycoheylmethy1)- 2 -oxo- 5- (phenyl)-2H-1, 5-benzodiazepin-3-yl] (2mnethyipropyl) (propyl) -butanediamide; (2R,3S) Nl-[l.
3 4 ,S-tetrahydro-l1(cyclopropylethy1)- 2 -oxo- (phenyl) -2H-1, 5-benzodiazepin-3-ylj (2inethyipropyl) (propyl) -butanediamide; (2R,3S) Nl-fl.
3 4 ,5-tetrahydro-1-(cyclobutylethyl)-2-ox0- (pheriyl) -2H-1, S-benzodiazepin-3-ylJ (2methyipropyl) (propyl) -butanediamide;- (2R,3S) Nl-[l.
3 4 ,5-tetrahydro1l(cyclopentylethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) (propyl) -butanediamide; (2R,3S) Nl[,,,-erhdol(ylhxlty)2oo (phenyl) -2H-1, S-benzodiazepin-3-ylj (2methyipropyl) (propyl) -butanediamide; (2R,3S) Nl-[, 3 ,4,5tetrahydro.1..(benzy1).2..oxoS-5 (phenyl)-2H-1. 5-benzodiazepin.3-y1] (2-methyipropyl) 3- (allyl) -butanediamide; -96- (2R,3S) N1-fl,3,4,5-tetrahydro--(phenethyl)-2-oxo-..
(phenyl) -2H-1. 5-benzodiazepin-3-yl] (2-methylpropyl) 3- (allyl) -butanediamide; (2R,3S) Nl-(l, 3 .,4,5-tetrahydro-l-((4-fuoropheny)methy).
2-oxo-5-(pheny1)-2H-1,S-benzodiazepin-3-yl1]2-2methyipropyl) -3-(allyl) -butanediamide; (2R,3S) Nl-[l.
3 ,4,5-tetrahydo--(cyclopropylmethyl)2- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) (allyl) -butanedianide; (2R,3S) Nl-[l, 3 ,4,5-tetrahydro-l-(cyclobutylmethyl)-2oxo-.
(phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) (allyl) -butanediamide;- (2R,3S) Nl-(1,3,4,5-tetrahydro--(cycopentymethy)2- (phenyl) -2H-1, 5-benzodiazepii-3'-yi] (2rethylpropyl) (allyl) -butan~diamide;' (2R.,3S) Nl-(1,3,4,5-tetrahydro--(cycloheylmethyl)2oxo- (phenyl) -2H-1. 5-benzodiazepin-3-yl] (2methyipropyl) Cal lyl) -butanediamide; 5- (phenyl) -2H-1. 5-benzodiazepin-3-ylJ (2inethyipropyl) (allyl) -butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-(cyclobutyethy)-2oxo- (phenyl) -2H-1. 5-benzodiazepin-3-yl] (2methyipropyl) (allyl) -butanediamide; (2R.3S) Nl-[l,3,4,S-tetrahydro--(cycopentyethy)2-oxo- (phenyl) -2H-1. 5-benzodiazepin-3-ylJ (2methyipropyl) (allyl) -butariediamide;- (2R,3S) Nl-[l,3,4,5-tetr6Lh3rdro-1-(cyclohexylethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2iethyipropyl) (allyl) -butanediamide; (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) Nl-[l, 3 4 ,-tetrahydro--(phenet hy) 2 (phenyl) -2H-1. S-benzodiazepin-3-ylI (2-methyipropyl) 3- (butyl) -butanediamide; -97- (2R,3S) NI-[l.
3 4 ,5-tetrahydro-l.((4-fluorophenyl)methyl)- 2 -oxo-5-(phenyl)-2H-1,5benzodiazepin3.y1] methyipropyl) (butyl) -butanediamnide;..
(2R,3S) Nl-[l.
3 ,4,5-tetrahydro-l-(cqyclopropylrmethy-)j 2 oxo-5- (phenyl) -2H-l, 5-benzodiazepin-3-yl) (2methyipropyl) (butyl) -butariediamide; (2R.,3S) Nl-[l.
3 ,4,5-tetrahydo-1-(cyclobutymethy).2-.oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2methyipropyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro..i(cyclopentylmethyl)- 2 (phenylj -2H-l, 5-benzodiazepin-:3-yl] (2- 'nethyipropyl) (butyl) -butanediamide; (2R,3S) Ni-[l, 3 4 ,5-tetrahydro1l(cyclohexy1methy).2-oxo- (phenyl) 5-benzodiazepin-3-yl) (2methyipropyl) (butyl) -butanediamnide; (2R,3S) Nl-[l.
3 4 ,5-tetrahydro--(cycopropyethyl)2-.oxo- (phenyl) -2H-1, 5-benzodiazepin-3-ylJ (2methyipropyl) (butyl) -butanediamide; (2R,3S) Nl-[l, 3 ,4,5-tetrahydro-l1(cycobutyethyl)2oxo- 5- (phenyl) -2H-l, 5-benzodiazepin-3-ylj (2methyipropyl) (butyl) -butanediamide; (2R,3S) Nl-(l.
3 ,4,5-tetrahydro.l-(cyclopentyethyl).2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-ylJ (2methyipropyl) (butyl) -butanediamide; and (2R,3S) Nl-[lI 3 4 ,5-tetrahydro-l(cycohexyehy..2-.oxo- (phenyl)-2H-1, S-benzodiazepin-3-yl] (2- Inethyipropyl) (butyl) -butanediamide.
[181 In another even more preferred embodiment the present invention provides compounds of Formula selected from: (2R,3S) Ni-I 3 S)-hexahydro--(3,3-diphenylpropyl).2oxo- 1H-azepin-3-ylJ -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanediamide; (2R,3s) Nl-( (3S)-hexahydro--(3-phenoybenzyl)2oxo..Hazepin-3-yl] -N4- (hydroxy) (2-methyipropyl) (propyl) butanedianide; -98- (2R,3S) Ni-f (3S)-hexahydro-l1-(phenyl)-2-oxo-1R-azepin-3yi] -N4- (hydroxy) (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni-f (35)-hexahydro-l-*(3-phenox-ybenzyl) -2-oxo-iHazepin-3-yl) -N4- (methyl) (2-methyipropyl)-3- (propyl)butanedianide; (2R,3S) Ni-f (3S)-hexahydro-l-(3-phenoxybenzyl)-2-oxo-lHazepin-3-ylJ -N4- (methoxy) -N4- (methyl) (2methyipropyl) (propyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-lHazepin-3-yl] -N4- (methd'xy) (2-methyipropyl) -3 (pr'opyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-iHazepin-3-yl) -N4- (amino) (2-methylpropyl)-3- (propyl) butanediamide; (2R,3S) Nl-E(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1Hazepin-3-yl) -N4- (hydroxy) (2-methyipropyl) (ailyl) butanediaxnide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(2,4dichlorophenyl) benzyl) -2-oxo-lH-azepin-3-yl) -N4- (hydroxy) (2-methyipropyl) (propyl) -butanediamide; (2R,3S) Nl-[(3S)-hexahydro-i-(3-(4-fluorophenyl)benzyl)-2oxo-iH-azepin-3-yl] -N4- (hydroxy) (2-iethyipropyl) -3- (propyl) -butanedianide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(4-methyiphenyl)*benzyi)-2oxo- 1H-azepin- 3-yi] -N4 (hydroxy) 2- (2-methyipropyl) -3 (propyl) -butanediamide; (2R,3S) Nl-fI(3S)-hexahydro-1-(3-(4-methoxyphenyl)benzyl)- 2-oxo-iH-azepin-3-yl] -N4- (hydroxy) (2-methyipropyl) -3- (propyl)-butanediamide; (2R,3S) Ni-f (3S)-hexahydro-i-(3-(3-methylphenyl)benzyi)-2oxo-iH-azepin-3-yi] -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanedamnide; (2R,3S) Ni-f (3S)-hexahydro-i-(3-(3-chloro-4f luorophenyl )benzyl) -2-oxo-1H-azepin-3-yl]-N4- (hydroxy) 2- (2-methyipropyl) (propyl) -butanedianide; -99- (2R,3S) N1-[(3S)-hexahydro-1-(3-(4trifluoromethylphenyl)benzyi) 2 -oxo-1H-azepin-3-yll -N4- (hydroxy) (2-methyipropyl) (propyl) -butanediamide; (2R,3S) Ni-(( 3 S)-hexahydro-1-(3-(3-methoxyphenyl)benzyl)- 2-oxo-1H-azepin-3-ylJ -N4- (hydroxy) (2-methyipropyl)-3.
(propyl) -butanedianide; (2R,3S) Nl-[( 3 S)-hexahydro-i-(3-(3-fluorophenyl)benzyl).
oxo-lH-azepin-3-yl] -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanediamide; (2R,3S) Ni-(( 3 S)-hexahydro-i-(3-(2-rnethoxyphenyl)benzy1)- 2-oxo-1H-azepin-3-yl -N4- (hydroxcy) (2-methyipropyl) (propyl) -butanediamide; (2R,3S) Nl(3)hxhdol(-2-ahhlbny)2oo 1H-azepin-3-yl] -N4-(hydroxy) (2-methyipropyl) -3is (propyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1- (3-phenoxybenzyl) -2-oxo-1Hazepin-3-ylI -N4- (butyl) (2-methyipropyl) (propyl) butanedianide; (2R, 3S) NI-f (3S)-hexahydro-1- (3-phenoxybenzyl) -2-oxo-1Hazepin-3-yl] -N4- (2-furylznethyl) (2-nethyipropyl) -3- (propyl) -butanediaiide; (2R, 3S) Ni-f (3S) -hexahydro-1- (3-phenoxybenzyl.) -2-oxo-1Hazepin-3-ylJ -N4- (cyclopentyl) (2-rnethylpropyl) -3- (propyl) -butanediamide; and (2R,3S) N1-((3S)-hexahydro--(3poxybenzy azepin-3-yl) -N4- (cinnamyl) (2-methylpropyl) (propyl) -butanediamide.
In another preferred embodiment of the present invention, Q is N(OH)H.
In another preferred embodiment of the present invention, Q is NH 2 In another preferred embodiment.
R
3 is R 4 -100-
R
3 a is H, methyl, ethyl, propyl, or butyl;
R
4 is Cl-C 6 alkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl
R
5 is CI-C 6 alkyl, C 2
-C
6 alkeiyl, C 2
C
6 alkyxiyl
R
5 a is H, methyl, ethyl, propyl, or butyL;- and the total number of carbon atoms in R 3 RJ8, R 5 and R 5 a equals seven or more.
In another preferred embodiment
R
3 is R 4
R
3 a is Hl;
R
4 is Cl-C 4 alkyl substituted with 1-2 R 4 a, 0a~, at each occurrence, is independently selected from
C
3
-C
6 cycloalkyl substituted with -0-3 R4b, phenyl substituted with 0-3 R 4 b, or to 6 membered heterocycle substituted with 0-3 R4b.
R4b, at each occurrence, is independently 'selected from H, OH, Cl, F, NR 1 5
R
16
CF
3 acetyl, SCH 3 S(=0)CH 3 S(=0)2CH3, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C 2 haloalkyl, and Cl-C 2 haloalkoxy;
R
5 is C 2
-C
4 alkyl substituted with 0-3 R515;
C
2
-C
4 alkenyl substituted with 0-2 R~b; or
C
2
-C
4 alkynyl substituted with 0-2 R~b; at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl., CF 3
OR
14
=Q;
C
3 -c 6 cycloalkyl. substituted with 0-2 RSc;phenyl substituted with 0-3 RSc; or -101to 6 membered heterocycle substituted with 0-2 RSc.
and RSc, at each occurrence, is independently selected from H, OH, Cl, F, NR 15
R
16 CF3, ac etyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C 2 haloalkyl, and CI-C 2 haloalkoxy.
In another preferred embodiment
R
3 is R 4 R~a is H;
R
4 is C 2
-C
4 alkyl. substituted with 0-2 R 4 a,
C
2
-C
4 alkenyl. substituted with 0-2 R 4 a,
C
2
-C
4 alkynyl substituted with 0-2 R 4 a,
R
4 a, at each occurrence, is independently selected from is H, F, CF 3
C
3
-C
6 cycloalkyl substituted with 0-3 R4b, phenyl substituted with 0-3 R 4 b, or to 6 membered heterocycle substituted with 0-3 R4b; R4b, at each occurrence, is independently selected from H,.
OH, Cl, F, NR 1 5
R
16
CF
3 acetyl, SCH 3
S(=O)CH
3
S(=O)
2
CH
3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and C 1
-C
2 haloalkoxy;
R
5 is Cl-C 4 alkyl substituted with 1-2 R~b; R~b, at each occurrence, is independently selected from:
C
3
-C
6 cycloalkyl substituted with 0-2 RSc; phenyl substituted with 0-3 R 5 c; or 5 to 6 membered heterocycle substituted with 0-2 RSc; and -102at each occurrence, is independently selected from H, OH, Cl, F, NR 15
R
16
CF
3 acetyl, SCH 3 S(=O)CH3, S(=0)2CH3, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Ci-C 2 haloalkyl, and C 1
-C
2 haloalkoxy.
In another preferred embodiment W is -(CH2)p-; p is 1, 2, or 3; X is a bond; phenyl substituted with 0-2 RXb;
C
3
-C
6 cycloalkyl substituted with 0-2 RXb; or 5 to 6 membered heterocycle substituted with 0-2 RXb; wherein the 5 to 6 membered heterocycle does not contain an oxo or imino substitued ring atom; and RXb, at each occurrence, is independently selected from H, OH, Cl, F, wR 15
R
16
CF
3 acetyl, SCH3, S(=O)CH 3 S(=0) 2 CH3, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Ci-C 2 haloalkyl, and C 1
-C
2 haloalkoxy.
In another preferred embodiment when R 1 is H, R 2 is hydroxy, and R 1 1 is H, then X is not a bond.
It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to descibe additional even more preferred embodiments of the present invention.
In a second embodiment, the present invention provides a pharmaceutical composition comprising a compound of Formula and a pharmaceutically acceptable carrier.
In a third embodiment, the present invention provides a method for the treatment of neurological disorders associated with V-amyloid production comprising administering to a host -103in need of such treatment a therapeutically effective amount of a compound of Formula In a preferred embodiment the neurological disorder associated with P-amyloid production is Alzheimer's Disease.
In a fourth embodiment, the present-invention provides a method for the treatment of neurological disorders associated with P-amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a metalloprotease inhibitor which inhibits y-secretase activity.
In a preferred embodiment the neurological disorder associated with P-amyloid production is Alzheimer's Disease.
In a preferred embodiment, the metalloprotease inhibitor is a hydroxamic acid.
In a more preferred embodiment, the metalloprotease Sinhibitor is a hydroxamic acid with an IC 50 value of less than 10 pM in the AP immunoprecipitation assay.
In a fifth embodiment, the present invention provides a method for inhibiting y-secretase activity for the treatment of a physiological disorder associated with.inhibiting ysecretase activity comprising administering to a host in need of such inhibition a therapeutically effective amount of a compound of Formula that inhibits y-secretase activity.
In a preferred embodiment the physiological disorder associated with inhibiting y-secretase activity is Alzheimer's Disease.
In a sixth embodiment, the present invention provides a' compound of Formula for use in therapy.
-104- In a preferred embodiment the present invention provides a compound of Formula for use in-therapy-of Alzheimer's Disease.
In a seventh embodiment, the present invention provides for the use of a compound of Formula for the manufacture of a medicament for the treatment of Alzheimer's Disease.
DEFINITIONS
As used herein, the term "Ap" denotes the protein designated AP, -amyloid peptide, and sometimes P/A4, in the...
art. AP is an approximately 4.2 kilodalton (kD) protein of about 39 to 43 amino acids found in amyloid plaques, the walls of meningeal and parenchymal arterioles, small.
arteries, capillaries, and sometimes, venules. The isolation and sequence data for the first 28 amino acids are described in U.S. Pat. No 4,666,829. The 43 amino acid sequence is: 1 Asp Ala Glu Phe Arg His -p Ser Gly Tyr -11 Glu Val His His Gin Lys Leu Val Phe Phe 21 Ala Glu Asp Val Gly Ser Asn Lys Gly Ala 31 Ile Ile Gly Leu Met Val Gly Gly Val Val 41 Ile Ala Thr.
However, a skilled artisan knows that fragments generated by enzymatic degradation can result in loss of amino acids 1-10 and/or amino acids 39-43. Thus, an amimo acid sequence 1-43 represents the maximum sequence of amino acids for Ap peptide.
The term "APP", as used herein, refers to the protein known in the art as P amyloid precursor protein. This protein is the precursor for Ap and through the activity of "secretase" enzymes, as used herein, it is processed into Ap.
-105- Differing secretase enzymes, known in the art, have been designated 0 secretase, generating the N-terminus of Ap, a secretase cleaving around the 16/17 peptide bond in Ap, and "y secretases", as used herein, generating C-terminal Ap fragments ending at position 38, 39, 40, 41, 42, and 43 or generating C-terminal extended precursors which are subsequently truncated to the above polypeptides.
The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto then 2 hydrogens on the atom are replaced.
When any variable R 5 b) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R 5b then said group may optionally be substituted with up to two R5b groups and R 5b at each occurrence is selected independently from the definition of
R
5 b. Also, combinations of substituents and/or variables are -106permissible only if such combinations result in stable compounds.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein, "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; for example, "C 1
-C
6 alkyl" denotes alkyl having 1 to 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl. Preferred "alkyl" group, unless otherwise specified, is "C 1
-C
4 alkyl".
As used herein, "alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain.
Examples of "C 2 -Cs alkenyl" include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3butenyl, 3-methyl-2-butenyl, 2-pentenyl, 3-pentenyl, hexenyl, and the like.
As used herein, "alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more carbon-carbon triple bonds which may occur in any stable point along the chain, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3butynyl, and the like.
"Alkoxy" or "alkyloxy" represents an alkyl group as defined above with the indicated number'of carbon atoms attached through an oxygen bridge. "Examples of aTkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and -107s-pentoxy. Preferred alkoxy groups are methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, .s-butoxy, t-butoxy.
Similarly, "alkylthio" or "thioalkoxy" is represents an alkyl group as defined above with the indicated number of carbon S atoms attached through a sulphur bridge.
"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo. Unless otherwise specified, preferred halo is fluoro and chloro. "Counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
"Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having.
the specified number of carbon atoms, substituted with 1 or more halogen (for example -CvyF where v 1 to 3 and w 1 to Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, heptafluoropropyl, and heptachloropropyl. "Haloalkoxy" is intended to mean a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge; for example trifluoromethoxy, pentafluoroethoxy, 2,2,2-trifluoroethoxy, and the like. "Halothioalkoxy" is intended to mean a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.
"Cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms. For example, "C 3
-C
6 cycloalkyl" denotes such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
As used herein, "carbocycle" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, -108adamantyl, or tetrahydronaphthyl (tetralin). Preferred "carbocycle" are cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
As used herein, the term "heterocycle" or "heterocyclic ringm is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3 or 4 heteroatoms, preferably 1, 2, or 3 heteroatoms, independently selected from the group consisting of N, O and S and including any bicyclic groupin which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized.
It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofurol2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, -109morpholinyl. naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2, 3-oxadiazolyl, 1,2,4-oxadiazolyl, 1.2, 5-oxadiazolyl. 1,3, 4-oxadi-azolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl,.
pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1, 2, 5-thiadiazinyl, 1,2, 3-thiadiazolyl, 1,2,4-thiadiazolyl, 1, 2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred 5 to 10 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, pyrazolyl, inidazolyl, oxazolyl, isoxazolyl, tetrazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, isoxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyli benzoxazolinyl, quinolinyl, and isoquinolinyl. Preferred 5 to 6 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, tetrazolyl; more preferred 5 to 6 memnbered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, and tetrazolyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
As used herein, the term "aryl", "C 6 -CIO aryl' or aromatic residue, is intended to mean an aromatic moiety containing the specified number of carbon atoms; for example -110phenyl, pyridinyl or naphthyl. Unless otherwise specified, "aryl" may be unsubstituted or substituted with 0 to 3 groups selected from H, OH, OCH 3 Cl, F, Br, I, CN, NO 2
NH
2
N(CH
3
N(CH
3 2
CF
3
OCF
3
C(=O)CH
3
SCH
3
S(=O)CH
3 S(=0) 2
CH
3
CH
3
CH
2
CH
3
CO
2 H, and CO 2
CH
3 The phrase "additional lactam carbons", as used herein, is intended to denote the number of optional carbon atoms in the lactam ring B of Formula Formula
B
(I represents the lactam ring B of Formula Additional lactam carbons are carbons in lactam:ring B other than the' carbons numbered 2 and 3 in the backbone of the formula. The additional lactam carbons may be optionally replaced by a heteroatom selected from oxygen, nitrogen and sulfur. Lactam ring B contains 1, 2, 3, 4, 5, 6 or 7 optional carbons, wherein one optional carbon may optionally be replaced by a heteroatom, such that the total number of members of lactam ring B, including atoms numbered 1, 2 and 3 in the backbone, does not exceed 10. It is preferred that the total number of atoms of lactam ring B is 6, 7 or 8; it is more preferred that the total number of atoms of lactam ring B is seven.
Examples of lactam ring B include: 0 o o N N N R" N Rll O R" RiO B1 B2 B3 -111- 0
N
Rt" B4 0
N
B7
NO
R"
B6 0
R
10 0 Bil 810 B12 -4
N-
R
10 B13 B14 0 B16 -112but are not intended to limit the invention. Preferred examples of lactam ring B are Bl, B2, B5, B6, B8, B9, 813, and B16; more preferred examples of lactam ri'ig B are Bl, B6, B8, B9, and B13. Preferred examples of substituent R 10 or
R
11 on lactam B are methyl, e-thyl, phtnyl, 4-fluorophenyl, 4chlorophenyl, 4-trifluorophenyl, (4-fluorophenyl) methyl, (4chlorophenyl)methyl, and (4-trifluorophenyl)methyl.
The compounds herein described may have asymmetric centers. One enantiomer of a compound of Formula may display superior chemical activity over the opposite enantiomer. For example carbon 3 of lactam ring B Formula may exist in either an S or R-configuration: Thus, an R or S configuration at carbon 3 in Formula is considered part of the invention. An example of such configuration includes, 0 5 H 0
N,
H
2 N N kN .W Y
R
3 0 and 0 0
H
2 NN
R
3 0 but is not intended to be limited to this example of ring B.
When required, separation of the racemic material can be achieved by methods known in the art. Additionally, the carbon atoms to which R 3 and R 5 are attached may describe chiral carbons which may display superior chemical activity over the opposite enantiomer. For example, where R 3 and R are not H, then the configuration of the two centers may be' described as (2R,3R), (2S,3R), or (2S,3S). All configurations are considered part of the invention; however, -113the (2R,3S) and the (2S,3R) are preferred and the (2R,3S) is more preferred.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are,owithin the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response,. or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, -114ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
"Prodrugs"are intended to include any covalently bonded carriers which release the active parent'drug-according to formula in vivo when such prodrug is administered to a mammalian subject. Prodrugs of .a compound-of formula are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula is administered to a mammalian subject, -cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula and the like.
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
SYNTHESIS
The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known- in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.
-115- The novel compounds of this invention may be prepared using the reactions and techniques described in this section.
The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art.: It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.
Methods for the synthesis of succinylamino lactams are known in the art and are disclosed in a number of references including PCT publication number WO 96/29313, which is hereby incorporated.by reference.
Disubstituted succinate derivatives can be prepared by a number of known procedures. The procedure of Evans A.
Evans et al, Org. Synth. 86, p83 (1990)).is outlined in Scheme 1 where acylation of..an oxazolidinone with an acylating agent such as an acid chloride provides structures 1. Alkylation to form 2 followed by cleavage of the chiral auxiliary and subsequent alkylation of the dianion of the carboxylic acid 1 provides a variety of disubstituted succinates which can be separated and incorporated into structures of Formula by those skilled in the art.
Additional examples are found in P. Becket, M. J. Crimmin, M.
H. Davis, Z. Spavold, Synlett, (1993), 137-138, incorporated herein by reference.
-116- Scheme 1 0 N LDA 0L N O COOf-u OH, H20 2 Br- Ot-Bu
H
2 0, THF 0 0 R 3 HO 'COOt-Bu 2 LDA HO' COOt-Bu
R
3 -X
-R.
3 4 Diastereomerically pure succinate derivatives can: be accessed using the chemistry outlined below, adapted from P.
Becket, M. J. Crimmin, M. H. Davis, Z. Spavold, Synlett, (1993), 137-138 incorporated herein by reference. This reference provides the synthesis below to obtain compound g.
Compound .1 is used as an intermediate and is prepared from 9 by hydrogenation of the allyl group followed by coupling of 9-fluorenemethanol under standard conditions using DCC and DMAP in CH 2 C1 2 Deprotection of the tert-butyl ester is accomplished by treatment with 50% trifluoroacetic acid.
Additional methods useful for the preparation of succinate derivatives are known by those skilled:in the art.
Such references include, McClure and Axt, Bioorganic Medicinal Chemistry Letters, 8 (1998) 143-146; Jacobson and Reddy, Tetrahedron Letters, Vol 37, No. 46, 8263-8266 (1996); Pratt et al., SYNLETT, May 1998, p. 531.- -117scheme 2 0N LDA Br"-hf t-BU 0 0 0 9 0 AN COOtBu LiOH, H 2 0 2
H
2 0, THF 0 2 LDA HO Coot-BU AllyI-Br 0 HO COOt-Bu 8 2 LDA, then methanol quench at -78 *C HO I" COO t-BU 'H 2 go 0OK 1. DCC, DMAP HO COOt-Bu FmOH, DCM 2. 50% TFA, 2h 1- 1-1 scheme A variety of compounds of Formula can be prepared by methods described in Scheme 4. The protected a-amine I of the a-amino-E-caprolactamf can be prepared by methods well known in the literature for amino protecting groups as discussed in Theodora W. Greene's book "Protective Groups in Organic Synthesis", like N-Boc using di-t-butyldicdrbonate in" an appropriate solvent like DM50. A sulfur atom can be introduced into the ring providing L-aX-amino-?,thio-ccaprolactam according to the procedure in S. A. Ahmed et al, FEBS Letters, (1984), vol. 174, pages 76-9 (Scheme One skilled in the art can extend this methodology to the synthesis of P-amino and oxygen containing rings by analogy.
The sulfur-containing molecules can also be oxidized to the sulfoxide and sulf one by methods known to one skil-led, in the art.
-118- Scheme 3 0 H2N 'OCH H2N H2N
L
J= O, S, NRo 1
L=H
The lactam nitrogen of compound 13 can be alkylated by generating the anion with bases such as LDA, lithium bis(trimethylsilyl)amide or sodium hydride in solvents like THF, with or without cosolvents such as DMPU or HMPA and reacting this with a variety of groups containing leaving groups like bromide, iodide, mesylate or tosylate.
Alkylating agents such as a-bromo amides, ketones and acids can be prepared by a number of literature methods including halogenation of amino acids by diazotization or are commercially available. Other suitable alkylating agents such as alkyl, allylic and benzylic halides can be formed form a variety of precursors such as free-radical addition of halides or activation of alcohols, and other chemistries known to those skilled in the art. For discussion of these types of reactions, see Carey, F.A. and Sundberg, R. J., Advanced Organic Chemistry, Part A, New York: Plenum Press, 1990, pages 304-305, 342-347, 695-698.
The N-Boc protecting group can be removed by any number of methods well known in the literature like TFA in methylene chloride to give the compound 15. The amine 15 can be coupled to an appropriately substituted carboxylic acid or acid chloride by methods well described in the literature for making amide bonds, like TBTU in DMF with a base like NMM to give the elaborated compound 16. Compounds 16 can be alkylated using standard bases like LDA, NaH, or NaHMDS to deprotonate the amide followed by addition of an alkylating agent with an appropriate leaving group like halide, mesylate, or triflate in an appropriate solvent to provide compounds 17 with an R 6 substituent. The t-butyl ester is -119then removed by treatment with TFA in methylene chloride to give the carboxylic acid 17.
Scheme 4
(BOC)
2 0
H
2 N NH DMSO
O
12 SLiHMDS 0 NH DMPU,.THF o W-X-V-Z-x" 0
N
)O
W-X-Y
Z
IA
TFA
CHCI
2 S R 3
NMM
:ON-
TBTU
"O N H W-X- Y-Z 0 DMF 16 (Optional alkylation to introduce R4)
R
3 O >OOH HzN- W-X-Y-Z TFA I CH 2 C1 2
R
3 0 HO I N w) 0 R 5 W X Y2
NMM
BOP
DMF
R'R
2
NH
R
1
R
3 0 R2 N O Rs
R
6
OWXYZ
17 The final compounds 18 were prepared by treating the activated carboxylic acid of 17 with an appropriately substituted amine. For instance, activation of the carboxylic acid with HATU (0-(7-azabenzotriazol-l-yl)- 1,1,3,3,-tetramethyluronium hexafluorophosphate) or PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate) or other coupling agents known to those skilled in the art allows condensation with ammonia to form primary amides. Similarly, condensation of the activated acid with hydroxylamine hydrochloride provides the hydroxamic acid, or reaction with a primary or secondary amine provides the substituted amine derivative. Activation of the acid with PyBrOP (bromo-tris-pyrrolidino-phosphonium hexafluorophosphate) followed by addition of an alcohol and 4-dimethylaminopyridine allows formation of the ester directly. For additional acylation reactions see for example -120- Carey, F.A. and Sundberg, R. Advanced Organic Chemistry, Part A, New York: Plenum Press, 1990, pages 475-479.
Additional Examples of compounds of Formula can be prepared as shown in Scheme 5. A suitable resin for solid phase synthesis such as Fmoc (Fluorenylmethylcarbonyl)protected hydroxylamine bound to polystyrene beads can be purchased from Novabiochem, Inc. Deprotection of the Fmoc group under standard conditions using 20% piperidine in DMF provides trityl-linked hydroxylamine resin. Coupling of a fluorenylmethyl-protected succinic acid derivative such as with a coupling agent such as HATU in a suitable solvent like DMF or N-methylpyrrolidinone provides the support-bound hydroxamate 21. The Fluorenylmethyl ester can be removed using 20% piperidine in DMF to provide the free carboxylic acid which can be coupled to amines like the caprolactam 22 (which is available using chemistry outlined"in Scheme 4) using PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate) and a suitable base like DIEA in DMF or NMP. The support-bound intermediate 23 can then be elaborated to biaryl structures of the type 24 using typical Suzuki coupling conditions employing a catalyst such as Palladium complexes like tetrakis(triphenylphosphine) palladium with 2M aqueous sodium carbonate as a base in a suitable solvent like THF or DME and an excess of a boronic acid: The final compounds are liberated from the support employing dilute trifluoroacetic acid in CH 2
CL
2 and purified by conventional chromatography.
-121scheme S Ph _~ONHFmoc 20% piperidine
QM
P h 0-NH 2 OFm HO :4DIEA 24 r 2. PyBOPIDIEA H 0
TFA-H
2
N.)I
(HO)2B-~ Pd(PPh 3 4
THF
2 MNa 2
CO
3 70 OC
%TWA
I-OHN'
CH
2
CI
2 Q polystyrene beads General procedure for solid-phase synthesis according to Scheme Resin 20 of Scheme 5: Fmoc-protected resin 19 g, 0.78 mmol/g, 1.56 mmol) is purchased from Novabiochem and swelled in 20 ml of CH 2 C1 2 for -1 hour. The CH 2 Cl 2 is remtoved and the resin is then treated with 25% v/v piperidine in DMF (8 niL) and allowed to shake slowly for 16 h. The solvent was removed by filtration and the resin was shaken with an additional 8 niL of 25% v/v piperidine in DMF for 2 h at rt.
The solvents were removed by filtration, and the resin 20 was rinsed 3 x with 20 niL of DMF, 3 x with 20 niL of methanol, -and 3 x with 20 mL~ of CH2C1 2 and dried in vacuo.
Succinate 10 of Scheme 2: Succinate 9 is prepared according to the literature procedure Becket, M. J.
Crimmin, M. HA. Davis, Z. Spavold, Synlett, (1993), 137-138).
-122- Succinate 9 (17.8 g, 66 mmol) is dissolved in 250 mL of ethyl acetate and placed in a Parr shaker bottle. To the solution is added 890 mg of 5% palladium on carbon, and the bottle is pressurized to 40 psi with hydrogen gas and shaken for 2.5 h at rt. The hydrogen is removed and the palladium catalyst is removed by filtration through a pad of celite. Concentration of the ethyl acetate solution provides 17.5 g of succinate No further purification is necessary. MS (M- 271.
Succinate 21 of Scheme-5: Succinate 10 (6.3 g,.23.1 mmol) is dissolved in 125 mL of CH 2 C1 2 and-4.8 g (23.3 mmol) of dicyclohexylcarbodiimide is added. The solution is stirred at rt for 30 min and then 4.6 g (23.4 mmol) of 9fluorenemethanol is addedfollowed by 122 mg (1 mmol) of 4dimethylaminopyridine. After 5 h of stirring at rt, the reaction solution was diluted with an additional 100 mL of CH2CI 2 and filtered through a pad of celite to remove precipitated dicyclohexylurea. The solution was then washed 3 x with 50 mL of a 1N HC1 solution, 3 x with 50 mL of a saturated sodium bicarbonate solution, and 2 x with 50 mL of brine. The crude product was dried over MgSO 4 and soncentrated onto 15 g of silica gel. Chromatography eluting with a gradient of 2.5% to 5% ethyl acetate/hexanes provided 6.4 g of the diester as an oil. The purified diester (6.4 g 14.2 mmol) is then dissolved in 25 mL of CH 2 C1 2 mL of trifluoroacetic acid is added, and the reaction solution is stirred at rt for 2 h. The reaction solution is directly concentrated in vacuo to an oil which is then redissolved in 25 mL of toluene and reconcentrated, followed by drying in vacuo to provide 6.3 g of the desired succinate 9 as an oil which solidifies on standing. MS .471, (M+2Na)* 439.
o Caprolactam 23 of Scheme 5: Boc-caprolactam 14 g 21.9 mmol) is dissolved in 60 mL of THF and chilled to -78 0 C. To the chilled solution is added 24 mL of a 1.0 M solution of lithium bis(trimethylsilyl)amide in THF, and the solution was brounght to 0°C and stirred for 15 min. To the anion solution was added 6.5 g (22 mmol) of 3-iodobenzyl -123bromide (Aldrich) and the the solution was allowed to warm to rt and stirred for 18 h. The reaction solution was diluted with 50 mL of water and extracted 3x with ethyl acetate. The combined organic layers were dried over MgSO 4 and concentrated in vacuo. The crude product was purified by chromatography eluting with a gradient of 5-20% ethyl acetate/hexanes to afford 7.0 g of the title compound as a white solid. MS 467.
Resin 22 of Scheme 5: Resin 22 (2.0 g, 0.78 mmol/g, 1.56 mmol) was swollen in 3 mL of DMF. In a separate flask, 1.85 g (4.68 mmol) of succinate 21 was dissolved in 3 mL.of DMF and 2.5 mL of N,N-diisopropylethylamine (14 mmol) wsa added, followed by 1.81 g (4.68 mmol) of HATU. The solution containing the active ester was added to the slurried resin and the reaction suspension was slowly shaken for 18 h. The resin was then washed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH 2 C1 2 Loading of the resin was determined by Fmoc quantitation to be 0.25 mmol/g, see Reddy, M. Voelker, P.J. Int. J. Pept. Protein Res.
1998, 1, 345-348.
Resin 24 of Scheme 5: Resin 22 (2.0 g 0.25 mmol/g, 0.5 mmol) was suspended in 10 mL of 25% piperidine in DMF. The suspended resin was shaken for 30 min at rt, and then the resin was washed 3 x with 20 mL of DMF, 3 x with mL of methanol, and 3 x with 20 mL of CH 2 C1 2 Deprotected resin (1.0 g, 0.25 mmol) was swollen in 2 mL of DMF. To the slurry was added 650 mg (1.25.mmol) of PyBOP and 217 mL (1.25 mmol) of DIEA. Separately, 443 mg (0.97 mmol) of caprolac.tam 23 was dissolved in 2 mL of DMF and 436 mL (2.5 mmol) of DIEA was added. The caprolactam solution was added to the resin slurry and the resin was mixed for 18 h at rt. The solvents were then removed and the coupling was repeated, with shaking at rt for 6 h. The resin was then washed 3 x with 10 mL of DMF, 3 x with 10 mL of methanol, and 3 x with 10 mL of
CH
2 C1 2 Products 25 of Scheme 5: A 70 mg (17.5 mmol) portion of resin 24 was suspended in 1 mL of THF in a screwcap vial. To the slurry was added a boronic acid (0.15 -124mmol), 150 mL of a 2 M solution of sodium carbonate, and mg (13 mmol) of tetrakis(triphenylphosphine)palladium. The vial was tightly closed and heated to 60 0 C for 16 h using a dry heater on a shaker table. The solvents were then removed by filtration and the resin was washed 3 x with THF (2 mL), 3 x with methanol (2 mL), 3 x with water, and 3 x with CH 2 C12.
The resins were then placed in a glass vial and cleaved with 1 mL of 5% trifluoroacetic acid in CH 2 C1 2 for 30 min. The solution ws filtered off and the resin was washed with an additional 2 mL of CH 2 C12 and the combined filtrates were evaporated to dryness to yield the crude products 25. The products were purified by chromatography eluting with 10-100%.
ethyl acetate in hexanes to yield 13.0 to 6.0 mg (14-60%) of the final products.
Additional Examples of compounds of Formula can be prepared as shown in Scheme 6. A suitable resin for solid phase synthesis such as Fmoc (Fluorenylmethylcarbonyl)protected peptide amide linker (PAL)-derivatized polystyrene beads can be purchased from Perkin Elmer Biosystems, Inc.
Deprotection of the Fmoc group under standard conditions using 20% piperidine in DMF provides the free benzylamine.
Coupling of a succinic acid derivative such as 28 (which is available using chemistry outlined in Scheme 4) with a coupling agent such as HATU in a suitable solvent like DMF or N-methylpyrrolidinone provides the support-bound amide 29.
The support-bound intermediate 29 can then be elaborated to biaryl structures of the type 24 using typical Suzuki coupling conditions employing a catalyst such as Palladium complexes like tetrakis(triphenylphosphine)-palladium with 2M aqueous sodium carbonate as a base in a suitable solvent like THF or DME and an excess of a boronic acid. The final compounds are liberated from the support employing trifluoroacetic acid in CH 2 C1 2 and can be purified by conventional chromatography or preparative HPLC.
-125scheme 6
OCH
3
OCH
3 0 i NHFmoc 20% piperidine OCH3 OCH3 "PALU resin HO.
N~IPA
o O~~IEA OL7- (HO)2B-~ 0 10R12 %TFA H 2 N -'A Pd(PPh3)4, THF CH 2 Cl 2 2 h 0 2 M NagCO 3 =polytrene beads General procedure f or solid-phase synthesis according to Scheme 6 Resin 27' of Scheme 6: Fmoc-protected PAL resin 26 (0.80 g, 0.50 mnmol/g, 0.40 mmol) is purchased from Advanced Chemtech and swelled in 20 ml of CH 2 Cl 2 for 1 hour. The
CH
2 C1 2 is removed and the resin is then treated with 25% v/v piperidine in DMF (6 rnL) and allowed to shake slowly for 1 h.
The solvents were removed by filtration; and the resin 27 wasrinsed 3 x with 20 mL of DM', 3 x with 20 znL of methanol, and 3 x: with 20 mL of CH 2 Cl 2 and dried in vacuo.
Acid 28 of Scheme 6: To a solution of 0.100 g (367 mmol) of succinate 10 dissolved in 2. 0 m.L of dry DMF was added 0.120 mL (1.10 mnmol) of N-methylmorpholine. A second solution containing 0.139 g (0.403 mmol) of caprolactan 2- of Scheme 5 dissolved in 2.0 niL of DM1' was then added. To the mixed solution was added 22 9 mg (0.440 mmrol) of PyBop and the reaction solution was stirred for 16 h at rt. The reaction solution was diluted with water (20 miL) and extracted 3 x with 100 niL of ethyl acetate. The combined organic layers -126were dried with Na 2
SO
4 and concentrated under reduced pressure. The resulting oil was purified by chromatography eluting with a gradient of 5-20%'ethyl-acetate in hexanes to provide 0.195 g (0.360 mmol, 98%) of the tert-butyl- ester of Acid 28 (MS M+Na= 621). The purified ester (0.195 g, 0.360 mmol) was dissolved in 10 mL of-25% trifluoroacetic acid in
CH
2 C1 2 and stirred for 2 h at rt. The solvents were removed under reduced pressure and the acid was Pedissolved-in 5 mL of toluene and reconcentrated 2 x to remove residual TFA.
The crude acid was found to be pure by 1 H NMR and was-used in Scheme 6 without further purification.
Resin 29 of Scheme 6. Resin 27 (800 mg, 0.40 mmol) was solvated in 4.0 mL of dry DMF and and 0.63 mL (3.6 mmol) of diisopropylethylamine was addedfollowed by a solution of Acid 28 dissolved in 4 mL of DMF. To the slurry was then added 0.465 g (1.2 mmol) of HATU and the slurry was shaken for 26 h at rt. The solvents were removed by filtration, and the resin 29 was rinsed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH 2 C1 2 and dried in vacuo.
Products 30 of Scheme 6: A 75 mg (0.38 mmol/g, 28.8 pmuol) portion of resin 24 was suspended in 1 mL of THF in a screw-cap vial. To the slurry was added a boronic acid (0.33 mmol), 150 mL of a 2 M solution of sodium carbonate, and mg (13 mmol) of tetrakis(triphenylphosphine)palladium. The vial was tightly closed and heated to 60 0 C for 16 h using a dry heater on a shaker table. The solvents were then removed by filtration and the resin was washed 3 x with THF (2 mL), 3 x with methanol (2 mL), 3 x with water, and 3 x with CH 2 C1 2 The resins were then placed in a glass vial and cleaved with 1 mL of 5% trifluoroacetic acid in CH2C12 for 2 h. The solution was filtered off and the resin was washed with an additional 2 mL of CH 2 C12 and the combined filtrates were evaporated to dryness to yield the crude products 25. The products were purified by chromatography eluting with 10-100% ethyl acetate in hexanes to yield 0.5 to 2.0 mg (14-60%) of the final products.
-127- The internal phenyl ring can be exchanged for a pyridine ring using chemistry outlined in Scheme 7. The chloromethyl pyidine 33 is prepared using a known-procedure reported in Nutaitis, Charles Ledeboer, Mark W. Org.'Prep. Proced.
Int. (1992), 24(2), 143-6 Incorporated herein by reference.
After freebasing the pyridine, alkylation with the Boccaprolactam provides pyridine intermediate which can be elaborated to the protected amide 35 with succinate 1Q.
Substitution can then be introduced using Suzuki methodology employing a palladium source such as tetrakis(triphenylphosphine) palladium(0) or bis(diphenylphosphinoferrocene) palladium(II) dichloride and a suitable base such as sodium carbonate or triethylamine in a solvent such as THF or toluene containing 10% methanol.
Stille chemistry is also possible using a suitable palladium source such as tetrakis(triphenylphosphine)palladium(0) and an aryl or vinyl tin derivative in a solvent such as benzene, toluene, or xylenes. The tert-butyl ester is then deprotected under standard acidic conditions using trifluoroacetic acid and the amide is formed under standard conditions to provide products 36.
-128- Scheme 7 Br OH 1. H 2
SO
4 EtOH B O 1 HC, ether B 2. NaBH4 Ethanol 2. SO(CI). ether H HCI 31 32 33 1. Freebase BocHN jN TFAICH CI r 2. N 2. HATU. NMM 0 J j BocH NNa 34 succinate 10 TFA. Then HATU H Pd (dppl)C12 NMM, NH3 H
H
2 N
-N
TEA. Boronic Acid or i: Pd(PPh 3 R-SnMe 3 36 General procedure for synthesis according to Scheme 7 The chloromethyl pyidine HC1 salt 33 is prepared using a known procedure reported in Nutaitis, Charles Ledeboer, Mark W. Org. Prep. Proced. Int. (1992), 24(2), 143-6.
Caprolactam 34: Pyridine HCl salt 33 (2.0 g, 8.3 mmol) is dissolved in 50 mL of a saturated NaHCO 3 solution and the solution is extracted with 30 mL of CHzC12 3 x followed by concentration of the organic layers to provide the free base.
Separately, 1.8 g (7.8 mmol) of caprolactam 13 is dissolved in 40 mL of dry THF and chilled to -78 To the solution was added 7 mL of a lM solution of sodium bis(trimethylsilyl) amide. The solution was brought to 0 C and stirred for 30 min. To the resultant anion was added a solution of 1.7 g (8.3 mmol) of pyridine 33 free base dissolved in 40 mL of THF. The resulting reaction solution was stirred at rt for 18 h and then heated to 50 OC and stirred an additional 3 h. The reaction solution was allowed to cool and then 50 mL of water was added and the aqueous layer was extracted 2 x with 100 mL of ethyl acteate. The combined organic layers were dried and concentrated under reduced pressure to provide the crude product which was -129purified by chromatography eluting with 20 to 100% ethyl acetate in hexanes to provide 1.5 g of caprolactam 34 as an oil.
Amide 35: Caprolactam 34 (0.40 g, 1.0 -mmol) isdissolved in 20 mL of 50% trifluoroacetic acid in CH 2 C1 2 and stirred at rt for 30 min. The solvents were then removed under reduced pressure and the resulting oil was redissolved in 5 mL of toluene and reconcentrated to remove residual TFA.
Separately, 0.270 g (1.0 mmol) of succinate 10 was dissolved in 5.0 mL of dry DMF and 0.44 mL (4 mmol)-of Nmethylmorpholine was added followed by 0.50 g (1.3 mmol) of HATU and the-resulting solution was stirred at rt for 30 min.
The crude deprotected caprolactam from above was dissolved in mL of dry DMF and added to the succinate solution and the resulting solution was heated to 50 *C and stirred for 2 days. The solution was then diluted with 20 mL of water and extracted with 3 50 mL portions of ethyl acetate. The combined organic layers were dried and concentrated under reduced pressure to provide an oil which was purified by chromatography eluting with 20 to 50% ethyl acetate in hexanes to provide 0.40 g of the Amide Additional examples can be prepared by the method shown in Scheme 8. Coupling of an amine onto a commercially available aldehyde-derived resin 37 under conditions for reductive amination such as sodium tris(acetoxy)borohydride in CH 2 C12 containing 1% acetic provides a support-bound amine 38. The carboxylic acid 39 can then be coupled to the support-bound amine generating an amide 40 which can be liberated from the support employing trifluoroacetic acid in
CH
2 C12.
-130- Scheme 8 Me Na(OAc)3BH OMe
CH
2
C
2 1% AcOH H R,-NH2 OMeH OMe 37 38 0 HO O 0CTFA Rt O O
O
SC
2
C
2
O
39 HATU, OIEA, DMF General procedure for solid-phase synthesis according to Scheme 8 Resin 38 of Scheme 5: Aldehyde-derived resin 31 (200 mg, 0.5 mmol/g, 0.1 mmol) is purchased from Perkin Elmer Biosystems and swelled in 3 ml of CH 2 C12 for 1 hour. An amine (1.0 mmol), sodium tris(acetoxy)borohydride (106 mg, mmol) and acetic acid (30 uL, are added and the reaction is shaken on a shaker table for 16 h at rt. The solvents were removed by filtration and the resin 38 was rinsed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH 2 C12- and dried in vacuo.
Products 40 of Scheme 8: Carboxylic acid 39 (23 mg, 0.045 mmol), diisopropylethylamine (13 L, 0.075 mmol) and HATU (17.1 mg, 0.045 mmol) were mixed in 0.5 mL of DMF for min. Amine-derived resins 38 (30 mg, 0.015 mmol) were then added and the suspension was shaken at rt for 16 h. The solvents were removed by filtration and the resins were rinsed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH 2 C1 2 The isolated resins were then cleaved by the addition of 0.50 mL of trifluoroacetic acid.
The product solutions were concentrated and redissolved in mL of methanol and reconcentrated 2x to remove residual TFA. Product yields ranged from 0-100% based on the structure of the amine.
-131- The compounds of Formula of the present invention can also be prepared from aminolactam 41 and succinic acid derivatives 42 using amide bond syntheses known .in the art, including methods commonly used in peptide syntheses, such as HATU, TBTU, BOP, pyBOP, EDC, CDI, DCC, hydroxysuccinimide, mixed carboxylic anhydride, and phenyl ester mediated couplings, as illustrated in Scheme 9 for the synthesis of aminolactam 43, an embodiment of the present invention.
Scheme 9 0 R 5 0 R 5 0 RR2NHY H2Niy-z
H
R 3 O B coupling agent R'R 2 N Y
R-
3 0 41 42 Depending on the structure of the final product, it is appreciated by those skilled in the art that protecting groups or precursor functionality convertable to the desired groups may be desireable. Protecting groups and their use in synthesis are described in Green and Wuts, Protective Groups Sin Organic Synthesis, (Wiley 1991). The use of protecting groups is further illustrated in Scheme 10, in which the succinate half-ester 44 (Becket et al., Synlett 1993, 137- 138) is coupled to the aminobenzodiazepine 45 (Sherrill and Sugg, J. Org. Chem. 1995, 60, 730-734; Bock et al., J. Med.
Chem., 1993, 36, 4276-4292) to give ester 46, followed by conversion of the ester group to the primary amide 47.
-132- Scheme Mee OH H 2 N(
-U
C HAT N-- I-u0i 0~ON DIEA N0 0.Me 1) TFA-CH 2
CI
2 1:1N 2) HATU/NH 3 /DIEA HNN- <0 47 Methods for the synthesis of lactams as contemplated by the present invention in lactam ring B in Formula including amino benzodiazepines, are known in the art and are disclosed in a number of references including PCT publication number WO 98/28268, which is hereby incorporated by reference. Additional references include Bock, et al, J.
Org. Chem., 1987, 52, 3232-3239 and-Sherrill et al., J. Org.
Chem., 1995, 60, 730-734; Walsh, D. Synthesis, September 1980, p.677.
Examples Chemical abbreviations used in the Examples are defined as. follows: "DMPUY for 1, 3-dimethyl-3,4, 5, 6-tetrahydrO72 (lH) pyrimidone, '"TBTU' for 0- (lH-benzotriazol---yl) tetramethyluronium tetrafluoroborate, and "BOP" for benzotriazol-l-yloxytris- (direthylamino) phosphonium hexafluorophosphate. It is understood that one skilled in the art can discern compounds used in the synthesis of Examples of the invention may be referred to by structure and nubr For example, Resin 20 refers to the. resin-,of. -133structure 20 in Scheme 5; succinate refers to the structure 9 found in Scheme 2 which is a succinate compound.
"HPLC" is an abbreviation used herein for high pressure liquid chromatography. Reverse-phase HPLC was carried.out using a Vydac C-18 column with gradient elution from 10% to 100 buffer B in buffer A (buffer A: water containing 0.1% trifluoroacetic acid, buffer B: 10% water, 90% acetonitrile containing 0.1% trifluoroacetic acid).
Example 1 (2R,3S) N- (3S)-hexahydro-l-(3,3-diphenylpropyl).-2-oxo-1H- azepin-3-yl]-N4-(hydroxy)- 2 -(2-methylpropyl)-3-(propyl)butanediamide.
HO, N Step Di-tert-butyldicarbonate (10.2 g, 46.7 mmoles) was added portion wise to a solution of L-(-)-a-amino-Ecaprolactam (5.0 g, 39.0 mmoles) in dimethyl sulfoxide mL). After 5 h at rt, the reaction was partitioned between water (100 mL) and ethyl acetate. The combined organic extracts were washed successively with 1 M HC1 (50 mL), brine, and dried (MgSO4) and concentrated in vacuo. The residue was recrystallized in 1:1 v/v ether-hexanes, two crops yielded the desired product (6.26 g, 70%) as white solid. MS (M+H-BOC)* 129.
Step Triphenylphosphine (3.0 g, 11.4 mmoles) and carbon tetrabromide (3.75 g, 11.7 mmoles) were added successively to a cooled solution of 3,3-biphenyl-lpropanol (1.5 mL, 7.5 mmoles) in dichloromethane (20 mL).
After 1.5 hours at rt, the mixture was concentrated in vacuo.
The residue was purified by flash chromatography on silica -134gel (hexanes) to give the desired product (1.93 g, 93% yield) as a clear oil. MS (M-BrC 2
H
4 167 Step A 1.0 M tetrahydrofuran solution of lithium bis(trimethylsilyl)amide (1.3 mL) was added-over 15 minutes to compound of Step (la) (0.29 g, 1.27 mmoles) in tetrahydrofuran (3 mL) and DMPU (2 mL) at -78 0 C. The iodo compound prepared from compound (ib) (0.85 g, 3.09 mmoles) by typical Finkelstein methodology, in tetrahydrofuran (4 mL) was added and the reaction was allowed to warm to rt slowly.
This was stirred for 10 hours at ambient temperature, partitioned between water and ethyl acetate. The combined organic extracts were washed successively with water (20 mL), brine (20 mL), and dried (MgSO4) and concentrated in vacuo.
The resulting residue was purified by silica gel column (ethyl acetate:hexanes, 5:95 then ethyl acetate:hexanes, 15:85) to give the desired product (0.16 g, MS (M-Ot- Bu)* 349.
Step Trifluoroacetic acid (3 mL) was added to a solution of compound of Step (Ic) (0.16 mg, 0.38 mmoles) in dichloromethane (9 mL). After 2 h at rt, the solvent was removed in vacuo. The residual trifluoroacetic acid was removed by azeotrope with dichloromethane (50 mL), toluene (50 mL), and dichloromethane (50 mL) successively to give the desired product (0.17 g, 99%) as a yellow oil. MS 323.
Step 4-Methylmorpholine (0.6 mL, 5.46 mmoles) and TBTU (0.11 g, 0.34 mmoles) were added to a solution of succinate acid Becket, M. J. Crimmin, M. H. Davis, Z. Spavold, Synlett, (1993), 137-138) (0.085 g, 0.31 mmoles) in N,Ndimethylformamide (3 mL). After 30 minutes at rt, the compound from step (Id) (0.17 g, 0.39 mmoles) was added to the mixture. The reaction was stirred for 16 h at rt, then partitioned between 1 M HC1 (20 mL) and ethyl acetate. The combined organic extracts were washed successively with saturated aqueous sodium bicarbonate (20 mL), water (20 mL), -135brine (20 mL), dried (MgSO4) and concentrated in vacuo. The residue was purified by silica gel chromatography (ethyl acetate: hexanes, 7:93 gradient to ethyl acetate:hexanes 2S:75) to give the desired product (120 mg, 67%) as a clear' oil. MS (M+NH 4 -0t-Bu)* =521.
Step Trifluoroacetic acid (3 mL) was added to a solution of compound of Step(le) (120 mg, 0.21mmoles) indichloromethane (9 mL). After 3- hours at rt, the mixture was concentrated in vacua. *The 'residual-trif luoroacetic: aeid waTremoved by azeotrope with toluene (1 X 50 mL) and dichloromethane (1 X SO xnL). The residue was triturated with- Et 2 O:Hexanes 95:5. to give the desired produQL (75 mg, as a white solid. MS 519.
Step 4-Methylmorpholine (0.05 niL, 0.45*mmoles) and BOP (73 mg, 0.17 imoles) were added to a solution of compound of Step (If) (60 mg, 0.12 nimoles) in N,N-dimethylformamide (2 niL). Hydroxylamine (33 mig, 0.47 inmoles) was added to the mixture, the reaction was stirred for 16 h at rt,'was concentrated in vacuo, was acidified with trifluoroacetic acid, then purified by reverse phase HPLC on a Vydac t-19 column, to give the desired hydroxamic acid as a white solid mg, MS 534.
Excample 2 (2R,3S) Ni-I (3S) -hexahydro-1- (3-phenoxybenzyl) -2--oxo-1Hazepin-3 -yl] -N4 -(hydroxy) (2-methyipropyl) (propyl) butanediamide.
HO- N K N Sten Triphenyiphosphile (3.40 g, 13.0 nimoles) and carbontetrabromide (4.20 g, 13.0 Inmoles) were added -136successively to a solution of m-phenoxybenzyl alcohol mL, 8.6 mmoles). After 4 h at rt the mixture-was concentrated and was purified by silica gel column (hexanes, then ethyl acetate:hexanes, 5:95) to give the desired bromide (1.3 g, 57%) as a yellow oil. MS (M-Br) 183.
Step A 1 M solution of lithium bis(trimethylsilyl) amide was added dropwise to a solution of compound of Step (la) (0.3 g, 1.31 mmoles) in tetrahydrofuran (5 mL) at -78 0 C. After 30 minutes a-solution of compound of Step (2a) (0.43 g, 1.63 mmoles) in tetrahydrofuran (4 -mL) was added to the mixture dropwise. The reaction was allowed to come to ambient temperature, stirred for 16 h, then partitioned between water and ethyl acetate. The combined organic extracts were washed successively with water (20 mL), brine (20 mL), dried (MgSO4) and concentrated in vacuo. The crude residue was purified by silica gel chromatography (ethyl acetate:hexanes, 5:95 then ethyl acetate:hexanes, 15:85) to give the desired product (360 mg, 67%) as a clear oil. MS (M-Ot-Bu)* 337.
Step Trifluoroacetic acid (5 mL) was added to a solution of compound of Step (2b) in dichloromethane (15 mL).
After 3 h at rt the solution was concentrated in vacuo. .The residual trifluoroacetic acid was removed from. residue -by azeotrope with toluene (50 mL) then dichloromethane (30 mL) to yield the desired amine (390 mg, 99%) as a clear oil. MS 311.
Step Following a procedure analogous to the preparation of Step but using the compound from of Step (2c) (390 mg, 0.88 mmoles) the amide-was prepared, The crude compound was purified by silica gel chromatography to give the desired product (0.38 g, 92%) as a yellow oil. MS (M-Ot-Bu) 491.
Step Following a procedure analogous to the preparation of step but using the compound from Step -137- (2d) (380 mg, 0.67 mmoles), the carboxylic acid was prepared.
The product was precipitated from ethyl ether with hexanes,.
to give the desired acid (227 mg, 66%) as a white solid.- MS 507. Step Following a procedure analogous to the preparation of compound of Step but using the compound from step (2e) (150 mg, 0.29 mmoles) the..title compound was prepared. The crude was purified by reverse phase HPLC on a Vydac C-18 column to give the desired product :(90 as a white solid. MS 522.
Example 3 (2R,3S) Nl-[(3S)-hexahydro-l-(phenyl)-2-oxo-1H-azepin-3-yl N4-(hydroxy) -2-(2-methylpropyl)-3-(propyl)-butanediamide.
HOH N H 0 Step (3al: Triethylamine (1.5 mL, 10.8 mmoles), copper (II) acetate (0.95 g, 5.2 mmoles) and phenylboric acid (1.6 g, 13.1 mmoles) were added successively to a solution of compound of Step (la) (1.0 g, 4.4 mmoles) in dichloromethane mL). After 2.5 h at rt, more phenylboric acid (0.5 g, 4.1 mmoles) was added to the mixture. After an additional 3 hours at rt more phenylboric acid (0.5 g, 4.1 mmoles) was added to the mixture. After 65 h at rt, the mixture was filtered over celite. The filtrate was concentrated in vacuo, and the residue was purified by silica gel chromatography (ethyl acetate:hexanes, 5:95 then 15:85) togive the desired product (250 mg, -231.
Step Following a procedure analogous to the.
preparation of compound of Step but using compound of -138- Step (3a) (250 mg, 0.82 mmoles), the amine (300 mg, 99%) was prepared as a yellow oil.. MS 205.
Step Following a procedure analogous to the preparation of compound of Step but using compound from Step (3b) (0.3g, 0.94 mmoles), the amide.was prepared.. The residue was purified by silica gel chromatography (ethyl acetate:hexanes, 5:95 to 20:80 in 5% increments, 500 mL each ratio) to give the desired product (210 mg, 60%) as a clear oil. MS 403.- Step Following a procedure analogous to the preparation of compound of Step but using compound from sStep (3c) (200 mg, 0.44 mmoles) the acid was prepared. The crude oil was triturated with ether:hexanes 1:1 to give the desired acid (114 mg, 65%) as a white solid. MS 385.
Step Following a procedure analogous to the preparation of compound of Step but using compound-from Step (3d) (82 mg, 0.20 mmoles) the title compound was prepared. The crude product was purified by reverse phase HPLC on a Vydac C-18 column to give the desired product mg, MS 416.
Example 4 (2R,3S) N1- (3S) -hexahydro-1- (3-phenoxybenzyl) -2-oxo-1Hazepin-3-yl] -N4-(methyl)-2- (2-methylpropyl)-3- (propyl)butanediamide.
H
H O Following a procedure analogous to the preparation of Example 3, compound of Step (2e) (100 mg, 0.20 mmol) was -139treated with HATU (7-azabenzotriazol-1-yl)-1,1,3,3, tetramethyluronium hexafluorophosphate) (114 mg, 0.30 mmol) and N-methyl morpholine (66 mL, 0.6 mmol) in 2 mL-_of DMF formin at rt. A solution of 2.0 M methylamine in THF (0.2.
mL, 0.4 mmol) was added and the reaction solution was stirred for 1 h at rt. The reaction solution was diluted with 1N HC1 mL) and extracted 3 x with 10 mL of ethyl acetate. The combined organic layers were washed with a saturated sodium bicarbonate solution (5 mL) and brine (5 mL), dried over magnesium sulfate, and concentrated in vacou to provide the crude amide. Purification by reverse phase HPLC on a Vydac- 18 column provided the desired amide (30 mg, MS 544. Example (2R,3S) N1-[ (3S)-hexahydro-1- (3-phenoxybenzyl) -2-oxo-lHazepin-3-yl] -N4- (methoxy) -N4- (methyl)-2- (2-methylpropyl) -3- (propyl)-butanediamide.
CH3 0O Following a procedure analogous to the preparation of Example 4, compound of Step (2e) (100 mg, .0.20 mmol) was activated and condensed with N, O-dimethylhydroxylamine hydrochloride (40 mg, 0.40 mmol). Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide (30 mg, MS (M+Na) 574.
-140- Example 6 (2R,3S) Nl-( (3S)-hexahydro-l-(3-phenoxybenzyl)-2-oxo-lHazepin-3-yl] -N4- (methoxy) (2-methylpropyl) -3-(propyl)butanediamide.
H
OCHa3 0 Following a procedure analogous to the preparation of Example 4, compound of Step (100 mg, 0.20 mmol) was activated and condensed with O-methylhydroxylamine hydrochloride (40 mg, 0.40 mmol). Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide mg, MS (M+Na) 560.
Example 7 (2R,3S) Nl-((3S)-hexahydro-l-(3-phenoxybenzyl)-2-oxo-lHazepin-3-yl] (2-methylpropyl)-3-(propyl) -butanediamide.
H
Following a procedure analogous to the preparation of Example 4, compound of Step (2e) (100 mg, 0.20 mmol) was activated and condensed with a 2.0 M solution of ammonia in dioxane (0.2 mL, 0.4 mmol). Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide (30 mg, MS 530.
-141- Exaiiple '7A (2R,3S) Nl1[H3S)-hexahydro--(3-pheloxybeflzyl)-2-oxo-1Hazepin-3 -yl I -N4- (amino) -2 (2 -methyipropyl) (propylbutahediannide.- Following a procedure analogous to the preparation of Example 4, compound of Step (2e) (100 mg, 0.20 mmol) was' activated and condensed with hydrazine 0.4 mmol).
Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide (11.1 mg, MS 542.
Example 8 (2R,3S) Ni-I (3S)-hexahydro-1i-(3-phenoxybenzyl) -2-oxo-1Hazepin-3 -yl]1 -2 (2 -methyipropyl) 3- (propyl) -butanediamide.
H
N,
(8a) Compound 8a was synthesized following a procedure analogous to the preparation of the compound le, but using the caprolactam 2c (2.5 g, 5.89 mmol), succinate 9 (1.64 g, rnmol). and HATLJ instead of TBTEJ. The compound was purified by chromatogrphy eluting with 5% methanol in CH 2 Cl 2 to afford-1.50 g of the desired ester.
(8b) The ester f rom 8a 18 g, 2. 10 mmol) was.
dissolved in 10 xuL of a 50% solution of trifluoroacetic acid in CH 2 Cl 2 and stirred at rt for 2 h. The solvents were removed by concentration under reduced pressure and the crude product was dissolved in 10 rnL of toluene and reconcentrated -142twice to remove residual TFA. The crude acid was used without further purification or characterization.
Following a procedure analogous to the preparation of Example 7, compound 8b (1.065 g, 2.10 mmol) was activaE21.
and condensed with an excess of gaseous ammonia.
Purification by reverse phase HPLC on a Vydac-iB column provided 500 mg of the desired compound of Example 8.
MS 528.- Example 9 (2R, 3S) Nl-( (3S)-hexahydro-l-(3-phenoxybenzyl) -2-oxo-lH-.
azepin-3-yl] -N4- (hydroxy) (2"-methyipropy.) (al lyl) butanediamide.
H
HO., N% Example 9 was synthesized following a procedure analogous to the preparation of Example 2. but using succinate P. (Scheme Purification by reverse phase IIPLC on a Vydac-18 column provided 150 mg of Example 9. MS 544.
Example (2R,3S) Nl-[ (3S)-hexahydro-1-(3-(2,4-dichlorophelyl)belzyl)- 2-oxo-1H-azepin-3-yl) -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanediamide.
-143- The general procedure reported for Scheme 5 was followed using 2,4-dichiorophenyl boronic acid. Purificationi afforded 6.0 mig of the desired product. MS 598.
Example 12.
(2R,3S) I'l-[(3S)-hexahydro-l-(3-(4-fluiorophenyl)benzyl)-2oxo-1H-azepin-3-yl] -N4- (hyclroxy) (2 -miZthyjlpropyl) -3 (propyl) -butanediatide.
N,
N J, The general procedure reported for Scheme 5 was. followed using 4-f luorophenyl boronic acid. Purification afforded mig of the desired product. MS 548.
Example 12 (2R,3S) N1-i1(3S)-hexahydro-1-(3-(4-methylphenyl)benzyl)-2oxo-lH-azepin-3-yl] -N4- (hydlroxy) (2-methyipropyl) -3- (propyl) -butanediamide
CH
3
H
HO,. NjR.
The general procedure reported for Scheme 5 was followed using 4-methyiphenyl boronic acid. Purification afforded mg of the desired product. MS 544.
-144- Example 13 (2R,3S) N1-((3S)-hexahydro-l-(3-(4-methoxyphenyl)benzyl)-2oxo-lH-azepin-3-ylJ -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanediamide.
CH
3
T
HO.N N N
H
0 The general procedure reported for Scheme 5 was followedusing 4-rnethoxyphenyl boronic acid. Purification afforded 3.0 mg of the desired product. MS 560.
Example 14 (2R,3S) Nl-[(3S)-hexahydro-l-(3-(3-methylphenyl)benzyl)-2oxo-lH-azepin-3-yl] -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanediamide.
H
3
H
HO,. HN N The general procedure reported for Scheme 5 was followed using 3-methylpheny. boronic acid. Purification-afforded mg of the desired product.- MS 544.
Example (2R,3S) N1-[ (3S)-hexahydro-1-(3-(3-chloro-4f luorophenyl)benzyl) -2-oxo-lH-azepin-3-yll -N4- (hydroxy) (2methyipropyl) -3 (propyl) -butanediamide.
-145- The general procedure reported for Scheme 5 was followed using 3-chloro-4-fluorophelyl boronic acid. Pur-ification afforded 4.0 mg of the desired product. MS (M+Na)- 582.
Example 16 (2R,3S) Nl-[(3S)-hexahydro-1-(3-_(4trif luoromethyphelyl) benzyl) -2 -oxo- 1H--azepin-3 -y1 -N~4 (hydroxy) -2 (2 -methyipropyl) -3 (propyl) -butanediamide.
HO N 'A N
F
The general procedure reported for Scheme 5 was*.followed using 4-trifluoromethylphelYl boronic acid. Purification afforded 4.0 mg of the desired product. MS (M+Na) 4 598.
Example 17 (2R,3S) Nl[3)hx~yr--3(-ehxpenlbny)2 oxo-lH-azepin-3-yl] -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanedianide.
CH
3 HO,. N) NJN
NIN
H
The general procedure reported f or Scheme 5 was followed using 3-methoxyphenyl boronic acid. Purification afforded 4.1 mig of the desired product. MS 560.
-146- Example 18 (2R,3S) N1-[(3S)-hexahydro-l-(3-(3-fluorophelyl)belzyl)-2oxo-1H-azepin-3-yl] -N4- (hydroxy) (2-methylpi-opyi:) -3- (propyl) -butanediamide.
F
HO~H
N -N The general procedure reported for .Scheme S5.was. followed using 3-f luorophenyl boronic acid.. Purification afforded mg of the desired product. MS (M+Na 4 548.
Example 19 (2R,3S) Nl-[(3S)-hexahydro-l-(3-(2-methoxyphenyl)elzyl)-2oxo-lH-azepin-3-yl] -N4- (hydroxy) (2-methylpropyl) -3- (propyl) -butanediamide.
H
3 C H I HN N.~N The general procedure reported for Scheme 5 was followed using 2-methoxyphenyl boronic acid. Purification afforded 1.3 mrg of the desired-product. MS (M+eNa) =560.
Example (2R,3S) Nl-[ (3S)-hexahydro-l-(3-(2-naphthyl)benzyl)-2-oxo-1Hazepin-3-yl] -N4- (hydroxy) (2-methyipropyl) (propyl) butanediamide.
-147- The general procedure reported for Scheme 5 was followed using 2-naphthyl boronic acid. _Purification afforded 3.0 mg of the desired product. MS (M+Na) "=580.
It will be understood by one skilled in the art that- Scheme 6 can be followed in a manner analogous to the procedure for Scheme Example 21.
(2R,3S) N1-( (3S)-hexahydro-l-(3-(4-methoxyphelyl)benzyl)- 2 oxo-1H-azepin-3-yll -2-(2-methyipropyl) (propyl) butanediamide.
H
0 CH 3 NjNI
H
2 N
N
The general procedure reported for Scheme 6 was followedusing 4-methoxyphenyl boronic: acid. Purification afforded 0. 5 mg of the desired product. MS (M+Na) 544.
Example 22 (2R,3S) Nl-1 (3S)-hexahydro-l-(3-(3-fluorophenyl)benzyl)- 2 oxo-1H-azepin-3-ylI (2-methyipropyl) (propyl) butanediamide.
-148- The general procedure reported for Scheme 6 was followed using 3-f luorophenyl boronic acid. Purification afforded 1.6 mg of the desired product. MS 532.
Example 23 (2R,3S). Nl-[(3S)-hexahydro-1-(3-(4trifluorornethylphenyl)benzyl) -2-oxo-flI-aei-y] -2(2methyipropyl) (propyl) -butanediamide.
0
F
3 The general procedure reported for Scheme 6 was followed using 4-trifluoromethyiphenyl boronic acid. Purification afforded 0.7 mg (4.3 of the desired product. MS (M+Na)* 582.
Example 24 (2R,3S) Ni- -hexahydro-1- (3-(2,4-dichlorophenyl)benzyl) 2-oxo-1H-azepin-3-yl] (2-methyipropyl) (propyl) butanediamide.
H
0
H
2 N N..)kN The general procedure reported for Scheme 6 was followed using 2,6-dichiorophenyl boronic acid. Purification afforded 1. 8 mg (11 of the desired product.- MS (M+Na) 582.
-149- Example (2R,3S) Nl[3)hxhdol(-4-ehlhnlbny)'* oxo-lH-azepin-3-ylI (2-methyipropyl) (propyl) butanediamide.
Me
HI
H
2
N
The general procedure reported. for -Scheme. 6 was. followed using 4-tolyl boronic acid. Purification af-forded 1.8 mg (12.
%)of the desired product. MS 528.
Example 26 (2R,3S) Nl-C (35) -hexahydro-1-(3-(4-mlethoxyphenylY)benzyl)-2oxo-1H-azepin-3-yl] (2-methyipropyl) (propyl) butanediamide.
Me
H
0
H
2
NN
The general procedure reported for Scheme 6 was followed using 4-methoxyphenyl boronic acid. Purification afforded 0. 5 mg (3.3 of the desired product. MS (M+Na) 4 544.
Example 27 (2R.3S) N1-1(3S)-hexahydro-l-(3-(3-chloro-4fluorophenyl)belzyl) -2-oxo-lH-azepin-3-yl].-2- (2methyipropyl) (propyl) -butax'iedihiide. -150- The general procedure reported for Scheme 6 was followed using 4-f luoro-3-chlorophenyl boronic acid. Purification afforded 0.5 mg (3.3 of the desired- product, MS- 567.
Example 28 (2R,3S) N1-((3S)-hexahydro-1-(3-(3-methoxphelyl)belzyl)-2oxo-lH-azepin-3-yl] (2-methyipropyl)-3 (propyl) butanediamide.
H
2 N -OMe The general procedure reported for Scheme 6 was f ollowed using 2-methoxyphenyl boronic acid. Purification afforded 0. 8 mg (5.3 of the desired product. MS (M+Na) =544.
Example 29' (2R,,3S) Nl-[ (3S)-hexahydro-1-(3-(2-methoxyphelyl)beflzyl)-2oxo-1H-azepin-3 -yl]1 -2 (2 -methyipropyl) -3 (propyl) butanediamide.
H
0 H2N 0 OC), The general procedure reported for Scheme 6 was followed using 2-inethoxyphelyl boronic acid. Purification afforded 1.5 mg (10 of the desired product. MS 544.
-151- It will be understood by one skilled in the art that Scheme 7 can be followed in a manner- analogous_.to the procedure for Schemes 5 and 6.
Example (2R,3S) N1-[(3S)-hexahydro-1-(3-(4-methoxyphenyl)pyrid-5ylmethyl) -2-oxo-1H-azepin-3-yl 2- (2-methylpropyl) -3- (propyl)-butanediamide.
S. CH 3
H
H2 Amide 35 of Scheme 7 (0.10 g, 0.18 mmol) was dissolved in 5 mL of toluene and 41 mg (0.27 mmol) of 4-methoxyphenyl boronic acid was added, followed by 31 mg (0.0147 mmol) of tetrakis(triphenylphosphine)palladium, 0.5 mL of a 2M sodium cabonate solution and 0.5 mL of methanol. The reaction Ssolution was heated to reflux for 16 h and then allowed to cool to rt. The reaction solution was diluted with 10 mL of water and extracted 2 x with 50 mL of ethyl acetate. The combined organic layers were dried and concentrated and the resulting oil was purified by chromatography eluting with to 100% ethyl acetate in hexanes as a solvent to provide mg of biaryl product. MS 580.
The purified biaryl product was dissolved in 10 mL of 1:1 trifluoroacetic acid/CH2Cl2 and stirred at rt for 2 h.
The solvents were then removed under reduced pressure and the resulting oil was redissolved in 5 mL of toluene and reconcentrated to remove residual TFA. The crude acid mg, 0.047 mmol) was then dissolved in 1 LoEMF of N-methylmorpholine (0.094 mmol) and 42 mg (0.062- mmol) HATU were added and the reaction solution was stirred at rt for 45 min. Gaseous ammonia was then bubbled in at a gentle rate for about 1 minute and the solution was stirred for an additional 1 min. The reaction solution was then diluted -152with 10 mL of water and extracted 3 x with 30 mL of ethyl acetate. The combined organic -layers -were dried and concentrated under reduced pressure to A -solid- which was purified by reversed phase HPLC to provide 3.5 mg of the compound of Example 30Oas its trifluoroacetic acid salt.
MS 523. Example 31 (2R,3S) Ni-f (3S)-hexahydro-l-(3-(4trifluoromethylphenyl)p'yrid-'5-ylmet-hy-i):-2-oxo-lH'azepin3
S'
ylI-- 2 (2 -methyipropyl) (propyl) -butanediamide.
Hj
F
3 HH2i ~0 y The general procedure reported for the compound of Example 30 was followed using 4-trifluoromethylphenyl boronic acid. Purification by HPLJC afforded 6.0 mg of the desired product from as its trifluoroacetic acid salt. MS (M+Na)+ 583.
Example 32 (2R,3S) Nl-f (3S)-hexahydro-1-(3-(3-chloro-4fluorophenyl) pyrid-5-ylmethyl) -2-oxo-lH-azepin-3-yl] (2methyipropyl) (propyl) -butanediamide.
F
H
N. N
H
2 N N~I.
Amide 35 (0.30 g, 0.54 mmol) was dissolved in 3 mL of DMF and 123 mg (0.70 rnmol) of 4-methoxyphenyl boronic acid was added, followed by 44 mg (0.0543 mmol) of bis(diphenylphosphinoferrocene) palladim, (II) dichloride and 1.0 mL (7.18 mmol) of triethylanine. The reaction solution -153was heated to 80°C for 24 h and then allowed to cool to rt.
The reaction solution was diluted with 10 mL of water and extracted 2 x with 50.mL of ethyl acetate. The combined organic layers were dried and concentrated and the resulting oil was purified by chromatography eluting with 20 to 100% ethyl acetate in hexanes as a solvent--to provide 140. mg of biaryl product. MS (M+Na) 624.
The general procedure reported for.:the compound of Example 30 was then fol-lowed to-provide the amide.
Purification by chromatography eluting with 20 to 100% ethyl acetate in hexanes afforded 45 mg of the desired product of Example 32 as its trifluoroacetic acid salt. MS 567.
Example 33 (2R,3S) N1-[(3S)-hexahydro-l-(3-phenoxybenzyl)-2-oxo-lHazepin-3-yl]-N4- (butyl) -2-(2-methylpropyl)-3-(propyl)butanediamide.
H
The general procedure reported for Scheme 8 was followed using butylamine. Analysis by 1HNMR integration relative to.an internal standard revealed a yield of 100 of the desired product. MS 586.
Example 34 (2R,3S) N1-((3S)-hexahydro-l-(3-phenoxybenzyl)-2-oxo-lHazepin-3-yl]-N4-(2-furylmethyl)-2-(2-methylpropyl)-3- (propyl)-butanediamide.
-154-
N-
The general procedure reported for Scheme 8 was followed using 2-furylmethylamine. Analysis by IHNmR integration relative to an internal standard revealed a yield of 75 %of the desired product. MS 610.
Example (2R,3S) Nl-f(3S)-hexahydro-1-(3-phenoxybenzyl) -2-oxo-lHa zep in- 3-yl]I -N4 (cyc lopentyl) 2- (2 -me thyipropyl) 3- (propyl) butanediamide.
0 The general procedure reported for Scheme 8 was followed using cyclopentylamine. Analysis by IHNMR integration relative to an internal standard revealed a yield of 42 of the desired product. MS 598.
Example 36 (2R,3S) Nl-( (3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-lHazepin-3-yl]-N4- (cinnamnyl)-2-(2-methylpropyl)-3- (propyl) butanediamide.
H 0N
Y
The general procedure reported for Scheme 8 was followed using cinnamylamine. Analysis by 1 HNMR integration relative -155to an internal standard revealed a yield of 100 of the desired product. MS 'tM+Na)* 646.
Excample 37' C2R,3S) Ni- (3S) -hexahydro-I- (benzophenon-3-yr-) -2-oxo-lHazepin-3-ylI (2-methyipropyl) (allyl) -butanediamide. H 0
H
2
N
3-Bromomethybelzophe1ofe. A solution of 3methylbenzophenone (20-g, 102 mnfol) dissolved in 40 mL of 1,2-dibromoethane was heated to ref lux. Over a period of about 3 hours a solution of 105 mmol of bromine dissolved in 6 mL of 1,2-dibromoethane was added to the ref luxing solution. After the addition was complete the solution was allowed to cool to rt and diluted with 100 mL of dichioromethane. The organic layer was extracted with.1 niL of 1 N HCl. 2 x 15 ML of NaHCO3 Solution, and 2 x 25 L. of brine. The organic layers were dried over magnesium sulfate and concentrated in vacuo. The residue was then distilled to af ford the product, 16. 5 g (60 as an-oil. that- solidi fied upon standing, b.p. 160 0 C at 300 mTorr. IH NMR analysis shows that the product contains approximately 7% of the dibromide.
.3-Cl, 1-dinethylethy1carbomethoxy-N- (benzophenone- 3-yl-methyl)caprolactam. Diisopropylamine (4.2 mL, nunol) was dissolved in 25 niL of THF and chilled to -78'C. To the solution was added 10 niL of 2.5M n-butyllithium in hexanes and the solution was warmed to--O 9 C -&-nalleaed Eo stir for 10 min. A solution of Boc-protected axninocaprolactan la (5.0 grams, 22 nimol) dissolved in 25 niL of THFf was then added and the reaction solution was stirred for 1 h at 0 0 C. Solid 3-bromomethyl-benzophelofe was then added and the reaction solution was allowed to warm to6 rt and -156stir overnight. The reaction solution was diluted with water and extracted into ethyl acetate (100 mL). The organic layer was rinsed with 2x 25 niL of 1 N HC1, 2 x 25 niL of saturated NaHCO 3 and 2 x 25 niL of brine, dried over magnesium sulfate, and dried in vacuo. Chromatography eluting with a gradient of 30% to 40% ethyl acetate in hexanes afforded the pure benzophenone-substituted caprolactam derivative (7.4 g, MS 445.
The compound of Example 10 was synthesized in a manner analagous to the synthesis-of the-compound-of-Example 8- using succinate 9 and the benz oph~enone- substi3.tuted caprolacuam derivative. The compound was'purif ied-byr ci-?st~llization' from ethyl acetate to afford 0.26 g of crystals. MS CM+Na)+ =540.
Example 38 (2R,3S) N1-[(3S)-hexahydro-1-(benzophenon-3-yJJ-2-oxo-1Hazepin-3 -yl] (2-methyipropyl) (propyl) -butanediamide.
0
H
2
NN
The compound of Example 11 was synthesized in a manner analagous to the synthesis of the compound of Example 8 using succinate 10 and the benz ophenone- subs t ituted caprolactan derivative. The compound was purified by crys'tallizationfrom ethyl acetate to afford 0.25 g of crystals. MS (M+Na)+ =542.
Example 39- (2R,3S) N1-( (3S) -hexahydro-1-(4-(4trifluoromethylphenyl)benzyl) -2-oxo-lH-azepin-3-yl]-2- (2methylpropyl) (propyl) -butanediamide. -157- (39-a) 3- -dimethylethylcarbomethoxy-&- (4br-omophenylmethyl)caprolactam. The title compound was synthesized in a manner analogous 10 the preparation .of 3- (1 ,l-dimethylethylcarbomethoxy-N- (benzophenone-3-yl rethyl)caprolactam in Example 10 but using 4-bromobenzyl bromide as the alkylaing agent. The compound was purified by chromatography eluting with 5-20% ethyl acetate in hexanes as eluent to provide 7.0 g of the title compound as a solid. MS 419.
(39-b) 3-(1,1-diraethylethylcarbomethoxy-N- trifluoromethylphenyl)phenylmethyl)caprolactam. To a solution of 3- 1-dimethylethylcarbomethoxy-N- (4bromophenylmethyl)caprolactan (0.5 g, 1.26 mmol) dissolved in mL of toluene was added 263 mg (1.38 mmol) of 4trifluoromethyiphenyl boronic acid, 1 ML, of methanol, and 1 mL of a 2M solution of potassium carbonate. The solution was degassed by nitrogen bubbling for 5 min, and then 33 mig of tris(dibenzylideneacetone)dipalladiwn chloroform adduct and 66 mg of triphenylphosphine was added. The solution ws heated to ref lux: for 16 h and then allowed to cool and diluted with 20 mL of water. The aqueous layer was extracted 3 x with 25 niL of ethyla acetate and concentrated.. The resulting oil was-purified by chromatography eluting with ethyl acetate in hexanes to afford 0.47g of an oil which crystallized on standing.
(39-d) The compound 39-d was' synthesized in analagous to the synthesis of the compound of Examiple 8 using succinate 10 (280 mg, 1.04 mnrol) and 3-(l,ldimethylethylcarbomethoxy-N- -trifluoromethyiphenyl) phenylmethyl)caprolactan. The compound was purified by -158chromatography eluting with 20-100% ethyl acetate in hexanes to afford 40 mg of a white powder. MS 560.
Example (2S,3R) Nl-[(3S)-hexahydro-l-(3-(2-tetrazolylphenyl)benzyl)- 2-oxo-lH-azepin-3-yl]-2-(propyl)-3-(2-methylpropyl)butanediamide.
H
H
2 N N N.
0 H N-N,
H
(40-a) The compound of Example 40 was synthesized in a manner analogous to the synthesis of the compound of Example 39, but using the substituted acid 28 of Scheme 6 (50 mg, 0.10 mmol) and o-((N-trityl)-tetrazole)phenylboronic acid under the conditions for the formation of the compound (39- The desired biaryl acid was isolated as an impure mixture (134 mg) and used directly in the next step.
The acid 40-a (134 mg, impure mixture) was converted to the amide under the-conditions reported for the compound of Example 8. The crude amide was then dissolved in 2 mL of 10% trifluoroacetic acid in methanol and allowed to stir at rt for 30 min. The solvents were removed and the residue was purified by chromatography eluting with methanol in ethyl acetate to provide 40 mg 2 steps) of the compound of Example 40 as a sticky powder. MS 582.
Example 41 (2S,3R) Nl-[(3S)-hexahydro-l-(3-phenoxybenzyl)-2-oxo-1Hazepin-3 -yl 1-2- (propyl) (2-methylpropyl) -butanediamide. -159-
H
2
N
(41-a) The compound of Example-4. is formed by coupling Succinate 23 (480 mg, 1.21 mmol) with the substituted caprolactan TFA salt 2c under the. cond4,tions repbfted for thesynthesis of the compournd of Example S. The crude fluorenylmethyl ester vas used in the next step with out further purification. MS 709.
(41-b) The crude fluorenylmethyl ester is dissolved in 2 mL of a 50% solution of piperidine in CH 2 and stirred for 3 h at rt. A 10 mL portion of 1N HCl was then added and the mixture was extracted 3 x with 10 mL of ethyl acetate. Tbe crude acid was used in the next step with out further purification. MS 509.
The compound of Example 41 was then prepared using the acid 41-b under the conditions reported for compound of Example 28. The compound was purified by chromatography -eluting with 5% methanol in CH2Cl2 to afford 120 mg 3 steps) of a white powder. MS =508.- Excample 42 (2S,3R) N1-(1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)- 2H-1. 4-benzodiazepin-3-ylI (2-nethyipropyl) (allyl) butanediamide.
0 H 0
H
2 N N>)k.N 0 N 3-1Phanoxybexxzyl iodide: To a solution of 3phenoxybenzyl chloride (10.0 g, 45.7mrmol) in 200 ml acetone -160was added sodium iodide (7 .6 g, 5O7mmol).- The mixture was stirred at temperature overnight. _The mixture was -diluted with 300m1 hexane and the organic layer was washed. twice with sodium bicarbonate, once with brine and then dried-over MgSQ 4 Evaporation of the filtrate gave a light. yellow oil.
The product was used in next step without purification. 1
H
NMR (CDCl 3 4.4 6.8-7.4 (in, 9H).
Synthesis of Example 42:
H
2 NH 00 H 0 N tBuOk* O ON).
To a solution of benzodiazepine EOl (910 mg, 3. 63inmol) succinate a (980 mg, 3.63inmol), hydrox ybenzotri-azole. (980 mg., 7.25mol) and EDC (870 mg,_ A.54nunol) in 100 ml. CH 2 Cl 2 at 0 degrees was added triethylamine (0.76 mil, 5.4Siniol). The reaction mixture was washed with saturated sodium bicarbonate solution, 1.ON HCl, brine and dried over MgSO4: Evaporation of the organic layer and purif ication by column chromatography on silica gel with hexane-ethyl acetate (7:3) gave 610 mig of benzodiazepine 51 as a white solid. M H 504.37. 1 H NMR (CDCl 3 0.8-1.0 (mn, 6H), 1.0-1.2 (mn, IH), 1.4- 9H), 1.6-1.9 (mn, 2H), 2.2-2.8 (mn, 4H), 4.9-5.2 (in, 2H), 5.6 (dd, 1H), 5.6-6.0 (mn, 1H), 7.0-7.6 (mn, 9H).
-161- H 00 H 0 -o0 IBuOO N NH tBuO 0 N\ 0 N 51 52 To a solution of benzodiazepine 51 (440 mg, 0.875mmol) in DMF (20 ml) at 0 degrees was added NaH (45 mg, 1.12mmol).
The mixture was stirred at 0 degrees for 1.5 hr and then a solution of 3-phenoxylbenzyl iodide (330 mg, 1.06mmol) in ml DMF was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. TLC using hexanes:EtOAc 6:4 (product Rf 0.31) indicated that the reaction was complete. The reaction mixture was quenched with water, and the solvent was evaporated under high vacuum, which provided a viscous yellow oil. The product benzodiazepine 52 was dissolved in ethyl acetate, which was washed with water brine and then dried over MgSO4.
Evaporation of solvent gave 600mg of benzodiazepine 52as a yellow oil which was not further purified. M+H 686.3, M+Na 708.3. 1 H NMR (CDC13) 0.8-1.0 6H), 1.0-1.3 (m, 1H), 1.4-1.5 9H), 1.5-1.9 2.2-2.7 4.6-4.8 4.9-5.2 2H), 5.6-5.9 3H), 6.6-7.6 18H).
A solution of benzodiazepine 52 in 40 ml of TFA/CH 2 C12 was stirred overnight at room temperature then evaporated to dryness. Repeated addition of toluene and evaporation provided 560 mg. of 53 as a yellow solid. (M H 629.1) -162- HO~> 0. Exampi e-42 0 ON 53 To a solution of benzQdiazepine 53 and'HATU (410mg, l.O8mmol) in 30 ml DMF was added diisopropylethylamine (0.6 ml, 3.44mmol) at 0 degrees. After 10 minutes, ammonia gas was bubbled through the solution for two minutes, and the reaction mixture was allowed to warm to room temperature and stirred overnight. Addition-of water and solvent evaporation under high vacuum provided a yellow solid. The solid was taken up in ethyl acetate-water and the organic layer was washed with water brine and then dried over MgSO 4 Evaporation of solvent gave a light yellow solid.
Chromatographic purification on silica gel using CH 2
CI
2 methanol (10:0.5) gave 256 mg of Example 42. H- 629.2 HNMR (CDC1 3 0.8-1.0 (in, 6H), 1.2-1.4 1.6-2.0 (mn, 2H), 2.2-2.8(4H), 4.6-4.8 1H1), 5.0-5.2(m, 6.2-7.8 (mn, 18H).
Example 43 (2R) -hexahydlro-l- (3-phenoxybenzyl) -2-oxo-1H-azepin- 3-yl] (2-methylpropyl) -butanediamide.
0 0 Step_(43a)': The compound of Ste p (43a) is formed by coupling succinate 2 (115 mg, 0.5 minol). with. the substituted caprolactam TFA salt (212 mg, 0.5 mmiol) from Step (2c) of -163- Example 2 under the conditions reported for the synthesis of the compound of Example 8. .The.crude- tert-butyl ester was taken on without further purification.
Step (43b): The compound of Step (43b) is formed by dissolving the crude product- from Step (43a). in 5 mL_of a 1:1 solution of TFA/CH 2 C12 and stirring at_room temperature for 2 hours. Concentration followed by reconcentration twice from mL of toluene provides :the-crude acid which was- taken on with no further purification.- Step (43c): The..title compound, Example 43, was prepared using the acid from Step (43b) under the conditionsreported for the compound of Example 7. The compound.was purified by chromatography eluting with 5%_methanol in CH 2 C1 2 to afford 50 mg 3 steps) of a white powder. MS (M+Na)" 488.
UTILITY
AP production has been implicated in the pathology of Alzheimer's Disease The compounds of the present invention have utility for the prevention and treatment of AD by inhibiting AB production. Methods of treatment target formation of AP production through the enzymes involved in the proteolytic processing of P amyloid precursor protein.
Compounds that inhibit P or ysecretase activity, either directly or indirectly, control the production of AP. Such inhibition of P or ysecretases reduces production of AP, and is expected to reduce or prevent the neurological disorders associated with Approtein, such as Alzheimer's Disease.
Cellular screening methods for inhibitors of AP production, testing methods for the in vivo suppression of AP production, and assays for the detection of secretase activity are known in the art and have been disclosed in numerous publications, including PCT publication aymber- WO 98/22493, EPO publication number 0652009, US pateht 5703129 and US patent 5593846;- all hereby incorporated by reference.
The compounds of the present invention have utility for the prevention and treatment of disorders involving AD production, such as cerebrovascular disorders.
-164- Compounds of the present invention have been shown to inhibit Ap production, as determined by the secretase inhibition assay described below.
Compounds of the present invention have been shown to inhibit AP production, utilizing the C-terminus P amyloid precursor protein accumulation assay-desciibed below.
Compounds of Formula are expected to possess ysecretase inhibitory activity. The:y-secretase inhibitory activity of the compounds of the present invention is demonstrated using assays for such activity, for Example, using the assay described below. Compounds of the present invention have been shown to inhibit the activity of 7secretase, as determined by the Ap immunoprecipitation assay.
Compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit AP production.
These would be provided in commercial kits comprising a compound of this invention.
As used herein "pg" denotes microgram, "mg" denotes milligram, denotes gram, "IL" denotes microliter, "mL" denotes milliliter, denotes liter, "nM" denotes nanomolar, denotes micromolar, "mM" denotes millimolar, denotes molar, "nm" denotes nanometer, "SDS" denotes sodium dodecyl sulfate, and "DMSO' denotes dimethyl sulfoxide, and "EDTA" denotes ethylenediaminetetraacetato.
A compound is considered to be active if it has an ICso or Ki value of less than about 100 pM for the inhibition of Ap production or inhibition of proteolytic activity leading to Ap production. Compounds, as demonstrated by use of the invention, have demonstrated IC 50 values, for the inhibition of A production, of less than- about 100 pM. Preferably compounds, as demonstrated by use of the invention, demonstrate ICso values, for the inhibition of Ap production, of less than about 1 pM. More preferably compounds, as demonstrated by use of the invention, demonstrate ICso values, for the inhibition of Ap production, of less than about 100 nM. Even more preferably compounds, as demonstrated by use of the invention, demonstrate ICso -165values, for the inhibition of AP production, of less than about 50 nM.
P Amyloid Precursor Protein Accumulation Assay (6APPAassay) An assay to evaluate the accumulation of Ap protein was developed to detect potential inhibitors of secretases. The assay uses the N 9 cell line, characterized for expression of exogenous APP by immunoblotting.and immunoprecipitation The effect of test compounds on the accumulation of AP in the conditioned medium is tested by .immunoprecipitation.
N 9 cells are grown to confluency in 6-well plates and washed twice with 1 x Hank's buffered salt solution. The cells are starved in methionine/cysteine deficient media for 30 min., followed by replacement with fresh deficient media containing 150uCi Tran35S-LABEL TM (ICN). Test compounds dissolved in DMSO (final concentration are added, over a range of 1 picomolar to 100 micromolar, together with the addition of the fresh media containing Tran35S-LABEL
TM
The cells are incubated for 4 h at 37 0 C in a tissue culture incubator.
At the end of the incubation period, the conditioned medium is harvested and pre-cleared by the addition of 5 p1 normal mouse serum and 50ul of protein A Sepharose (Pharmacia), mixed by end-over-end rotation for 30 minutes at 4 0 C, followed by a brief centrifugation in-a microfuge. The supernatant is then harvested and transferred to fresh tubes containing 5ug of a monoclonal antibody (examples of antibodies include but are not limited by, clone 1101.1, directed against an internal peptide sequence in Ap;-or 6E10 from Senetek; or 4G8 from Senetek; additionally polyclonals from rabbit antihuman A from Boehringer Mannheim) and 50 .1 protein A Sepharose. After incubation overnight at 4 0 C, the samples are washed three times with high -salt washing buffer Tris, pH 7.5, 500mM NaCl, 5mM EDTA,.. ,5..Nor4e.tP-40), three times with low salt wash buffer (50mM Tris- pH 150mM NaCl, 5mM EDTA, 0.5% Nonidet P-40), and three times with 10mM Tris, pH 7.5. The pellet after the last wash is resuspended in SDS sample buffer (Laemmli U.K. Cleavage of structural proteins during the assembly of the head of -166- "bacteriphage T4. Nature 227, 680-5, 1970.) and boiled for 3 minutes. The supernatant is then-fractionated on either Tris/Tricine SDS gels or on 16.5%. Tris/Tricine SDS The gels are dried and exposed to X-ray. film or analyzed by phosphorimaging. The resulting image-is analyzed for the presence of AP polypeptides. The.steady-state level of Ap in the presence of a test compound is compared to wells treated with DMSO alone. A typical test compound in this assay blocks Ap accumulation in the conditioned medium, and is considered active with an IC 50 less than 100 pM.
C-Terminus 0 Amyloid Precursor Protein Accumulation Assay....
(CTF assay) The effect of test compounds on the accumulation of Cterminal fragments is determined by immunoprecipitation of APP and fragments thereof from cell lysates. N 9 cells are metabolically labeled, as above, with media containing in the presence or. absence, of test compounds. At the end of the incubation period, the conditioned medium are harvested and cells lysed in RIPA buffer (10 mM Tris, pH 8.0 containing 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 150mM NaC1, 0.125% NaN3). Again,.
lysates are precleared with 5ul normal rabbit protein A Sepharose, followed by the addition of BC-- antiserum and 50l- protein A Sepharose for 16 hours at 4 0 C. The immunoprecipitates are washed as above, bound proteins eluted by boiling in SDS sample buffer and fractionated by Tris/Tricine SDS-PAGE. After exposure to Xray film or phosphorimager, the resulting images are analyzed for the presence of C-terminal APP fragments. The steadystate level of C-terminal APP fragments is compared to wells treated with DMSO alone. A typical test compound in this assay stimulates C-terminal fragment accumulation in the cell lysates, and is considered active with an ICso less than 100 IM.
Accumulation-Release Assay -167- This immunoprecipitation assay is specific for y secretase activity proteolytic activity required to generate the C-terminal end of AD either by direct cleavage or generating a C-terminal extended species which is subsequently further proteolyzed). N 9 cells are pulse labeled with media containing Tran35S-LABELTM in the presence of a reported y secretase inhibitor (MDL 28170; Higaki J, Quon D, Zhong Z, Cordell B. Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14, 651-659, 1995) forIl h, followed by washing to remove 35 S radiolabel and MDL 28170.
The media is replaced and test compounds are added-over a dose range (for example O.lnM to 100uM). The-cells are chased for increasing periods of times and Ap is isolated from the conditioned medium and C-terminal fragments from cell lysates (see accumulation assay above). The activity of test compounds are characterized by whether a stabilization of C-terminal fragments is observed and whether Ap is generated from these accumulated precursor. A typical test compound in this assay prevents the generation of Ap out of -accumulated C-terminal fragments and is considered active with an IC 5 0 less than 100 M.
Dosage and Formulation The compounds determined from the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration. The active ingredient can be supplied in solid dosageTforms such as dry powders, granules, tablets or capsules; or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treatise with respect to pharmaceutical dosage forSi's Remington's Pharmaceutical Sciences, Mack Publishing.
The compounds determined from the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, -168tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed to prevent or treat neurological disorders related to P-amyloid production or accumulation, such as Alzheimer's disease and Down's Syndrome.
The compounds of this-invention can be administered by any means that produces contact of the active agent with-the agent's site of action in the body of a host, such as a human or a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The dosage regimen for the compounds determined from the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient,and the effect desired. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.
Advantageously, compounds determined from the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
The compounds identified using the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, -169using those forms of transdermal skin patches wall known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittant throughout the dosage regimen..
In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with. suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein.as carrier materials).
suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural.sugars such as glucose or p-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the Like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
The compounds determined from the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large -170unilamallar vesicles, and multilamellar vesicles. Liposomes can'be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds determined from the present invention may be coupled to-a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
Similar diluents can be used to make compressed tablets.
Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also -171used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
CZ -172- The Tables below provide representative Examnples of the compounds of Formula of the. present invention.
Table 1 Ex R1_ R2__ 1 H OH propyl 3;3-dinheny1 ropy1 2 H OH propyl 3-Phenoxybenzyl 3 1 H OH propyl Phenyl 4 H CH3 propyl 3-phenoxcybenzyl CH3 OCH3 prapyl 3-Phenoxybenz!A- 6 H OCH3 propyl 3-phenoxybenzyl 7 H H propyl 3 -phenoxcybenzyl 7A H NH2 propyl 3-Dhenoxybenzyl 8 H H ally 1 3-phenoxybenzyl 9 H OH allyl 3 -phenoxybenzyl H OH Propyl 3- 4-dichiorophenyl))-binz 1 11 H OH propyl 3-(4-fluoropheny1)-benzyI 12 H OH propyl 3- (4-methlyphenyl) -benzyl 13 H OH _propyl 3-(4-methoxyphenyl)-benzyl 14 H OH propy 3-(3-methy1 heny1)-benzy1 H OH propyl 3-(3-chloro-4-fluorophenyl)- 16 H OH propyl 3-W4trifluoromethylbenzyl 17 H OH p2ropyl 3-(3-methoxyphenyl)-benzyl 18 H OH propyl 3-(3-fluorophenyl)-benzyl 19 H OH propyl 3-(2-methoxyphenyl)-benzyl H OH propyl 3- (2-naphthy1)benzyI F21 H H propyl 13-(4-methoxyPhenyl)-benzyl -173- 22 H- H propyl 3-(3-fluorophenyl)-beizyl 23 H H prpl 3-(4-F 3 C-phenl1benfzyl 24 H4 H propyl 3-2, -C 2 -phenyl)benzyl 2S H H propyl 3-(4-H 3 C-phelyl)beflzyl 26 H H prpy 3-(4-H 3 CO-pheny1)belzyl 27 H H propyl 3-(3-Cl,4-F-phenyl)-benzyl 28 H H propyvl 3-(3-H3CO:-phenyl)benzyl 29 H H propyl 3-(2-H 3 CO-phenyl)benzyl H H .propyl 3-(4rH 3 31 H H propyl (4-F 3 C-phenyl) _____ylmethyl 32 H H propyl 3-(3-Cl,4-F-phenyl)-pyrid-5methyl 33 H n-butyl propyl 3-Ephenoxybenzyl 34 H 2-furyl- propyl 3-phenoxybenzyl H C5H9 Propyl 3-phenoxybenzyl 36 H cinnamyl propyl 3-phenoxybenzyl 37 H H ally1 benzoph norie-3-yl-methyl 38 H H propyl benzophenone-3-yl-methyl 39 H Hi propyl 4-(4-F 3 C-phenyl)beizy1 H H i-butyl 3-(2-tetrazo1yI-phenyI)-benzyl 5 =propyl 41 H H i-butyl 3-phenoxybenzyl 5 =propyl 43 H H H 3-phenoxvbenzyl For these adjacent to compounds the i-butyl substituent on the carbon
CR
3 in the captioned figure is actuallyJ-p1ropy1.
.Table 2 demonstrates representative compounds envisaged within the scope of the present invention. Each formulae at the start of Table 2 are intended to be paired with each entry in the table which-follows.
-174- For example the compound (2R, 3S) -hexahydro-1- (3 4 -dime thoxyphenyl) benzyl) -2 -oxo-1H-azepin-3 -yl] -2 (2 methyipropyl) (allyl) -butanediamide is represented by Example #139-A-j, which comprises the core A, SUCCInatej.
and entry #139.
For example the compound (2R,3S) N1-[6,7-dihydro-5-(3- 4-diinethoxyphenyl)benzyl) -6-oxo-5H-dibenz (b,djIazepin-7yl) (2-methyipropyl) (allyl) -butanediamide is represented by Example #139-B-j, which comprises the core succinate and entry #139.
For example the compound (2R,3S) Nl!-j1,3,4,5-tetrahydro- 1- 4-dimethoxyphenyl)benzyl) -2-oxo'-5- (phnhyl) -2H-l, benzodiazepin-3-yl]-2- (2-methyipropyl) (butyl) butanediaiide, is represented by Examiple 4139-C-ab,' which comprises the core C, succinate ab, and entry #13-9.
Table 2 o R, 0
H
2 N: LO'_N 'W-X-Y-z
R
3 0
A
o RS 0
H
2 NIK N.WXY.Z
R
3 0
C
H
2 N)YY -wx--
B
o
R
5 M 0
YZ
R
3 0 N\
D
o
R
5 0 Y Z
R
3 0 N\ o RS 0
H
2 NfiSkN 2" N W-X.Y.Z
R
3 0 N49
F
-175o R 5 H 0
N
R
3
G
H
2 N~Yf N .X--Z
R
3 0 wherein R 3 and R 5 are: o Rs H
R
3 0
F
H
o
R
0
Z
H2N
H
3
C
K
H
2
N'
a
HA
2
H
2 N0 f -176- 0
H
H
2 Ny <0 0
H
H
2
N
0.
H
0I 0
H
Ny H2NIi, r 0 0
H
H
2 N3 NVj
H
H
2
N~
t -177-
H
2 N :0
V
H
2
NN
~0
H
2 NN/ 0 H H2N H 2
NI
0 0 HNk aa 0
H
H
2
N:
0
AS-
0
H
2 N 0y 0 ae 0
H
N
H
2 Nk f0 ah
H
2 N0 *0
H
2
N'
-178- 0
H
H
2 NK
I
0
H
H
2 N N 0 0
H
H
2
N
0 0
H
H
2 N 0F an 0
H
H
2
N
0
H
2
N'
:0H
H
2
NN/
0~
H
2
N'
0
H
2
N'
0
H
H
2
NN'
_gI aw0
II
jO
H
2
N-
-179- 0 H H 0 HH Ny N N
HNH
2 N '1 H 2 N H 2 0 0 0l az ba bb 0 00
H
2 N y H 2 N NyHN bc bd 0 H0 H0 H
H
2 N N.,H 2 N Nyt- 2
NN
bf b bh 0 H 0
H
2 NY ItN H 2 N t H 2 Nk,- -180bi bm b bn Ex x y z 100 -CH2- phen-1.3-diyl bond phenyl..
101 -CH2- phen-1,3-diyl bond- 3,3-diphenylmethyl 102 -CH2- phen-1,3-diyl bond 2-F-phenyl 103 -CH2- phen-1,3-diyl band 3-F-phenyl 104 -CH2- phen-1,3-diyl band 4-F-phenyl 105 -CH 2 phen-1,3-diyl bond 2-Cl-phenyl 106 -CH2- phen-1,3-diyl bond 3-Ci-phenyl 107 -CH2- phen-1.3-diyl bond 4-Cl-phenyl 108 -CH2- phen-1,3-diyl bond 2-Me-phenyl 109 -CH2- phen-1,3-diyl bondc 3-Me-phenyl 110 -CH2- phen-1.3-diyl bond 4-Me-phenyI il -12 phen-1,3-diyl bond 2-Meo-phenyl -181- 112 -CH2 phen-1,3-diyl bond 3-Meo-phenyl 113 -CH2- phen-1.3-diyl bond 4-MeO-phenyl 114 -CH 2 phen-1,3-diyl bond 2-MeS-phenyl 115 -CR2- phen-1.3-diyl bond 3-iMeS-phienyl.
116 1-CH 2 phen-1,3-diyl bond 4.-MeS-phenyl 117 -CH 2 phen-1.3-dijyl bond 2-1F3C-pheiny1 118 -CH2 phen-1.3-diyl bond 3--F3C-phenyl 119 -CH2- phen-1,3-diyl bond 4-F3C-phelyl 120 -CR2- phen-1,3-diyl bond 2.3-diF-phenyl 121 -CR2- phen~l, 3-diyl bond 2.4-diF-phenyl 122 -CR2- phen-1,3-diyl bond 123 -CR2- phen-1.3-diyl bond 2,.6-diFmpheny1 124 -CH2- phen-1,3-diyl bond .3.4-ndiFrphen'1 125 -CH2- phen-1,3-diyl bond 126 -CR2- phen-1.3-diyl bond 2.'3-diC)-phenyd-- 127 -CR2- phen-1.3-diyl bond 2-di-phenyl 128 -CR 2 phen-1,3-diyl bond 129 -CR 2 phen-1,3-diyl bond 2,6-diCi-phenyl 130 -CR2- phen-1.3-diyl bond. 3,4-diCi-phenyl 131 -CR 2 phen-1,3-diyl bond 132 -H phen-1,3-diyl bond 2-Cl-3-F-phenyl 133 -CH2- phen-1,3-diyl bond 2-Cl-4-F-phenyl 134 -CR2- phen-1,3-diyl bond 2-C1-5-F-phenyl 135 -CR 2 phen-1,3-diyl bond 3-C1-4-F-phenyl 136 -CH2- phen-1,3-diyl bond 3-C1-5-F-phenyl 137 -CR2- phen-1,3-diyl bond 4-C1-2-F-phenyl 138 -CR 2 phen-1,3-diyl -bond.. 4-CI-3-F-Phenyl 139 -CR2- phen-1,3-diyl bond 2.3-di-MeO-phenyl 140 -CR2- phen-1,3-diyl bond 2,4-diMeo-phenyl 141 -CH2- phen-1,3-diyl bond 142 -CR2- phen-1,3-diyl bond 2',6-diMeO-phenyl 143 -CR2- phen-1,3-diyl bond 3.4-dimeo-phenyl 144 -CR2- phen-1,3-diyl bond 3, 145 -CR2- pheri-1,3-diyl bond. cyclopropyl 146 -CH2- phen-1,3-diyl bond cyclobutyl 147 -CR 2 phen-1.3-. diyl bond cyclopentyl 148 -CR2- 15hen-1,3-diy1 bond cyclohexyl 149 -CR2- phen-1. 3-diyl bond 2-furariyl 150 -CH 2 phen-1,3-diyl bond 2-thienyl 151 -CR2- phen-1,3-diyl bond 2-jimidazolyl 152 -CR2- phen-1.3-diyl bond 2-pyriayl 153 -CH2- phen-1,3-diyl bond-- 3 gyiyI vw- 154 -CR 2 phen-1,3-diyl bond 4-pyridyf-! 155 -CR 2 phen-1.3-diyl bond N-morpholinyl 156 -CR2- phen-1,3-diyl bond N-piperidinyl 1S7 -CR 2 phen-1.3-diyl bond 3-Ne-2-pyridyl 158 -CR 2 phen-1,3-diyl t bond 14-Me-2-pyridyl 1_!591 -CR 2 phen-1,3-diyl bond I1-indolyl -182- 160 -CH2 phen-1,3-diyl bond 2-benzothienyl 161 -CH- 2 phen-1,3-diyl bond 2-benzofuranyl 162 -CH2- phen-1,3-diy1 bond 1-benzimidazole 163 -CH2- phen-1,3-diyl bond 2-nap~hthyl 164 -CH2- pyridin-3,5-diyl bond lphenyl 165 -CH2- pyridin-3,5-diyl bond 3,3-diphenylmethyl 166 -CH2- pyridin-3,5-diyl bond 2-F-phenyl.- 167 -CH2- pyridin-3,5-diyl bond 3-F-phenyl 168 -CH2- pyridin-3,5-diyl bond 4-F-phenyl 169 -CH2- pyridin-3.5-diyl bond I2-Cl-phenyl.
170 -CH2- pyridin-3,5-diyl bond 3-Ci-phenyl 171 -CH2- pyridin-3,5-diyl bond 4-Ci-.phenyl 172 -CH2- pyridin-3,5-diyl bond 2-Me--phenyl 173 -CH2- pyridin-3,5-diyl bond 3-M~e-pheny1 174 -CH2- pyridin-3,5-diyl bond 4-Me-phenyl 175 -CH2- pyridin-3,5-diyl bond J2-Meo-phenyl 176 -CH2- pyridin-3,5-diyl- bond 3-Meo-phenyl 177 -CH2- pyridin-3,5-diyl bond 4-MeO-phenyl 178 -CH2- pyridin-3,5-diyl bond 2-MeS-phenyl 179 -CH2- pyridin-3,5-diyl bond 3-HeS-phenyl 180 -CH 2 pyridin-3,5-diyl bond 4-MeS-phenyl 181 -CH2- pyridin-3,5-diyl bond 2-F3C-phenyl 182 -CH2- pyridin-3,5-diyl bond 3-F3C-phenyl 183 -CH2- pyridin-3,5-diyl bond 4-F3C-phenyl 184 -CH2- pyridin-3.5-diyl bond 2.3-diF-phanyl 185 -CH-2- pyridin-3,5-diyl bond 2,4-diF-phenyl 186 -CH2- pyridin-3,5-diyl bond 187 -CH2- pyridin-3,5-diyl bond_ 2,6-diF-phenyl 18e -CH2- pyridin-3,5-diyl bond 3,4-diF.-phenyl 189 -CH 2 pyridin-3,5-diyl bond- 190 -Cl- 2 pyridin-3,5-diyl bond 2,3-diCI-phe!nyl_ 191 -CH2- pyridin-3,5diyl' bond 2,4-diCl-phenyl 192 -CH2- pyridin-3,5-diyl bond 193 -CH2- pyridin-3,5-diyl bond 2,6-diCl-pieryl 194 -CH-2- pyridin-3,5-diyl bond 3,4-diCl-phenyl 195 -CH2- pyridin-3.5-diyl bond 196 -CH2- pyridin-3,5-diyl bond 2-C1-3-F-phenyl 197 -CH2- pyridin-3,5-diyl bond 2-C1-4-F-phenyl 198 -CH2- pyridin-3,5-diyl bond 199 -CH2- pyridin-3,5-diyl- bond 3-C1-.4-F-phenyl 200 -CH2- pykidin-3,5-diyl bond 201 -CH2- pyridin-3,5-diyl bond 4-C1-2-F-phenyl 202 -CH2- pyridin-3,5-diyl bond 4-C1-3-F-phenyl 203 -CH 2 pyridin-3,5-diyl bond 2.3-diMeO--phenyl 204 -CH 2 pyridin-3,S-diyl bond 2,4-diMeO-phenyi -CH2- pyridin-3,5-diyl bond 2. 26 -CH2- pyridin-3.S-diyl bond 2.6-di~e0-phenyl 207 CH 2 pyridin-3,5-liyl bond 3,4-di~eO-phenyl -183- 209 -CR2 pyridin-3, 5-diyl bond 3,S-diMeo-phell 209 -CR2- pyridin-3,5-diyl bond cyclopropyl 210 -CR2- pyridin-3, 5-diYl bond cyclobutyl 211 -CR2- pyridin-3,5-diYl bond cyclopentyl 212 -CR2- pyridin-3,5-diyl bond cyclohexyl 213 -CH2- pyridin-3.5-diYl bond 2-f uranyl 214 -CR2- pyridin-3,5-diYl bond 2-thienyl 215 -CH2- pyridin-3,5-dil bond 2-imidazolyl 216 -CH2- pyr-dirx-3,5-diyl bond 2-pyridyl 217 -CH2- pyridin-3,5-diYl bond. 3-pyridyl- 28 C 2 pyridin- 3, 5- diyl bond 4-pyridyl 219 -CI1 2 pyridin-3, S-.diyl bond N-morpholinYl 220 -CH2 pyridin.-3, 5-diyl bond N-piperidinyl- 221 -CH2- prdn35il bod 3-Me-2-pyridyl 22 C2 pyridin-3,5-diYl .bond -M-pyil 223 -CR2 pyridin-3.5-diyl bond 4-e-indolyl 224 -CH2- pyridin-3.5-diyl bond 1-inolyltiey 224 -CH 2 pyridin-3,5-diYl bond -2-benzoturanyl 226 -CR2- pyridin-3,5-diYl bond 1-benzomldanole 227 -CR2- pyridin-3,5-diYl bond 2-nphthyl ol 228 -CR2- pyridin-2,6-diYl bond 2phyl 229 -CH2- pyridirx-2.6-diyl bond 3p-henyylehy 230 -CH2- pyridin-2.6-diyl bond 2,--phenylmty 231 -CR2- pyridin-2,6-diyl bond 3-F-phenyl 232 -CR2- pyridin-2.6-diyl bond 4-F-phenyl 233 -CR2- pyridin-2,6-diyl bond 2-C-phenyl 234 -CH2- pyridin-2,6-diYl band 3-Cl-phenyl 235 -CH2- pyridin-2,6-diyl bond 4-Cl-phenyl 235 -CR2- pyridin-2,6-diyl bond 2-Me-phenyl 237 -CH2- pyridin-2,6-diyl~ bond 3-Me-phenyl 238 -CR2- pyridin-2,6-diyl bond 4-Me-phenyl.
239 -CH2- pyridin-2,6-diyl bond 2-kMe-peny1, 240 -CH2- pyridin-2,6-diYl' bond 3-MeO-phenyl 241 -CH2- pyridin-2,6-diYl bond 4-MeOrphenyl 242 -CR2- pyridin-2,6-diYl bond 2-MeS-phenyl 243 -CH2- pyridin-2,6-diyl bond 3-MeS-pheny.
244 -CR2- pyridin-2,6-diyl bond 3-M~eS-pheny1 245 -CH2- pyrdin-2,6-diyl bond 2-F3C-phenyl 246 -CR2- pyridin-2,6-diyl bond 2-F3C-phenyl- 247 -CH2- pyridin-2,6-diyl bond 3-F3C-phenyl 248 -CR2- pyridin-2,6-diyl bond 2. -F-pheny].
249 -CH2- pyridin-2,6-diy- bond 2,3-dj.F-phenyl- 240 -CR2- pyridin-2,6diyl bond 2,5-di iF PULL 251 -CR2- pyridin-26-diyl bond 2.6-diF-phnyl 252 -CR2- pyridin-2.6-diyl -bond 3.4-diF-phenyl -CH2- nyridin-2,.6-divi. bond ,-iFpey 253 254 -CH2- -CR2- -CH2- J 4 bond bond I i3-diC-pheny nvridin-2,.6-diyl bond 2,3-diCl-phenyl 4 bond I 2,4-diCi-pheny] nvridin-2. 6-diyl bond 2,4-dicl-phenyl I I -184- 256 -H pyridin-2,6-diyl bond 257 -CU 2 pyridin-2,6-diyl bond 2,6-diCl-phenyl 258 -CH2- pyridin-2,6-diyl *bond 3,4-diCi--phenyl 259 -0112- pyridin-2,6-dikl -bonid 3 260 -CH 2 pyridin-2,6-diyl -bond 2-C1-3-F=Phenyl 261 -0112- pyridin-2,6-diyl bond. 2-C1-47F-phenyl 262 -CH2- pyridin-2. 6-diyl bond 2-C1-5-F-phenyl 263 -CH2- pyridin-2,6-diyl bond 3-C1-4-F-phenyl 264 -0112- pyridin-2,6-diyl bond 3-Cl-S-F-phenyl 26S -H pyridin-2,6-diyl bond. 4-C1-2-F-phenyl 266 -0112- pyridin-2,6-diyl bond 4-Cl-3-F-phenyl 267 -CH 2 pyridin-2,6-diyl bond 2,3-diMeO-phenyl 268 -0112- pyridin-2, 6-diyl-- bond. 2.4-diMeO-phenyl 269 -0112- pyridin-2,6-diyl bond 270 -CH 2 pyridin-2,6-diyl -bond 2,6-diMeO-pheny.
271 -CH2- pyridin-2, 6-dliyl bond 3.4-di~eO-phenyl 272 -CH2- pyridin-2,6-diyl bond 273 -CU 2 pyridin-2,6-diyl bond cyclopropyl 274 -C112- pyridin-2,6-diyl bond cyclobutyl 275 -CH2- pyridin-2,6-diyl bond cyclopentyl 276 -0112- pyridin-2. 6-diyl bond cyclohexyl 277 -0112- pyridin-2,6-diyl bond 2-furanyl 278 -CH2- pyridin-2,6-diyl bond 2-thienyl 279 -CH 2 pyridin-2,6-diyl bond- 2-imidazolyl 280 -CH2- pyridin-2,6-diyl bond 2-pyridyl 281 -0112- pyridin-2,6-diyl bond 3-pyridyl 282 -CH 2 pyridin-2,6-diyl bond 4-pyXridyl 283 -CH2- pyridin-2, 6-diyl. bond- 9--morpholinyl 284 -CH2- pyridin-2.6-diyl bond N-piperidinyl 285 -CH 2 pyridin-2,6-diyl bond 3-Me-2-pyridyl 286 -CH 2 pyr idin-2,6-diyl bond 4-Me-2-pyridyl 287 -012- pyridin-2.6-diyl bond 1-indolyl 288 -CH 2 pyridin-2,6-diyl bonrd -2-benzothienyl 289 -0112- pyridin-2,6-diyl bond 2-benzofuranyl 290 -C112- pyridin-2,6-diyl bond 1-benzimidazole 291 -0112- pyridin-2,6-diyl bond 2-niphthyl 292 -CH2- pyridin-2,4-diyl bond phenyl 293 -0112- pyridin-2.4-diyl bond 3,3-diphenylniethyl 294 -0112- pyridin-2.4-diyl bond 2-F-phenyl 295 -C112- pyridin-2,4-diyl bond 3-F-phenyl 296 -CH2- .pyridin-2,4-diyl bond 4-F-phenyl 297 -0112- pyridin-2,4-diyl bond 2-C1-phenyl 298 -CH2- pyridin-2.4-diyl bond 3-C1-phenyl 299 -CH2- pyridin-2.4-diyl bond 4-01-phenyl 300 -0112- pyridin-2.4-diyi bond. 2-Me-phenyl -11- yrdi-24-iy bnd 3-e-hey 302 -CH2- pyridin-24-diyl bond 4-Me-phenyl 303 -0112- pyridin-2.4-diyl bond 2-Me-phenyl -185- 304 -CH2- pyridin-2,4-aiyl bond 3-MeO-phenyl 305 -CR2- pyridin-2,4-diyl bond 4-MeO-phenyI 306 -CR2- pyridin-2,4-diyl bond 2-MeS-phenyl 307. -CR2- pyridin-2,4-diyl bond 3-MeS-phenyl 308 -CH2- pyridin-2,4-diyl-.- bond 4-MeS-phelny1A 309 -CR2- pyridin-2,4-diyl bond 2-F3C-phenyl 310 -CH2- pyridin-2,4-diyl bond 3-F3C-phenyl 311 -CR2- pyridin-2,4-diyl bond 4-F3C-pherlyl 312 -H pyridin-2,4-diyl bond 2,3-diF-phenyl 313 -CR2- pyridin-2,4--diyl bond _2,4-diF-:Pl nyl 314 CR2- py'din-24dy bad 314 -CR2 pyridi-2,4-diyl bond 26dFpey 315 -CR2- pyridin-2,4-diyl bond 3,4-diF-phenyl.
316 -CR2- pyridin-2,4-diyl bond 318 -CH2- pyridin-2,4-diyl- bond 2,3-diF-phenyl 319 -CR2- pyridin-2,4-diyl bond 2,4--diCl-phienyl 320 -CR2- pyridin-2,4-diyl bond 321 -CR2- pyridin-2,4-diyl bond 2,6-diCl-phenyl 322 -CR2- pyridin-2.4-diyl bond 3,4-diCi-phenyl 323 -CH2- pyridin-2,4-diyl- bond 3, 324 -CH2- pyridin-24-diyl bond 2-1-3--phenyl 325 -CR2- pyridin-2,4-diyl bond 2-C1-4-F-phenyl 326 -CR2- pyridin-24-diyl. bond 2-C1-5-F-phenyl 326 -C2- pyridin-2,4-diyl bond 3-C1-4-F-phenyl 328 -C2- pyridin-2,4-diyl bond 3-C1-5-F-phenyl 329 -CR 2 pyridin-24-diyl bond 3-CL-2-F-phenyl 330 -CR2- pyridin-24-diyl bond 4-Cl-3-F-phenyl 331 -C2- 'rdin-2,-diyl band 2,Cl3-ie-phenyl 332 -CR2- pyridi-2,4-dy od 24d~Opey 333 -CR2- pyridin-2,4-diyl bond- 334 -CR2- pyridin-2,4-diyl bond 2,4-diMeo-phenyl 335 -CR2- pyridin-2,4-diyl bond 3,-diMeO-phenyl 336 -CH2- pyridin-2,4-diyl bond. 335 -CR2- pyrjdin-2,4-diyl bond cyclopro0plhy 338 -CR2- pyridin-2,4-diyl bond cycli~obutyl y 337 -CR2- pyridin-2,4-diyl bond cyclopentyl 340 -CR2- pyridin-2,4-diyl bond cyclohexyl 341 -CR 2 pyridin-2,4-diyl bond 2-furnyl 342 -CH 2 pyridin-2,4-diyl bond 2-tlheyl 343 -CR2- pyridin-2,4-diyl bond 2-imiazyl 344 -CH2- pyridin-2.4-diyl bond. 2-pyidyl 345 -CH2- pyridin-2,4-diyl bond.. 2-imidayl 344 -CR2- pyridin-2,4-diyl bond 2-pyridyl.
345 -CH2- pyridin-2,4-diyl bond N3-moyrpiyl e 348 -CR2- pyridin-2,4-diyl bond N-pipridriyl 349 -CR2- pyridin-2.4-diyl bond 3-Me-2-pyridyl 350 -CR2- pyridin-2,4-diyl bond 4-Me-2-pyridyl 351 -CR2- pyridin-2,4-diyl bond 1-indolyl -186- 352 -CR2- pyridin-2,4-diyl bond 2-benzothienyl 353 -CR2- pyridin-2,4-diyl bond 2-benzofuranyl 354 -CH2- pyridin-2.4-diyl bond I -benz imida Zole- 355 -CH2- pyridin-2,4-diyl -bond 2-naphthyl- 356 1-CH2- pyridin-4,2-diyf_' bonid- Ohei- 357 -CR2- pyridin-4,2-diyl bond 3,3-diphenylmethyl 358 -CH2- pyridin-4.2-diyl. bond 2-F-phenyl,.
359 -H pyridin-4,2-diyl bond 3-F-iphenyl 360 -CR2- pyridin-4,2-diyl bond 4-F-phenyl 361 -CR2- pyridin-4,2-diyl bond 2-Ci-phenyl 362 -CR2- pyridin-4,2-diyl. bond 3-Cl-phenyl.
363 -CH 2 pyridin-4,2-diy. bond .4-Cl-pheny.
364 -CH2 -yii-,-il bond -2-Me-phenyl 365 -C2- pyridin-4,2-dy bod 3-ephnl 366 -CH2- pyridin-4,2-diyl bond 4-Me-phenyl.
367 -cH2- pyridin-4,2-diy. bond 2-Me-phenyl 368 -CR2- pyridin-42-diyl bond 3-MeO-phenyl 369 -CR2- pyridin-4,2-diyl bond 3-MeO-phenyl 370 -CR2- pyridin-4,2-diyl bond 2-MeS-phenyl 371 -CR2- pyridin-4,2-diyl bond 3-HeS-phenyl 372 -CH2- pyridin-42-diyl bond 4-MeS-phenyl 373 -CR2- pyridin-4.2-diyl bond 2-F3C-phenyl 374 -CH2- pyridin-4,2-diyl bond 3-F 3 C-phenyl 375 -CH2- pyridin-4.2-diyl bond 4-F3C-phenyl 376 -CR2- pyridin-4,2-diyl bond 2.-F-phenyl 376 -CR2- pyridin-4,2-diyl bond 2,4-diF-phenyl 378 -CH2- pyridin-42-diyl bond 2,4-diF-phenyl 379 -CH2- pyridin-4,2-diyl bond 2.65-diF-phenyl 380 -CR2- pyridin-4,2diyl band 3,4-diF-phenyl 381 -CR2- pyridin-4,2-diyl bond 3,4-diF-phenyl 382 -CR2- pyridin-4,2-diyl bond 2.3-diF-phenyl 383 -CR2- pyridin-42-diyl bond 2.4-diCi-phenyl 384 -CR2- pyridin-4,2-diyl .Bond 385 -CR2- pyridin-4,2-diyl bond 2,6-dli Ci-phenyl 386 -CR2- pyridin-4,2-diyl bond 3,4-didi-phenyl 387 -CH2- py'ridin-42-diyl bond 388 -CR2- pyridin-4.2-diy l bond 2-C1-3-F-phenyl 389 -C2- pyridin-42-diyl bond 2-Cl--F-phenyl 389 -C2- pyridin-42-diyl bond 2-Cl-4--phenyl 390 -CR2- pyridin-4,2-diyl bond 392 -CR2- pyridin-4,2-diyl bond 393 -CH~m pyridin-4,2-diyl bond 3-Cl-2-F-phenyl 393 -CH2- pyridin-4,2-diyl bond 4-C1-3-F-phenyl 394 -CH2- pyridin-4,2-diyl band 2,Cl3-iP-phenyl 396 -CH2- pyridin-4,2-diyl bond 2,-diMeo-phenyl 396 -CR2- pyridin-4,2-diyl bond 2,4-di~eo-phenyl 398 -CH2- pyridin-42-diyl bond 2,-diZ~eo-phenyl 38 -CR2- pyridin-4,,27diyl bond 3,4-diMeO-phenyl -187- 400 -CH2- pyridin-4,2-diyl bond 401 -CH2- pyridin-4,2-diyl bond cyclopropyl 402 -CH2- pyridin-4,2-diyl bond cyclobutyl 403 -CR2- pyridin-4.2-diyl bond cyclopentyl 404 -CR2- pyridin-4,2-diyl bond cyclohexyl 405 -CH2- pyridin-4,2-diyl bond 2-furanyl 406 -CR2- pyridin-4,2-diyl bond 2-thienyl 407 -CH2- pyridin-4.2-diyl bond 2-imidazolyl 408 -CR2- pyridin-4,2-diyl bond 2-pyridyl 409 -CH2- pyridin-4.2-iyl bond 3-pyridyl 410 -CH2- pyridin-4,2-diyl -bond 4-pyridyl 411 -CH2- pyridin-4,2-diyl -bond N-rnorpholinyl 412 -CH2- pyridin-4,2-diyl bond N-piperidinyl 413 -CH2- pyridin-4,2-diyl bond 3-Me-2-pyridyl 414 -CH 2 pyridin-4,2-diy(l bond 4-Me-2-pyridyl 415 -CH2- pyridin-4,2-diyl bond 1-indolyl 416 -CH2- pyridin-4,2-diyl bond 2-benzothienyl 417 -CH 2 pyridin-4,2-diyl bond 2-benzofuranyl 418 -CR2- pyridin-4.2-diyl bond 1-benzimidazole 419 -CR2- pyridin-4.2-diyl bond 2-naphthyl 420 -CR2- piperidin-1,3-diyl bond phenyl 421 -CR2- piperidin-1,3-diyl bond 3,3-diphenylmethyl 422 -CH2- piperidin-1.3-diyl bond 2-F-phenyl 423 -CH2- piperidin-1,3-diyl bond 3-F-phenyl 424 -CR2- piperidin-1,3-diyl bond 4-F-phenyl 425 -CH2- piperidin-1,3-diyl band 2-Ci-phenyl 426 -CR 2 piperidin-1,3-diyl bond 3-Ci-phenyl 427 -OH 2 piperidin-1,'3-diyl bond 4-Ci-phenyl 428 -CR2- piperidin-1,3-diyl bond 2-Me-phenyl 429 -OH 2 piperidin-1,3-diyl bond 3-Me-phenyl 430 -CR2- piperidin-1,3-diyl bond 4-Me~phenyl 43L- -CH2- piperidin-1,3-diyl bond 2-MeO-phenyl 432 -CH 2 piperidin-1,3-diyl band 3-MeO-phenyl 433 -CR2- piperidin-1,3-diyl bond 4-KeO-pheiy 434 -CR2- *piperidin-1,3-diyl bond 2-MeS-phenyl 435 -CR2- piperidin-1,3-diyl bond 3-MeS-phenyl 436 -CR2- piperidin-1,3-diyl bond 4-MeS-phenyl 437 -OH 2 piperidin-1,3-diyl bond 2-F3C-phenyl 438 -CR2- piperidin-1,3-diyl bond 3-F3C-phenyl 439 -CR2- piperidin-1,3-diyl bond 4-F3C-phenyl 440 -CR2- piperidin-1,3-diyl bond 2,3-diF-phenyl 441 -CR2- piperidin-1,3-diyl bond 2,4-diF-pheiyl 442 -CR2- piperidin-1,3-diyl band 443 -CR 2 piperidin-1,3-dliyl bond 2.6-diF-phenyl 444 -CR 2 piperidin-1,3-diyl bond 3.4-diF-phenyl 4S -CR2- piperidin-1,3-diyl band 446. -CR 2 piperidin-1,3-diyl band 2.3-diCi-phenyl 447 -CR 2 piperidin-1. 3-diyl bond 2,4-diCl-phenyl -188- 448 -C112- piperidin-1,3-diyl bond 449 -CH2- piperidin-1,3-diyl bond 2,6-diCi-phenyl 450 -CH2- piperidin-1.3-diyl bond 3,4-diCi-phenyl 451 -CH2- piperidin-1,3-diyl bond 452 -CH2- piperidin-1.3-diyl. bond 2-Cl-3:-F-phenyl 453 -C2- piperidin-i.3-diyl bond 2-Cl-4-F-phenyl 454 -CII2- piperidin-1,3-diyl bond 455 -CH2- piperidin-1,3-diyl bond 3-C1-4-F-phenyl 456 -CH 2 piperidin-1,3-diyl bond 3-C1-5-F'-phenyl 457 -CH2- piperidin-1,3-diyl bond 4-Cf7-2-F-phenyl 458 -CH2- piperidin-1,3-diyl bond 4-Cl-3-F-phenyl 459 -H piperidin-1,3-diyl bond 2,3-diMeO-phenyl 460 -CH2- piperidin-1.3-diyl bond 2,4-dixeO-phenyl 461 -CH2- piperidin-1, 3-diyl bond 2, 462 -CH 2 piperidin-1,.-diyl bond 2,6-di~eO-phenyl 463 -CH2- piperidin-1,3-diyl bond 3,4-diMeO-phenyl 464 -CH2- piperidin-1.3-diyl bond 465 -CH2- piperidin-1,3-diyl bond cyclopropyl 466 -CH2- piperidin-1,3-diyl bond cyclobutyl 467 -CH2- piperidin-1,3-diyl band cyclopentyl 468 -CH2- piperidin-1,3-diyl bond cyclohexyl 469 -CH2- piperidin-1,3-diyl bond 2-furanyl 470 -CH2- piperidin-1.3-diyl bond 2-thienyl 471 -CH2- piperidin-1,3-diyl bond 2-imida2olYl 472 -CH2- piperidin-1,3-diyl bond 2-pyridyl 473 -H piperidin-1,3-diyl bond 3-pyridyl 474 -H piperidin-1,3-diyl. bond4-pyridyl 475 -CH2- piperidin-1,3-diyl bond N-morphplinyl.
476 -CH2- piperidin-1,3-diyl bond ?-piperidinyl 477 -CH2- piperidin-1,3-diyl bo-nd -37f- Z-2.pyr idyl 478 -CH2- piperidin-1,3-diyl bond 4-Me-2-pyrid'1 479 -CH2- piperidin-1.3-diyl bond 1-indolyl 480 -CH2- piperidin-1,3-diyl bond 2-benzothienyl 481 -CH2- piperidin-1,3-diyl bond 2-benzof~uranyl 482 -CH2- piperidin-1,3-diyl bond 1-benzimidazole 483 -CH2- piperidin-1,3-diyl bond 2-naphthyl 484 -CH2- piperidin-3,1-diyl bond phenyl 485 -CH2- piperidin-3,1-diyl bond 3,3-diphenylmethyl 486 -CH2- piperidin-3.1-diyl bond -2-F-phenyl 487 -CH2- piperidin-3,1-diyl bond 3-F-phenyl 488 -CH 2 piperidin-3.1-diyl bond 4-F-phenyl 489 -CH2- piperidin-3,1-diyl bond 2-Ci-phenyl 490 -CH2- piperidin-3,1-diyl bond 3-Ci-phenyl 491 -CH2- piperidin-3,1-diYl bond 4-Ci-phenyl 492 -CH2- piperidin-3.1-diyl 'bond 2-Me-phienyl' 493 -CH2- piperidin-3.1-diYl bond 3-Me-phenyl 494 -CH2- piperidin-3,1-diyl bond 4-Me-phenyl 495 -CH2- piperidin-3.1-diyl bond 2-MeO-phenyl -189- 496 -CR2 piperidin-3.1-diyl- bond 3-MeD-phenyl 497 -CH2- piperidin-3,1-diyl bond 4-Meo-phenyl 48 -CR2- piperidin-3.1-diyl bond 2-MeS-phenyl 499 -CH2- piperidin-3,1-diyl bond 3-ieS-phenyl- 500 -CH2 piperidin-3.1-diyl bond 4-MeS-phenyl.-.
501 -CR2- piperidin-3.1-diyl bond 2-F3C-phenyl 502 -CR2- piperidin-3.1-diyl bond. 3-F3C-phenyl- 503 -CR2- piperidin-3.1-diyl *bond 4-F 3 C-phenyl- 504 -CR 2 piperidin-3,1-diyl bond 2,3-diF-phenyl 505 -CH2- piperidin-3.1-diyl bond 2,4-diF-phenyl.
506 -CR2- piperidin-3.1-diyl bond 507 -CH2- piperidin-3,1-diyl bond 2,6-diF-phenyl 508 -CR2- piperidin-3.1-diyl bond 3,4-diF-phenyl.
509 -CH2- piperidin-3.1-diyl bond 510 -CR2- piperidin-3.,l-diyl bond 2.3-diCl-phenyl 511 -CH2- piperidin-3.1-diyl bond 2.4-diCl-phenyl 512 -CH2- piperidin-3.'1-diyl bond 513 -CR2- pi.peridin-3,1-diyl bond 2. 6-diCl-phenyl 514 -CR2- piperidin-3,lrdiyl bond 3,4-diCl-phenyl.
515 -CH2- piperidin-3.1-diyl bond 516 -CR2- piperidin-3,1-diy. bond 2-Cl-3-F-phenyl 517 -CR2- piperidin-3.1-diyl bond 2-C1-4-F-phenyl 518 -CR2- piperidin-3.1-diyl bond 2-C1-5-F-phenyl 519 -CR2- piperidin-3.1-diyl bond 3-C1-4-F-phenyl 520 -CH2- piperidin-3,1-diyl bond 3-C1-5-F-phenyl 521 -CR2- piperidin-3.1-diyl bond 4-Cl-2-F-phenyl 522 -C112- piperidin-3,1-diyI bond 4-C1-3-F-phenyl 523 -CR2- piperidin-3,1-diyl bond 2, 3-diMeO-phenyl 524 -CH2- piperidin-3,1-diyl bond 2,4-diMeo-phenyl 525 -CR2- piperidin-3,1-diyl bond 526 -CR2- piperidin-3.1-diyl bond 2.6-diMeO-.phenyl 527 -CR2- piperidin-3*.1-diyl bond 3,4-diMeO-phenyl 528 -CR2- piperidin-3,l-diyl bond 3. 529 -CR2- piperidin-3,1-diyl bond- cyclopropyl 530 -CR2- piperidin-3,1-diyl bond cyclobutyl 531. -CR2- piperidin-3.1-diyl bond cyclopentyl 532 -CH2- piperidin-3,1-diyl bond cyclohexyl 533 -CH2- piperidin-3,1-diyl bond 2-furanyl 534 -CH2- piperidin-3,1-diyl bond 2-thienyl -CR2- piperidin-3,1-diyl bond 2-imidazolyl 536 -CR2- piperidin-3.1-diyl bond 2-pyridyl 537 -CR2- piperidin-3.1-diyl bond 3-pyridyl 538 -CH2- piperidin-3.1-diyl bond 4-pyridyl 539 -CR 2 piperidin-3,1-diyl bond N-zuorpholinyl 540 -CR2- piperidin-3,1-diyl bond N-piperidinyl 541 -CH2- piperidin-3*1-diyl bond 3-Me-2-pyridyl 542 -CR2- piperidin-3,1-diyl bond 4-Me-2-pyridyl 54ii31 -CR2- 1-piperidin-3,1-diyl bond 1-indolyl -190- 544 -H piperidin-3,1-diyl bond 2-benzothienyl 545 -CR2- piperidin-3,1-diyl -bond 2-benzofuranyl 546 -CR2- piperidin-3.1-diyl bond 1-benzimidazole 547 -CH 2 piperidin-3.1- diyl .bond 27naphthyl 548 -CH 2 cyclohex-1,3-diyl bond phenyl 549 -H cyclohex-I,3-diyl bond S-,3 -diphenylmeihylj 550 -CR 2 cyclohex-1,3-diyl bond 2-F-phenyl 551 -CR2- cyclohex-1,3-diyl bond 3-F-phenyl 552 -cR2- cyclohex-1,3-diyl bond 4-F-phenyl 553 -CH2- icyclohex-1.3-diyl bond 2-Ci-phenyl- 554 -CR2- cyclohex-1,3-diyl bond 3-Ci-phenyl 555 -CH2- cyclohex-1,3-diyl bond 4.-Ci-phenyl 556 -CR2- cyclohex-1,3-diyl bond 2-Me-phenyl.
557 -CR2- cyclohex-1,3-diyl bond 3-Me-phenyl 558 -CR2- cyclohex-1,3-diyl bond 4-Me '-phen=yl 559 -CR2- cyclohex-1,3-diyl bond 2-14e0-phenyl 560 -CR2- cyclohex-1,3-diyl bond 3-MeU-phenyl 561 -CH 2 cyclohex-1,3-diyl bond 4-Meo-phenyl 562 -CH2- cyclohex-1,3-diyl bond 2-MeS-pheny.
563 -CH2- cyclohex-1,3-diyl bond 3-MeS-phenyl 564 -CR 2 cyclohex-1,3-diyl bond 4-MeS-phenyl 565 -CH2- cyclohex-1,3-diyl bond 2-F3C-phenyl 566 -CR2- cyclohex-1,3-diyl bond 3 -F3C-phenyl 567 -CR2- cyclohex-1,3-diyl bond 4-F3C-phenyl 568 -cR2- cyclohex-1,3-diyl bond, 2,3-diF-phenyl 569 -CH2- cyclohex-1,3-diy. bond 2,4-diF-phenyl 570 -CR2- cyclohex-1.3-diyl bond 2,5-diF-phenyl 571 -CH2- cyclohex-1,3-diyl bond 2,6-diF-phenyl 572 -CH2- cyclohex-1,3-diyl bond 3,4-diF-phenyl 573 -CH2- cyclohex-1,3-diyl bond 574 -CH2-. cyclohex-1,3-diyl bond 2.3-diCi-phenyl 575 -CR2- cyclohex-1,3"diyl bond 2;4-diCl-phenyl 576 -CR2- cyclohex-1,3-diyl bond 577 -CR2- cyclohex-1,3-diyl bond 2. 6-diCi-phenyl 578 -CR2- cyclohex-l,.3-diyl bond 3,4-diCl-phenyl 579 -CR2- cyclohex-1,3-diyl bond 580 -CR2- cyclohex-1,3-diyl bond 2-Cl-3-F-phenyl 581 -CR2- cyclohex-1,3-diyl bond 2-C1-4-F-phenyl 582 -CR2- cyclohex-1,3-diyl bond 2-C1-5-F-phenyl 583 -CR2- cyclohex-1,3-diyl bond 3-Cl-4-F-phenyl 584 -CR2- cyclohex-1,3-diyl bond 3-Cl-S-F-phenyl 585 -CR2- cyclohex-1,3-diyl bond.~* 586 -CH2- cyclohex-1,3-diyl bond 4-Cl-3-F-phenyl 587 -CH2- cyclohex-1,3-diyl bond 2,3-diMeo-phenyl 588 -CR2- cyclohex-1,3-diy. bond 2,4-diMeo-phenyl 589 -CR2- cyclohex-1. 3-diyl bond 2, 590 -CR2- cyclohex-1,3-diyl bond 2,6-diMeo-phenyl 51 -CR2- cyclohex-1,3-diyl bond 3,4-dimeo-phenyl -191- 592 -CH2- cyclohex-1,3-diyl bond 593 -CH 2 clclohex-1,3-di'yl bond cyclopropyl 594 -CH2- cyclohex-1.3-diyl bond- -cyplobutyl 595 C2 cyclohex-1,3-diyl bond cyclopentylrj 596 -C112- cyclohex-1,3-diyl bond cyclohexyl S97 -CH2- cyclohex-1,3-diyl bond 2-furanyl 598 -CH2- cyc Iohex- 1.3 -diyrl bond 2tiey 599 -CH2- cyclohex-1,3-diyl bond 2-itnidazolyl 600 -CA 2 cyclohex-1,3-diyl bdnd 2-pyridyl 601 -CH2- cyclohex-1,3-diyl bond 3:pyridyl 602 -CH2- cyclohex-&,3-diyl band 4-pyridyl 603 -CH2- cyclohex-1,3-diyl. 'bond N-mor holinyl 604 -CH2- cyclohex-1,3-diyl bond N-piperidinyl 605 -CH2- cyclohex-1.3-diyl band 3-Me-2-pyridyl 606 -CH2- cyclohex-1,3-diyl bond 4-Me-2-pyridyl 607 -d112- cyclohex-1,3-diyl bond 1-iridolyl 608 -CH2- cyclohex-1.3-diyl bond 2-benzothienyl 609 -CH 2 cyclohex-1,3-diyl bond 2-benzofuranyl 610 -C112- cyclohex-1,3-diyl bond 1-benziniidazole 611 -CH 2 cyclohex-1,3-diyl bond 2-naphthyl 612 -CH2- cyclopropan-1,2-diyl. bond phenyl 613 -CH2- cyclopropan-1,2-diyl bond 3,3-diphenylmethyl 614 -CH2- cyclopropan-1,2diyl bond 2-F-phenyl 615 -CH2- cyclopropan-1,2-diyl bond 3-F-phenyl 616 -CH2- cyclopropan-1,2-diyl bond 14-F-phenyl 617 -CH2- cyclopropan-1,2-diyl bond 2i-Ci-phenyl 61.8 -CH2- cyclopropan-1,27diyl band 3-Ci-phenyl 619 -CH2- cyclopropan-1,27diyl bond 4-Cl-phenyl 620 -CH2- cycloprapan-1,2-diy1 bond 2-Me-phenyl' 621 -CA 2 cyclopropan-1,27diYl bond 3-Me-phenyl 622 -CH2- cyclopropan-1.2-diyl bond 14-Me-phenyl 623 -CH2- cyclopropan-1, 2-'diyl bond 2-MeO-phenyl 624 -CH 2 cyclopropan-:-1,2-diyl bond 3-HeO-Phenyl 625 -CH2- cyclopropan-1.2-diyl bond 4-HeO-phenyl 626 -CH2- cyclopropan-1,2-diyl bond 2-MeS-pheny.
627 -CH2- cyclopropan-1,2-diyl b~ond' 3-MeS-phenyl..
628 -CH2- cyclopropan-1,2-diyl bond 4-MeS-phenyl 629 -CH2- cyclopropan-1,2-diyl bond 2-F3C-phenyl 630 -CH2- cyclopropan-1,2-diyl bond 3-P3C-phenyl 631 -CH2- cyclopropan-1,2-diy. bond 4-F3C-phenyl 632 -CH2- cyclopropan-1,2-diyl bond. 2.3-diF-phenyl 633 -CH2- cyclopropan-1,2-diyl bond 12.4-diF-phenyl 634 -CH2- cyclopropan-1.2-diyl bond 635 -CH2- cyclopropan-1.2-diyl bond 2,6-diF-phenyl 636 -C112- cyclopropan-1,2-diyl bond 3,4-diF-phenyl 637 -dM2- cYclopropan-1,2-diyl bond 638 -CH2- cYclopropan-1,2-diyl band 2.3-diCi-phenyl 639 -CH2- cYclopropan-1,2-diyl Iband i2,4-diCi-phenyl -192- 640 -CR2- cyclopropan-1,2-diyl bond 641 -CH2- cyclopropan-1,2-diyl bond 2.6-diCi-phenyl 642 -CI1 2 cyclopropan-1.2-diyl band 3,4-diCi-phenyl 643 -CH2- cyclopropan-1,2-diyl bond 644 -CH2- cyclopropan-1,2-diyl bond' 2-Cl-3-F-phenyj- 645 -CR2- cyclopropan-1,2-diyrl -Tfnd 2 4__F-ihey I 646 -CR2- cyclopropan-*1,2-diyl -bond 2-cl.-S-F.-phenyi- 647 -CH2- cyclopropan-1,2-diyl bond 3-Cl-4-F-phenyl 648 -CR2- cyclopropan-1 ,2-diyl bond 649 -CH 2 cyclopropan-1,2-diyl bond 4-Cl-2-F-phenyl 650 -CR2- cyclopropan-1,2-diyl bond 4-C1-3-F-phenyl 651 -CR2- cyclopropan-1,2-diyl -bond 2,3-diMeO-phenyl.
652 CR2 cyloprpan1,2diyl bon 2.-di~O-pen7 653 -CH2- cyclopropan-1,2-diyl bond 2,S-diMeO-phenyl- 654 -CH2- cyclopropan-1,2-diyl bond 2.6-diMeO-phenyl 655 -CR2- cyclopropan-1,2-diyl, .bond 3.4-diMeo-phenyl 656 -C 2 cyclopropan-1,2-diyl bond 3,S-dimeo-phenyl 657 -CH2- cyelopropan-1,2-diyl bond cyclopr~op n 658 -CR2- cyclopropan-1,2-diyl bond cyclobutyl 659 -CR2- cyclopropan-1,2-diyl bond cyclopenty).
660 -CR 2 cyclopropan-12-diyl bond cyclohexyl 661 -CR2- cyclopropan-12-diyl bond 2-clurmnyl 662 -CR2- cyclopropan-1,2-diyl bond 2-thienyl 663 -CH 2 cyclopropan-1,2-diyl bond 2-tiidzyl 664 -CH2- cyclopropan-1,2-diyl bond 2-pyidayl 665 -C 2 cyclopropan-1,2-diyl bond 3-pyridyl 666 -C2- cyclopropan-1.2-diyl bond 4-pyridyl 667 -CH2- cyclopropan-1,2-diyl bond 4-morpiyl 668 -CR2- cyclopropan-1,2-diy. bond N-piperidinyl 669 -CH2- cyclopropan-1,2-diyl bond N--pridyl 670 -CR2- cyclopropan-1,2-diyl bond 4-Me-2-pyridyl 671 -CR2- cyclopropan-1,2-diyl bond 4-7-poiyX 672 -CH2- cyclopropan-1.2-diy1 bo6nd 2-bnohieny 673 -CR2- cyclopropan-1,2-diyl bond 2-benzothianyl' 674 -CR2- cyclopropan-1,2-diyl bond 1-benzimidazole 675 -CH2- cyclopropan-1,27diyl bond 2-naphthyl 676 -CH2- cyclopentan-1,3-diyl bond phenyl 677 -CR 2 cyclopentan-1,3-diyl bond 3,3-diphenylmethyl 678 -CH 2 cyclopentan-1,3-diyl bond 2-F-phenyl 679 -CR2- cyclopentan-1,3-diyl bond 3-F-phenyl 680 -CR2- cyclopentan-1,3-diyl bond 4-F-phenyl 681 -CR2- cyclopentan-1.3-diyl bond 2-Cl-pirfly,,.
682 -CR2- cyclopentan-1,3-diyl bond 3-Cl-phenyl..
683 -CR2- cyclopentan-1,3-diyl bond 4-Ci-phenyl 684 -CR2- cyclopentan-1,3-diyl bond 2-Me-phenyl 685 -CR2- cyclopentan-1,3-diyl bond 3-Me-phenyl 686 -CH 2 cyclopentan-1,3-diyl bond 4-me-phenyl 687 -CR2-. cyclopentan-1,3-diyl bond 2-MeO-phenyl -193- 688 -CH2- cyciopentan-1,3-diyl bond 3-MeO-phenyl 689 -CH2- cyclopentan-I.3-diyl bond 4-MeO-phenyi 690 -CH2- cyclopentan-1,3-diyl bond 2-MeS-phenyl 691. -CH2- cyclopentan-1,3-diyl bond 3-MeS -phenyr'- 692 -CH2- cyclopentan-1,3-diyl bond 4-MeS-phenyl 693 -CH2- cyclopentan-1,3-diyl bond 2-F 3 C-phenyl 694 -CH2- cyclopentan-1,3-diV' 5o-d_ -3 F3C jheiy 695 -CH2- cyclopentan-1,3-diyl bond 4-F 3 C-phenyl 696 -CH2- cyclopentan-1,3-diyl bond 2,3-diF-phenyl 697 -CH2- cyclopentan-1.3-diy1 bond 2,4-diF'-phenyl 698 -CH2- cyclopentan-1,3-diyl bond 699 -CH2- cyclopentan-1,3-diyl bond 2,6-diF-pheny.
700 -CH2- cyclopentan-1,3-diyl bond 3,4-diF-phenyl 701 -CH 2 cyclopentan-1,3-diyl bond 702 -CH2- cyclopentan-1,3-diyl- _bond 2.3-diCl-phenyl.- 703 -CH2- cyclopentan-1,3-diyl bond 2,4-diCl-phenyl 704 -CH 2 cyclopentan-1,3-diyl bond 2,5-diC3i-phenyl 705 -CH27 cyclopentan-1,3-diy1 bond' 2,6-diCi-phenyl 706 -CH2- cyclopentan-1,3-diyl bond 3,4-diCi-phenyl 707 -CH2- cyclopentan-1.3-diy. bond 708 -CH2- cyclopentan-1,3-diyl bond 2-C1-3-F-phenyl 709 -CH2- cyclopentan-1,3-diy1 bond 2-Cl-4-F-phenyl 710 -CH2- cyclopentan-1.3-diyl bond 2-C1-5-F-phenyl 711 -CH 2 cyclopentan-1,3-diyl bond 3-Cl-4-F-phenyl 712 -CH2- cycloperitan-1,3-diyl bond 3-C1-5-F-phenyl 713 -CH2- cyclopentan-l*.3-diyl bond 4-Cl-2-F-phenyl 714 -CH2- cyclopentan-1,3-diyl bond 47Cl-3-F-phenyl 715 -CH2- cyclopentan-1,3-diyl bond 2,3-diMcO~pheny1 716 -CH2- cyclopentan-1.3-diyl bond 2,4-diKeO-phenyl 717 -CH2- cyclopentan-1,3-diyl bond 718 -CH2- cyclopentan-1,3-diyl bond7 2,6-dit~eO-phenyl 719 -CH2- cyclopentan-1, 3-diyl bond 3,.7d*Me0-phenyl 720 -CH2- cyclopenitan-1, 3-diy. bond 3. 721 -CH2- cyclopentan-1, 3-diyl bond cyclopropyl 722 -CH2- cyclopentan-1,3-diyl bond cyclobutyl 723 -CH2- cyclopentan-1,3-diyl bond cyclopentyl 724 -CH2- cyclopentan-1,3-diyl bond cyclohexyl 725 -CH2- cyclopentan-1,3-diyl bond 2-furanyl 726 -CH2- cyclopentan-1.3-diyl bond 2-thienyl 727 -CH2- cyclopentan-1,3-diyl bond 2-iniidazolyl '728 -CH2- cyclopentan-1.'3-diyl bond 2-pyridyl 729 -CH2- cyclopentan-1. 3-diyl bond. 3-pyridyl 730 -CH2- cyclopentan-1,3-diyl bond 4-pyridyl 731 -CH 2 cyclopentan-1. 3-diyl bond N-mrpholinyl 732 -CH2- cyclopentan-1.3-diyl bond. N-piperidinyl 733 -CH2- cyclopentan-1,3-diyl bond 3-Me-2-pyridyl 734 -CH 2 cyclopentan-1. 3-diYl bond 4-Me-2 -pyridyl 735 -CH2- cyclopentan-1,3-diYl bond 1-indolyl -194- 736 -CH2- cyclopentan-1.3-diyl bond 2-benzoth ienyll 737 -CM 2 cyclopentan-1,3-diyl bond. 2-benzofurany1 738 -CH 2 cyclopentan-1,3-diyl bond 1-benziinidazoi 739 -CII2- cyclopentan-1, 3-diyl bond 2-thVYth'j.
740 -CH2- phen-1,3-diyl phenyl 741 -CH2- phen-1,3-diyl 3. 3-diphenylmethyl 742- -CH 2 phen-1,3-diyl 2-F-pheiyl 743 -CI12- phen-1,3-diyl 3-F-phenyl 744 -CH2- phen-1,3-diyl 4-F--phenyil 745 -ClI2- phen-1.3-diyl 2-Ci-phenyl 746 -CH2- phen-1,3-diyl 0- 3-Ci-phenyl 747 -CH2- phen-1,3-diyl 4-Ci-phenyl 748 -CH2- phen-1,3-diyl 2-Me-phenyl 749 -CH2- phen-1,3-diyl 3-Me-phenyl 750 -CH2- phen-1,3-diyl 4-Me-phenyl 751 -CH2- phen-1,3-diyl 0- 2-MeG-phenyl 752 -dM2- phen-1,3-diyl 3-MeO-phenyl 753 -CH2- phen-1,3-diyl 4-MeO-phenyl 754 -CH2- phen-1,3-diyl 2-MeS-phenyl 755 -CH2- phen-1,3-diyl 3-MeS-phenyl 756 -CH2- phen-1,3-diyl 1-0- 4-MeS-phenyl 757 -CH2- phen-1,3-diyl 2-F3C-phenyl 7.58 -CH2- phen-1,3-diyl 3-F3C-phenyl 759 -CR2- phen-1.3-diyl 4-F3C-phenyl 760 -CR2- phen-1,3-diyl 2, 3-diF-phenyl 761 -CH2- phen-1,3-diyl 2,4-diF-phenyl 762 -dM2- phen-1,3-diyl 763 -CH 2 phen-1,3-diyl 2,6-diF-phenyl 764 -CH2- phen-1,3-diyl 4dFpey 765 -CH2- phen-1,3-diyl 3.5-diF-phenyl 766 -CH2- phen-1,3-diyl 0 2. 3-diCl-phenyl 767 -CR2- phen-1,3-diyl 2.'-diCl-phenyl 768 -CH2- p .hen-1,3-diyl 769 -CH2- phen-1,3-diyl 2,6-diCl-phenyl 770 -CH2- phen-1,3-diyl 3,4-diCl-phenyl 771 -CR2- phen-1,3-diyl 772 -dM2- phen-1,3-diyl 2-Cl-3-F-phenyl 773 -CH2- phen-1,3-diyl 2-C1-4-F-phenyl 774 -CH2- phen-1,3-diyl 2-C1-5-F-phenyl 775 -CH 2 phen-1,3-diyl 3-C1-4-F-phenyl 776 -CH2-- phen-1,3-diyl 3-C1-5-F-phenyl 777 -CH2- phen-1,3-diyl 4-Cl-2-F-phenyl 778 -CR2- phen-1,3-diyl 4-Cl-3-F-phienyl 779 -CH2- phen-1,3-diyl -0 2,37:diMeO- i;njl 780 -CM 2 phen-1,3-diyl 2,4-diMeo-phenyl 781 -CR2- phen-1,3-diyl 782 -CH2- phen-1,3-diyl 2,6-diMeo-phenyl 783 -CR2- phen-1,3-diyl 3,4-diMeo-phenyl 784 -CR2- phen-1,3-diyl 785 -CR2- jphen-1,3-diyl cyclopropyl -195- 786 -CH2- phen-1,3-diyl cyclobutYl 787 -CH2- phen-1.3-diyl cycloperityl 788 -CH2- phen-1.3-diyl cyclohexyl 789 -CR2- phen-1,3-diyl 2-furanyl 790 -CH2- phen-1,3-diyl 0- 2-thienyl 791 -CH2- phen-1,3-diyl CR2CH2 2-imidazolyl 792 -CR2 phen-1,3-diyl 2-pyridyl 793 -CR2- phen-1,3-diyl 3-pyridyl 794 -CH2- phen-1,3-diyl 4-pyridyl 795 -CR2- phen-1,3-diyl CH2CH2 N-morpholinyl 796 -CR2- phen-1.3-diyl CH2CH2 N-piperidinyl 797 -CH2- phen-1,3-diyl 3-Me-2-pyridyl 798 -CR2- phen-1.3-diyl 4-Me-2-pyricyl 799 -CH2- phen-1,3-diyl CH2CH2 1-indolyl 800 -CR 2 phen-1.3-diyl 2-benzothieiyl 801 -CH2- phen-1,3-diyl 2-benzofuranyl 802 -CR 2 phen-1,3-diyl CH2CH2 1-benziinidazole 803 -CR2- phen-1,3-diyl 2-naphthyl 804 -CR2- pyridin-3,5-diyl pheniyl SOS -CH2- pyridin-3.5-diyl 3,3-diphenylmethyl 606 -CR2- pyridin-3,S-diyl 2-F-phenyl 807 -CR2- pyridin-3,5-diyl 3-F-phenyl 808 -CH2- pyridin-3,5-diyl 4-F-phenyl 809 -CH2- pyridin-3,5-diyl 2-Ci-phenyl 810 -CR2- pyridin-3,5-diyl 0- 3-Ci-phenyl 811 -CR2- pyridiri-3,5-diyl 4-C1-pheiyl 812 -CH2- pyridin-3,5-diyl 2-Me-phenyl 813 -CR2- pyridin-3,5-diyl 3-Me-phenyl 814 -CR2- pyridin-3,5-diyl 4-Me-phenyl 815 -CR2- -pyridin-3,5-diyl 2-MeO-phenyl 816 -CR2- pyridin-3,S-diyl 3-MeO-phenyl 817 -CH2- pyridin-3,5-diyl 818 -CH2- pyridin-3,5-diyl 2-MeS-phenyl 819 -CH2- pyridin-3,5-diyl 3-MeS-phenyl 820 -CR pyridin-3,5-diyl 4-MeS-phenyl 821 -CR2- pyridin-3,5-diyl 2-F3C-phenyl 822 -CR2- pyridiri-3,S-diyl 3-F3C-phenyl 823 -CH2- pyridin-3.5-diyl 4-F3C-pbenyl 824 -CH2- pyridin-3,5-diyl 2,3-diF-phenyl 825 -CH2- pyridin-3,5-diyl 2.4-diF-phenyl 826 -CR2- pyridin-3,5-diyl 827 -CH2- pyridin-3,5-diyl 2,6-diF-phexyl 828 -CH2- pyridin-3,5-diyl 3,4-diF-phenyl 829 -CR2- pyridin-3,5-diyl 830 -CR2- pyridin-3,5-diyl 2,3-diCi-phenyl 831 -CR2- pyridin-3,5-diyl 2,4-diCi-phenyl 832 -CH2- pyridin-3,5-diyl' 833 -CR2- pyridin-3,5-diyl 2,6-diCi-phenyl 834 -CR2- pyridin-3,5-diyl 3,4-diCl-pheiyl 835 -CR2- pyridin-3,S-diyl 836 -CR2- pyridin-3,5-diyl 2-C1-3-F-phenyl 837 -CR2- Pyridin-3,5-diYl 2-C1-4-F-phenyl -3.96- 8318 -CH2- pyridlin-35-diyl 2-C1-5-F-phenyl 839 -CH2- p~yridiri-3,S-diyl 3-C1-4-F-phenyl 840 -CH2- pyridin-3,5-diyl 3-C1-5-F-phenyl 841 -CR2- pyridin-3,5-diyl7 -0 '4-C*-2-F--phenyl 842 -CH2- pyridin-3,5-diyl 4-C1-3-F--phenyl 843 -CR2- pyridin-3.5-diyl 2, 3 -diMeO- ohenyl 844 -CR2- pyridin-3,5-diyl 2,47diMe0-phenyl 845 CR2- pyridin-3,5-diyl 846 -C2 pyridin-3,5-diyl 2,6-diMeO-phenyl 847 -CH2- pyridin-3.5-diyl 3,4-diMe0-phenyl 848 -CR2- pyridin-3.5-diyl 849 -CR2- pyridin-3,5-diyl cyclopropyl 850 -CR2- pyridirx-3,5-'4iyl cyclobutyl 851 -CR2- pyridin-3,5-diyl cyclopentyl 852 -CR2- Pyridin-3,5-diyl cyclohexyl 853 -CR2- pyridin-3,5-diyl -Or 2-furanyl- 854 -CH2- pyridin-3,5-diyl 2-thienyl 855 -CH2- pyridin-3,5-diyl CH2CH2 2"ihiUCazolyl 856 -CH2- pyridin-3.5-diyl 2-pyridyl 857 -CH2- pyridin-3,5-diyl. 3-pyridyl 858 -CH2- pyridin-3,5-diyl 4-pyridyl 859 -CH2- pyridin-3,5-diyl CHCH N-morpholiiyl 860 -CH2- pyridin-3.5-diyl CH2CH2 N-piperidinyl 861 -CH2- pyridiri-3'5-diyl 3-ke-2-pyridyl 862 -CR2- pyridin-3,5-diyl 4-Me-2-pyridyl 863 -CR 2 pyridin-3,5-diyl CH2CH2 I-indolyl 864 -CH2- pyridin-3,5-diyl 2-benzothienyl 865 -CR2- pyridin-3,5-diyl 2-benzofuranyl 866 -CR2- pyridin-3,5-diyl CH2CH2 1-benzimidazole..
867 -CR2- pyridin-3,5-diyl 2-naphthyl 868 -CR2- pyridin-2.6-diyl phenyl 869 -CR2- pyridin-2,6-diyl 3,3-diphenylmethyl 870 -CR 2 pyridin-2,6-diyl 2-F-phenyl 871 -CH2- pyridin-2,6-diyl 3-F-phen'1 872 -CR2- pyridin-2.6-diyl 4-F-pjhe~yl.
873 -CR2- pyridin-2,6-diyl 2-Ci-phenyl 874 -CR2- pyridin-2,6-diyl 3-Ci-phenyl 875 -CR2- pyridin-2,6-diyl 4-Cl-pheiyl 876 -CR2- pyridin-2,6-diyl 2-Me-phenyl 877 -CR2- pyridin-2,6-diyl 3-Me-phenyl 878 -CR2- pyridin-2,6-diyl 4-Me-phenyl 879 -CR2- pyridin-2,6-diyl 2-MeO-phenyl 880 -CR2- pyridin-2,6-diyl 3--MeO-phenyl 881 -CR2- pyridin-2,6-diy. 4-MeO-phenyl 882 -CR2- pyridin-2,6-diyl -0 27ZleS-pheny.
883 -CR2- pyridin-2.6-diyl 3-MeS-phenyl 884 -CH2- pyridin-2,6-diy. 4-MeS-phenyl 885 -CR2- pyridin-2,6-diyl 2-F3C-phenyl 886 -CR2- pyridin-2,6-diyl 3-F3C-phenyl 887 pyridin-2.6-diyl 4-F3C-phenyl 888 -CH2- pyridin-2,6-diy. 2,3-diF-phenyl 89 -CR2- pyridin-2,6-diyl -0 2,4-diF-phenyl -197- 890 -CH2- pyridin-2.6-diYl 891 -CR2- pyridin-2,6-diyl .2.6-diF-phen yl 892 -CR2- pyridin-2,6-diyl 3,4-diF-phenyl 893 -CH2- pyridin-2.6-diyl. 3.5- diF-jpheny1 894 -CH2- pyridiri-2,6-diyl 2,3-diCi-phenyl 895 -CH2- pyridin-2,6-diyl.---- -0 2.4-diCi-phenyl- 896 -CR2- pyridin-2,6-diyl 897 -CH2- pyridin-2.6-diyl 0- 2.6-diCl-phenyl 898 -CR2- pyridin-2,6-diyl .3,4-diCl-phenyl 899 -CH2- pyridirx-2,6-diyl 900 -CR2- pyridin-2,6-diyl, 2-C1-3-F-phenyl 901 -CR2- pyridin-2,6-diyl 2-Cl-4-F-pheiyl 902 -CH2- pyridin-2,6-diyl 2-ti-S'P-phenyl71.
903 -CH2- pyridin-2,6-Adiy1 3-C1-A-F-phenyl- 904 -CH2- pyridin-2,6-diyl 3-C1-5-F-pheiyl 905 -CR2- pyridin-2.6-diyl- 4 C1-2-F-pheiy1' 906 -CR2- pyridin-2,6-diyl 4-C1-3-F-phenyl 907 -CR2- pyridin-2.6-diyl 2,3-dil~eO-phenyl 908 -CH2- pyridin-2,6-diyl 2.4-diMO0-phenyl 909 -CH2- pyridin-2,6-diyl 910 -CH2- pyridiri-2,6-diyl 2.6-diMeO-phenyl 911 -CH2- pyridin-2,6--diyl 3,4-dil~eO-phenyl 912 -CHZ- pyridin-2,6-diyl 3.5-diMe0-pheriyl 913 -CR2- pyridin-2,6-diyl cyclopiooyl 914 -CR2- pyridin-2,6-diyl cyclobutyl 915 -CH2- pyridin-2,6--diyl cyclopentyl 916 -CR2- pyridin-2.6-diyl cyclohexyl 917 -CR2- pyridin-2.6-diyl 2-furanyl 918 -CH2- pyridin-2,6-diyl 2-thienyl: 919 -CH2- pyridin-2.6-diyl- CH2CH2 2-inmidazolyl 920 -CR2- pyridin-2,6-diyl 2-pyridyl 921 -CH2- pyridin-2,6-diyl 3-pyridy.
922 -CH2- pyridin-2.6-diyl 4-pyridyl 923 -CH2- pyridin-2, 6-diyl CH2CH2 N-morphdlinyl 924 -CH2- pyridin-2,6-diyl CH2CH2 Il-piperidinyl 925 -CR2- pyridin-2,6-diyl 3 -Me-2-pyridyl,.
926 -CR2- pyridiri-2,6-diyl 4-Ke-2-pyridyl- 927 -CR2- pyridin-2,6-diyl CH2CH2 1-indolyl 928 -CH2- pyridin-2,6-diyl 2-benzothienyl 929 -CR2- pyridin-2,6-diyl 2-benzofuranyl 930 -CR2- pyridin-2,6-diyl CH2CH2 1-benzimidazole 931 -CR2- pyridin-2,6--diyl 2-naphthyl 932 -CR2- pyridin-2,4-diyl pheniyl 933 -CR2- pyri'din-2,4-.diyl 3,3-diphenylmethyl 934 -CR2-_ pyridin-2,4-diyl 2-F-phenyl 935 -CR2- pyii-.-il-0- 3-F-pheriyl 936 -CH2- pyridin-2,4-diyl 4-F-pheriyl 937 -CR2- pyridin-2,4-diyl 2-Ci-phenyl 938 -CR2- pyridin-2,4-diyl -3-C1-pheiiyl 939 -CR2- pyridin-2,4-diyl 4-Ci-phenyl 940 -CH2- pyridin-2,4-diyl 2-Me-phenyl 941 -CH2- lpyridin-2,4-diyl 13-Me-phenyl -198- 942 -CH2- pyridin-2,4-diyl 4-Me-phenyl 943 -CH2- pyridin-2,4-diyl 2-MeO-phenyl 944 -CH2- pyridin-2,4-diyl 3-1e0-phenyl 945 -CH2- pyridin-2,4-diyl 946 -CH2-- pyridin-2,4-diyl 2-MeS-phenyl_ 947 -CH 2 pyridin-2,4-diyl 3-MeS-phenyl 948 -CH2- pyridin-2,4-diyl 4-MeS-phenyl 949 -CH2- pyridin-2,4-diyl 2-F3C-pbenyl 950 -CH2- pyridin-2,4-diyl 3-F3C-phenyl 951 -CH2- pyridin-2,4-diyl 4-F3C-phenyl' 952 -CH2- pyridin-2,4-diyl 2,3-diF-pheiyl 953 -CH2- pyridin-2,4-diyl 2.4-diF.-phenyl 954 -CH2- pyridin-2,4-diyl -CH2- pyridin-2,4-diyl 2,6-diF-phenyl 956 -CH2- pyridin-2,4-diyl 3,4-diF-phenyl 957 -CH2- pyridin-2.4-diyl 3,S-diF-phenyl.
959 -CH2- pyridin-2,4-diyl 2, 3-diCl-phenyl 959 -CH2- pyridin-2,4-diyl 2,4-diC -phexyl 960 -CH2- pyridiri-2,4-diyl 961 -CH2- pyridiri-2,4-diyl 2,6-diCi-phenyl 962 -CH2- pyridin-2,4-diyl 3. 4-diCl-phexyl 963 -CH,2- pyridin-2,4-diyl 964 -CH2- pyridin-2,4-diyl 2-C1-3-F-phenyl 965 -CH2- pyridin-2,4-diyl -2-Cl-4-F-phenyl 966 -CH2- pyridin-2,4-diyl 967 -CH2- pyridin-2,4-diyl 3-C1-4-F-phenyl 968 -CH2- pyridin-2,4-diyl 969 -CH2- pyridin-2,4-diyl 4-C1-2-F-phenyl 970 -CH2- pyridin-2,4-diyl 4-C1-3-F-phenyl 971 -CH2- pyridin-2,4-diyl 2,3-diMeO-phenyl 972 -CH2- pyridin-2.4-diyl 2,4-diMeO-phenyl 973 -CH7- pyii-,-dy 0 ,-d1opey, 94 pyridin-2,4-diyl 2,-diMeO-phenyl 975 -CH2- pyridin-2,4-diyl 3.4-diMeo-phenyl- 976 -Cfl2- pyridin-2,4-diyl 3, 977 -CH2- pyridin-2,4-diyl cycli~oprplny 978 -CH2- pyridin-2,4-diyl cyclobutyl 979 -CH2- pyridin-2.4-diyl cyclopetyl 980 -CH2- pyridin-2,4-diyl cycloextyl 981 -CH2- pyridin-2,4-diyl 2-f uranyl 982 -CH2- pyridin-2.4-diyl 2-thienyl 983 -CH2-- pyridin-2,4-diyl CH2CH2 2-imnidazo Ilyl 984 -CH2- pyridin-2,4-diyl 0- 2-pyridyl 985 -CH2- pyridin-2,4-diyl 3-pyridyl 986 -CH2- pyridin-2,4-diyl 4-pyridyl 987 -CH-2- pyridin-2.4-diyl CH2CH2 N-nmorpholinyl 988 -CH2- pyridin-2.4-diyl CH2CH2 N-piperidinyl 989 -CH2- pyridin-2,4-diyl 3-Me-2-pyridyl 990 -CH2- pyridin-2,4-diyl 4-He-2-pyridyl 991 -CH2- pyridin-2,4-diyl CH 2 CH2 1-indolyl 992 -CH 2 pyridin-2,4-diyl -12-benzothienyl 993A -CH2- lpyridiri-2.4-diyl 2-benzofuranyl -199- 994 -CH2 pyridin-2,4-diyl CH2CH2 1-benzirnidazole 995 -CH2- py-ridin-2.4-diyl 2-naphthyl 996 -CH2- pyridiri-4,2-diyl pheniyl 997 -CH2- pyridiri-4,2-diyl 3..3-diphenylithyl 998 -CH2- pyridin-4.-2-diyl 2-F-phenyl 999 -CH2- pyridin-4,2-diyl 3-F-phenyl- 1000 -CR2- pyridin-4,2-diyl 4-F-phenyl 1001 -CR2- pyridin-4.2-diyl 2-Ci-phenyl 1002 -CR2- pyridin-4,2-diyl 3-Cl-phenyl 1003 -CR2- pyridin-4.2-diyl 4-Ci-phenyl 1004 -CR2- pyridin-4,2-diyl 2-Me-phenyl 1005 -CH2- pyridin-4,2-diyl 3-14e-phenyl 1006 -CR2- pyridin-4,2-diyl 4-tMe-.phenyl.
1007 -CR2- pyridin-4,2-diyl 2-MeG-phenyl.- 1008 -CR2- pyridin-4,2-diyl. 3-meO-phenyj 1009 -CH2- pyridin-4,2-diyl 4-?AeO-phenyl 1010 -CR2- pyridin-4,2-diyl 2-MeS-phenyl 1011 -CR2- pyridijw4,2-diyl 3-MeS-phenyl 1012 -CH2- pyridin-4,2-diyl 4-MeS-phenyl 1013 -CH2- pyridin-4,2-diyl 2-F3C-phenyl 1014 -CR2- pyridin-4,2-diyl 3-F3C-phenyl 1015 -CR2- pyridin-4,2-diyl 4-F3C-phenyl 1016 -CR2- pyridin-4.2-diyl 2, 3-diF-phenyl 1017 -CR2- pyridin-4.2-diyl 2,4-diF-phenyl 1018 -CR2- pyridin-4,2-diyl 2, 1019 -CR2- pyriditi-4,2-diyl 2,6-diF--phenyl 1020 -CR2- pyridin-4,2-diyl 3. 4-diF--phenyl 1021 -CR2- pyridin-4,2-diyl 3. 1022 -CR2- pyridlin-4,2-diyl 2,-3-diCl-7pheTiyl 1023 -CR2- pyridin-4.2-diyl 2.4-diCl-phenyl 1024 -CR2- pyridin-4,2-diyl 1025 -CH2- pyridin-4,2-diyl 2, 6-diCi-phenyl 1026 -CH2- pyridin-4,2-diyl 4-diCi-phenyl 1027 -CH2- pyridin-4,2-diyl 3. 1028 -CR2- pyridin-4,2-diyl 2-C1-3-F-phenyl 1029 -CR2- pyridin-4,2-diyl 2-C1-4-F-phepyl 1030 -CR2- -pyridin-4,2-diyl 2-Cl1-5-F-phenyl 1031 -Cl12- pyridin-4.2-diyl 3-Cl-4-F-phenyl 1032 -CR2- pyridin-4,2-diyl 3-C1-5-F-:phenyl 1033 -CR2- pyridin-4,2-diyl 47Cl-2-F-phenyl 1034 -CR2- pyridin-4,2-diyl 4-C1-3-F-phenyl 1035 -CR2- pyridin-4,2-diyl 2.3-dimeo-phenyl 1036 -CR2- pyridin-4,2-diyl 2,4-diMeo-phenyl 1037 -CR2- pyridiri-4,2-diyl 1038 -C pyridin-4,2-diyl 2.6-diMeo--phenyl 1039 -CR2- pyridin-4,2-diyl 3,4-diMeo-phenyl 1040 -CR2- pyridin-4,2-diyl 1041 -CR2- pyridin-4,2-diyl cyclopropyl 1042 -CH2- pyridin-4,2-diyl- cyclobutyl 1043 -CR2- pyridin-4,2-diyl 0- cyclopentyl 1044 CH2- payridin-4.2-diyl cyclohexyl ft -CR2- lpyridin-4.2-diyl 2-furanyl -200- 1046 -CH2- pyrjdjn-4,2-diyl 2-thienyl 1047 -CH2- pyridin-4,2-diyl CH2CH 2 2-iniidazolyl 1048 -CH2- pridin-,2-diy 2pyridy 109 -CH2- pyridin-4, 2-diyl 0- 23-pyridyl 1049 -CH2- pyridin-4, 2-djyl 3-pyridyl 1051 -C142- pyridin-4,2-diyl CH2CH2 N-inorpholinyl 1052 -CH2- pyridin-4, 2-diyl CH2CHI 0-piperidinyl 1053 -CH 2 pyridin-4,2-diyl 3-Me-2-pyridyl 1054 -CH2- pyridin-4.2-diyl 4-Me-2-pyridyl 1055 -CH2- pyridin-4,2-diyl CH2CH2 _1-indolyl 1056 -CH2- pyridin-4,2-diyl 2-benzothienyl 1057 -CH 2 pyridin-4,2-djyl '2-benzofurany1 1058 -CH2- pyridin-4,2-diyl CH2CH 2 l1-benzimidazole 1059 -CH2- pyridin-4,2-diyl *2-raphthyl 1060 -CH2- piperidin-1,3-diyl phenyl 1061 -CH2- piperidin-1,3-diyl 3,3-dipheiylmethyl1 1062 -CH2- piperidin-1,3-diyl 2-F-phenyl 1063 -CU 2 piperidin-1,3-diyl '3-'F-phenyl 1064 -CH2- piperidin-1, 3-diyl 4-F-phenyl 1065 -CH 2 piperidin-1,3-diyl 2-Ci-phenyl 10,66 -CU 2 piperidin-1,3-diyl 3-C1-pheriyl 1067 -CH2- piperidin-1,3-diyl 4-Ci-phenyl 1068 -CH2-' piperidin-1,3-diyl 2-He-phenyl 1069 -CH2- piperidin-1,3-diyl 3-Me-phenyl 1070 -CH2- piperidiri-1,3-diyl 4-Me-pheny1 1071 -CH2- piperidin-1.3-diyl 2-MeO-phenyl 1072 -CH2- piperidin-1.3-diyl 3-MeO-phenyl 1073 -CH2- piperidin-1,3-diyl 4-MeO-pheiyl 1074 -CH2- piperidin-1,3-.diyl '2-MeS-phenyl- 1075 -CH2- piperidiri-1,3-diyl. 3-MeS-phenyl 1076 -CH2- piperidin-1,3-diyl 4-MeS-phenyl 1077 -CH 2 piperidin-1,,3-diyl 2-EC-pheny1 1078 -CU2- piperidin-1, 3-di'yl 3-F3C-phenyl 1079 -CH2- piperidin-1.3-diyl. 4-F3C-phenyl.
1080 -CH2- piperidin-1. 3-diyl 12, 3-diF.-phenyl* 1081 -CH 2 piperidin-1.3-diyl 2,4-diF-pheiyl 1082 -CH2-_ piperidin-1,3-diyl 1083 -CH2- pi peridii- 1, 3-diyl 2,6 -dF-phenyl 1084 -CH2- piperidin-1.3-diyl 3,4-diF-phenyl- 1085 -CH2- piperidin-1,3-diyl 1086 -CH2- piperidin-1,3-diyl 2,3-diCi-phenyl 1087 -CH 2 piperidin-1,3-diyl 2.4-diCi-phenyl 1088 -CI( 2 piperidin-1.3-diyl 1089 -CH2- piperidin-1,3-diyl 2.6-diCl-phenyl 100 -CH2- piperidin-1, 3-diyl 3, 4-diCl-phenyl- 1091 -CH2- piperidin-1.3-diyl 3,S-diCl-pheiyl 1092 -CH 2 piperidin-1.3-diy. -0O- 2-CI-3-F-phenyl 1093 -CH2- piperidin-2.,3-diyl 2-CL-4-F-phenyl 1094 -CH- 2 piperidin-1,3-diyl 1095 piperidin-1,3-diyl 3-Cl-4-F-phenyl 1096 -CH 2 piperidin-1,3-diyl 3-C1-5-F-phenyl 1097 -CU2- piperidin-1.3-diyl 4-CI-2-F-phenyl -201- 1098 -CH2- piperidin-1,3-diyl 4-C1-3-F-phenyl 1099 -CH2- piperidin-1. 3-diyl 2. 3-dilMeO-phenyl 1100 -CH2- piperidin-1,3-diyl 2.-4-diMe0-pheiyl 1101 -CH2- piperidin-1,3-diyl-- 1102 -CH2- piperidin-1,3-diyl 0- 2,.6-4iMeO-Phenyl 1103 -CH2- piperidin-1. 3-diyl. 3, 4-diMeo-phenyl 1104 -CH2- piperidiri-1.3-diyl 1105 -CH2- piperidin-1.3-diyl cyclopropyl 1106 -CH2- piperidin-1,3-diyl cyclobutyl 1107 -CH2- piperidin-1.3-diyl c~~pny 1108 -CH2- piperidin-1.3-diyl cyclohexyl 1109 -CH2- piperidin-1,3-diyl 2-furanyl 1110 -CH2- piperidin-1,3-diyl 2-thi-enyl 1111 -CH2- piperidin-1,3-diyl CH2CH2 2-imidazolyl 1112 -CH2- piperidin-1.3-diyl 2-pyridyl' 1113 -CH2- piperidin-1.3-diyl. 3-pyridyl 1114 -CH2- piperidin-1.3-diyl 4-pyridyl 1115 -CH2- piperidin-1.3-diyl CH2CH2 IN.-norPholinyl 1116 -CH2- piperidin-1,3-diyl_ CH2CH2 N-piperidinyl 1117 -CH2- piperidin-1,3-diyl 3-14e-2-pyridyl 1118 -CH2- piperidiri-1,3-diyl 4-Me-2-pyridyl 1119 -CH2- piperidin-1.3-diyl CH2CH2 1-indolyl 1120 -CH2- piperidirx-1,3-diyl 2-benzothienyl 1121 -CH2- piperidin-1,3-diyl 2-benzofuranyl 1122 -CH2- piperidin-1.3-diyl CH2CH2 1-benzirnidazole 1123 -CH2- piperidin-1,3-diyl 2-naphthyl 1124 -CH2- piperidiri-3.1-diyl phenyl 1125 -CH2- piperidin-3.1-diyl 3,3-diphenylinethyl 1126 -CH2- piperidin-3,1-d.iyl 2-1F-pheny1 1127 -CH2- piperidin-3,1-diyl 3-F-phenyl 1128 -CH2- piperidin-3,1-.diyl 4-F-phenyl 1129 -CH2- piperidin-3.1-diyl 2-Ci-phenyl 1130 -CH2- piperidin-3,1-diyl 3zC1-'pheny1 1131 -CH2- piperidin-3,1-diyl 4 -CI;icihny.1 1132 -CH2- piperidin-3,1-diy)l 2-14e-phenyl 1133 -CH2- piperidin-3,1-diyl 3-14e-phenyl 1134 -CH2- piperidirx-3,1-diyl 4-Me-phenyl 1135 -CH2- piperidin-3,1-diyl 2-14e0-phenyl.
1136 -CH2- piperidirx-3,1-diyl 3-MeO-phdnyl 1137 -CH2- piperidin-3.1-diyl. 4-HeO-phenyl.
1138 -CH2- piperidirx-3,1-diyl 2-MeS-phenyl 1139 -CH2- piperidin-3.1-diyl 3-MeS-phenyl 1140 -CH2- piperidin-3,1-diyl 4-IMeS-phenyl 1141 -CH2- piperidin-3,1-diyl 2-F3C-phenyl 1142 -CH2- piperidin-3,1-diyl 3-F3C-phenyl 1143 -CH2-- piperidin-3,1-diyl 4-F3C-phenyl 1144 -CH2- piperidin-3,1-diyl 2,3-diF-phenyl 1145 -CH2- piperidin-3,1-diyl 2,4-diF-phenyl 1146 -CH2- Piperidin-3,1-diyl 1147 -CH2- Piperidin-3,1-diyl 2,6-diF-phenyl 1148 -CH27 piperidin-3,1-diyl 3.4-diF-phenyl 1149 -CH2- piperidin-3,1-diyl- 0- -202- 1150 -CR2 piperidin-3.1-diyl .2,3-diCi-phenyl 1151 -CR2- piperidin-3.1-diyJl 2,4-diCl-phenyl 1152 -CH2- piperidin-3,1-diYl 1153 -CR2- piperidin-3,1-diyl 2,6-diCli-phenyl- 1154 -CR2- piperidin-3,1-diyl 3,4-diCl-phenyl 1155 -CR 2 piperidin-3,1-diyl 1156 -CH2- piperidin-3,1-diyl 2-C1-3-F-phenyl 1157 -CR2- piperidin-3,1-diyl 2-CI-4-F -phenyl 1158 -CR2- piperidin-3,1-diyl 12-CI-5-F-phenyl 1159 -CH2- piperidin-3. 1-diyl 3-Cl-4-F-phenyl 1160 -CH2- piperidin-3. 1-diyl 3-C1-5-F-phenyl 1161 -CR2- piperidin-3,1-diyl. 4-C1-2-F-phenyl 1162 -CR2- piperidin-3,1-diyl 4-Cl-3-F-phenyl 1163 -CH2- piperidin-3,1-diyl 2.3-diMeO-Phenyl 1164 -CR2- piperidiri-3.1-diyl 2.4-diMe0-Phenyl 1165 -CH2- piperidiri-3,1-diyl 2.5S-diMe0-Phenyl 1166 -CR2- piperidin-3.1-diyl. 2,6-diMeO-phenyl 1167 -CH2 piperidin-3. 1-diyl 3 4-diMeO-phenyl 1168 -CH2- piperidin-3,1-diyl 1169 -CR2- piperidin-3,1-diyl 1cyclopropyl 1170 -CR2- piperidin-3.1-diYl cyclobutyl 1171 -CR2- piperidin-3,1-diyl cyclopentyl 1172 -CR2- piperidin-3,1-diyl cyclohexyl 1173 -CR2- piperidin-3,1-diyl 2-furanyl 1174 -CR2- piperidin-3,1-diyl 2-thienyl 1175 -CR2- piperidin-3,1-diyl CH2CH2 2-imidazdlyl 1176 -CH2- piperidin-3.1-diYl 2-pyridyl 1177 piperidin-3,1-diyl 3-pyridyl 1178 -CR2- piperidin-3, 1-diyl 4-pyridyl 1179 -CH2- piperidin-3,1-diyl CH2CH2 N-morpholinyl 1180 -CR2- piperidin-3,1-diyl CH2CH2 N-piperidinyl 1181 -CR2- piperidin-3,1-diyl 3-Me-2-pyridy.
1182 -CR2- piperidin-3,1-diyl 4-Me -2-piyridyl 1183 -CR2- piperidin-3. 1-diyl. CH2CH2 1-indolyl 1184 -CH2- piperidin-3,1-diyl 2-benzothiienyl 1195 -CR2- piperidin-3.1I-diYl 2-benzofuranyl 1186 -CH2- piperidin-3,1-diyl CH2CH2' 1-benzimidazole 1187 -C2 piperidin-3,1-diyl 2-naphthyl 1188 -CR2- cyclohex-1,3-diyl phenyl 1189 -C2 cyclohex-1,3-diyl 3,3-diphenylniethyl 1190 -CH2- cyclohex-1,3-diyl 2-F-phenyl 1191 4-CRH2- cyclohex-1, 3-diyl 3-F-phenyl 1192 -CR2- -cyclohex-1.3-diyl 4-F-phenyl 1193 -C cyclohex-1,3-diyl 2-Ci-phenyl 1194 -H cyclohex-1,3-diyl 3-Ci-phenyl 119S -CR2- cyclohex-1,3-diyl 4-Ci-phenyl 1196 -CR2- cyclohex-1,3-diyl 2-Me-phenyl 1197 -CR2- cyclohex-1.3-diyl 3-Me-phenyl 1198 -CR2- cyclohex-1,3-diyl 4-Me-phenyl 1199 -CR2- cyclohex-1,3-diyl 1200 -CR2- cyclohex- 1, 3-diyl 3-MeO-phenyl 1201 -CR2- cyclohex-1,3-diyl 4-MeO-phenyl -203- 1202 -CH2- cyclohex-1,3-diyl 2-MeS-phenyl 1203 -CH 2 cyclohex-1,3-diyl 3-MeS-phenyl 1204 -CH 2 'cyclohex-1,3-diyl 4-MeS-phenyl 1205 -CH2- cyclohexc-1.3-diyl 2-F3C.-phenyl 1206, -CH2- cyclohex-1,3-diyl 3-F3C-phenyl 1207. -CH 2 cyclohex-1,3-diyl 4-F3C-phenyl 1208 -CH2- cyclohex-1,3-diyl 2,3-diF-phenyl 1209 -CH2- cyclohex-1,3-diyl 2,4-diF-phenyl 1210 -CH2- cyclohex-1,3-diyl 1211 -CH 2 cyclohex-1,3-diyl 2,6-diF-phenyl 1212 -CH2- cyclohex-1,3-diypl 3.4-diF-phenyl 1213 -CH2- cyclohex-1,3-diyl 1214 -CH2- cyclohex-1,3-diyl 2,3-diCl-phenyl 1215 -Cl- 2 cyclohex-1,3-diyl 2.4-diCl-phenyl 1216 -CH 2 cyclohex-1.3-diyl 2, S-diCl-phenyl 1217 -CH 2 cyclohex-1.3-diyl 2,6-diCl-phenyl 1218 -CH2- cyclohex-1,3-diyl 0- 3,4-diCi-phenyl 1219 -CH2- cyclohex-1,3-diyl 1220 -CH 2 cyclohex-1,3-diyl 2-C1-3-F-phenyl 1221 -CH 2 cyclohex-1.3-diyl 2-C1-4-F-phenyl 1222 -CH2- cyclohex-1,3-diyl 2-C1-5-F-phenyl 1223 -CH2- cyclohex-1.3-diyl 3-C1-4-F-phenyl 1224 -CH2- cyclohex-1,3-diyl 3-C1-5-F-phenyl 1225 -CH2- cyclohex-1,3-diyl 4-Cl-2-F-phehyl 1226 -CH2- cyclohex-1,3-diyl 4-C1-1.-F-phenyl 1227 -CH 2 cyclohex-1,3-diyl 2.3-diMeO-phenyl 1228 -CH2- cyclohex-1,3-diyl 2,4-diMeO-phenyl 1229 -CH2- cyclohexc-1,3-diyl 2.S-diMeO-phenyl 1230 -CH-2- cyclohex-1,3-diyl 2.,6-diMe0-phenyl 1231 -CH 2 cyclohex-1,3-diyl 3,4-dixeo-phenyl 1232 -CH2- cyclohex-1,3-diyl 3,S-dileo-phenyl 1233 -CI12- cyclohex-1,3-diyl cyclopropyl 1234 -CH2- cyclohex-1,3-diyl cyclobutyl 1235 -CH2- cyclohex-1,3-diyl cyclopentyl 1236 -CH2-- cyclohex-1,3-diyl cyclohexyl 1237 -CH2- cyclohex-1,3-diyl 2-furanyl 1238 -CH2- cyclohex-1,3-diyl 2-thiehyl 1239 -CH2- cyclohex-1,3-diyl CH2CH2 2-imidazolyl 1240 -CH2- Cyclohex-1.3-diyl 2-pyridyl 1241 -CH2- cyclohex-1,3-diyl 3-pyr2.dyl 1242 -CH2- cyclohex-1,3-diyl 4-pyridyl 1243 -Cl 2 cyclohex-1,3-diyl CH2CH2 N-iuorpholinyl 1244 7CH2- cyclohex-1.3-diyl CH2CH2 N-piperidiriyl 1245 -CH 2 cyclohex-1,3-diyl 3-1e-2-pyridyl 1246 -CH2- cyclohex-1,3-diyl 4-Me-2-pyridyl 12 47 -CH2- cyclohex-1,3-diyl CH2CH2 1-indolyl 1248 -CH- 2 cyclohex-1,3-diyl 2-benzothieny.
1249 -CH2- cyclohex-1.3-diyl 2-benzofuraxyl 1250 -CH2- cyclohex-1,3-diyl CH2CH2 1-benzimidazole 1251 -CH2- cyclohex-1.3-diyl 2-naphthyl 1252 -CH2- cycloprapan-1,2-diyl 'phenyl.
_1253 cyclopropan-1.2-djyl 3,3-diphenylmethyl -204- 1254 -CR2- cyclopropan-1,2-diyl 2-F-phenyl 1255 -CH 2 cyclopropan-1,2-diyl 3-F-pheiyl 1256 -CR2- cyclopropan-1.2-diyl 4-F-phenyl 1257 -CH 2 cyclopropan-1,2-diyl 2-dl-pfierny1 1258 -CH2- cyclopropan-1,2-diy1 3-Ci-phenyl 1259 -CH 2 cyclopropan-1,2-diyl 4-Cl-phenyl' 1260 -CR2- _cyclopropan-1.2-diyl 2-Me-phenyl 1261 -CR 2 cyclopropan-1,2-diyl .3-me-phny1 1262 -CR2- cyclopropan-1,2-diyl 4-t'e-phenyl 1263 -CH2- cyclopropan-1,2-diyl 2-12e0-phenyl 1264 -CH 2 cyclopropan-1,2-diyl 3-MeO-phenyl 1265 -CR 2 cyclopropan-1,2-diyl 4-MeO-phenyl 1266 -CR2-- cyclopropan-1, 2-diyl.*-0-* 2-MieS--phenyl- 1267 -CR2- cyclopropan-1,2-diyl 3-MeS-phenyl 1268 -CR 2 cyclopz-opan-1,2-diyl 4-MeS-phenyl.
1269 -CH 2 cyclopropan-1,2-diyl 2-F3C-phenyl 1270 -CH2>- cyclopropan-1,2-diyl 3-F3C-phenyl 1271 -CR2- cyclopropan-1,2-diyl 4-F3C-phey' 1 1272 -CR2- cyclopropan-1, 2-diyl 2, 3-diF-phenyl- 1273 cyclopropan-1.2-djyl 2,4-diF-phenyl 12714 -CR2- cyclopropan-1, 2-diyl 2, 1275 -H cyclopropan-1,2-diyl 2.6-diF-phenyl 1276 -CR2- cyclopropan-1.2-diyl 3.4-diF-phenyl 1277 -CR2- cyclopropan-1,2-diyl 1278 -CR2- cyclopropan-1.2-diyl 2,3-diCi-phenyl 1279 -CH2- cyclopropan-1, 2-diyl 2, 4-diCi-phenyl 1280 -CR2- cyclopropan-1,2-diyl 1281 -CR2- cyclopropan-1,2-diyl 2,6-diCi-phenyl 1282 -CH2- cyclopropan-1,2-diyl -O -3.-4-diCl-phenyl 1283 -CR2- cyclopropan-1,2-diyl 1284 -CH2- cyclopropan-1,2-diyl 2-C1-3-F-phenyl 1285 -CH 2 cyclopropan-1,2-diyl 2-C1-4-F-phenyl 1286 -CHR2- cyclopropari-1,2-diyl -0 2-C1-S-F-pheny l 1287 -CH2- cyclopropan-1.2-diyl 3-C1-4-F-heny.
1288 -CH2- cycloapropan-1.2-diyrl 3.t-1--phenyil 1289 -CR 2 cyclopropan-1.2-diyl '4-C1-2-F-phenyl 1290 -CR2- cyclopropan-1.2-diyl _4-Cl-3-F-phenyl 1291 -CR2- cyclopropan-1,2-diyl 2.3-diMeo-phenyl 1292 -CR2- cyclopropan-1.2-diyl 2,4-diMeo-phenyl 1293 -CR2- cyclopropan-1,2-diyl 1294 -CH2- cyclopropan-1,2-diyl 2,6-diMeO-phenyl 1295 -CH7- cyclopropan-1,2-diyl 3,4-diMeO-phenyl 1296 -CR2- cyclopropan-1,2-diyl 1297 -CR2- cyclopropan-1,2-diyl cyclopropyl 1298 _-CH 2 cyclopropan-1,2-diyl cyclobutyl 1299 -CR2- cyclopropan-1.2-diyl cyclopentyl 1300 -CR 2 cyclopropan-1.2-diyl cyclohexyl 1301 CR2- cyclopropan-1,2-diyl 2-f uranyl 1302 _-CR2- cycloprop an-1,2-diyl 12-thienyl M1303 -CR- cyclopropan-1,2-diyl CH2C 2 2-imidazolyl" 1304 -C 2 cyclopropan-1,2-diyl 2-pyridyl 130 icyclopropan-1,2-diyl 3-pyridyl -2 1306 -CR2 icyclopropan-1.2-diyl 4-pyridyl 1307 -CR2- cyclopropan-1,2-diyl CH2CH2 N-morpholinyl 1308, -CR 2 cyclopropan-1,2-dy. CH2CH2 N-piperidinyl 1309 -CR2- cyclopropan-1,2-diyl 3-14e-2-py'ridyl 1310 -CR 2 cyclopropan-1,2-diyl 4-Me-2-pyridyl 1311 -CR2- cyclopropan-1,2-diyl CH2CH2 1-indolyl 1312 -CR2- cyclopropan-1,2-diyl 2-b~nzothienyl 1313 -CR2- cyclopropan-1,2-diyl 2-berizofuranyl 1314 -CR2- cyclopropan-1, 2-diyl CH2CH2 1-benzimidazole 1315 -CR2- cyclopropan-1,2-diyl 2-naphthyl 1316 -CR2- cyclopentan-1.3-diyl phenyl 1317 -CR2- cyclopentan-1,3-diyl .3,3-diphenyrnethyl 1318 -CR2- cyclopentari-1,3-diyl 2-F-phenyl 1319 -CR2- cyclopentan-1,3-diyl 3-F-phenyl 1320 -CR 2 cyclopentan-1,3-diyl 4-F-phenyl 1321 -CH2- cycloperitan-1,3-diyj 2-Ci-phenyl 1322 cyclopentan-1,3-diyl 3-Ci-phenyl 1323 -CH2- cyclopentan-1.3-diyl 4-Ci-phenyl 1324 -CR2- cyclopentan-1.3-diyl 2-Me-phenyl 1325 -CR2- cyclopentan-1.3-diyl 3-Me-phenyl 1326 -CH, 2 cyclopentan-1,3-diyl 4-Me-phenyl 1327 -CH2- cyclopentan-1.3-diyl 2-MeO-phenyl 1328 cyclopentan-1.3-diyl 3-MeO-phenyl 1329 -CR2- cyclopentan-1,3-diyl 4-MeO-phenyl 1330 -CH2- cyclopentan-1,3-diyl 2-MeS-phexyl 1331 -CH2- cyclopentan-1,3-diyl 3-MeS-phenyl 1332 -CR 2 cyclopentan-1,3-diyl 4-MeS-phexyl 1333 -CR2- cyclopentan-1,3-diyl 2-F3C-phenyl' 1334 -CR2- cyclopentan-1,37diYl 37-F3C-phenyl 1335 -CH2- cyclopentan-1,3-diyl 4-F3C-phelyl 1336 -CRj- cyclopentan-1. 3-diyl 2, 3-diF-phenyl 1337 -CR2- cyclopentan-1.3-diyl 2,4-diF-phenyl 1338 -CR 2 cyclopentan-1, 3-diyr- 1339 -CR2- cyclopentan-1,3-diyl 2,6-diP-phenyl 1340 -CR 2 cyclopentan-1,3-diyl 3,4-diF-phenyl 1341 -CR2- cyclopentan-1,3-diyl 1342 -CR2- cyclopentan-1,3-diyl 2,3-diCl-phenyl 1343 -CH2)- cyclopentan-1,3-diyl 2,4-diCl-pheiyl 1344 -CH2- cyclopentan-1,3-diyl 2.5-diCi -phenyl 1345 -CR2- cyclopentan-1,3-diyl 2.6-diCi-phenyl 1346 -CR2- cyclopentan-1,3-diyl 3,4-diCl-pheiyl 1347 -CR2- cyclopentan-1,3-diyl 1348 -CR2.- cyclopentan-1.3-diyl 2-C1-3-F-phenyl 1349 -CR2- cyclopentan-1.3-diyl 2-C1-4-F-phenyl 1350 -CR2- cyclopentan-1.3-diyl 2-C1-5-F-phenyl.
135. -CR2- cyclopentan-1.3-diyl 3-C1-4-F-phenyl 1352 -CR2- cyclopentan-1,3-diyl 1353 -CR 2 cyclopentan-1,3-diyl 4-C1-2-F-phenyl 1354 -CR2- cyclopentan-1,3-diyl 4-Cl-3-F-phenyl 1355 -CR2- cyclopentan-1,3-diyl 2,3-diMeO-phenyl 135 -C2 cyclopentan-1,3-diyl 24d~opey 1357 -CR2- cyclopentan-1,3-diyl -206- 1358 -CR2- cyclopentan-1.3-diyl 2,6-diMeO-phenyl 1359 -CR 2 cyclopentan-1,3-diyl, -3;4-dik~eO-phenyl 1360 -CR2- cyclopentan-1,3-diyr- -3,.5-di~e0-pheny1 1361 -CH2- cyclopentan-1,3-di-yl, :0 cyc~lopropyl 1362 -CR 2 cyclapentcln-1,3-diy1 cyclobutyl 1363 -CR2- cyclopentan-1,3-diyl cyclopentyl 1364 -CH2- cyclopentan-1,3-diyl- cyclohexyl 1365 -CR2- cyclopentan-1,3-diyl 2-furanyl 1366 -CR 2 cyclopentan-1,3-diyl 2-thienyl 1367 -CR2- cyclopentan-1, 3-diyl CH2CH2 2-7imidazoly1 1368 -CH2- cyclopentan-1,3-diyl .2-pyridyl 1369 -CH2- cyclopentan-1,3-diyl 0- .3-pyridyl 1370 -CR2- cyclopentan-1,3-diyl. -4-ydl 1371 -CH2- cyclopentan-1,3-diyl CHC2 N-Morlplinyl 1372 -CR2- cyclopentan-1,3-diyl. CH2CH2 N-piperidinyl 1373 -CH2- cyclopentan-1,3-diyl -3me-2-pyridyl 1374 -CH2- cyclopentan-1,3-diyl 4-Me-2-pyridyl- 1375 -CR2- cyclopentan-1,3-diYl 0420i2 1-indolyl 1376 -CH2- cyclopentan-1,3-diyl 2-benzothienyl 1377 -CR2- cyclopentan-1,3-diyl- .2-benzofuranyl 1378 -CR2- cyclopentan-1,3-diyl CH2CH2 1-benzimidazole 139 -CR2- cyclopentan-1,3-diyl 2-naphthyl 1380 -CH2- bond band phenyl 1381, -CR2- bond bond 3, 3-diphenyl 1382 -CH2- bond bond 2-F-phenyl 1383 -CH 2 bond bond 3-F-phenyl 1384 -CH2- band bond 4-F-phenyl 1385 -CR2- bond bond 2-Ci-phenyl 1386_ -CH2- bond bond 3-Cl-phenyl 1387 -CR2- bond -bond 4-Ci-phenyl.
1388 -CR2- bond bond 2-Me-phenyl 1389 -CR2- bond bond 3 3-Me-phenyl 130 -CH2- bond bond 4-ke-phenyl 1391 -CR 2 bond bond 2-MeOm-phenyl 132 -CR2- bond bond 3-MeO-phenyl 1393 -CH2- bond bond 4-MeO. -phenyl -39 -CR2- bond bond 2-MeS-phenyl 135 -CH 2 bond bond 3-MeS-phenyl 1396 -CR2- bond -band 4-KeS-phenyl 1397 -CR 2 bond bond 2-F3C-phenyl 1398 -CR 2 bond -*band 3-F3C-phenyl 1399 -CH2- bond bond 4-F3C-phenyl 1400 -CR2- bond bond 2.3-diF-phenyl 1401 -CR 2 bond bond 2,4-diF-phenyl 1402 -CH2- bond -bond 2. 1403 -CR 2 bond bond 2,6-diF-phenyl 1404 -CR2- bond band 3.4-diF-phenyl 1405 -CH2- bond bond 1406 -CH 2 bond bond 2.3-diCi-phenyl 1407 -CR2- bond bond 2.4-diCl-phenyl -207- 1408 -CH2- bond bond 1409 -CH2- bond bond -2--6-diC---phenyl 1410 -CR2- bond bond 3,4-diCl-phenyl 1411 -CR2- bond bwond 1412 -CH2- bond bond 2-Cl-3-F-phenyl 1413 -CR2- bond bond" 2-Cl-4--F-phenyl 1414 -CR2- bond bond 2-C1-S-F-pheny-1---- 1415 -CR2- bond bond 3-C1-4-P-phenyl 1416 -CR2- bond bond 1417 -C112- bond bond 4-Cl-2-F-phenyl 1418 -CR2- bond bond 4-Cl-3-F-phenyl 1419 -CR2- bond bond 2,3,-diMeO-phenyl 1420 -CR2- bond bond- 2, 1421 -CR2- bond bond 2, S-dime0-phenyl 1422 -CR2- bond bond 2,6-diMeO-phenyl 1423 -CH2- bond bond -3.4-di~eO-phenyl1 1424 -CH2- bond bond 3. ,-diMeo-phenyl 1425 -CH2- bond bond cyclopropyl 1426 -CH2- bond bond cyclobutyl 1427 -CH2- bond bond cyclopentyl 1428 -CR2- bond bond cyclohexyl 1429 -CR2- bond bond 2-furanyl 1430 -CH2- bond bond 2-thienyl 1431 -CH 2 bond bond 2-imidazolyl 1432 -CR2- bond bond 2-pyridyl 1433 -CH2-- bond bond 3-pyridyl 1434 -CR2- bond bond 4-pyridyl 1435 -CH2- bond bond N-morpholinyl 1436 -CR2- bond bond N-piperidinyl 1437 -CH2- bond -bond- 3-Me-2-pyridyl 1438 -CR2- bond bond 4-Me-2-pyridyl 1439 -CH 2 bond bond 1-indolyl 1440 -CR2- bond bond -benzothienyl 1441 -CR2- bond bond. 2-benzofuranyl 1442 -CR2- bond bond 1-benzimidaziole 1443 -CR2- bond bond 2-naphthyl 1444 -CH2CH2- bond bond' phenyl 1445 -CH2CH2- bond bond 3,3-diphenyl 1446 -CH2CH2- bond bond 2-F-phenyl 1447 -CR2CH2- bond bond 3-F-phenyl 1448 -CH2CH2- bond bond 4-F-pheny.
1449 CH2CR2- bond bond 2-Ci-phenyl 1450 -CH2CH2- bond bond 3-Ci-phenyl, 1451 -CH2CH2- bond bond 4-Ci-phenyl 1452 -CH2CH2- bond bond 2-Me-phenyl 1453 -CH2CH2- bond bond 3-Me-phenyl 1454 -CH2CH2- bond bond 4-ile-phenyl 1455 -CH2CH2- bond bond 2-Meo-phenyl 1456 -CH2CH2- bond bond .3-Meo-phenyl 1457 -CH2CH2- bond bond 4-MeO-phenyl 1458 -CH2CH2- bond bond 2-MeS-phenyl 1459 1 CH2CH2- bond bond' 3-MeS-phenyl -208- 1460 -CH2CH2- bond bond 4-meS-phenyl 1461 -CH2CH 2 bond bond 2-F 3 C-phenyl 1462 -CH2CH2- bond bond 3- 3 -hfyl 1463 -CH2CH2- bond bn. -4-F3C-phenyl 1464 -CH2CH2- bond bond 2,3-diF-phenyl 1465 -CH2CH2- bond bond 2;4-diF-phenyl 1466 -CH2CH2- bond bond 1467 -CH2CH2- bond bond 2,6-diF-phenyl 1468 -C112CH2- bond bond 3,4-diF-phenyl 1469 -CH2CH2- bond bond 1470 -CH2CH2- bond bond 2*,3-diCl-phenyl 1471 -CH2CH2- bond bond 2,4-diCi-phenyl 1472 -CH2CH2- bond bond 1473 -CH2CH2- bond bond-. 2,6-diCl-phenyl 1474 -CH2CH2- bond bond 3,4-diCi-phenyl 1475 -CH2CH2- bond- bond 1476 -CH2CH2- bond bond 2-C1-3-F-phenyl 1477 -CH2CH2- bond bond 2-C1-4-F-phenyl 1478 -CH2CH2- bond bond 2-C1-5-F-phenyl 1479 -CH2CH2- bond bond 3-Cl-4-F-phenyl 1480 -CH2CH2- bond bond 3-C1-S-F-phenyl 1481 -CH2CH2- bond bond 4-C1-2-F-phenyl 1492 -CH2CHi2- bond bond 4-C1-3-F-phenyl 1483 -CH2CH2- bond bond 2,3 -diMeO-phenyl 1494 -CH2CH2- bond bond. 2,4-diMeo-phenyl 1485 -CH2CH2- bond bond 1486 -CH2CH2- bond bond 2.6-diMeO-phenyl 1487 -CH2CH2- bond bond 3,4-di~eO-phenyl 1488 -CH2CH2- bond bond 1489 -CH2CH2- bond bond cyclopropyl 1490 -CH2CH2- bond bond cyclobutyl 1491 -CH2CH2- bond bond cyclopentyl 1492 -CH2CH2- bond bond.bon cyclbhex1.J.
1493 -CH2CH2- bond bond -2-furanyl 1494 -CII2CH2- bond bond.- 2-thienyl 1495 -CH2CH2- bond bond 2-imidazolyl 1496 -CH2CH2- bond bond. 2-pyridyl 1497 -CH2CH2- bond bond 3-pyridyl 1498 -CH2CH2- bond bond 4-pyridyl 1499 -CH2CH2- bond bond N-morpholinyl 1500 -CH 2 CH2- bond bond li-piperidinyl 1501 -CH2CH2- bond bond' 3-Me-2-pyridyl 1502 -CH2CH2- bond bond- 4-Me--2-pyridyl 1503 -CH2CH2- bond bond 1-indolyl 1504 -CH2CH?2- bond bond 2-benzothienyl 1505 -CH2CH2-_ bond bond 2-benzofuranyl 1506 -CH2CH2- bond bond 1-benzimidazole 1507 -CH2CH2- bond bond .2-naphthyl 1508 -CH2CH2CH2- bond bond p3henyl 1509 -CH2CH2CH2- bond bond 3,3-diphenyl 1510 -CH2CH CH2- bond bond 2-f-phenyl 1511 -CH2CK2CH2- bond bond 3-F-phenyl -209- 1512 -CH2CH2CH2- bond bond 4-F-phenyl 1513 -CH2CH2CH2- bond bond 2-Cl-phenyl 1514 -CH2CH2CH 2 bond bond 3-Cl-phenyl 1515 -CH2CH2CH2- bond bond -4-Cl-phenyl 1516 -CH2CH2CH2- bond -bond 2-Me-phenyl 1517 -CH2CH2CH2- bond bond 3-Me-phenyl 1518 -CH2CH2CH2- bond bond 4-Me-phenyl 1519 -CH 2CH2CH2- bond bond 2-MeO-Phenyl 1520 -CH2CH2CH2- bond bond 3-MeO-Phenyl 1521 -CH2CH2CH2- bond bond 4-NeO-phenyl 1522 -CH2CH2CH2- bond bond" 2-MeS-pheny l 1523 -CH2CH2CH2- bond bond 3-MeS-phenyl 1524 -CH2CH2CH2- bond bond 4-MeS-pheny-1 1525 -CH2CH2CH 2 bond bond 2-F3C-phenyl1 1526 -CH2CH2CH2- bond bond 3-F3C-phenyl 1527 -CH2CH2CH2- bond bond 4-F3C-phenyl 1528 -CJ{2CH2CH2- bond bond 2,3-diF-phenyl 1529 -CH2CH2CH2- bond bond 2,4-iF -phenyl 1530 -CH2CH2CH2- bond bond 1531 -CH2CH2CH 2 bond bond 2,6-diF-phenyl 1532 -CH2CH2CH2- bond bond 3,4-diF-phenyl 1533 -CH2CH2CH2- bond bond 3 1534 -CH2CH2CH2- bond bond 2,3-diCi-phenyl 1535 -CH2CH2CH2- bond bond 2.4-diCi--phenyl 1536 -CH2CH2CH2- bond bond 1537 -CH2CH2CH2- bond bond 2,6-diCi-phenyl 1538 -CH;CI{ 2
CH
2 bond bond 3,4-diCl-phenyl 1539 -CH2CH2CH2- bond bond 3, 1540 -CH2CH 2
CH
2 bond bond 2-Cl-3-F-phenyl 1541 -CH2CH2CH2- bond bond 2-C1-4-F-pheny.
1542 -CH2CH2CH2- bond bond 2-C1-5-F-phenyl 1543 -CH2CH2CH2- bond bond 3-C1-4-F-phenyl 1544 -CH2CH2CH 2 bond bond.- 3-C1-5--F.-phenyl 1545 -CH2CH2CH2- bond bond 4-C1-2-F-phenyl.
1546 -CI42CH2CH 2 bond bond 4-C1-3-F-phenyl 1547 -CH2CH2C12- bond bond 2,3-diMeO-phepyl 1548 -CH2CH2C12- bond bond. 2.4-diMeO-phenyl 1549 -CH2CH2CH2- bond bond 2,S-diMeO-phenyl 1550 -CH2CH2CH2- bond bond 2,6-dimeo-phenyl 1551 -CH2CH2CH2- bond bond 3,4-di~eo-phenyl 1552 -CH2CH2CH2- bond bond 1553 -CH2CH2CH2- bond bond cyclopropyl 1554 -CH2CH2CH2- bond bond cyclobutyl 1555 -CH2CH2CH2- bond bond cyclopentyl 1556 -CH2CH2CH2- bond bond cyclohexcyl 1557 -CH2CH2CHi2- bond bond 2-furanyl 1558 -CH2CH2CH2- bond bond 2-thienyl 1559 -CH 2
CH
2
CH
2 bond bond 2-imidazolyl 1560 -CH2CH2CH2- bond bond 2-pyridyl.
1561 -CH2CH2CH2- bond bond 3-pyridyl 1562 -CH2cH2CH2- bond bond 4-pyridyl 1563 -CH2C1{2CH 2 bond bond IN-zorpholinyl.
-210- 1564. -CH2CH2CH 2 bond bond Nrpiperidinyl 1565 -CH2CH2CH 2 bond bond 3-Me-2-pyridyl 1566 -CH2CH2CH 2 bond band 4-Me-2-pyridyl 1567 -CH2CH2CH2- bond bond 1-i-doklyl1 1568 -CH2CH2CH2- bond bond 2-benzothienyl 1569 -CH2CH2CH2- bond .bond .2-benzofuranyl::- 1570 -CH2CB2CH2- bond bond 1-benzimidazole 1571 -CH2CH2CH2- bond bond 2-naphthyl 1572 -CH2CH2- bond phenyl 1573 -CH2CH2- bond .3,3-diphenylmethyl 1574 -CH2CH2- bond 2-F-phenyl 1575 -CH2CH2- bond 3 -F-phenyl 1576 -CH2CH2- bond 4-F-phenyl 1577 -CH2CH2- bond 2-Cl-phenyl 1578 -CH2CH2- bond 3-Ci-phenyl 1579 -CH2CH2- bond -Cl-phenyl 1580 -CH2CH2- bond 2-Me-phenyl 1581 -CH2CH2- bond 3-14e-phenyl 1582 -CH2CH2- bond 4-Me-phenyl 1583 -CH2CH2- bond 2-MeO-phenyl 1584 -CH2CH2- bond 3-M~eo-pheny1 1585 -CH2CH2- bond 4-tleO-phenyl 1586. -HC2 bond 2-MeS-phenyl 1587 -CH2CH2- bond .3-MeS-phenyl 1588 -CH2CH2- bond 4-MeS-phenyl 1589 -CH2CH2- bond 2-F3C-phenyl 1590 -CH2CH2- bond 3-F3C-phenyl 1591 -CH2CH2- bond 4-F3C-phenyl 1592 -CH2CH 2 bond 2.3-diF-phenyl 1593 -CH2CII2- bond 2,4-!diF-phenyl 1594 -CH2CH2- bond 1595 -CH2CH2- bond 2,6-diF-phenyl 1596 -CH2CH2- bond 3,4-diF-phenyl 1597 -CH2CH2- bond S-diFpheny1.
1598 -CH2CH 2 bond 23 -diCi-phenyl 1599 -CH2CH12- bond -2,4-diCl.-phenyl 1600 -CH2C1H2- bond 1.601 -CH2CH2- bond 2. 6-diCi-phenyl 1602 -CH2CH2- bond 3,4-diCl-phenyl 1603 -CH2CH2 bond 1604 -CH 2
CH
2 bond 2-C1-3-F-phenyl 1605 -CH2CFI2- bond 2-C1-4-F-phenyl 1606 -CH2CH2- bond 2-CI7-5-F-phenyl 1607 -CI12CH2- bond 3-Cl-4-F-phenyl 1608. -CH2CH2- bond. 3-C1-5-F-phenyl 1609 -CH2CH2- band 4-Cl-2-F-phenyl 1610 -CH2CH2- bond -13Fhey 1611 -CH2CH2- band 2,3-cdi~eo-phenyl 1612 -CH2CH2- bond .2,4-dliMeo-phenyl 1613 -CH2CH 2 bond 1614 -CH 2 CH2- bond 2,6-di~eO-phenyl 1615 -CH2CH2- bond 3. 4-diMeO-phenyl -211- 1616 -CH2CH2- bond 3 ,S-diMeO-phenyl 1617 -CH2CH 2 bond cyclopropyl 1618 -CH2CH 2 bond cyclobutyl 1619 -CH2CH 2 bond cyclopentyl 1620 -CH2CH 2 bond cyc- oh xyl 1621 -CH2CH 2 bond -2 -f uranyl1 1622 -CH2CH2- bond 2-thienyl 1623 -CH 2
CII
2 bond 2-pyridyl 1624 -CH2CH2- bond -3-pyridyl 1625 -CH2CH 2 bond 4-pyridyl 1626 -CH2CH2- bond 3 -Me-2-pyridyl.
1627 -CH 2 C14 2 bond 4- Me-27PYridYl 1628 -CH2CH2- bond 2-benzpthienyl 1629 -CH2CH 2 bond 2-benzofuranyl 1630, -CH2CH 2 bond -07 -_27-ndphthyl 1631 -CH2CH2CH 2 bond phenyl 1632 -CH2CH2CH2- bond 3 ,3-diphenylmethyl 1633 -CH2CH2CH 2 bond 2-F-phenyl 1634 -CH2CH2CH2- bond 3-F-phenyl 1635 -CH2CH2CH 2 bond 4-F-pheny.
1636 -CH2CH2CH2- bond 2-Cl-phenyl 1637 -CH2CH2CH2- bond 3-Cl-phenyl 1638 -CH7CH2CH2- bond 4-Cl-phenyl 1639 -CH2CH2CH 2 bond 2-Me-phenyl 1640 -CH2CH2CH2- bond 3-Me-phenyl 1641 -CH2CH2CH 2 bond 4-Me-phenyl 1642 -CH2CH2CH2- bond 2-MeO-phenyl 1643 -CH2CH2CH 2 bond 3-MeO-phenyl 1644 -CH2CH2CH2- bond. 4-Me0O-phenyl- 1645 -CH2CH 2
CH
2 bond 2-MeS-phenyl 1646 -CH2CH2CH2- bond 3-MeS-phenyl 1647 -CH2CH2CH 2 bond 4-MeS-phenyl 1648 -CH2CH2CH 2 bond 2-F3C-phenyl 1649 -CH2CII2CH2- bond 3-FiC-phenyl 1650 -CH2CH2CH2- bond 4-F3C-phenyl 1651 -CH2CH 2
CH
2 bond 2,3-diF-phenyl 1652 -CH2CH2CH2- bond 2,4-diF-phenyl 1653 -CH2CH2CH2- bond 2. 1654 -CH2CH2CH 2 bond 2.6-diF-phenyl 1655 -CH2CH2CH 2 bond -3,4-diF-pheny.
1656 -CH2CH2CH2- bond 1657 -CH2CH 2
CH
2 bond 2,3-diCl-phenyl 1658 -CH2CH2CH2- bond 2 ,4-diCl-phenyl 1659 -CH2CH2CH 2 bond 1660 -CH2CH2CH2- bond 2,6-diCl-phenyl 1661 -CH2CH2CH2- bond 3,4-diCl-phenyl 1662 -CH2CH2CH2- bond 163 -CH2CH2CH 2 bond 2-Cl-3-F-phenyl 1664 -CH2CH2CH2- bond 2-C1-4-F-phenyl 1665 -CH2CH2CH 2 bond 2-Cl-S-F-phenyl 1666 1-CH2CH2CH2- bond 3-C1-4-F-phenyl 116671 -CH2CH2CH-bn i3-Cl-S-F-phenyl -212- 1668 -CH 2
CH
2 CH2- bond 4-C1-2-F-phenyl 1669 -CH 2 CI4 2 CH2- bond -0 4-C1-3-F-phelyl 1670 -CH 2
CH
2 CH2- bond 2,3-diMe0-phenyl 1671 -CH 2
CH
2 CH2- bond 2,4-diMeO-pheny.
1672 -CH- 2
CH
2
CH
2 bond 1673 -CH 2
CH
2
CH
2 bond 2,6-diMeo-phenyl 1674 -CH 2
CH
2
CH
2 bond 3,4-diMe0-phenyl 1675 -CH 2
CH
2 CH2- bond 3, 1676 -CH 2
CH
2 CH2- bond cyclopropyl 1677 j-CH 2 CH2CH2- bond cyclobutyl 1678 1-CH 2
CH
2
CH
2 bond cyclopentyl 1679 -CH 2
CH
2
CH
2 bond cyclohexyl 1680 -CH 2
CH
2 CH2- bond 2-furanyl 1681 -CH 2
CH
2
CH
2 bond 2-thienyl 1682 -CH 2
CH
2 CH2- bond 2-pyridyl 1683 -CH 2
CH
2 CH2- bond.- 3-pyridyl 1684 -CH 2
CH
2
CH
2 bond 4-pyridyl 1685 -CH 2
CH
2
CH
2 bond -3-Me-2-pyridyl 1686 -CH 2
CH
2 CH2- bond 4-Me-2-pyridyl 1687 -CH 2
CH
2 CH2- bond 2-beniothienyl 1688 -CH 2
CH
2
CH
2 bond 2-benzofuranyl 1689 -CH 2
CI{
2 CH2- bond 2-naphthyl Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof.
This is a divisional application of 756830 (53378/99), the disciosureof which is incorporated herein by way of reference.
213 2323 /04/03,sw13 348sp, 213
Claims (11)
1. A compound of Formula (I) or a pharmaceutically acceptable salt or-prodrug thereof, wherein: Q is -OR 1 or -NR 1 R 2 R 1 at each occurrence, is independently selected from H; C 1 -C 6 alkyl substituted with 0-3 Rla; C 2 -C 6 alkenyl substituted with 0-3 Rla; C 3 -C 10 carbocycle substituted with 0-3 Rlb; C 6 -C10 aryl substituted with 0-3 Rib; and to 10 membered heterocycle substituted with 0-3 Rib; R l a at each occurrence, is independently selected from H' C1-C 6 alkyl, OR 1 4 Cl, F, Br, I, CN, NO 2 NR15R 16 CF 3 C 3 -C 10 carbocycle substituted with 0-3 Rlb; C 6 -CIo aryl substituted with 0-3 Rib; and to 6 membered heterocycle substituted with 0-3 Rib; Rib, at each occurrence, is independently selected from H, OH, C1, F, Br, I, CN, NO 2 NR 15 R 1 6 CF3, CI-C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, and C 1 -C 4 haloalkoxy; -214- R 2 is independently selected from H, M]- 2 OH, CI-C 6 alk-yl Ci- C 6 alkoxy, phenoxy, benzyloxy, 6 3 -C 1 0 carbocycle, C 6 -C 1 0 aryl and 5 to 10 memnbered heterocycle; R 3 is -(CR 7 R 7 a),-R 4 (CR 7 R 7 a) n-S- (CR 7 R 7 a) m-R 4 C7~)n0 (RRa -4 (CR 7 R 7 a) -N (R 7 b) (CR 7 R 7 a) m-R 4 (CR 7 0a n-S (CR 7 R 7 a) m-R 4 .0 (CR 7 R 7 a)n-S 2-(CR7R 7 a)m-R 4 (CR 7 R 7 a) rC -(CR 7 R 7 a) m-R 4 (CR 7 R 7 a)n-N(R 7 b) -(CR 7 R 7 a)m R 4 (CR 7 R 7 a) -C N(R 7 b) (CR 7 R 7 a) m-R 4 or (CR 7 R 7 a)n-S 2 N(R~b) -(CR 7 R 7 a)m-R 4 n is 0, 1, 2, or 3; mn is 0, 1, 2, or 3; R 3 a is OH, Cj-C 4 alkyl, Cl-C 4 alkoxy, or C 2 -C 4 alkenyloxy; R4is H, OH, OR1 4 a, Cl-Cs alkyl substituted with 0-3 R 4 a, C 2 -C 6 alkenyl substituted with 0-3 R 4 a,. C 2 -C 6 alkynyl 'Substituted with, 0-3 R 4 a, C 3 -CI 0 carbocycle substituted with 0-3 R4b, C 6 -CI 0 aryl substituted with 0-3 R4b, or to 10 membered heterocycle substituted with 0-3 R4b; R 4 a, at each occurrence, is independently selected from is H, F, Cl, Br, I, CF 3 C 3 -C 10 carbocycle substituted with 0-3 R4b, C 6 -Cj 0 aryl substituted with- 0-3 R4b, 'or- 10 membered heterocycle substituted with 0-3 -R4b; R 4 b, at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, NO 2 NR 15 R 1 6 CF 3 acetyl, SCH 3 -215- S(=O)CH 3 S(=O) 2 CH 3 Cj-C 6 alkyl, CI-C 4 alkoxy, Cl-C 4 haloalkyl, C 1 -C 4 haloalkoxy, and CI-C 4 halothioalkoxy; R 5 is H, OR 14 ;0 C 1 -C 6 alkyl substituted with 0-3 R~b; C 1 -C 6 i alkoxy substituted with-0-3 R~b; C 2 -C 6 alkenyl substituted with 0-3 R~b; C 2 -C 6 alkynyl substituted with 0-3--R 5 C 3 -C 1 O carbocycle substituted with 0-3 RSC; C 6 -Cj 0 aryl substituted with 0-3 RSc; or to 10 membered heterocycle substituted with 0-30c; RS8 is H, OH, Cl-C 4 alkyl, Cl-C 4 alkoxy, C 2 7:C 4 alkenyl, or C 2 C 4 alkeriyloxy; R~b, at each occurrence, is independently selected from: H, Cl-C6 alkyl, CF 3 OR 14 Cl, F, Br, I, CN, NO 2 NR 15 R 16 C 3 -C 10 carbocycle substituted with 0-3 RSc; C 6 -CI 0 aryl substituted with 0-3 RSc; or to 10 membered heterocycle substituted with 0-3 R 5 C; RSc, at each occurrence, is independently selected from H, OH, C1, F, Br, 1, CN, N02, NR 15 RI 6 CF3, acetyl,, SCH 3 S CH 3 S 2 CH3; >Cl-C6 alkyl, C 1 -C 4 alkoxy, C 1 -c 4 haloalkyl, Cj-C 4 haloalkoxy, and Cl-C 4 halo thioalkoxy; R 6 is H; Cl-C 6 alkyl substituted with 0-3 R 6 a; C 3 -CI 0 carbocycle substituted with. 0-3 R6b; or C 6 -CI 0 aryl substituted with 0-3R6b- R 6 a, at each occurrence, is independently selected from H, Cj-C 6 alkyl, OR 1 4 Cl, F, Br, I, CN, NO 2 NR 15 R 16 phenyl. or CF3;- -216- R~b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 NRISR 1 6 CF3, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, and Cl-C4 haloalkoxy; R 7 at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 CF 3 and Ci-C 4 alkyl; R 7 a, at each occurrence, is independently-selected from OH, Cl, F, Br, I, CM, N0 2 CF 3 aryl and Cl-C 4 alkyl; R 7 b is independently selected from H and C 1 -C 4 alkyl; W is -(CRBR 8 a)p-; p is 0, 1, 2, 3, or 4; R 8 and R 8 a, at each occurrence, are independently selected from H, F, Cl-C 4 alkyl, C2-C4 alkenyl, C 2 -C 4 alkynyl and C 3 -C 8 cycloalkyl; X is a bond; C 6 -Cj 0 aryl substituted with 0-3 Rxb; C 3 -C 10 carbocycle substituted with 0-3 Rxb; or to 10 membered heterocycle substituted with 0-2 Rxb; Rxb at each occurrence, is independently sele cted from H, OH, Cl, F, Br, I. CN, N02, NR 1 5 R 16 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 CI-C6 alkyl, C 1 -C 4 alkoxy, Cl-C 4 haloalkyl, Cl-C 4 haloalkoxy, and Cl-C 4 halothioalkoxy; Y is a bond. or -(CR 9 R 9 a)t-V-.(CR 9 R 9 a)u-; t is 0, 1, 2, or 3; u is 0, 1, 2, or 3; R 9 and R 9 a, at each occurrence, are independently selected from H, F, Cl-C6 alkyl or C 3 -CB cycloalkyl1; -2 17- V is a bond, 2 -N(R 1 9 -C(=O)NR 9 -NRl 9 bC(QO)-, -N19bS(=0) 2 S(=O) 2 NRl 9 .b- -N19bS(=p.., -S(=O)NR1 9 or Z is Cl-C 3 alkyl substituted with 1-2 Ri 2 C6-Clo aryl substituted with 0-4 Rl2b; C 3 -Cl 0 carbocycle substituted with 0-4 Rl2b; or to 10 memibered heterocycle- substituted with 0-3 Rl12b; R 12 is C 6 -Cj 0 aryl substituted with. 0-74 .R?.b;L C 3 -CI 0 carbocycle substituted with ,0-4 Rl2b; or 10 membered heterocycle, substituted *with 0-3 R1,2b;' R1 2 b, B is at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, PO 2 NR 1 5 R 1 6 'CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 Cl-C 6 alkyl, Cl-C 4 alkoxy, C 1 -C 4 haloalkyl, Cl-C 4 haloalkoxy, and C 1 -C 4 halothioalkoxy; a 5 to 10 membered lactam, wherein the lactani is saturated, partially saturated or unsaturated; wherein each additional lactanm carbon is substituted with 0-2 Ri 1 and, optionally, the lactain contains a heteroatom selected.. from and -N(R 1 0 RIO is H, C(=O)R 1 7 C(=O)0R 1 7 C(=O)NRISR 1 9 S(=O) 2 NRl 8 R 1 9 Cl-C 6 alkyl substituted with 0-2 Rl0a; C 6 -Cl 0 aryl substituted with 0-4 C 3 -Cl 0 carbocycle substituted with 0-3 Ri0b; or to 10 membered heterocycle optionally. substituted -with 0-3 Ri0b; R 1 0 a, at each occurrence, is independently selected from H, Cl-CE alkyl, OR 1 4 Cl, V, Br, I, CN, NO 2 NRlSR 1 6 CF 3 or aryl substituted with 0-4 -218- Riob, at each occurrence, is independently selected f rom H, OH, Cl-C 6 alkyl, CI-C 4 alkoxy, Cl, F, Br, I,.CN, NO 2 NR1 5 R 16 CF 3 acetyl, SCH 3 'S CH 3 S 2 CH 3 C 1 -C 6 alkyl, Cl-C 4 alkoxy, Cl-C 4 haloalkyl, Cl-C 4 haloalkoxy, and C 1 C 4 halothioalkoxy; RI 1 at each, occurrence, is independently 'selected' from C 1 -C 4 alkoxy. Cl, F, Br, I, CN, NO 2 NR 1 8 R 19 ~C R 17 C O~i 7 C (--0)NR 1 8 R 19 S 2 NR 1 8 Rl 9 CF 3 C 1 -C 6 alkyl substituted with- 0-1 R11a'; C 6 -CIO aryl. substituted with 0-3 R11b; C 3 -C 10 carbocycle substituted with 0-3 Ru1b; or 5 to 10 membered heterocycle substituted with R11b; alternatively, two R 11 substituents on the same or adjacent carbon atoms may be combined to form a C 3 -C 6 carbocycle or a benzo fused radical; R 1 1 a, at each occurrence, is independently selected from H, CI-C 6 alkyl, OR 1 4 Cl, F, Br, 1, CN,.NO 2 NR 1 5 R 16 CF 3 or phenyl substituted with 0-3 R1b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N0 2 NR 15 R 16 CF 3 acetyl, SCH 3 S(=O)CH3, S(='0)2CH 3 Ci-C6 alkyl, Cu-C 4 alkoxy, Cl-C 4 haloalkyl, Cl-C 4 haloalkoxy, and C 1 -C 4 halothioalkoxy; R 14 at each occurrence, is independently selected from H, phenyl, benzyl, Cl-C 6 alkyl, or C 2 -C 6 alkoxyalkyl; R 14 a is H, phenyl, benzyl, or Cl-C 4 alkyl; R 15 at each occurrence, is independently selected from H, CI-C 6 alkyl, benzyl., phenethyl, 6 alkyl) and -S 2- (Cl-C 6 alkyl) V-21'9- R 16 at each occurrence, is independently selected from H, OH, CI-C 6 alkyl, benzyl, phenethyl, -C -C 6 alkyl) and 2 -(C 1 -C 6 alkyl); R 1 7 is H, aryl, aryl-CH 2 C 1 -C6_ alkyl, or C2-C6- alkoxyalkyl; R 18 at each occurrence, is independently selected from H, Cl-C 6 alkyl, benzyl, phenethyl, 1 C 6 alkyl) and 2 -(Cl-C 6 alkyl); and R 1 L 9 at each occurrence,: is' independently'selected f rom- H, OH, Cl-C 6 alkyl, phenyl, benzyl, 'phenethyl, 1 C 6 alkyl) and -S 2 (Cl-C 6 alkyl) and Rl9b is H, Cl-C 6 alkyl, C 3 -C 8 cycloalkyl, phenyl, benzyl or phenethyl.
2. A compound of Claim 1 wherein Q is -NRlR 2 R 1 at each occurrence, is independently selected from: H; Cl-Cs alkyl substituted with 0-3 Ria; C 2 -C 6 alkenyl substituted with 0-3 Ria; Ria, at each occurrence, is independently selected from H, OR 14 F, NR 15 RI 6 CF 3 C3-C 6 cycloalkyl substituted with 0-3 Rib; phenyl. substituted with 0-3 Rib; and to 6 memibered heterocycle substituted with 0-3 Rib; Rib, at each occurrence,-is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 NR 1 5 R 1 6 CF 3 C: 1 -C 4 alkyl', CI-C 4 alkoxy, C 1 -C 4 haloalkyl, and Cl-C 4 hdloalkoxy; R 2 is independently selected from H, NH 2 OH, Cl-C 6 alkyl, Cj- C 6 alkoxy, phenoxy, and benzyloxy; -220- R 3 is (CR 7 R 7 a),-R 4 -(CR 7 R 7 a (CR 7 R 7 a) m-R 4 -(CR 7 R 7 a )n-O-(CR 7 R 7 a)m-R 4 (CR 7 R 7 a -N (R 7 b) (CR 7 R 7 a) m-R 4 (CR 7 R 7 a -S (CR 7 R 7 a) m-R 4 (CR 7 R 7 a) n-S 2 -(CR 7 R 7 a) R 4 (CR 7 R 7 a -C (CR 7 R 7 a) m-R 4 (CR 7 R 7 a nNHC CR 7 R 7 a) mR 4 -(CR 7 R 7 NH- (CRR 7 P9--mR 4 -(CR 7 R 7 a),-NHS (CR 7 R 7 a)m-R 4 -(CR 7 R 7 a 2 NH- (CR 7 R 7 a)m-R 4 or, n is 0, 1, 2, or 3; mn is 0, 1, 2, or 3; R~a is H, OH, Cl-C 4 alkyl, Cl-C 4 alkoxy, or C 2 -C 4 alkenyloxy. R 4 is H, OH, OR 14 a, C 1 -C 6 alkyl substituted with 0-3 R 4 a, C 2 -C 6 alkenyl substituted with 0-3 R 4 a, C 2 -C 6 alkynyl substituted with 0-3 R~a C 3 -C1O carbocycle substituted with 0-3 R4b, C 6 -Cj 0 aryl substituted. with Ob., or to 10 membered heterocycle substituted with 0-3 R4b; R~a, at each occurrence, is independently selected. from is H, F, Cl, Br, I, CF 3 C 3 -C 10 carbocycle substituted with 0-3 R 4 b, C 6 -C 1 0 aryl substituted with 0-3 R4b, or to 10 memnbered heterocycle substituted with 0-3 R 4 b; R 4 b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 NR 1 5 R 16 CF3, acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 Cj-C 6 alkyl, C 1 -C 4 alkoxy, C 1 C 4 haloalkyl, and Cl-C 4 haloalkoxy; -221- R 5 is H, OR 14 Cl-C 6 alkyl substituted with 0-3 Cl-C 6 alkoxy substituted with 0-3 R~b; C 2 -C 6 alkenyl substituted with 0-3 R~b; C 2 -C 6 alkynyl substituted with 0'.3 C 3 -C 1 O carbocycle substituted with 0-3 R 5 c; C 6 -Cj 0 aryl substituted with0O-3R~c; to 10 membered heterocycle substituted with 0-3RSc; R 5 a is H, OH, Cj-C 4 alkyl, CI-C 4 alkoxy, C 2 -C 4 alkenyl, or C 2 C 4 alkenyloxy; at each occurrence, is independently selected from: H, Cl-C 6 alkyl, CF 3 OR 14 Cl, F, Br, I, CN, NO 2 NR 15 R. 16 C 3 -C 10 carbocycle substituted with 0-3 RSc; C 6 -Cj 0 aryl substituted with 0-3 R 5 c; or to 10 membered heterocycle substituted with 0-3 RSc; RSc, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N0 2 NR 1 5 R 1 6 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 CI-C 6 alkyl, CI-C 4 alkoxy, C 1 -C 4 haloalkyl, and Cl-C 4 haloalkoxy; R 6 is H; C 1 -C 6 alkcyl substituted with 0-3 R 6 a; C 3 -C 6 carbocycle substituted with 0-3 R6b; or C 6 -Cj 0 aryl substituted with 0-3R6b; R~a, at each occurrence, is independently selected from H, CI-C 6 alkyl, OR 14 Cl, F, Br, I, CN, NO 2 NR 15 R 16 phenyl or CF 3 R6b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N02, NR 1 5 R 1 6 CF 3 Cl-C 6 alkyl, Cj-C 4 alkoxy, Cl-C 4 haloal-kyl, and Cl-C 4 haloalkoxy; -222- R 7 at each occurrence, is inideendenitly selected f rom H, OH, Cl, F, Br, I, CN, N,02, CF 3 and Cl-C 4 alkyl; R~,at each occurrence, is independenitly selected f-roni H, OH, Cl, F, Br, I, CN, NO 2 CF 3 aryl and Cj-C 4 alkyl; R 7 b is independently selected from H and CI-C 4 -alkyl; W. is (CRO 8 a) P-; p is 0, 1, 2, 3, or 4; R 8 and at each occurrence, are independently selected from H, F, CI-C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl and C 3 -C 8 cycloalkyl;- X is a bond; C 6 -C 10 aryl substituted with 0-3 Rxb; C 3 -C 1 O carbocycle substituted with 0-3 Rxb; or 5 to 10 membered heterocycle substituted with 0-2 Rxb; Rxb, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N02, NR 1 5 R 1 6 CF 3 acetyl, SCH 3 S(=0)CH 3 S(=0) 2 CH 3 Ci-C 6 alkyl, -C.-C 4 alkoxy, CI-C 4 haloalkyl, and Cl-C4 haloalkoxy; Y is a bond or (CR 9 R 9 a) t-V-(CR 9 R 9 a) U-; t is 0, 1, 2, or 3; u is 0, 1, 2, or 3; R 9 and R 9 a, at each occurrence, are independently selected from H, F, Cl-C 6 alkyl. or C3-C 8 cycloalkyl; V is a bond, 2 -N(R 1 9 -C (=O)NR 9 R19bC Rl9bS 2 NRl9b-, -NR19bS(=Q)., -S(=0)NR1 9 or -OC(0O)-; -223- Z is Cl-C 3 alkyl substituted with 1-2 R 2 2 C 6 -Cj 0 aryl1 substituted with 0-4 Rl2b; C 3 -C 10 carbocycle substituted with 0-4 R12b; or 5 to 10 membered heterocycle substituted with 0-3 Rl2b, R 12 is C 6 -C 1 0 aryl substituted with 0-4 R12b; C 3 -C1O carbocycle substituted with 0-4 R12b; or to 10 mnembered heterocycle- substituted with 0-3.R12b; Rl 2 b, at each occurrence",".is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 'NR 1 5 R 1 6 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 C 1 -C 6 alkyl, CI-C 4 alkoxy, cj-C 4 haloalkyl, and C 1 -C 4 haloalkoxy; B is a 6, 7, or 8 memnbered lactam, wherein the. lactan is saturated, partially saturated or unsaturated; wherein each additional lactan carbon is substituted with 0-2 R 1 1 and, optionally, the lactan contains a heteroatom selected from 2 and -N(Rl 0 R1 0 is H, C(=O)Rl 7 C(=O)0R 1 7 C(=O)NR 18 RI 9 S 2 NR 1 8 RI 9 S=)R7 CI-C 6 alkyl substituted with 0-1 Rl0a; C 6 -Cj 0 aryl substituted with 0-4 Ri0b; C 3 -CI 0 carbocycle substituted with 0-3 RiOb; or to 10 memnbered heterocycle optionally substituted with 0-3 R 10 a, at each occurrence, is independently selected from H, C 1 -C 6 alkyl, OR 14 Cl, F, Br, I, CN, NO 2 NR 1 5 RI. 6 CF 3 or phenyl substituted with 0-4 Ri0b; at each occurrence, is independently selected f rom H, OH, CI C 6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CN, NO 2 NR 15 R 1 6 or CF 3 -224- R 1 1 at each occurrence, is independently -selected from Cl-C 4 alkoxy, Cl, F, Br, I, CN., NO 2 NR 1 8 R 19 C(=O)Rl 7 C(=O)0R 17 C(=O)NR 1 8 R 1 9 S(=O) 2 NR 1 8 Rl 9 CF 3 Cl-C 6 alkyl substituted with 0-1 R1la; C 6 -CI 0 aryl substituted with 0-3 R11b; C 3 -C 10 carbocycle substituted with .0 3.R11b; or to 10 memnbered heterocycle substituted with 0-3 R11b; alternatively, two R 11 substituents on the same or adjacent:' carbon atoms may be combined to form a C 3 -C 6 carbocycl or a benzo fused radical; R1la, at each occurrence, is independently selected from H, Cl-C 6 alkYl, OR 14 Cl, F, Br, I, CN, NO 2 NR 15 RI 6 CF 3 or phenyl substituted with 0-3 R11b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 NR 15 R 16 CF 3 Cl-C 6 alkyl,' Cl-C 4 alkoxy, Cl-C 4 haloalkyl, and CI-C 4 haloalkoxy; R 14 is H, phenyl, benzyl, CI-C6 alkyl, or C 2 -C 6 alkoxyalkyl; R 15 at each occurrence, is independently selected from H, C 1 -C 6 alkyl, benzyl, phenethyl,- C(=O)-(Cl-C 6 alkyl) and 2 -(CI-C 6 alkyl); R16 at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl); R 17 is H, aryl, (aryl)CH 2 Cl-C 6 Alkyl, or C 2 -C 6 alkoxyalkyl; R 18 at each occurrence, is independently selected from H, Cl-C 6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl); and -225- R 19 at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, phenyl, benzyl. phenethyl, -CC=O)-(Cl- C 6 alkyl) and 2- (Cl-C 6 .alky-l) :hd z R19 is H, Ci-C 6 -alkyl, C 3 -C 8 cycloalkyl, phenyl, benzyl or phenethyl.
3. A compound of Claim 2 of Formula (Ia.) 0 R5RaF 6 0 H 2 N NNl N RR 3 aO B (Ia) or a pharmaceutically acceptable salt or prodrug thereof, wherein: R 3 is -(CR 7 R 7 a )n-R 4 (CR 7 R 7 a (CR 7 R 7 a)m-R 4 -(CR 7 R 7 a )n-O-(CR 7 R 7 a)m-R 4 or (CR 7 R 7 a n-N (R 7 b) (CR 7 R 7 a) m-R 4 n is 0, 1, or 2; m. is 0, 1, or 2; R 3 a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, or butoxy; R 4 is H, OH, ORl 4 a, Cj-C 4 alkyl substituted with 0-2 R 4 a, C 2 -C 4 alkenyl substituted with 0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-2 R 4 a, C 3 -C 6 cycloalkyl substituted with 0-3 R4b, C 6 -Cj 0 aryl substituted with 0-3 R4b, or to 10 membered heterocycle substituted with 0-3 R 4 b; -226- 1 4a, at each occurrence, is independently selected f rom is H, F, Cl, Br, I CF 3 C 3 -C 1 O carbocycle substituted- with 0-3- R~b, C 6 -C 10 aryl substituted with 0-3 R4b, or 5 to 10 membered heterocycle substituted with- 0-33:-R4b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN4, NO 2 ,.NR15R1, CF 3 acetyl, SCH3, S(=O)CH 3 S(=O) 2 CH 3 Cl-C 6 alkyl, CI-C 4 alkoxy, Cl-C 4 haloalkyl, and CI-C 4 -haloaikoxy, R 5 is H, OR 1 4 Cl-C 6 alkyl substituted with 0-3 R~b; c 2 -C 6 alkenyl substituted with 0-3 C 2 -C6 alkynyl. substituted with 0-3 R~b; C 3 -C 1 O carbocycle substituted with 0-3 R 5 c; C 6 -Cj 0 aryl substituted with 0-3 R 5 c; or to 10 membered heterocycle substituted with 0-3RSc; RS8 is H, OH, Cl-C 4 alkyli -CI-C 4 alkoxy, C 2 -C 4 alkenyl, or C 2 C 4 alkenyloxy; at each occurrence, is independently selected from: H, CI-C 6 alkyl, CF 3 OR 1 4 Cl, 1, =0,'CN,._NQ 2 NR 15 R 16 C 3 -C 10 carbocycle substituted with 0-3 R 5 c; C 6 -C 10 aryl substituted with 0-3 R5C; or S to 10 membered heterocycle substituted with 0-3 RSc; RSc, at each occurrence, is independently selected from Hi, OH, Cl, F, Br, I, CN, N02, NR 15 RI 6 CF 3 ac'etyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 C 1 C 6 ,alkyl, CI-C 4 alkoxy,. Ci.-C 4 haloalkyl. and Cl-C 4 haloalkoxy; R 6 is H, methyl, or ethyl;, R 7 at each occurrence, is independently selected from H, OH,- Cl, F, Br, I, CN, N0 2 CF3, and CI-C 4 alkyl; -227- R 7 8, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 _CF 3 phenyl-and-:CiL-C 4 'alky-l; R 7 b is independently selected from H, methyl, ethyl, propyl, and butyl; W is -(CR8R~a)p-;- p is 0, 1, or 2; R 8 and RB8, at each occurrence, are independently selected from H, F, Cl-C 3 alkyl, C 2 -C3 alkenyl, C 2 -C 3 alkynyl and-. C 3 -C 6 cycloalkyl; X is a bond; C 6 -Cj 0 aryl substituted with 0-3 Rxb; C 3 -Cl 0 carbocycle substituted with 0-2 Rxh; or to 10 membered heterocycle substituted with 0 -2 Rxb; RIat each occurrence, is independently selected from H, OH, Cl, F, Br, I, CM, NO 2 NR 15 R 16 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH3, Ci-C 6 alkyl, Cj-C 4 alkoxy, C 1 -C 4 haloalkyl, and Cl-C 4 haloalkoxy;- Y is a bond or -(CR 9 R 9 a)t-V-(CR 9 R 9 t is 0, 1, or 2; u is 0, 1, or 2; R 9 and R 9 a, at each occurrence, are independently selected from H, F, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; V is a bond, 2 -N(Rl 9 -C (=Q)N19b.. 19bC(=O) -,,.-NR1bS 2 NR9b.. -NR9b(=O-,or -S(=O)NR1 9 b-; -228- Z is CI-C 3 alkyl substituted with 1-2 Ri 2 C 6 -Cj 0 aryl substituted with C-4.Rl 2 b; C 3 -C 10 carbocycle substituted with O-4 'Rl2b-: or to 10 membered heterocycle substituted with 0-3 Rl2b; R 12 is *C 6 -Cj 0 aryl substituted with 0-4 Rl2b; C 3 -C1 0 carbocycle substituted with 0-4 Rl2b; or to 10 membered heterocycle substituted with 0-3 R12b; Rl 2 b, B is at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 NR 1 5 R 16 CF 3 acetyl, SCft 3 S(=O)CE 3 S(=O) 2 CH 3 Cl-C 6 alkyl, Cl-C 4 'alkoxy, Cj-C 4 haloalkyl, and C 1 -C 4 haloalkoxy; a seven memnbered lactam, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R 11 and, optionally, the lactarn contains a heteroaton selected from and R 10 is H, C(=O)Rl 7 C(=O)0R 17 C(=O)NR 18 R 19 S 2 NR 18 R 19 Cj-C 6 alkyl substituted with. 0-1 C 6 -Cj 0 aryl substituted with 0-4 C 3 -C 10 carbocycle substituted- with 0-3 R10b; or to 10 memnbered heterocycle optionally substituted with 0-3 R0,at each occurrence, is independently selected from -H, C 1 -C 6 alkyl, OR 14 Cl, F, Br, I, CN, NO 2 NR 1 5 R 1 6 CF 3 or phenyl substituted with 0-4 R21cb, at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, Cj-C 4 alkoxy, Cl, F, Br, I, CN, NO 2 NR 1 5 Rl 6 or CF 3 -229- R 1 at each occurrence, is independently selected from Cl-C 4 alkoxy, Cl, F, NRlSRl 9 7 ,-C(=O)0R1 7 C(=O)NRlBR 1 9 S(=o) 2 NR 1 8 Rl9,; CF3; C 1 -C 6 alkyl substituted with 0-1 Rila; C 6 -C 1 0 aryl substituted 'With *0-3 R11b; C 3 -C 10 carbocycle substituted with 0-3 R11b; or to 10 membered heterocycle substituted with 0-3 R11b; alternatively, two R 11 substituents on the same or adjacent carbon atoms may be combined to -fori- aC'3-C6 carbocycle or a benzo fused radical; R11a at each occurrence, is independently selected from H,. Cl-C 6 alkyl, OR 14 Cl, F, Br, I, CM, NO 2 NR 1 5 R 1 6 CF 3 or phenyl substituted- with 0-3 R11b; R11b, at each occurrence, is independently selected from H, OH, C1, F, Br, I, CN, NO 2 NR 1 5 R 1 6 CF 3 Cj.-C 6 alkyl, Cl-C 4 alkoxy, CI-C 4 haloalkyl, and C 1 -C 4 haloalkoxy; R 14 is H, phenyl, benzyl, Cl-Cs alkyl, or C 2 -C 6 alkoxyalkyl; R 1 5 at each occurrence, is independently selected from H, Cl-C 6 alkyl, benzyl, phenethyl, 1 -C6*alky1) and 2 -(C 1 -C 6 alkyl); R 1 6 at each occurrence, is independently selected from H, OH, Cl-C 6 alkyl, benzyl, phenethyl, alkyl)- and 2 -(C 1 -C 6 alkyl); R 1 7 is H, aryl, (aryl)CH2-, Ci-C6 alkyl, or C 2 -C 6 alkoxyalkyl; R 1 8 at each occurrence, is independently selected from H, Cl-C 6 alkyl, benzyl, phenethyl, alkyl) and 2 -(Cl-C6 alkyl.); and -23 0- R 19 at each occurrence, is independently.selected from H, OH, CI-C 6 alkyl, phenyl, benzyl, phenethyl, 1 C 6 alkyl) and 2 -(Cl-C 6 alkyl); and R19 is H, Cl-C6 alkyl, C 3 -C 8 cycloalkyl, ph'enyl, benzyl or phenethyl.
4. A compound of Claim 3 wherein: R 3 is -(CR 7 R 7 a)n-R 4 -(CR 7 R 7 a) -S (CR 7 R 7 a) M-R 4 -(CR 7 R 7 a) n-0 (CR 7 R 7 a) -R 4 I or -(CRU) -N (CR 7 R 7 a) m-R 4 n is 0 or 1; m is 0 or 1; R 3 a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, or butoxy; R 4 is H, OH, Cl-C 4 alkyl substituted with 0-2 R 4 d, C 2 -C 4 alkenyl substituted with 0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-1 R 4 a, C 3 -C 6 cycloalky. suibstituted with 0-3 ROb, C 6 -CIO aryl substituted with 0-3 R 4 b, or to 10 membered heterocycle substituted with 0-3 R4 b; R 4 a, at each occurrence, is independently selected from is H, F, Cl, CF 3 C 3 -C 6 cycloalkyl substituted with 0-3 R4b, phenyl substituted with 0-3 R4b, or to 6 membered heterocycle substituted with 0-3 R4b; R4b, at each occurrence, is independently selected from H; OH, Cl, F, Br, I, CN, N402, NR 15 R 1 6 CF3, acetyl, SCH 3 -231- S(=O)CH 3 S(=o) 2 CH 3 Cl-C 4 alkyl, Cl-C 3 alkoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; R 5 is H, OR 1 4 Cl-C 4 alkyl substituted with 0-3 C 2 -C alknylsubsitutd wth 02 o C 2 -C 4 alkynyl substituted with 0-2 R5b; o R 5 a is H, OH, methyl, ethyl, Propyl-, butyl, methoxy, ethoxy, propoxy, butoxy, or allyl; R~b, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF 3 OR 14 =0; C 3 -C 6 cycloalkyl substituted with 0-2 R 5 c; is phenyl substituted with 0-3 R 5 c; or to 6 mnembered heterocycle substituted with 0-2 R~c; RSc, at each occurrence, is independently selected from H, OH, C1, F, Br, I, CN, N0 2 NR 15 R 1 6 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 Cj-C 4 alkyl, CI-C 3 alkoxy, CI-C2 haloalkyl, and Cl-C 2 haloalkoxy; R 6 is H; R 7 at each occurrence, is independently selected f rom, H, F, CF 3 methyl, and ethyl;- R 7 a, at each occurrence, is independently selected from H, F, CF 3 methyl, and ethyl; R 7 b is independently selected from H, methyl, and. ethyl; W is a bond, -CH2-, -OHi(CH 3 -CH2CH2- or. -CH(CH 3 )CH 2 X is a bond;- phenyl substituted with 0-2 Rxb; C 3 -C 6 cycloalkyl substituted with 0-2 Rxb; or to 6 memnbered heterocycle substituted with 0-2 Rxb; -232- Rxat each occurrence, is independently selected from H, OH, Cl, NR 15 RI 6 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH3, C 1 -C 4 alkyl, CI-C 3 alkoxy, Cl-C 2 -haloalkyl, and Cl-C 2 haloalkoxy;- Y is a bond, -CH 2 or -V-CH 2 V is a bond, -N(CH 3 or -N(CH 2 CH 3 Z is Cl-C 2 alkyl substituted with 1-2 R1 2 C 6 -Cj 0 aryl substituted with 0-4 R1 2 b; C 3 -C6 carbocycle substituted with 0-3 R12b; or 5 to 10 memnbered heterocycle substituted with 0-3 Rl2b;- R 1 2 is C 6 -CI 0 aryl substituted with 0-4 R12b C 3 -C 6 carbocycle substituted with 0-3 R1 2 b; or to 10 memibered heterocycle substituted with 0-3 R12b; Rl 2 b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 L 5 R 1 6 CF 3 acetyl, SCH4 3 S(=O)CH 3 S(=O) 2 CH 3 Cl-C 4 alkyl, Cl-C 3 alkoxy. Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; B is a seven membered lactan, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R11; arnd, optionally, the lactan contains a heteroatom selected from 2 and -N(Rl 0 RIO is H, C(0)Rl 7 C(0)0R 1 7 Cl-C4 alkyl. substituted with 0-1 R 1 0 a. phenyl substituted with 0-4 Ri0b; c 3 -c 6 carbocycle substituted with 0-3 Ri0b; or -23 3- to 6 membered heterocycle optionally substituted with 0-3 Ri0b; Raat each occurrence, is independently selected from H, cl-c 4 alkyl, OR' 4 C-1, F, Br-, CN, NO 2 NR 15 R 16 CF3, or phenyl substituted with -0-4 R10b; at each occurrence, is independently selected fr4* Hi, OH, CI-C 4 alkyl, 'Cl-C 3 alkoxcy, Cl, F, Br, I, CN, NO 2 NR 15 R 1 G, or CF 3 R 11 at each occurrence, is independently, selected from Cl-C 4 alkoxy, Cl, F, NR 18 R 1 9 C(=O)Rl 7 C(=O)OR1 7 CF 3 cl-c 4 alkyl substituted with 0-1 R1la; phenyl substituted with 0-3 R1ub; C 3 -C6 carbocycle substituted with 0-3 R11b; or to 6 membered heterocycle substituted with 0-3 R11b; alternatively, two R 11 substituents on the same or adjacent carbon atoms may be combined to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a benzo fused radical; R 11 a, at each occurrence, is independently selected from H, CI-C 4 alkyl, OR 14 F, NR 15 R 16 CF 3 or phenyl' substituted -with 0-3 Ru1b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, NR 15 R 1 6 CF 3 Cl-C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and Cl-C 2 haloalkoxy; R 14 is H, phenyl, benzyl, CI-C 4 alkyl, or C 2 -C 4 alkoxyalkyl; R1 5 at each occurrence, is independently selected from H, Cl-C 4 alkyl, benzyl, phenethyl, 4 alkyl) and 2 -(Cl-C 4 alkyl); -234- R 16 at each occurrence, is independently selected from H, OH, Cl-C 4 alkyl, benzyl, phenethyl, 1 -C 4 alkyl)- and 2 -(Ci-C 4 alkyl);- R 17 is H, phenyl, 4-f luorophenyl, 4-chloropheryl, 4-. methyiphenyl, 4-trifluorophenyl, (4-f luoro-phenyl) methyl, (4-chiorophenyl) methyl, (4-methyiphenyl )methyl, (4- trifluorophenyl) methyl, methyl,. ethyl;, propyl; butyl,- methoxymethyl, methyoxyethyl, ethoxymethyl, or. ethoxyethyl; R 18 at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and R 19 at each occurrence, is independently selected from H, methyl, and ethyl. A compound of Claim 4 of Formula (Ib) wherein: H H 2 NZ R 3 0 (Ib) or a pharmaceutically acceptable salt or prodrug thereof, wherein: R 3 is -CH 3 -CH 2 CH 3 -CH 2 CH 2 CH 3 -CH 2 CH 2 CH 2 CH 3 -CH 2 (CH3) 2 -CH(CH3)CH 2 CH 3 -CH 2 CH(CH 3 -CH 2 C(CH3)3, -CF 3 -CH 2 CF3, -CH 2 CH 2 CF 3 -CH 2 CH 2 CH 2 CF 3 -CH=CH 2 -CH 2 CH=CH2, -CH 2 C (CH 3 =CH 2 -CH 2 CH=C (CH 3 2, -CH 2 CH 2 CH=CH 2 -CH 2 CH 2 C (CH3) =CH2, -CH 2 CH 2 CH=C (CH 3 2 cis-CH2CH=CH(CH 3 cis-CH 2 CH2CHCH(CH3), trans- CH2CH=CH (CH 3 trans -CH 2 CH 2 CH=CH (CH 3 -C=ECH, -CH 2 C--CH, -CH2CEC(CH 3 -23 cyclopropyl-CH2-, cyclobutyl-Ci2-. cycloperityl-CH 2 cyclohexyl-C.H2-, cyclopropyl-CH 2 CH 2 cyclobutyl- CH 2 CH2 cyclopentyl-CH2CH2 cyc lohexyl -CH 2 CH 2 phenyl -CM 2 (2-F-phenyl)CH2-, (3-F-phenyl)CH2-, (4-F-phenyl)CH 2
12-Cl-phenyl)CH2-, (3-Cl-pheny1)CH2-, (4-Cl- phenyl)CH2-, (2,3-diF-phenyl)CH2-, 4-djF-phkenyl).CH2-,- (2,S-diF-phenyl)CH2-, 6-diF-phenyl)CH2-, (3,4-diF-phenyl)CH2--, (3,5-diF-Vhenyl)CH 2 (2,3-diCl-phenyl)CH2-;' (2,4-diCl-pherxyl-)CH 2 2 6-djC.1:phftnyl) CH2-, (3,4-diCl-phenyl)CH2-, (3,5-diCl-phenyl)CH2-, (3-F-4-Cl-phenyl)CH2-, (3-F-5-C1-phenyl)CH 2 (3-Cl-4-F-phenyl)CH2-, phenyl-CH2CH2-, (2-F-phenyl) CH 2 CH2-, (3 -F-phenyl) CH 2 CH 2 (4-F-phenyl)CH2CH2-, (2-Cl-phenyl)CH2CH2-, (3-Cl-pheriyl)CH2CH2-, (4-Cl-phenyl)CH2CH 2 3-diF-phenyl)CH2CH-2-, 4-diF-phenyl)CH2CH2-, 5-diF-phenyl)CH 2 CH2-, 6-diF-phenyl)CH 2 CH 2 4-diF-phenyl)CH2CH2-, 5-diF-phenyl)CH2CH2--, 3-diCl-phenyl)CH 2 CH2-, 4-diCl-phenyl)CH 2 CH2-, 5-diCl-phenyl)CH2CH2-, 6-diCl-phenyl) CH 2 CH2-, 4-diCl-phenyl)-CH2CH2-, 5 diCl -phenyl) CH 2 CH 2 (3-F-4-Cl-phenyl) CH 2 CH 2 (3-F-5-Cl-phenyl )CH 2 CH2-. or R 5 is -CH 3 -CH2CH3, -CH 2 CH 2 CH3., -CH 2 (CH 3 2 -CH 2 CH 2 CH2CH3, -CH(CH 3 )CH2CH3, -CH 2 CH(CH3)2, -CH 2 C(CH 3 3 -CH 2 CH 2 CH 2 CH2CH3, -CM (CH3) CI 2 CH 2 CH3, -CH 2 CH (CH3) CH2CH3, -CH 2 CH 2 CH (CH3) 2. -CH (CH2CH3) 2. -CF3, -CH 2 CF 3 -CH 2 CH 2 CF 3 -CH 2 CH 2 CH 2 CF3, -CH 2 CH2CH 2 CH2CF3, -CH=CH 2 -CH 2 CH=CH2, -CH=CHCH3, cis-CH2CH=CH(CH3), trans -CH2CH=CH (CH 3 trans-CH 2 CH=CH (C 6 H 5 -CH 2 CH=C(CH3) 2 cis-CH 2 CH CHCH2CH3, trans -CH 2 CH=CHCH2CH3, cis -CH 2 CH 2 CHCH (CH 3 trans- CH 2 CH2CH=CH trans -CH 2 CHCH-CH2- -CH 2 C--CH, -CH2C-C (CH3), -C 2 CW 6 H 5 -CH 2 CH 2 C--CH, -CH2CH2C(CH3), -CH 2 CH2C2=C(C 6 HS) -236- -CH 2 CH 2 CH 2 C5-CH, -CH 2 CH2CH 2 C:-C (CH3). -CH 2 CH 2 CH 2 C=-C (C 6 HS) cyclopropyl-CH 2 cyclobutyl-CH 2 -i cyclopentyl-CH 2 cyc]lohexy1 -CH 2 (.2-CH 3 -cytlopropyl) CH (3-CH 3 -cyclobutyl) CH 2 cyclopropyl-CH 2 CH 2 cyclobutyl-CH 2 CH 2 cyclopentyl-CH 2 CH 2 cycl ohexyl-CH 2 CH 2 (2-CH3-cyclopropyl)CH 2 CH 2 (3-CH3-cyclobutyl)CH 2 CH 2 phenyl-CH 2 (2-F-phenyl)CH 2 (3-F-phenyl)'CH 2 (4-F-phenyl) CH 2 furanyl-CH 2 thienyl-CH 2 pyridyl-CH 2 1-imidazoly.-CH 2 "oxazolYl-CH 2 isoxazolyl-CH 2 phenyl -CH 2 CH 2 (2 -F-phenyl )CH 2 CH 2 (3 -F-phenyl) CH 2 CH 2 (4-F-phenyl) CH 2 CH2 furanyl -CH 2 CH 2 thienyl -CH 2 CH 2 pyridyl-CH 2 CH 2 1-imidazolyl-CH 2 CH 2 oxazolyl-CH 2 C~i 2 isoxazolyl-CH 2 CH 2 W is a bond, -CH 2 or -Hc 3 X is a bond; UN Y is a bond, -CH 2 or -V-CH 2 V sabond, -S 2 NH-, or Z is phenyl 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Ci-phenyl, 3-Ci-phenyl, 4-Cl-phenyl, 2, 3-diF-phenyl, 2, 4-diF-phenyl, 2, 5-diF-phenyl, 2, 6-diF-phenyl, 3, 4-diF-phenyl, 3, 5-diF-phenyl, -2,3-diCi-phenyl, 2, 4-diCi-phenyl, 2, 5-diCi-phenyl, 2, 6-diCi-phenyl, 3,4-diCi-phenyl, 3, 5-diCl-phenyl, 3-F-4-Cl-phenyl, -237- 3-C1-4-F-pheiyl, 2-MeO-phenyl, 3 -MeO--phenyl, 4 -MeO-phenyl, 2-Me-phenyl, 3 -Me-phenyl, 4 -Me-phenyl. 2 -MeS-phenyl, 3 -MeS-phenyl-, 4 -MeS.-phenyl, 2-CF 3 O-phenyl, 3-CF3O-phenyl, A-CF 3 O phenyl,. furanyl, thienyl, pyridyl, 2-Me-pyridyl, Me6- pyridyl, 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl, 1-benzimidazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholino ,N-piperinyl, phenyl-CH 2 (2-F-pheny1)CH 2 -3 F-phenyl)CH 2 (4-F-phenyl) CH 2 (2-C1-phenyl)CH 2 (3-Cl-phenyl)CH 2 (4-Cl-phenyl)CH2-. 3-diF-phenyl)CH 2 -o 4-diF-phenyl)CH 2 5-diF-phenyl)CH 2 6-diF-phenyl)CH2-, (3,4-diF--phenyl)CH 2 5-diF-phenyl)CH 2 3-diCl-phenyl)CH 2 (2,4-diCl-phenyl)CH2-, (2,5-diCl-phenyl)CH 2 6-diCl-phenyl)CH 2 (3,4-diCl-phenyl)CH 2 (3,5-diCl-phenyl)CH2-, (3-F-4-C1-phenyl)CH 2 2 (3-Cl-4-F-phenyl)CH 2 (2-MeQ-phenyl)CH 2 (3-Meo-phenyl)CH 2 (4-MeQ-phenyl)CH 2 (2-Me-phenyl)CH 2 (3-Me-phenyl) CH 2 (4-Me-phenyl) CH 2 (2-MeS-phenyl)CH 2 (3-MeS-phenyl)CH 2 4-MeS-phenyl) CR 2 (2-CF 3 Q-phenyl-)CH 2 (3-CF 3 O-phenyl)CI 2 (4-CF 3 O-pheny.)CH 2 (furanyl) CH 2 (thienyl) CR 2 (pyridyl-)CH 2 (2-Me-pyridyl)CH2-, (3-Me-pyridyl)CH 2 (4-Me-pyridyl)CH 2 (1-imidazolyl) CR 2 (oxazolyl)CH2-, (isoxazolyl)CH 2 (1-benzimidazolyl) CH 2 (cyclopropyl)CH 2 (cyclobutyl) CH 2 (cyclopentyl)CH 2 (cycJlohexyl)CH 2 (morpholino)CH2-, (N-pipridinyl)CH 2 phenyl-CH 2 CH 2 (phenyl) 2 CHCH 2 .(2-F-phenyl) CH 2 CH 2 (3-F-phenyl)CH2CH 2 (4-F-phenyl).CH 2 CH 2 (2-C1-phenyl)CH 2 CH 2 (3-C1-phenyl)CH 2 CH 2 (4-Cl -phenyl) CH 2 CH 2 (2,3 -diF-phenyl) CH 2 CH 2 4-diF-phenyl)CH 2 CH 2 5-diF-phenyl)CH 2 CH 2 -238- 6-diF-phenyl)CH 2 CH2-, 4-diF-phenyl)CH2CH 2 5-diF-phenyl)CH2CH2-, (2,3-diCl--phenyl)CH 2 CH 2 (2,4-diCl-pheny1)CH2CH 2 5-diCl--phenyl)C-H 2 CH 2 6-diCl-phenyl)CH2CH2-, 4-cliCl-phenyl)CH 2 CH 2 5-diCl-phenyl)CH2CH2-, (3-F-4-C1-phenyl)CH 2 CH 2 (3-F-5-Cl-phenyl)CH2CH2-, (3-C1-4-F-phenyl)CH 2 CH 2 (2 -MeO-pheriyl) CH 2 CH2-, (3 -MeO-phenyl )CH 2 CH 2 (4 -MeO-phenyl) CH 2 CH2 (2 -Me-phenyl.).CH 2 CH 2 7,: (3 -Me-phenyl )CH 2 CH2-, (4-Me-phenyl )CH 2 CH 2 (2 -MeS-phenyl) CH 2 CH2-, (3 -MeS-phenyl) CH 2 CH 2 (4-MeS-phenyl)CH2CH2-, '(2-CF3O-phenyl)CH 2 CH 2 (3 -CF 3 O-pheriyl) CH 2 CH 2 .(4-CF3O-phenyl) CH 2 CH (furanyl) CH 2 CH 2 (thienyl) CH 2 CH 2 (pyridyl)CH 2 CH 2 (2-Me-pyridyl) CH 2 CH2-, (3 -Me-pyridyl )CH 2 CH 2 (4 -Me-pyridyl) CH 2 CH 2 (imidazolyl )CH 2 CH 2 (oxazolyl) CH2CH2-, (isoxazolyl) CH2CH 2 (benzimidazolyl) CH2CH2-, (cyclopropyl) CH2CH2-, (cyclobutyl) CH2CH2-, (cyclopentyl) CH2CH2-, (cyclohexyl) CH2CH 2 (morpholino) CH 2 CH 2 (N-pipridinyl) CH 2 CH 2 B is a seven mnembered lactam, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R 1 1 and, optionally, the lactam contains a heteroatom selected from 2 and -NCR 10 RIO is H, methyl, ethyl, phenyl, benzyl, phenethyl, 4-F- phenyl, (4-F-phenyl)CH2-, '(4-F-phenyl)CH 2 CH 2 4- Cl- phenyl, (4-Cl-phenyl)CH2-, (4-Cl-phenyl)CH 2 CH2-, 4-CH3- phenyl, (4-CH 3 -phenyl)CH2-, (4-CH3-phenyl)CH 2 CH 2 4-CF 3 phenyl, (4-CF 3 -phenyl)CH2-, or (4-CF 3 -phenyl) CH 2 CH2-; R 11 at each occurrence, is independently selected from H, methyl, ethyl, phenyl, benzyl, phenethyl, 4-F- -23 9- phenyl, phenyl, phenyl, phenyl, and (4-F-phenyl)CH 2 (4-F-phenyl)CH 2 CH 2 4-Cl- (4-C1-phenyl)CH2-, (4-Cl-pheny1)CH 2 CH 2 4-CH 3 (4-CH 3 -phenyl)CH2-, (4-CH 3 -phenyl) CH 2 CH 2 4-CF3- (4-CF 3 -phenyl)CH2-, or (4-CF3-phenyl) CH 2 CH 2 alternatively, two R 11 substituents on the sanie or adjacent carbon atoms may be combin~d to form a cyclopropyl;, cyclobutyl, cyclopentyl, cyclohexyl, or a benzo fused radical. 6. A compound of Claim 4 wherein: B is 0 N R N R) N R) 1. 0 A" -240- 0 0 0 N N or \I N-I 7. A compound of Claim 4 of Formula wherein: a H- H 2 N N N. X Yz R 3 0z J R" 1 <l (Ic) or a pharmaceutically acceptable salt or prodrug thereof, wherein: R 3 is R 4 R 4 is C 1 -C 4 alkyl substituted with 0-2 R$a, C 2 -C 4 alkenyl substituted with 0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-2 R 4 a, R 4 a, at each occurrence, is independently selected from'is H, F, CF 3 C 3 -C 6 cycloalkyl substituted with 0-3 R 4 b, phenyl. substituted with 0-3 R4b, or to 6 membered heterocycle substituted with 0-3 R 4 b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, NR- 5 R' 6 CF 3 acetyl, SCH 3 S(=0)Ci 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C 2 ,haloalkyl, and Cl-C 2 haloalkoxy; R 5 is Cl-C 4 alkyl substituted with 0-3 R~b; C 2 -C 4 alkenyl substituted with 0 -2 R~b; or -241- C 2 -C 4 alkynyl substituted with 0-2 R~b; R~b, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butiyl, CF 3 R0 4 =0; C 3 -C 6 cycloalkyl substituted -with 0-2 1R 5 c; phenyl substituted with 0-3 RSc; or to 6 memnbered heterocycle substituted with 0-2 RSc; Rsat each occurrence, is independently selected from H, OH, Cl, F, NR 1 5 R 1 6 CF 3 acetyli SCH 3 P; S(=O)CH 3 S(=0) 2 CH 3 methyl, ethyl, propyl, butyl, .methoxy, ethoxy, propoxy, Cl-C 2 halo'alkyl, and Cl-C 2 haloalkoxy; W is -CH 2 or -CH(CH 3 X is a bond; phenyl substituted with 0-2 Rxb; C 3 -C 6 cycloalkyl substituted with 0-2 Rxb; or to 6 membered heterocycle substituted with 0-2 Rxh; Rxb at each occurrence, is independently selected from H, OH, Cl, F, NR 15 R1 6 CF3, acetyl, SCH 3 O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and Cj -C 2 haloalkoxy; is a bond, -CH 2 or -V-CH 2 V is a bond, 2 -NH-, -N(CH 3 or -N(CH 2 CH 3 Z is Cl-C 2 alkyl substituted with 1- Ri 2 C 6 -C 1 0 aryl substituted with 0-4 Rl2b; C 3 -C 6 carbocycle substituted with 0-3 R1 2 b; or to 10 membered heterocycle substituted with 0-3- Ri2b; R 12 is C 6 -CI 0 aryl substituted with 0-4 R12b; C 3 -C 6 carbocycle substituted with 0-3 R12b; or to 10 membered heterocycle substituted with 0-3 R12b;- -242- Rl 2 b. at each occurrence, is independently selected f rom H, OH, Cl, F, NR1 5 R 16 CF 3 acetyl, SCH3V-S(=O)CH3, S(=O)2CH 3 methyl; ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl-j and- C 1 -C2 halOalkoxy; R 11 is methoxy, ethoxy, propoxy, butoxy, Cl, F, NR 18 R 1 9 CF 3 Cl-C 4 alkyl substituted with 0-1 Rila; phenyl substituted with 0-3 R11b; C 3 -C 6 carbocycle substituted with 0-3 Rllb: or. to 6 membered heterocycle substituted with 0-3 R1ub; alternatively, two R 11 substituents on the same or adjacent carbon atoms may be combined to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a benzo fused radical; R 11 a, at each occurrence, is independently selected from H, Cl-C 4 alkyl, OR 14 F, NR 1 5 R 1 6 CF 3 or phenyl substituted with 0-3 R11b; R1ub, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5 R 1 6 CF 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl;I anid- C-C 2 haloalkoxy; R 1 4 is H, phenyl, benzyl, methyl, ethyl, propyl, butyl; R 15 at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl; R 1 6 at each occurrence, is independently selected from H, OH, Cu-C 4 alkyl, benzyl, phenethyl, 4 alkyl) and 2 -(Cu-C 4 alkyl); -243- R 1 8 at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl.,.benzyl, and phenethyl; and R 19 at each occurrence, is independently. selected from -H, methyl, and ethyl.- 8. A compound of Claim 4 of Formula.-(Id). wherein:. 0 R 5 H 2 N NN 10R1 (Id) or a pharmaceutically acceptable salt or prodrug thereof, wherein: R 3 is R 4 R 4 is Cl-C 4 alkyl substituted with 0-2 R 4 a, C 2 -C 4 alkenyl substituted with .0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-2 R4a, R 4 a, at each occurrence, is independently selected from is H, F, CF 3 C 3 -C 6 cycloalkyl substituted with 0-3 R4b, phenyl substituted with 0-3 R4b, or to 6 memnbered heterocycle substituted with 0-3 R 4 b; R4b, at each occurrence, is independently selected from H, OH, Cl, F, NR 15 R 16 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH- 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Ci-C 2 haloalkyl, and Cl-C 2 haloalkoxy; R 5 is CI-C 4 alkyl substituted with 0-3 Rbb; -244- C 2 -C 4 alkenyl substituted with 0-2 R~b; or C 2 -C 4 alkynyl substituted with 0-2 RSb; at, each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF 3 OR1 4 C 3 -C 6 cycloalkyl substituted with 0-2. R.5c; phenyl substituted with 0-3 RSc; or to 6 membered heterocycle substituted with 0-2 RSc; R~c, atec'curne-is~,1ndependently-selected- from--H, OH, Cl, F, NR 1 5 R 16 CF 3 *acetyl, SCH 3 S(=-O)CH3. S(=O)2CH 3 methyl, ethyl, propyl, butyl-,*inethoxy,'. ethoxy, propoxy, CI-C 2 haloalkyl, and Cl-C 2 haloalkoxcy; W is -CH 2 or -CH(CH 3 X is a bond; phenyl substituted with 0-2 Rxb; C 3 -C 6 cycloalkyl substituted with 0-2 Rxh; or 5 to 6 membered heterocycle substituted with 0-2 Rxb; Rxh, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5 R 1 6 CF 3 acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, inethoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, -and Cl-C 2 haloalkoxy; Y is a bond, -CH 2 or -V-CH 2 V is a bond, 2 -NH-, -N(CH 3 or -N(CH 2 CH 3 Z is C 1 -C 2 alkyl substituted with 1-2 Ri 2 C 6 -CjO aryl substituted with '0-4 R1 2 b; C 3 -C 6 carbocycle substituted with 0-3 R12b; or 5 to 10 membered heterocycle substituted with 0-3 R12b; R 12 is C 6 -Cj 0 aryl substituted with 0-4 R12b; C 3 -C6 carbocycle substituted with 0-3 R12b; or -2 to 10 memnbered heterocycle substituted with 0-3 R12b; Rl2b, at each occurrence, is independently selected from H, OIH, Cl, F, NR 1 5 R 16 CF3, acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, inethoxy,. ethoxy, propoxy, CI-C 2 haloalkyl, and C 1 -C 2 haloalkoxy; R 1 0 is H, C(=O)Rl 7 C(0)R 1 7 Cl-C 4 alkyl substituted with 0-1 phenyl substituted with 0-4 Ri0b; C 3 -C 6 carbocycle substituted- with 0-3. R10b; 'or- to 6 membered heterocycle optionally substituted with 0-3 R1 0 b; R 10 a, at each occurrence, is independently selected from H, Cl-C4 alkyl, OR 14 Cl, F, Br, I, CN, NO 2 NR 1 5 R 16 CF 3 or phenyl substituted with 0-4 Ri0b; at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, inethoxy, ethoxy, propoxy, Cl, F, Br, I, CN, N0 2 NR 15 R 16 or CF 3 R 1 4 is H, phenyl, benzyl, methyl, ethyl,- propyl, butyl; R 15 at each occurrence, is independently selecte~d from H, methyl., ethyl, propyl, and butyl; R 1 6 at each occurrence, is independently selected from H, OH, Cl-C 4 alkyl, benzyl, phenethyl, 4 alkyl) and 2 -(Cl-C 4 alkyl); and R 17 is H, phenyl, 4-f luorophenyl, 4-chlorophefiyl, 4- methyiphenyl, 4-trifluorophenyl, fluorophenyl )methyl, (4-chiorophenyl) methyl, (4-methylphenyl) methyl, (4- trifluorophenyl)methyl, methyl, ethyl, propyl, butyl, methoxymethyl, methyoxyethyl, et0ioxymethyl*, or ethoxyethyl. -24 6- 9. A compound of Claim 4 of Formula (Ie)'%wherein: 0o H N .Y H 2 N N X> R 3 0 (Ie) or a pharmaceutically acceptable salt or prodrug thereof; wherein: R 3 is R 4 R 4 is Cl-C 4 alkyl substituted with 0-2 R 4 a, C 2 -C 4 alkenyl substituted with 0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-2 R 4 a, R 4 a, at each occurrence, is independently selected from is H, F, CF 3 C 3 -C 6 cycloalkyl substituted with 0-3 R4b, phenyl substituted with 0-3 R 4 b, or to 6 membered heterocycle substituted with 0-3 R4b; R 4 b, at each occurrence, is independently: selected f rom H, OH, Cl, F, NR 1 5 R 1 6 CF 3 acetyl, SCH 3 S{=0-)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C 2 haloalkyl, and Cl-C 2 haloalkoxy; R 5 is Cl-C 4 alkyl substituted with 0-3 R~b; C 2 -C 4 alkenyl substituted with. 0-2 R~b; or C 2 -C 4 alkynyl substituted with 0-2 R~b; R5b, at each occurrience, is independently selected from: H, methyl, ethyl, propyl, butyl, CF 3 OR 1 4 =0; C 3 -C 6 cycloalkyl substituted with 0-2 RSc; phenyl substituted with 0-3 RSc; or -247- to 6 mnembered heterocycle substituted with 0-2 RSc; RSc, at each occurrence, is independently. seljected _from H., OH, F, NR 15 P 1 6 CF 3 acetyl, SCH 3 S(=O)CH 31 S(=O)2CH3, methyl, -ethyl, propy1,--butAy,-methox,- ethoxy, propoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; W is -CH 2 or -CH (CH 3 X is a bond,- phenyl substituted wit h 0-2 Rxb; C 3 -C 6 cycloalkyl substituted with 0-2 Rx-; or to 6 membered heterocycle substituted with 0-2 Rxb; Rxb, at each occurrence, is independently selected from H, OH, C1, NR1SR1 6 CF3, acetyl, SCH3, S(=O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C2 haloalkyl., and Cl-C 2 haloalkoxy; Y is a bond, -CH2-V-, or -V-CH 2 V is a bond, 2 -NH-, or -N(CH2CH3)-, Z is Cl-C 2 alkyl substituted with 1-2 Ri 2 C 6 -CIO aryl substituted -with 0-4. R12b; C 3 -C6 carbocycle substituted with 0-3 Rl 2 b; or to 10 membered heterocycle substituted with R 12 is C 6 -CjO aryl substituted with 0-4 R12b; C3-C6 carbocycle substituted with 0-3 R1 2 b; or to 10 memibered heterocycle substituted with 0-3 Rl2b; 0-3 -R12b; Ri2b, at each occurrence, is independently selected from H, OH, Cl, F, NR1 5 R1 6 CF3, acetyl, SCH3, S(=O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C2 haloalkyl, and C 1 -C 2 haloalkoxy; -248- R 11 is methoxy, ethoxy, propoxy, butoxy, Cl, F, NR 8 R 19 CF 3 C 1 -C 4 alkyl substituted with 0-1 R 11 a; phenyl substituted with 0-3 R 1 1 b; C 3 -C 6 carbocycle substituted with 0-3 R 11 b; or to 6 membered heterocycle substituted with 0-3 R 11 b; R 1 1 a, at each occurrence, is independently selected from H, CI-C 4 alkyl, OR 14 F, NR 1 5 R 1 6 CF 3 or phenyl substituted with 0-3 R 1 1 b; R 1 1 b, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5 R 16 CF 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Ci-C 2 haloalkyl, and C 1 -C 2 haloalkoxy; R 14 is H, phenyl, benzyl, methyl, ethyl, propyl, butyl; R 15 at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl; R 16 at each occurrence, is independently selected from H, OH, CI-C 4 alkyl, benzyl, phenethyl, 1 -C 4 alkyl) and 2 -(Ci-C 4 alkyl); R 18 at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and R 19 at each occurrence, is independently selected from H, methyl, and ethyl. A compound of Claim 4 of Formula (If) wherein: -249- (if) or a pharmaceutically acceptable -sal.t -or prodrug thereof, wherein: R 3 is R 4 R 4 is CI-C 4 alkyl substituted with 0-2 R 4 a, C 2 -C 4 alkenyl substituted with 0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-2 R 4 a, R 4 a, at each occurrence, is independently selected from is H, F, CF3;' C 3 -C 6 cycloalkyl substituted with 0-3 ROO, phenyl substituted with 0-3 R 4 b, or to 6 memnbered heterocycle substituted with 0-3 R4b; R 4 b, at each occurrence, is independently selected from H,' OH, Cl, F, NR 15 R 1 6 -CF3, acetyl, SCH 3 S(=O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, CI-C 2 haloalkyl, and Cl-C 2 haloalkoxy; R 5 is Cl-C 4 alkyl substituted with 0-3 C 2 -C 4 alkenyl substituted with 0-2 R~b; or C 2 -C 4 alkynyl substituted with 0-2 R~b, at each occurrence, is independently selec ted from: H, methyl, ethyl, propyl, bu-ty-,. CF3-, 0R 14 =0; C 3 -C 6 cycloalkyl substituted- -with-, 0-2 RSc; phenyl substituted with 0-3 RSc; or to 6 membered heterocycle" substituted with 0-2 RSc; -2 RSc. at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5 R 1 6 CF 3 acetyl., SCH3, S(=O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and Cj-C2 -haloalkox)y;l W is -CH 2 or -CH(CH3)-; X is a bond; phenyl substituted with 0-2 Rxb; C 3 -C 6 cycloalkyl substituted with 0-2 R~b; or to 6 membered heterocycle substituted with 0-2. Rxb;' Rxb at each occurrence, is independently selected from H, OH, Cl, F, NR15R1, CF 3 acetyl, -SCH 3 S(=O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl-C 2 haloalkyl, and C 1 -C 2 haloalkoxy; Y is a bond, -CH 2 or -V-CH2-; V is a bond, 2 -NH-, -N(CH 3 or -N(CH 2 CH 3 Z is Cl-C 2 alkyl substituted with 1-2 R1 2 C 6 -Cj 0 aryl substituted with 0-4 R12b; C 3 -C6 carbocycle substituted with 0-3 R12b; or to 10 memibered heterocycle substituted With 0'-3 R1 2 b; R 1 2 is C 6 -Cj 0 aryl substituted with 0-4 Rl2b;I C 3 -C 6 carbocycle substituted with 0-'3 R12b; or 5 to 10 membered heterocycle substituted with 0-3 Rl2b; Rbat each occurrence, is independently selected from H, OH, Cl, F, NR 1 5 RI 6 CF3, acetyl, SCH3, S(0O)CH 3 S(=O) 2 CH 3 methyl, ethyl, propyl1, butyl, -methoxy, ethoxy, propoxy, CI-C2 haloalkyl,. and Cl-C 2 haloalkoxy; R 14 is H, phenyl, benzyl, methyl. ethyl,- propyl, butyl; -251- R 1 5 at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl; and R 16 at each occurrence, is independently selected from H, OH, Cl-C 4 alkyl, benzyl, phenethyl, 4 alkyl) arnd 2 (Cl-C 4 alkyl). 11. A compound of Claim 2 of Formula (ha) 0 R 5R 5 a r 6 HO, N W Y 3 R 3 a B (Iha) or a pharmaceutically acceptable salt or prodrug thereof, wherein: R 3 is (CR 7 R 7 a )n-R 4 (CR 7 R 7 a (CR 7 R 7 a) m-R 4 (CR 7 R 7 a) n-0- (CR 7 R 7 a) mR 4 or (CR 7 R 7 a -N (R 7 b) (CR 7 R 7 a) m-R 4 n is 0, 1, or 2; m. is 0, 1, or 2; R 3 a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, or butoxy; R 4 is H, OH, OR 14 a, Cl-C 4 alkyl substituted with. 0-2 R 4 a, C 2 -C 4 alkenyl substituted with 0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-2 R 4 a, C 3 -C 6 cycloalkyl substituted with 0-3 R4b, C 6 -CI 0 aryl substituted with 0' 3 RQ, 'or to 10 memibered heterocycle substituted with 0-3 R4b; -252- R 4 a, at each occurrence, is independently selected from is H, F, Cl, Br, I CF 3 C 3 -Clo carbocycle substituted with 0-3 R4b, C 6 -CjO aryl substituted with 0-3 R4b, or 5 to 10 muembered heterocycle substi tuted .with b-3 R4b; R4b, at each occurrence, is independently-selected from H, OH, Cl, F, Br, 1, CN, N02, NR 15 RI 6 -CF 3 acetyl', SCH 3 S(=O)CH3, S(=O) 2 CH 3 C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, 'and Cl.-C 4 haloalkoxy; R 5 is H, OR 14 C 1 -C 6 alkyl substituted with 0-3 C 2 -C 6 alkenyl. substituted with 0-3-R~b;- C2-C6 alkynyl substituted with 0-3 R~b; C 3 -ClO carbocycle substituted with 0-3 RSc; C 6 -C1O aryl substituted with 0-3 R 5 c; or to 10 membered heterocycle substituted with 0-30Sc; R 5 a is H, OH, CI-C 4 alkyl, CI-C 4 alkoxy, C 2 -C 4 alkenyl, or C 2 C 4 alkenyloxy; at each occurrence, is independently selected from: H, C 1 -C 6 alkyl, CF 3 OR 1 4 Cl, F, Bt, 1, CN, NO 2 NR 15 R 1 6 C 3 -C 1 0 carbocycle substituted with 0-3 RSc; C 6 -CIO aryl. substituted with 0-3 RSc; or to 10 memnbered heterocycle substituted with 0-3 R 5 c; RSC, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N0 2 NR 1 5 RI 6 CF 3 acetyl, SCH 3 S(=O)CH3, S(=O) 2 CH 3 C 1 -C 6 alkyl, _CI-C 4 ,alkoxY, C 1 -C 4 haloalkyl, and Cl-C 4 haloalkoxy; R 6 is H, methyl, or ethyl;' R 7 at each occurrence, is independently selected from H, OH, CI, F, Br, I, CN, NO 2 CF 3 and Cl-C 4 alkyl; -2 53- R 7 a, at each occurrence, is independently selected f rom H, OH, Cl, F, Br, I, CN, N02, CF3, phenyl and CI-C 4 alkyl; R 7 b' is independently selected from H, methyl, ethyl, propyl, and butyl; W is -(CRBR~a)p-; p is 0, 1, or 2; R 8 and R 8 a, at each occurrence, -are independently selected from H, F, C 1 -C3 alkyl, C 2 -C 3 alkenyl, C 2 -C3 alkynyl and C 3 -C6 cycloalkyl; X is a bond; C6-CIO aryl substituted with 0-a Rxb; C 3 -Clo carbocycle substituted with 0-2 Rxb; or to 10 membered heterocycle substituted with 0-2 Rxb; R~b at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N02, NR 1 5 R 1 6 CF3, acetyl, SCH 3 S(=O)CH3, S(=O) 2 CH3, CI-C 6 alkyl, C 1 -C 4 alkoxy-, Cl-C 4 haloalkyl, and Cj-C4 haloalkoxy; Y is a bond or (CR9R9a) t-V-(CR 9 R 9 a) u_; t is 0, 1, or 2; u is 0, 1, or 2; R 9 and R 9 a, at each occurrence, are independently.- selecteci from H, F, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; V is a bond, 1 -S -S -N (R 1 9 -c NR1 9 -NR.19biC NR 19bS 27, S(=O),2NR19b_, -NR19bS(=O)-, or -S(=O)NR1 9 b-; -254- Z is C 1 -C 3 alkyl substituted with 1-2 R 1 2 C 6 -Cj 0 aryl substituted with 0-4 R1 2 b; C 3 -C 1 o carbocycle substituted with 0-4 R12b; or to 10 membered heterocycle substituted with 0-3 R12b; R3- 2 is C 6 -CjO aryl' substituted with 0-4 R12b; C 3 -C 10 carbocycle substituted with 0-4 R1 2 b; or to 10 mnembered heterocycle substituted with 0-3 Rl2b; R12b, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, N02, NR 1 5 R 1 6 CF 3 acetyl,- SCH 3 S(=O)CH 3 S(=O) 2 CH 3 Ci-C 6 alkyl, Cl-C 4 alkoxy, Cl-C 4 haloalkyl, and C 1 -C 4 haloalkoxy; B is a seven membered lactan, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R11; and, optionally, the lactam contains a heteroatom selected from 2 and -N(RI 0 R 1 0 is H, C(=O)Rl 7 C(=O)0R 1 7 C(=-O)NR 1 8 Rl 9 S(=O) 2 NR 1 8 Rl 9 S 2 Rl 7 Ci-C 6 alkyl substituted with .0-1lR0a; C 6 -C 1 0 aryl substituted with 0-4 Ri0b; C 3 -C 10 carbocycle substituted with 0-3 Ri0b; or to 10 membered heterocycle optionally substitu ted with 0-3 Ri0b; Rica, at each occurrence, is independently selected from H,' Cl-Cs alkyl, OR 1 4 Cl, F, Br, 1, CN, NO 2 NR 1 5 R 1 6 CF 3 or phenyl substituted with 0-4-R 0 IA4= w- R1b at each occurrence, is independently selected from H, OH, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CM, NO 2 NR 1 5 R 1 6 or CF 3 -255- R 1 1, at each occurrence, is independently selected from C 1 -C 4 alkoxy, Cl, F, NR 1 8 R 19 C(=O)R- 7 C( =0)0R 17 C(0)NR 1 8 Rl 9 2 NR 1 8 R 1 9 CF 3 C 1 -C 6 alkyl substituted with 0-1 Rila; C 6 -C 1 0 aryl substituted with 0-:3 Rulb 4 C 3 -CI 0 carbocycle substituted with 073 R1b; or to 10 membered heterocycle substituted with 0-3 R11b; alternatively, two R 1 1 substituents on the same. or adjacent carbon atoms may be combined to form a C 3 -C 6 carbocycle or a benzo fused radical; R 1 1 a, at each occurrence, .1is independently selected from H,- Cj-C 6 alkyl, OR 14 Cl, F, Br, I, -CN..N0 2 NR 1 5 R 1 6 CF 3 or phenyl substituted with 0-3 R11b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, Br, 1, CN, NO 2 NR 1 5 R 16 CF 3 Cl-C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, 'and C 1 -C 4 haloalkoxy; R 1 4 is H, phenyl, benzyl, Ci-C 6 alkyl, Or C 2 -C 6 alkoxyalkyl; R 15 at each occurrence, is independently selected from H, Cl-C 6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(CI-C 6 alkyl); R 16 at each occurrence, is independently selected from H, OH, CI-C 6 alkyl, benzyl, phenethyl, 6 alkyl) and 2 -(Cl-C 6 alkyl); R- 17 is H, aryl, (aryl)CH 2 Cl-C 6 alkyl, or C 2 -C 6 alkoxyalkyl; R 1 8 at each occurrence, is independently. sei-ectedpr-m-H, CI-C 6 alkyl, benzyl, phenethyl, 1 -C-6alkyl) and 2 -(Cl-C 6 alkyl); and -256- R 1 9 at each occurrence, is independently selected from H, OH, CI-C6 alkyl, phenyl, benzyl, phenethyl, 1 C 6 alkyl) and 2 -(Cl-C6 alkyl); arnd R19 is H, Cl-C 6 alkyl, C 3 -C8 cycloalkyl, phenyl, benzyl or phenethyl. 12. A compound of Claim 11 of FormulaL (Ib) wherein: HON. N N R 3 0 (Ib) or a pharmaceutically acceptable salt or prodrug thereof, wherein: R 3 is R 4 n is 0 or 1; mn is 0 or 1; R 4 is H, OH, C 1 -C 4 alkyl. substituted with 0-2 R 4 a, C 2 -C 4 alkenyl substituted with 0-2 R 4 a, C 2 -C 4 alkynyl substituted with 0-1 R 4 a,, C 3 -C 6 cycloalkyl substituted with 0-3 R 4 b, C6-CiLO aryl substituted with 0-3 R4b, or to 10 mem~bered heterocycle substituted with 0-3 R'b; R 4 a, at each occurrence, is independently selected f rom is H, snip- F, Cl, CF 3 C 3 -C 6 cycloalkyl substituted with 0-3 R4b,' phenyl substituted with 0-3 R 4 b, or to 6 membered heterocycle substituted with 0-3 R 4 b; -257- R 4 b, at each occurrence, is independently selected froin H, OH, Cl, F, Br, I, CN, NO 2 NR 1 5 R 1 6 CF 3 acetyl, SCH 3 S(=O)CH3, S(=O) 2 CH3, C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; R 5 is H, OR 1 4 C 1 -C 4 alkyl substituted with 0-3 R~b; C 2 -C 4 alkenyl substituted with 0-2 RSb; or C 2 -C 4 alkynyl substituted with 0-2 R~b; at each occurrence, is independently, selected from: H, methyl, ethyl, propyl, butyl, CF 3 OR 1 4 =0; C3-C 6 cycloalkyl substituted with 0-2 RSC; phenyl substituted with 0-3 RSC; or 5 to 6 membered heterocycle substituted with 0-2 at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 NR 1 5 R 1 6 CF 3 acetyl., SCH 3 S(=O)CH 3 S(=O) 2 CH 3 C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; V is a bond, -CH 2 -CH(CH 3 -CH 2 CH 2 or -CH(CH3)CH 2 X is a bond; phenyl substituted with 0-2 Rb; C 3 -C 6 cycloalkyl substituted with 0-2 Rxb; or to 6 membered heterocycle substituted with 0-2 RXb; Rxb, at each occurrence, is independently selected from H, OH, Cl, F, NR 1 5 R 1 6 CF 3 acetyl, SCi 3 S(=O)CH 3 S(=O) 2 CH 3 C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C1-C2 haloalkoxy; Y is a bond, -CH 2 or -V-CH 2 V is a bond, 2 -NH-, or -N(CH 2 CH 3 -258- Z is Cl-C 2 alkyl substituted. with 1-2 Ri 2 C 6 -Cj 0 aryl substituted with 0-4 R12b; C 3 -C 6 carbocycle substituted with 0-3 R12b; or to 10 membered heterocycle substituted with 0-3 R12b; R 12 is C 6 -CjO aryl substituted wit-h 0-4 R12b.- C 3 -C 6 carbocycle substituted with .0-3 Ri2b; or to 10 memibered heterocycle substituted with 0-3 Rl2b; Rl 2 b, at each occurrence, is independently selected from H-, OH, Cl, F, NR 1 5 R 1 6 CF 3 acety1j-.:-CH3, S(=O)CH 3 S(=O) 2 CH 3 Cl-C 4 alkyl, Cl-C 3 alkoxy, Cl-C 2 haloalkyl, and Cl-C 2 haloalkoxy; B is a seven memnbered lactam, wherein the lactani is saturated, partially saturated or unsaturated; wherein each additional lactain carbon is substituted with 0-2 Ri 1 and, optionally, the lactai contains a heteroatom selected 2 and -N(Rl 0 R 1 0 is H, C(0O)Rl 7 C(=0)0R 1 7 Ci-C 4 alkyl substituted with 0-1 phenyl. substituted with 0-4 Ri0b; C 3 -C 6 carbocycle siibstituted with 0-3 Ri0b; or to 6 membered heterocycle optionally substituted with 0-3 Rl0a, at each occurrence, is independently selected from H, C 1 -C 4 alkyl, OR 1 4 Cl1 F, Br, I, CN, NO 2 NR 1 5 R 16 CF 3 or phenyl substituted with 0-4 Ri0b; Ri0b, at each occurrence, is independently selectEed from H, OH, CI-C4 alkyl, Cl-C 3 alkoxy, Cl, Br, I, CN, N0 2 NR 1 5 R 1 6 or CF 3 R 11 at each occurrence, is independently selected from -259- CI-C 4 alkoxy, Cl, F, =0,..NR 1 8 R 1 9 C(=0)Rl 7 C(=0).OR1 7 CF 3 C 1 -C 4 alkyl substituted with 0-1 Rila; phenyl substituted with 0-3 R11b; C 3 -C 6 carbocycle substituted with 0-3 R11b; or to 6 memnbered heterocycle. substituted with 0-3 R11b; alternatively, two R 11 substituents on the same or adjacent carbon atoms may be combined to f orm a cyclopropyl, cyclobutyl, cycJlopentyl, cyclohexyl, or a benzo fused radical; R 1 1 a, at each occurrence, is independently selected from.H,- Cl-C 4 alkYl, OR 14 F, NR 1 5 R 1 6 CF3,-or- phenyl. substituted with 0-3 R11b; R11b, at each occurrence, is independently selected from H, OH, Cl, F, NRISR 1 6 CF 3 Cl-C 4 alkyl, Cl-C 3 alkoxy,. C 1 L-C 2 haloalkyl, and C 1 -C 2 haloalkoxy; SR 1 4 is H, phenyl, benzyl, Cl-C 4 alkyl, or C 2 -C 4 alkoxyalkyJ.; R 15 at each occurrence, is independently selected from H, CI-C 4 al~kyl, benzyl, phenethyl, -C -(Cl-C 4 alkyl) and 2 -(Cl-C4 alkyl); R 16 at each occurrence, is independently selected from H, OH, Cl-C 4 alkyl, benzyl, phenethyl, -C -(Cl-C 4 alkyl) and 2 -(Cl-C 4 alkyl); R 1 7 is H, phenyl, 4-f luorophenyl, 4-chiorophenyl, 4- methyiphenyl,. 4 -trifluorophenyl, (4-f luorophenyl) methyl, S( 4-chiorophenyl )methyl, (4mtypey Yfj :y trifluorophenyl )methyl, methyl, ethyl, propyl, butyl, methoxymethyl, methyoxyethyl, ethoxymethyl, or ethoxyethyl; -2 R 18 at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl,* phenyl, benzyl, and phenethyl; and R 19 at each occurrence, is independently -selected from Ii, methyl, and ethyl.
13. A c:mpound of Claim 12 wherein.: B is N- 0 R10>R1 N1 N 0 N CR 0 0 N or ,N b R 10 -261-
14. A compound according to Claim 1 selected from:.. (2R,3S) N1-II(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-lH- azepin-3-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-[ (3S)-hexahydro-l-(3-(4-methoxyphenyl)benzyl)-. 2-oxo-1H-azepin-3-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-113S)-hexahydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-1H-azppi-n-3-yl] -2- (2-methyipropyl) (propyl) -butanediamide; (2R,3S) N1-[(3S)-hexhydro-1-(3'-(4-methylphenyl)benzyl)'. oxo-1H-azepin-3-ylI (2-methyipropyl) (propyl) butanediamide; (2R,3S.) N1-U(3S)-hexahylro-1-(3-(2,4- dichlorophenyl)benzyl) -2-oxo-1H-azepin-3-ylJ (2- methyipropyl) (propyl) -butanediamide; (2R,3S) Nl-[ (3S)-hexahydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-1H-azepin-3-yl] (2- methyipropyl) (propyl) -butanediamide; (2R,3S) N1-[ (3S)-hexahydro-1-(benzophenon-3-yl)-2-oxo-H. azepin-3-yl] (-methylpcopyl) (propyl) butanedianiide; (2R,3S). Ni-[l(3S)-hexahydro-1-(3-(2-naphthyl)benzyl)-2-oxo. 1H-azepin-3-yl] (2-methyipropyl) (propyl) butanedianide; (2R,3S) N1-( (3S)-hexahydro-1-(3-(3-fluorophenyl)benizyl)-2- oxo-1H.-azepin-3-yl]-2- (2-methyipropyl) (propyl) butanediamide; (2R,3S) Nl-Il(3S)-hexcahydro-1-(3-(3-methoxyphenyl)benzyl). 2-oxo-1H-azepin-3-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Nl-[ (3S)-hexahydro-1-(3-(2-methoxyphenyl)benzyl). 2-oxo-1H-azepin-3-yl] (2-methylpropy1)i-z3- (po.epy~ butanedianiide; (2R,3S) Nl-l(3S)-hexahydro-l-(3-(4-methoxyphenyl)pyrid-5-.. ylmethyl) -2-oxo-1H-azepin-3-yl] (2-methyipropyl) (propyl) -butanedianide; -262- (2R,3S) N1-[(3S)-hexahydro-i-(3-( 4 trifluoronlethYiPhenYl )pyrid-'5-yimethYi) -2-oxo-iH-azepil 3-yi] -2-(2-methyipropyl) (propyl) -butanedianide; (2R,3S) Ni-I (3S)-hexahydroil(3(3-chloro- 4 fluorophenyl)pyrid-YlmethYi)2 b~x6o-iH-a~epiV-3-Sri] -2- (2-methYiproPYl) (propyl) -butariedi1flide-; (2R,3S) Ni-I (3S)-hexahydro-i-( 4 4 trifluoromethYlphenYl)benzyl) -2--oxo-iH-azePifl-3-y)-2- (2-methyipropyl) (propyl) -butanediamfide; (2S,3R) N1-I(3S)-hexahydro-i-( 3 2 tetrazoiylpheflYl)benzYl) -2-oxo-iH-azeil- 3 -yl] -2- (propyl) (2-methyipropyl) -butaniediamfide; (2S,3R) Ni-I 3 S)-hexahydro-(3phenoxybenzyl) 2 -oxo-lH- azepin- 3 -yiI (propyl) (2-methyiPropyl) butanediamide; (2R, 35) Ni-I (35) -hexahydXo-l- (3-phenoxybelzyl) -2-oxo-1H- azepin- 3 -yi] (2-methyipropYl) (allyl) -butanedianide; (2R, 3S) Ni-I (3S) -hexahydro-l- (benzopheflofl 3 -yi) -2-oxo-1H- azepin- 3 -yi] (2-methyiPropYl) (allyl) -butanediamide; (2R) Ni-I 3 S)-hexahydlrol(3-phenox~ybnzyl) 2 oxo-lH azepin- 3 -yi] (2-methyiproPYl) -buta-Ciediamide' (2R,3S) Nl-[( 3 S)-hexahydrol(3-(4methoxyheny)benzyl)- 2-oxo-1H-azepifl 3 -yl] (2-methylProPYl) (ally 1 butanediamide; (2R,3S) Ni-I (3S)-hexahydro-i-( 3 4 trifluoromethYlPhenYl) benzyl) -2 -oxo-lH-azePil- 3 -yi] -2- (2-methyiProPYl) (allyl) -butanediamide; (2R,3S) Ni- -hexahydro-l-(3- (4-methylphefl)bezl~) -2- oxo-iH-azepil-3-Yl] (2-methYiPropYl) (ailyl) butanediamide; (2R,3S) Ni-I (3S)-hexahYdro-l-( 3 2 4 dichiorophelyl)bel~) -2-oxo-iH-azepil-' 3 -yl) methyipropyl) (ally1) -butanediamide; (2R, 35) Ni-I (35) -hexahydro-i-(3- (3-chloro-4- fluoropheli)beflzyl) -2-oxo-iH-azepifl- 3 -yl] (2- methylpropYl) (ally 1 -butanediamide; -263- (2R,3S) Ni-[( 3 S).-hexahydro-l-(3..(2.naphthy)benzy). 2 -ox 1H-azepin-3-yl] (2-methyipropyl) (ailyl) butanedianiide; (2R,3S) Ni-f S-eayr-l(-hnxbnzl--x-H azepin-3-yi] -2-(2-methyipropyl) (butyl) -butanediamride; (2 R, 3 S S 1hxhdo-I-( 4-m h. hnl e y) 2 -oxo-iH-azepin-3-yi] 2 -(2-methylpr~opyi,).-3.(butyl) butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-i- trifluoromethyiphenyl) benzyl) -2 -oxo-1H-azepin-3 -yi] -2- (2-Inethyipropyl) (butyl).-butanediamide; (2R,3S) Ni-f (3S) -hexahydro-1l-(3-(47methyipheny1)benzyl)- 2 oxo-1H-azepin-3-yij (2-methyilpropyl) (butyl) butanedianide; (2R,3S) Ni-f (3S)-hexahydro-.(3-.(2,4- dichlorophenyl)benzyi) 2 -oxo-1H-azepin-3-yl] (2- methyipropyl) (butyl) -butanediamide; (2R,3S) Ni-f 3 S)-hexahydro-i-(3-(3-choro 4 fluorophenyi)benzyl) -2-oxo-iH-azepin-3-yl] (2- methyipropyl) (butyl) -butanediamide; (2R, 3S) Ni-f -hexahydro-1- (benzophenon-3-yl) -2-oxo-1H- azepin-3 -yl]1 -2 (2 -methyipropyl) -3 (butyl) -butanediamide; (2R,35) Ni-f S-eayr-l(-2nptylbny)2oo iH-azepin-3-yi) (2-methyipropyl) (butyl) butanediainide; (2R,3S) Ni-f 3 S) -hexahydro-i--(3:-phenoxcybenzyl) -2-oxo-1H- azepin-3-yl] (cyclopropylmethyl) (propyl) butanediarnide; (2R,3s) Ni-f 3 S)-hexahydro-l-(3(4..methoxphenyl)benzyl)- 2 -oxo-iH-azepin-3-yl] (cyciopropylmethyl) (propyl) butanediainide; (2R, 3S) Ni-f (3S) -hexahydro-1- (4- trifluoromethyiphenyl) benzyi) -2-oo i.aeir l-2- (cyciopropylmethyi) (propyl) -butanediamide; (2R,3S) Ni-f 3 S)-hexahydro-i-(3-(4-.methypheny)benzyl 2 oxo-1H-azepin-3 -yi)1 (cyciopropylmethyi) -3 (propyl) butanediamide; -264- (2R,3S) N1-[(3S)-hexahydro-1-(3-(2,4- dichlorophenyl) benzyl) -2-oxo-1H-azepin-3-yl] -2- (cyclopropylmethyl) (propyl) -butanediarnide; (2R,3S) N1-[ (3S)-hexahydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-1H-azepin-3-yl] -2- (cyclopropylmethyl) (propyl) -butanedianide; (2R,3S) Ni-A (3S)-hexahydro-1-(benzophenon-3-yl)-2-oxo-1H- azepin-3 -yl]1 -2 (cyclopropylmethyt) -3 (propyl) butanedianide; (2R,3S) N1-[(3S)-hexahydro-1-(3-(2-naphthyl)bpenzyl)-2-oxo- iH-azepin-3-yl] (cyclopropylmethyl-)-3-- (p'ropyl) butanediamide; (2R,3S) N1-( (3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-iH- azepin-3-yl] (cyciopropylmethyl)-3- (allyl) butanediamide; (2R,3S) N1-II(3S)-hexahydro-1-(3-(4-methoxyphenyl)benzyi)- 2-oxo-1H-azepin-3-yil (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) N1-[ (3S)-hexahydro-1-(3-(4- trif luoromethylphenyi)benzyl) -2-oxo-lH-azepin-3-yl 1-2- (cyclopropyimethyl) -3 (allyl) -butanediamide; (2R,3S) NI-[ (3S)-hexahydro-1-(3-(4-methyipheny-I)benzyl)-2- oxo-1H-azepin-3-yl] (cyclopropylme'thyl) (allyl) butanediamide; (2R,3S) N1-[(3S)-hexahydro-1-(3-(2,4- dichiorophenyl) benzyi) -2-oxo-1H-azepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R, 3S) Ni-f (35) -hexahydro-1- (3-chioro-4- fluorophenyl )benzyi) -2-oxo-1H-azepin-3-yi] -2- (cyclopropyirnethyl) (ailyl) -butanediamide; (2R, 35) Ni-f (3S) -hexahydro-1- (benzophenon-3.-yl) -2-oxo-1H- azepin-3 -yl]1 -2 (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) Nl-f(3S)-hexahydro-i-(3-(2-naphithyi)benzyi)-2-oxo- 1H-azepin-3 -yi]1 -2 (cyclopropyimethyl) 3- (allyl) butanedianiide; -265- (2R,3S) Ni-f (3S)-hexahydro--(3-phenoxybenzy-2..oo..1-H... azepin-3-yiJ (cyciopropylmethyl) (butyl) butanediamide; (2R,3S) Ni-f 3 S)-hexahydro-i-(3-(4-methoxypheny)benzy). 2 -oxo-1H-azepin-3-yi] (cyciopropylmethyl) (butyl) butanediamide; (2R,3S) Ni-[(3S)-hexahydlro-1-(3-(4- tri fiuorornethyiphenyl)benzyi) 2 -oxo-1H-azepin-3-yi) -2- (cyciopropylmethyi) (butyl) -butanediaiide (2R,3S) Ni-f 3 S)-hexahydlro-1-(3-(4-methylphenyl)benzyl). 2 oxo-1I--azepin-3-yl] (cyciopropyimethyi) -3.-(butyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(2,4- dichiorophenyl) benzyi) -2 -oxo-1H-azepin--3-y1] -2- (cyclopropyimethyl) (butyl) -butanedianide; (2R, 3S) Ni- -hexahydro-i- (3-chloro-4- fiuorophenyi) benzyi) -2-oxo-1H-azepin-3-ylJ -2- (cyciopropyimethyl) (butyl) -butanediamide; (2R,3S) Ni-f (3S) -hexahydro-1- (benzophenon-3'-yi)-2-oxo-1H- azepin-3-yl] (cyciopropylmethyl) (butyl) butanediaiide; X(2R,3S) Ni-f 3 S)-hexahydro-l-(3-(2-naphthy.)benzyl) -2-oxo- iN-azepin-3-yi] (cyciopropyimethyl) (butyl) but arediamide; (2R,3S) Ni-f (3S) -hexahydro--(3-pheoxb~nzy)2oxoilH azepin-3-yl] (cyclobutylmethyl) (propyl)'- butanediaiide; (2R,3S) Ni-f 3 S)-hexahydro-l-(3-(4-methoxphny)benzy). 2-oxo-1H-azepii-3-yi] (cyclobutylmethyi) (propyl) 'butanediaxnide; (2R,3S) Ni-f (3S)-hexahydro-i-(3-(4- trifluoromethyiphenyl )benzyi) 2 -oxo-1H-azepin-3-'yJ2.. (cyciobutyirnethyl) (propyl) -butanxkedipiide; (2R,3S) Ni-f 3 S)-hexahydro-i-(3-(4 methylpheyj-)bzyl)- 2 oxo-1H-azepin-3-yl] (cyclobutyimethyl) (propyi) butanediamide; -2 66- (2R,3S) Ni-((3S)-hexahydro-i-( 3 2 4 dichiorophenyl)belzyl) -2-oxo-lH-azepifl->3Yl] -2- (cyclobutyrlethyi) (propyl) -butanediamide; 3S) Ni-[I(3S) -hexahydro-1- (3-chioro-4- fiuorophel)bezl~) -2-oxo-1H-azePifl-3-yl] -2- (cyclobutylmethYl) (propyl) -bu-t-a-ie-dafiide; (2R,3S) Ni-I (3S)-hexahydro1l(beflzopheflon 3 yl)- 2 oxo-lH- azepin- 3 -Yi] (cyclobutylmethY))-3- (propyl) butanediamide; (2R,3S) Ni-I g-eair-l(-2nptylbny)2oo 1H-azepifl- 3 -yi] (cyclobutYimethYl) (prjop~y) butanedianide; (2R,3S) Ni-I (3S)-hexahydro-i-(3-pheloxybenzyi) -2-oxo-1H- azepin- 3 -Yl) (cyciobutylmfethYl) (allyl) butanediamide; (2R,3S) Nl-[(3S)-hexahydro1l(34methoyphenyl)benzyl)- 2-oxo-lH-azepin- 3 -YiI (cyciobutYlmethYl) (allyi) butanediamide; (2R,3S) N1-I(3S)-hexahydro-l-( 3 4 trifluoromethylphefl)bnzyl) -2-oxo-lH-azepil-3-Yl) -2- (cyciobutylmethYl) (allyl) -butanediamide; (2R,3S) Nl-t( 3 S)-hexah~ydroi-3-(4-methylphenyi)benzyl)- 2 oxo-iH-azePifl- 3 -y 1 (cyciobutyimethYi) (allyl) butanediamide; (2R,3S) Ni-I (3.c)-hexahydro-i-(3-( 2 4 dichiorophelyl) benzyl) -2-oxo-lH-azepifl3-yiI'- 2 (cyclobutYlmethYl) (allyl) -butanedamride; (2R, 3S) Ni-f (3S) -hexahydro-1- (3-chloro-4- fluorophelyl) benzyl) -2-oxo-1H-azepil-3 -yl 1-2- (cyciobutYltnethYi) (allyl) -butanedianide; (2R, 3S) Ni- I (3S)-hexahydro-l- (benzophelof-3-Yl) -2-oxo-1H- azepin-3-yi) (cyclobutylmethYl) (allyl) butanediamide; (2R,3S) Nl[3)hxhdol(-2-ahhlbny)2oo 1H-azepin- 3 -yil (cyclobutylmfethYl) (ailyl) butanediamide; -267- (2R,3S) Ni-f (3S)-hexahydro-1-(3-phenoxybenzyi) -27oxo-iH- azepin-3-yiJ (cyciobutylmethyl) (butyl) butanediamide; (2R,3S) Ni-[(3S)-hexahydro-i-(3-(4-methoxyphenyi)benzyl)- 2-oxo-iH-azepin-3-yi]-2-(cyciobutyimethyi)-3-(butyl)-- butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-i- trifiuoromethylphenyi).benzyl) -2-oxo-1H-azepin-3-yij -2- (cyciobutyimethyi).-3- (butyl).-butanediamide;- (2R,3S) Ni-f (3S)-hexahydro-i-(3-(4-methyiphenyl)benzyi)-2- oxo-iH-azepin-3-yi]-2- (cyciobutylmet-hyl) -3-4butyi) butanediainide; (2R, 3S) Ni- (3S) -hexahydr07i-73-(.4-, dichiorophenyl )benzyl) -2-oxo-1H-azepin------yi] -2- (cyciobutyirnethyl) (butyl) -butanediamide; (2R,3S) N1-[ (3S)-hexahydro-1-(3- (3-chloro-4- fluorophenyl) benzyi) -2-oxo-1H-azepin-3-yi)-2- (cyciobutylmethyl) (butyi) -butanediamide'; (2R,3S) Ni-f (3S) -hexahydro-1- (benzophenon-3-yi) -2-oxo-1H- azepin-3-yl] (cyclobutyimethyl) (butyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-i-(3-(2-naphthy)benzy)-2-oxo- iH-azepin-3-yi] (cyclobutylmethyl) (butyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-i-(3-phenoxybenzyi) -2-oxo-iH- azepin-3-yl] (cyclopentylinethyl) (propyl).- butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(3-(4-methoxyphenyi)benzyl)- 2-oxo-1H-azepin-3-yil]-2- (cyclopentyimethyl) (propyl) butanediamide; (2R,3S) Ni-f (3S)-hexahydro-l-(3-(4- trifiuoromethylphenyl) benzyi) -2-oxo-1H-azepin-3-yi]--2- (cyciopentyimethyl) (propyi) -butanedimidew-- (2R,3S) Ni-f (3S)-hexahydro-1-(3-(4-methyphenyl)benzyl)-2- oxo-iH-azepin-3-yl)-2- (cyciopentyimethyi) (prop~ylj- butanediamide; -268- (2R,3S) Nl-[(3S)-hexahydro-i-( 3 2 4 dichiorophelyl) benzyi) -2-OXO-1H-azepifl3-Yi)-2- (cyciopentylmethYl) (propyl) -butanedanide; (2R,3S) Nl-[(3S)-hexahydo1l-(3-(3chloro- 4 fluorophenyl)belzyl)2oxolHazepin- 3 -yl (cyclopeltYlfethYl) (propyl) -butanedianide; (2R,3S) Ni-Il(3S)-hexahydro1l(beflzophenon3yl)>:oxo7lH- azepin-3-yl) (cyclopefltYlmethYi) (propyl) butanedianide; (2R,3S) Nil-[(3S)heahydro1l(3(2naphthyl)benzyl)- 2 -oxo- iH-azepil- 3 -yl-1-2- (cyciopent-yimethYl) (propyl) butanediamide; (2R,3S) N1-t (3S)-hexahydro1l(3phefloxbenzyl) 2 xolH- azepin-3-yll (cyciopentyJlmethyl) (allyl) butanediamide; (2R,3S) Nl[3)hxhdol(-4-ehxpey~ezl- 2-oxo-1H-azepifl-3-yl1-2- (cyciopentylmethYl) (ailyl) butanediamide; (2R, 3S) Ni- -hexahydro-1- (4- trifluoromethYiphel) benzyl) -2 -oxo-lH-azepifl-3-yi] -2- (cyclopentylmethYl) (allyl) -butanediamide; (2R,3S) Nl-[(3S)-hexahydro-1-(3-(4-methyiphenyl)benzyl)- 2 oxo-1H-azepil- 3 -yl1 (cyclopentylfethYl) (ailyl) butanediamide; (2R,3S) Nl-((3Sc)-hexahYdrO-1-( 3 2 4 dichiorophelyl) benzyl) -2-oxo-1lH-azepil-3 -yl 1-2 (cyclopentylmethYl) (allyl) -butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-1- (3-chloro-4- fluorophenyl) benzyl) -2-oxo-1H-azepil-3-Yl] -2- (cyclopentylmethYl) (ailyl) -butanediamide; (2R,3S) N1-[(3S)-hexahydro-1-(beflzophelon- 3 yl)- 2 oxoIH- azepin-3-yll (cyclopentylfethYi) (allyl).- butanediamide; (2R,3S) Nl-((3S)-hexhydro-l1(3-(2laphthyl)benzyl)- 2 -oxo- 1H-azepifl-3-Yi] (cyclopentYlmethyl) -3-(ailyl) butanediamide; -269- (2R,3S) N1-[ (3S)-hexahydro-1-(3-phenoxybenzyl)-2-ox6-1H- azepin-3-ylj (cyclopentyimethyl) (butyl) butanediamide; (2R,3S) Ni-[ (3S)-hexahydro-i-(3-(4-nlethoxyphenyl)benzyl)-- 2-oxo-1H-azepin-3-yi] (cyclopentylinethyl) (butyl) butanedianide; (2R, 3S) Ni- -hexahydro-1- trifiuoromethylphenyljbenzyi) -2-oxo-1H-azepii-3-yl] (cyciopentylmethyl) (butyl) -butaned-aide-- (2R,3S) Ni-[(3S)-hexahydro-i-(3-(4-methylphenyl)benzy)-2.. oxo-iH-azepin-3-yi] (cyclopentylmethyl) (butyl),. butanediainide; (2R,3S) Ni-[(3S)-hexahydro-i-(3-(2,4- dichiorophenyl) benzy.) -2 -oxo-1H-azepin-3--yi 1-2- (cyciopentyimethyl) (butyl) -butanediamide; (2R, 3S) Ni- -hexahydro-1- (3-chloro-4- fluorophenyl) benzyi) -2-oxo-1H-azepin-3 -yl] -2- (cyciopentylmethyl) (butyl) -butanediaide; (2R, 3S) Ni- -hexahydro-1- (benzophenon-3-yl)-2-oxo-lH- azepin-3-yl] (cyciopentyimethyl) (butyl) butanediamide; and (2R,3S) Ni-[ (3S)-hexahydro-i.-(3-(2-laphthyl)benzyl)-2-oxo. 1H-azepin-3-yl] (cyciopentylmethyl) (butyl)-7 butanediamide; (2R,3S) Ni-[ (3S)-hexahydro-i-(benzyl)-2-oxo-1H-azepin-3- yl] (2-methyipropyl) (propyl) -butanediamide;. (2R,3S) Ni-f (3S) -hexahydro-1- (phenethyl) -2-oxo-1H-azepin- 3-yl] (2-methyipropyl) (propyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-i-( (4-fiuorophenyl)methyi)-2- oxo-1H-azepin-3-yl] (2-methyipropyl) -3-(propyi) butanediamide; (2R,3S) Ni-f (3S) -hexahydro-1- (cyclopropylinethyl) -2-oxo-1H- azepin-3 -yi] (2-xnethyipropyl) (prepy14 1-- butanediamide; (2R,3S) Ni-f (3S) -hexahydro-1- (cyclobutyJlmethyi) -2-oxo-iM- azepin-3 -yiI1 -2 (2 -methyipropyl) -3 (propyl) butanediamide; -270- (2R,3S) N1-[f(3S)-hexahydro-1-(cyclopelty~lethyl)-2-oxo-1H- azepin-3-ylI (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni-( (3S)-hexahydro-1-(cyclohexylmethyl)-2-oxo-1H- azepin-3-yl] (2-methylpropyl)--3- (propyl) butanediarnide; (2R,3S) N1-[ (3S)-hexahydro-i-(cyclopropyiethyl)-2-oxo-iH- azepin-3-yll (2-methyipropyl) (propyl) butanedianide; (2R,3S) Ni-f (3S)-hexahydro-i-(cyclobutYiethYi)-2-oxo-iH- azepin-3-yl] (2-methylpropyl)V-3--'(jp10opyl butanedianide; (2R,3S) Ni-f (3S)-hexahydro-i-(cyciopentyiethyl)--2-oxo-iH-- azepin-3-yi] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni-f (3S) -hexahydiro-i- (cyclohexylethyl) -2-oxo-iH- azepin-3-yi] (2-rethyipropyi) (propyl) butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-i- (benzyi) -2-oxo-iH-azepin-3- yi) (2-methyipropyl) (ailyl) -butanedianide; (2R,3S) Ni-f (3S) -hexahydro-i- (phenethyl) -2-oxo-iH-azepin- 3-yi] (2-methyipropyl) (ailyl) -butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-l- ((4-fiuorophenyl)methyl) -2- oxo-iH-azepin-3-yi] (2-methyipropyl) (ailyl) butariediamide; (2R, 3S) Ni-f (3S) -hexahydro-i- (cyciopropyimethyl)-2-oxo-iH- az epin-3-yi] (2-methyipropyl) (allyl) -butanedianide; (2R, 3S) N4i-f((3S) -hexahydro-i- (cyciobutylmethyl) -2-oxo-iH- azepin-3-yl) (2-methyipropyl) (ailyl) -butanedianide; (2R, 3S) Ni-f (3S) -hexahydro-i-(cyciopentylmethYi)-2-oxo-iH- azepin-3-yl] (2-methyipropyl) (ailyl) -butanediamide; (2R,3S) Ni- -hexahydro-i- (cyciohexyimethyl) -2-oxo-1H- azepin-3-yll (2-methyipropyl) (allyl) -butanediamide;. (2R,3S) Ni- -hexahydro-i- (cyciopropylethyl) -2-oxo-1H- azepin-3-yl] (2-methyipropyl) -3'-(ailyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-i-(cyciobutylethyi)-2-oxo-1H- azepin- 3-yl I 2- (2 -methyipropyl) -3 (ailyl) -butanediainide; -271- (2R,3S) Ni-[ (3S)-hexahydro-i--(cyciopentylethyl)-2-.oxo-iH- azepin-3-yi] (2-methyipropyl) (ailyl) -butane dianide; (2R,3S) Ni-f (3S)-hexahydro-i-(cyciohexylethyl).-2-oxo-1H- azepin-3-yi] (2-methyip~ropyi) (ailyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-i-(benzyi)-2-oxo-iH-azepin-3-- yl] (2-rethylpropyi) (butyl,)-butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-i- (phenethyl) -2-oxo-iH-azepin- 3-yi] (2-methyipropyl) (butyl) -butanediamide; (2R, 3S) Ni-f (3S) -hexahy.dro-i- ((4-fluorophenyi)-methyi)-2 oxo-lH-azepin-3-yi] (2-methyipropyl) (butyl) butariediamide; (2R, 3S) Ni-f (3S) -hexahydro-i- (cyclopropyimethyl) -2-oxo-1H- azepin-3-yi] (2-methyipropyl) (buityl) -butanedianide;,--. (2R,3S) Nl-f(3S)-hexahydro-l-(cyciobuty-Ime~hyi) -2-oxo-iH- azepin-3-yi] (2-iethyipropyl) (butyl) -butanedianide; (2R,3S) Ni-f (3S) -hexahydro-i-(cyclopentylmethyl) -2-oxo-1H- azepin-3-yi) (2-methyipropyl) (butyl) -butanediamide; (2R,3S) Ni-f (3S) -hexahyd.ro-1-(cyciohexyimethyi)-2-oxo-iH- azepin-3-yl] (2-methyipropyl) (butyl) -butanediamide; (2R,3S) Ni-f (3S)-hexahydro-1-(cyclopropyiethyl)-2-oxo-lH-' azepin-3-yi) (2-methyipropyl) (butyl) -butanedianide; (2R,3S) Ni-f (3S) -hexahydro-i- (cyclobutylethyl) -2-oxo-iH- azepin-3-yl] (2-methyipropyl) (butyl) -butanediamide; (2R,3S) Ni-[ (3S)-hexahydro-i-(cyclopentyiethyl)-2-oxo-1H- azepin-3-yi) (2-methyipropyl) (butyl) -butanedianide; and (2R,3S) Ni- -hexahydro-i-(cyclohexylethyi) -2-oxo-1F{- a zepin-3-yl] (2-methylpropyi) (butyl) -butanediamide.
15. A compound according to Claim 1 selected from: (2R,3S) Ni-(i,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-i, 4-benzodiazepin-3-yl] (2.:methyipropyl).- (2R,3S) Ni-f l,3-dihydro-1-(3-phenoxybenzyi.) (phenyl) -2H-i, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanedianide; -272- (2R,3S) N1-[1,3-dihydro-1-(3-(4-inethoxyphenyl)benzyl)-2- (pheny.) -2H-1, 4-benzodiazepin-3-yl] (2- mrethyipropyl) (propyl) -butanediamide;- (2R,3S) N1-[1,3-dihydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-5- (phbenyl) -2H-1, 4- benzodiazepin-3-yl] (2-methyipropyl) (propyl)-- butanediamide; (2R,3S) N-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- oxo-5-(phenyl)-2H-14-benzodiazepin-3-yl]-27-(2,- methyipropyl) (propyl) -butanediaxnide; (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichlorophenyl):ben-zylV-- (phenyl) -2H-1, 4-benzodiazepin-3-yl] methyipropyl) (propyl) -butanediamide; (2R,3S) N1-II1,3-dihydro-1-(3-(3-chloro-4- 1s fluorophenyl)benzyl)-2-oxo-5-(phenyl)-2H-1,4- benzodiazepin-3-ylI (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(benzophenon-3-yl)-2-oxo-5- (pheny.) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanediamide; CMR,3S) N1-(1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanedianide; (2R,3S) Nl-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- oxo-5- (pheny -2H-1, 4-benzodiazepin-3-y.] methyipropyl) (allyl) -butanediamide;- (2R,3S) N1-[1,3-dihydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-5- (pheny))-2H-1, 4- benzodiazepin-3-yl] (2-methyipropyl) (allyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl] methyipropyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- 2-oxo-5- (phenyl)-2H-1, 4-benzodiazepin-3-yl] methyipropyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(3-chloro-4- fJluorophenyl) benzyl) -2-oxo-5- (phenyl) -2H-1, 4- -273- benzodiazepin-3-yl] (2-methyipropyl) (allyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2--12-methyipropyl) 3-(allyl)-butanediaiide; (2R, 3S) Nl 1 -iyr--(zpenxbny)-2Ox-z- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(3-(4-methoxypheyl1t-enz1)=.2 oxo-5- (phenyl) -2H-1,4-benzodiazepin-3-y11 (2- methyipropyl) (butyl) -butanediamide;-- (2R,3S) N1-[1,3-dihydro-1-(3- (4- trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-methylpropyil)-73- (butyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-niethylphenyrl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-y11 (2- methyipropyl) (butyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- 2 -oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3 -yl]1 (2 methyipropyl) (butyl) -butanediamide; (2R,3S)- N1-(1,3-dihydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4- benzodiazepin-3 -yl]1 -2 (2 -methylpropyl) -3 (butyl) butanediamide; (2R, 3S) Ni- 3-dihydro-1- (benzophenon-3-yl),-2-oxo-5- (pheny.) -2H-1, 4-benzodiazepin-3-yl] (2 -methyipropyl 3- (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydr7o-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H- 1, 4 -benzodiazepin-3 -yl]1 -2 (2 -methyipropyl) 3- (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylj1 pmpw: (cyclopropylmethyl) (propyl) -butanediainide; (2R,3S) Nl-[1,3-dihydro-l-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3 -yl]1 -2- (cyclopropylmethyl) (propyl) -butanediaiide; -274- (2R,3S) Nl-II1,3-dihydro-1-(3-(4- trifluorornethylphenyl)benzyl) (phenyl) -2H-1, 4- benzodiazepin-3-yl] (cyclopropylmethyl) (propyl) butanediamide; (2R,3S) Nl(,-iyr~-3(-ehypi y'bfgl.2- oxo-5-(phenyl)--2H-1,4-benzodiazepin*-3-ylV'--2--§--. (cyclopropylmethyl) 3- (propyl) -butanediamnide;- (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichloropheny.)benzyl)- 2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2- (cyclopropylmethyl) (propyl) -butanediaiide; (2R,3S) N1-[1,3--dihydro-1-.(3-(3-'chlo'ro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl') -2H-1,4- benzodiazepin-3 -yl -2 (cyclopropylmtliyl-)'-3 (propyl) butanediamide; (2R,3S) N1-II1,3-dihydro-1-(benzophenon-3-yl)-2-oxo-S- (phenyl) -2H-1. 4-benzodiazepin-3-yll -2- (cyclopropylmethyl) (propyl) -butanedianide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -2- (cyclopropyJ !nethyl) (propyl) -butanedianide; (2R,3S) N1-[1,i5-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3--iI-2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-inethoxyphenyl)benzyl)-2- oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopropylniethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-5- (pheny.) -2H-1, 4- benzodiazepin-3-yl] (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- 2-oxo-5- (phenyl)-2H-1, 4-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1,4- -275- benzodiazepii-3-ylI-2- (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(benzophenon-3-yl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopropylmethyl -(allyl) -butanediamide; (2R,3S) Nl[,-iyr--3(7apty~ezl--x-r- (phenyl) -2H-1, 4-benzodiazepin-3-ylI -2- (cyclopropyrnethyl) (allyl) -boutanediamide; (2R,3S) Nl-[1,3-dihydro-l-(3-phenoxybenzy1)-2-:Oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yil (cyciopropylmethyl) -3:-(butyl) -butanediamide;- (2R,3S) N1-[1,3-dihydro-1-(3-(,4-methoxyphenyl)benzyl')-2- (phenyl) -2H-1, 4-benzodiazepin-3-ylI (cyclopropylmethyl) -3 (butyl) -butanedianrkde (2R,3S) N1-[1,3-dihydro-1-(3-(4- trifluoromethyiphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4- benzodiazepin-3-yi] (cyclopropylmethyl) (butyl) but anediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- oxo-5- (phenyl) -2H-1,4-benzodiazepin-3-yi) -2- (cyclopropylmethyl) (butyl) -butariediarnide; (2R,3S) N1-fI1,3-dihydro-1-(3-(2,.4-dichlorophe nyl)benzyl)- (phenyl) -2H-1, 4-benzodiazepin-3-yl) -2- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) N1-j11,3-dihydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4- benzodiazepin-3-yl] (cyclopropylmethyl) (butyl) butanediamide; (2R, 3S) Ni- 3-dihydro-1- (benzophenon-3-yl) (phenyl) -2H-1, 4-benzodiazepin-3-yiI -2- (cyclopropylmethyl) -3 (butyl-) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yJ--2----:.c p,- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yli-2- (cyclobutylmethyl) (propyl) -butanedianide; -276- (2R,3S) N1-(1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- -2H-1,4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (propyl) -butanediamide.; (2R,3S) N1-[1,3-dihydro-1-(3-(4- -trif luoromethy-lphenyl) benzyl) -2*-oxo-5- (phefiyl) -2H-1- 4- benzodiazepin-3-ylI (cyclobutyirnethyl) (propyl) butanediamide; (2R,3S) Nl-I1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- oxo-5-(phenyl)-2H-1,4-benz-odiazepin-3-Y1]-2- (cyclobutylmethyl) (propy-l) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(2,'4-dichlorpheny)beizyl)-- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (propyl) -butanediamide;, (2R,3S) N1-I1,3-dihydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4- benzodiazepin-3-yl] (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(benzophenon-3-yl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (pro~vl) -butanediamide; (2R,3S) N1-(1,3 -dihydro-1-(3-,2-naphthy1)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl) -2- (cyclobutylmethyl) (propyl) -butanediamnide; (2R,3S) N1-I1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl-2- (cyclobutyimethyl) (allyl) -butaedainide;-- (2R,3S) N1-[1,3-dihydro-1-(3-(4-methoxyphenyljbenzy-l)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-. trifluoromethylphenyl)benzyl) -2-oXo-5- (phenyl) -2H-1, 4-- benzodiazepin-3-yll (cyclobutyimethyl) (allyl) butanedianide; (2R,3S) N1-[1,3-dihydro-1-(3--(4-rnethylphenyl)benzyl)-2- oxo-5- (phenyl) 4-benzod-iazepin-3-yl] -2- (cyclobutyirnethyl) (allyl) -butanedianide; -277- (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichiorophenyl)benzyl)- (phenyl) -2H-l, 4-benzodiazepin-3-yl) -2- (cyclobutylmethyl) -3 (allyl) -butariediamide; N1-[1..3-dihydro-l-(3-(3-chioro-4- fluorophenyl)benzyl)-2-oxo-5-(phenyl)-2H-1,-4,- benzodiazepin-3-ylI (cyclobutylmethyl) (ally-.)- butanediamide; (2R,3S) N1-II1,3-dihydro-1-(benzophenon-3-yl)-2-oxo-5- (phenyl) 4-benzodiazepin-3-:yl] (cyclobutylmethyl) (allyl) -butanediamide; (2R, 3S) 3-dihydro-- (2-lahthyl)benzyl7)-2-oxo7-.: (phenyl) -2H-1, 4-benzodiazepin-3-yl] (cyclobutylmethyl) (allyl.) butanedianijde; (2R,3S) Nl-[1,3-dihydro-1-(3-phenoxybenzy1)--2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yll -2- (cyclobutylmethyl) (butyl.)--butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (butyl) -butanediamide; (2R,3S) N1-i[l,3-dihydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4- benzodiazepin-3-ylI (cyclobutylmethyl) (butyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methylphenyl)benzyl)-2- oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylnethyl) (butyl) -butanediaxnide; (2R,3S) N1-[1,3-dihydro-l-(3- (2,4-dichlorophenyl)benzyl)- 2 -oxo- 5- (phenyl) -2H- 1, 4 -benzodiazepin-3 -yl -2 (cyclobutylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3--(3-chloro-4- f luorophenyl) benzyl) 2-oxo-5 (phenyl) -2H- 1, 4 benzodiazepin-3-yl] (cyclobutylmethyl) (butya-) butanediamide; (2R,3S) N1-[1,3-dihydro--(benzophenon-3-yl)-2-oxo-5- (phenyl) -2H- 1, 4 -benzodiazepin-3 -yl -2 (cyclobutylmethyl) (butyl) -butanediamide; -278- (2R.3S) N1-(1,3-dihydro-1-(3-(2-flaphthYl)beflzyl)20ox-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro--(3-pheloxybeflzyl)-2-oxo-5- (phenyl)-2H-1,4-benzodiazepin---3-yi-2- (cyclopentyirnethyl) (propyl)-butanediami-de;- (2R,3S) N1-[1,3-dihydro-1-(3-(4-methoxyphelyl)belzyl)-2- (phenyl) -2H-1, 4-b~enzodiazepin-'--yl] -2- (cyclopentyirnethyl) (propyl) -buitanedianide;- (2R,3S) N1-(1,3-dihydro-1-(3-(4- trif luoromethylphenyl)'benzyl) -2-oxo-5,- (phenyl) 4- benzodiazepin-3-ylI (cyclopentyirnethyl')-3--(propyl) butanediamide; (2R,3S) Nl-(1,3-dihydro-1-(3-(4-methylphelyl)benzyl)-2- oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) N1-(1,3-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-l-(3-(3-Chloro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2-i1,4- benzodiazepin-3-ylJ (cyclopentylmethyl) (propyl) butanediamide; (2R,3S) N1-[1,3-dihydro-1-(benzophenofl-3-y1)-2-oxo-5- (phenyl) -2H 1, 4-benzodiazepin-3-yl] -2- (cyclopentyirnethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiaz'epin-3-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl) -2- (cyclopentyirnethyl) -3 -(allyl) -butanedianide; (2R,3S) N1-(1,3-dihydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4- -279- benzodiazepin-3-ylJ (cyclopentylmethyl) (allyl) butanedian.ide; (2R,3S) Nl-i1,3-dihydro-1-(3-(4-methylphelyl)belzyl)-2- (phenyl) -2H-1,4-benzodiazepil-3-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(2,4-dichlorophenyl benzyi) (phenyl) -2H-1, 4-benzodiazepin-3-ylI -2- (cyclopentylmethyl) (allyl) -butanedianide; (2R,3S) N1-(1,3-dihydro-1--(3-(3-chloro-4- fluorophenyl)benzyl)-2-oxo-5- (phenyl) -2H-1, 4- benzodiazepin-3-yll (cyclopentylmethiyl)-3- (allyl) butanediamide; (2R,3S) NlI-[1,3-dihydro--(benzophenon -3-yl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ -Z- (cyclopentylmethyl) (allyl) -butanedianide; (2R,3S) N1-[1,3-dihydro-1-(3-(2-naphthyl)belzyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5- (phenyl) -2H-1 1 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-methoxyphenyl)benzyl)-2- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-- trifluorornethyiphenyl) benzyl) -2 -oxo-5 -(phenyl) -2H-1, 4- benzodiazepin-3 -ylJ (cyclopentylmethyl) (butyl butanediamide; (2R,3S) N1-[1,3-dihydro-1-(3-(4-xnethylphenyl)benzyl)-2- oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (butyl) -butanediamide; (2R,3S) Nl-[1,3.-dihydro-1-(3-(2,4-dichlorophenyl)benzyl)- (phenyl) -2H-1, 4-benzodiaze in-3zy4] (cyclopentylmethyl) (butyl) -butanediami de; (2R,3S) N1-[1,3-dihydro-1-(3-(3-chloro-4-, fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, 4- benzodiazepin-3-yl] (cyclopentylmethyl) (butyl) butanediamide; -280- (2R,3S) Ni-[i.3-dihydro--(benzophenon3yl)> 0 -x- 5 (phenyl)-2H-1,4-benzodiazepin-3y...2-.- (cyclopentyimethyl) (butyl) -butanedianide; and (2R,3S) Ni-[i,3-dihydro-1-(3-(2-naphthyl).benzyl)-2-.oxo-5.- (phenyl) -2H-i, 4-benzodiazepin-3-yij--- (cyciopentyrnethyl) (butyl) -butanediamide; (2R,3S) Ni-fl, 3 -dihydro--(benzy)2oxo-5(pheny).2H.-- 1, 4-benzodiazepin-3-yl] (2-methyipropyl) (propyL) butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(phenethy)-2-oxo5.(pheriyl)-2H- 1, 4-benzodiazepin-3-ylJ (2-methyipropyl)'7-3 (propyl-) butanediamide; (2R,3S) Ni- [1,3-dihydro-1-( 4 -fluoropheny1-)methylY--2-oxo.... (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2- zethylpropyl) (propyl) -butanediamide; (2R,3S) Ni- 3-dihydro-1- (phenyl) -2H-1, 4-benzodiazepin-3-ylJ (2-methyipropyl) 3- (propyl) -butanediamide; (2R,3S) Ni- I1,3-dihydro-1- (cyclobutyixnethyl) (phenyl) -2H-i, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanedianide; (2R,3S) Nl-[1,3-dihydro--(cycloentyj (phenyl) -2H1-i, 4-benzodiazepin-3-yl) (2-mhethyipropyl) 3- (propyl) -butanediamide; (2R,3S) Ni-[1,3-dihydro--(cyhxyhehyl)...yl)...oxo-5-.. (phenyl) -2H-i, 4-benzodiazepin-.3-yl] (2-methyipropyl) 3- (propyl) -butanediamide; (2R,3S) Ni-(1,3-dihydxo-i- (cyclopropylethyl) (phenyl) -2H-i,4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanediamide; (2R,3s) Nl-[1,3-dihydro--(cycobuttyl)...l2o 0 (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (propyl) -butanediarnide; (2R,3S) Ni- 3-dihydro-1- (phenyl) -21, 4-b~enzodiazepin-3-yJ.-2- (2-methyipropyl) 3- (propyl) -butanediamide; -281- (2R, 3S) Ni-Il, 3-dihydro-1- (cyclohexylethyl) (phenyl) -2H-i, 4-benzodiazepin-3-yl] -2-.(2-methyipropyl) 3- (propyl) -butanedinide; (2R,3S) N1-[1,3-dihydro-1-(benzyl)-2-oxo-5-(phenyl)-2H- 1, 4-benzodiazepin-3-yl] (2-methylpropyl)-3- (a-llyi-)- butanedianide;- (2R,3S) Ni-Il, 3-dihydro-1- (phenethyl).t-2-oxo-5-.(phenyl) -2H*- 1, 4-benzodiazepin-3-yll (2-inethyipropyl) (allyl) butanediamide; (2R,3S) N1-[1,3-dihyditc-l-( (4-fluorophenyi)methyi)-2-oxo- (phenyl) -2H-l, 4-benzodiazepin-3zyl] (2- methyipropyl) (allyl) -butanediamide;- (2R,3S) Nl-[l,3-dihydro-1-(cyclopropymethyl)-2-roxo-5- (phenyl) -2H-1, 4 -benzodiazepin-3 -yl]1 -2 2-methylpropyl) 3- (allyl) -butanediamide; (2R,3S) Nl-II1,3-dihydro-1-(cyciobutylmethyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yll (2-methyipropyl) 3- (allyl) -butanediamide; (2R,3S) Nl-(1,3-dihydro-1-(cyclopentymethyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3 -yl]1 -2 (2 -methyipropyl) 3- (allyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-i-(cycohexylmethyl)-2-oxo-5- (phenyl) -2H- 1, 4 -benzodiazepin-3 -yl) -2 (2 -methyipropyl) 3- (allyl) -butanedjanide; (2R,3S) Ni-[1,3-dihydro-1-(cycilopropylethyl)-2-oxo-5- (phenyl) -2H-i1, 4 -benzodiazepin-3 -ylI1 -2 (2 -methyipropyl) 3- (allyl) -butanediamide; (2R, 3S) Ni-Li, 3-dihydro-1-(cyclobutylethyl) (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (allyl) -butanediamide; (2R,3S) NJ-[1,3-dihydro-1-(cyclopentylethyl)-2-oxo-5- (phenyl) -2H-l1, 4 -benzodiazepin- 3-yl 1 -2 (2 -methyipropyl) 3- (allyl) -butanediamide; (2R,3S) N-I1,3-dihydro-1-(cyclohexylethyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3- (allyl) -butanediamide; -282- (2R,3S) Ni-fl,3-dihyciro-1-(benzyl)-2-oxo-5-(phenyl)-2H- 1,4-benzodiazepin-3-yl]-2-(2-rnethylpropyl,)-3-(butyl) butanediamide; (2R,3S) N1-[l,3-dihydro-1-(phenethyl)-2-oxo-5-(phenyl)-2H- 1, 4-benzodiazepin-3-yl] (2-nmethylpropy1) (butyl) butanediamide;- (2R,3S) N1-[1,3-dihydro-l-( (4-fluorophenyl)methyl)-2-oxo- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2- methyipropyl) -3 (butyl) -butanediamide; (2R,3S) Nl-[1,3-dihydro-1-(cyclopropylmethyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3--ylI (2-methyipropyl) 3 (butyl) -butanediainide; (2R, 3S) 3-dihydro-i- (cyc-lobutylmethyl) (phenyl) -2H-1, 4-benzodiazepin-3-yli (2-methyipropyl) 3 (butyl) -butanediamide; (2R,3S) Ni- (1,3-dihydro-l-(cyclopentylmethyl) (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3 (butyl) -butanediamide; (2R,3S) N1-[1,3-dihydro-l-(cyclohexylmethyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylj (2-methyipropyl) 3- (butyl) -butanedianide; (2R,3S) N1-[1,3-dihydro-l-(cyclopropylethyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yl] (2-methyipropyl) 3 (butyl) -butanediauide;. (2R,3S) Ni-(1,3-dihydro-l-(cyclobutylethyi)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-yll (2-methyipropyl) 3 (butyl) -bultanedianide; (2R,3S) Ni- [1,3-dihydro-1-(cyclopentylethyl) (phenyl) -2H-1, 4-benzodiazepin-3-yll (2-methyipropyl) 3-(butyl)-butanediamide; and (2R,3S) N1-t1,3-dihydro-l-(cyclohexylethyl)-2-oxo-5- (phenyl) -2H-1, 4-benzodiazepin-3-ylI (2-methyipropyl) 3 (butyl) -butanediamide.
16. A compound according to Claim 1 selected* from: (2R,3S) Ni- (6,7-dihydro-5-(3-phenoxybenzyl) -6-oxo-5H7 dibenz [b,dlazepin-7-y.]-2- (2-methylpropyl).-3- (propyl) butanediamide; -283- (2R,3S) Ni-16,7-dihydro-5-(3-(4-methoxyphenyl)belzyl)-6- [b,dlazepin-7-yl] (2-methyipropyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4- trifiuorornethylphenyl)belzyl) dibenz azepin-7-yl] (2-meth-ylpropyl) (propyl) butanediainide; (2R,3S) Ni-(6,7-dihydro-5-(3-(4-methYipheli)belzyl)-6- (b,d~azepin-7-yi] (2-methy1propyi) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(.2,-4-dichioropheny)-benzyi)-. fb, d]azepin-7--yl] (2-methyipropyl) -3- (propyl) -butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4-- fluorophenyl)benzyl) -6-oxo-5H-dibenz lb. d)azepin-7-ylJ -2- (2-methyipropyl) (propyl) -butanediamide; (2R. 3S) Ni- [6,7-dihydro-5- (benzophenon-3-yl) dibenz [b,dlazepin-7-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(2-naphthyl)bel~)-6-oxo-5H- dibenz Ibgd] azepin-7-yl] (2-methyipropyl) (propyl) butanedianide; (2R,3S) Ni-[6,7-dihydro-5-(3-phenoxybezl~y)-67oxo-5H- dibenz[b,d]azepin-7-yll-2-(2-methyipropyl)>i-ally)- butanediamide; (2R,3S) Ni-[6,7-dihydro-5-(3-(4-methoxyphelYl)belzyl)-6- (b,d]azepin-7-yiJ (2-methyipropyl) -3- (al lyl) -butanediamide; (2R,3.S) N-(6,7-dihydro-5-(3-(4- trifluoronethyiphenyi)benzyl) dibenz [b,dlazepin-7-yl) (2-methyipropyl,)-3- (ailyl) but anediamnide; (2R,3S) Ni- (6,7-dihydro-5- (4-methylphetiilben!Mi-6- fb,d] azepin-7-yl] (2-methyipropyl) (allyl) -butanediamide; (2R,3S) Ni-[6,7-dihydro-5-(3-(2,4-dichlorophefl)beflzyi)- dlazepin-7-yl] (2-methyipropyl) -3- (ailyl) -butanediamide; -284- (2R,3S) Nl-[6,7-dihydro-5-(3-(3-chloro- 4 fluoropheny.)belzyl) -6-oxo-5H-dibeflz[b,dazepin 7 -yl]-2- (2-methyipropYl) (allyl) -butanedianide;. (2R,3S) Nl-[ 6 ,7-dihydro-5(3(2flaphthyl)benzy)6oxoSH- dibenz(b,dazepif7yV2-(2-ethyl-p*ropy1l)- 3 -(allyl)- butanedianide; (2R,3S) Nl[,-iyr--3peoyezl--x-H dibenz dlazepin- 7 -yll (2-methyiproPYl) (butyl) butanedianide; (2R,3S) Nl[,-iyr--3(-mtoyhnlbny)6 d) azepin- 7 -yll (2-methyilpropyl) -3- (butyl) -butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-( 4 trifluoromfethylpheflYl )benzyl) dibenz fb,dlazepin-7-yl) (2-methyipropyl) (butyl) butanediamide; (2R,3S) Nl-[6,7-dihydro-5(3(4methylphenyl)benzyl)- 6 Ib,d] azepin- 7 -yl] (2-methyipropYl) -3- (butyl) -butanediamide; (2R,3S) Nl-(6,7dihydo5-(3(2,4-dichorophenyl)bnzyl) (b,dlazepin-7-yllb 2 -(2-methyipropYl) -3- (butyl) -butanedafide; (2R,3S) N1-[6,7dihydo-53(3-chloro- 4 fluorophenyl)bezyl) -6-oxo-5H-dibelz azepin- 7 -yl] -2- (2 -methyipropYl) (butyl) -bultahediamide; (2R, 3S) N1-16,7-dihydroS -(benzophelof- 3 -Yl) -6-oxo-SH- dibenz [b,dlazepin-7-yll (2-methyiproPYl) -3-(butyl) butanediamide; (2R,3S) Nl(,-iyr--3(-apty~ezl--x-H dibenz ~b,dlazepin-7-yl1 (2-methyiproPYl) -3-(butyl) butanediamide; (2R,3S) N1-(6, 7-dihydro-5- (3-phenoxybelzyl) dibenz (b,dlazepifl-7-yl] -2-(cyclopropylmethy1) -3- (propyl) -butanediamide; (2R,3S) Nl[,-iyr--3(-mtoyhnlbny)6 azepin- 7 -Yl) (cyclopropylmethY l) -3- (propyl) -butanediamide; -285- (2R,3S) N1-[6,7-dihydro--5-(3-(4- trifluoromethyiphenyl )benzYl) dibenz [b,djazepin-7-ylI (cyclopropylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-methylph-enyljbenzyl)-6- d)azepin-7-yl] (cyclopropylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2,4-dichlorophenyl)benzyl)- [b,d)azepin-7-ylJ (cycl1Qprppylmethy1) 3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4-. fluorophenyl)benzyl)-6-oxo-5H-dibenz[b,dlazepin-7-ylI -2- (cyclopropylmethyl) (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(benzophenon-3-yl)-6-oxo-5H- dibenz [b,dlazepin-7-yl) (cyclopropylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2-naphthyl)benzyl)-6-oxo-5H- dibenz [b,dlazepin-7-yl] (cyclopropylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihyclro-5-(3-phenoxybenzyl)-6-oxo-5H- dibenz~b,dlazepin-7-yl] (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) N1-[6,7-dibydro-5-(3--(4-methoxyphenyl)benzyl)-6- d]azepin-7-yl] (cyclopropylmethyl) -3- (allyl) -butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(4- trifluoromethyiphenyl )benzyl) dibenz fb,dlazepin-7-yl] (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5'-(3-(4-methylphenyl)benzyl)-6- tb.d]azepin-7-yl] (cyclopropylmrethiyl) -3- (allyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2,4-dich4 orgp~enbnz1) (b,dlazepin-7-yl] (cycfopz'6pylmethyl) 3- (allyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4- fluorophenyl )benzyl) -6-oxo-5H-dibenz d]azepin-7-yl] -2- (cyclopropylmethyl) (allyl) -buitanedianide; -2 86- (2R,3S) N1-[6,7-dihydro-5-(benzophenon-3-yl)-6-0x0-5H- dibenz fb,dlazepin-7-ylI (cyclopropylmethyl) (llyl)- butanediamide; (2R,3S) Nl-[6,7-dihydro-5-(3-(2-iaphthyl)berizyl)-6-oxo-SH- dibenz[b,d~azepin-7-yl]-2-(c'yclopropylrnethyl)->3(allyl) butanedianide; (2R,3S) N1-(6,7-dihydro-5-(3-phenoxybenzyl)-6-oxo-5H- dibenz tb~d) azepin-7-yl] (cyclopropylniethyl) (butyl) butanediamide; (2R,3S) Nl-[6,7-dihydro-S-(3-(4-niethoxyphenyl)benzyl)-6- oxo-5H-dibenz[b,d]azepin-7-yl]-2'-(c yclopropylmethyl) (butyl) -butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-- trifluoromethyiphenyl )benzyl) dibenz ib,dlazepin-7-yl] -2-(cyclopropylmethyl)-3- (butyl) butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-methylphenyl)benzyl)-6- oxo-5H-dibenz~b,dlazepin-7-yl] (cyclopropylmethyl) -3- (butyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-S-(3-(2,4-dlichlorophenyl)benzyl)- d]azepin-7-yl] (cyclopropylmethyl) 3- (butyl) -butariediamide; (2R,3S) N1-(6,7-dihydro-5-'(3-(3-chloro-4- fluorophenyl)benzyl) -6-oxo-5H-dibenz [b,d~azepin-7-ylJ -2- (cyclopropylmethyl) (butyl) -butanediamide; (2R,3S) Nl-[6 1 7-dihydro-5- (benzophenon-3-yl)-6-oxo-SH- dibenz azepin-7-yl] (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) N-[6,7-dihydro-5-(3-(2-naphthyl)benzyl)-6-oxo-5H- dibenz [b,dl azepin-7--yl] (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5- (3-phenoxybenzyl) dibenz (b,dI azepin-7-yl] (cyclobutylmethyl) (propyl) butanediainide; (2R,3S) N1-(6,7-dihydro-5-(3-(4-rnethoxyp henyl)benzyl)-6- (b,d]azepin-7-yl] (cyclobutylmethyl) -3- (propyl) -butanediamide; -287- (2R,3S) N1-[6,7-dihydro-5-(3-(4- trifluoromethyiphenyl) benzyl) dibenzfb,dlazepin-7-yl] (cyclobutylmethyl)-3- (propyl) butanediamide; (2R,3S) N1-16,7-dihydro-5-(3-(4-rnfethylphenyl)benzyl)-6-.. [b,d]azepin-7-yl] (cyclobutyirnethyl) -3- (propyl) -butanediaiide; (2R,3S) N1-[6,7-dihydro-5-(3-(2,4-dichlorophenyrl)benzyl)- [b,d~azepin-7-yl) (cyclobutylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-f6,7-dihydro-5'-(3-(.3-chloro-4--- fluorophenyl)benzyl) -6-oxo-5H-dibenz dlazepin-7-yl] -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R, 3S) N1-[6,7-dihydlro-5- benzophenon-3--yIJ-6-oxo-5H- dibenz[b,dlazepin-7-yl] (cyclobutylmethyl) (propyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2-naphthy)benzy)6oxo5H dibenzfb,dlazepii-7-yl] (cyclobutylniethyl) (propyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-phenoxybenzyl)-6-oxo-,5H- dibenz (b,djazepin-7-yl] (cyclobutylmethyl) (allyl) butanediamide; (2R,3S) Nl-16,7-dihydro-S-(3-(4-methoxyphenyl)benzy-1)-6.. [b,d)azepin-7-yl] (cycJlobutylinethyl) -3- (allyl) -butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-(4- trifluoromethyiphenyl )benzyl) -6 dibenz [b,dlazepin-7-yl] (cyclobutylmethyl) (allyl) butanediamide; (2"R,3S) N1-[6,7-dihydro-5-(3-(4-methylphenyl)benzyl-G. d] azepin-7-yl) (cyclobutylmethyl) -3- (allyl) -butanediamide; (2R,3S) N1-[6,7-dihydro--(3-(2,4-dicopny4bezy1). dl azepin-7-yl] (cyclobut3Flmethy1) -3- (allyl)-butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4- fluorophenyl) benzyl) -6-oxo-5H-dibenz d]azepin-7-ylJ -2- (cyclobutylmethyl) (allyl) -butanediamide;- -288- (2R,3S) N1-t6,7-dihydro-5-(belzopheflof-3-yi)-6-oxo-5H- dibenz (b,dlazepin-7-y) 1-2- (cyclobutylmhethyl) (ailyl) butanedianide; (2R,.3S) Ni-[6,7-dihydro-5-(3-(2-naphthyl)bezl~y)-6-oxo-5H- dibenz dlazepin-7-yi]1-2- (cyclobutylm'ethyi)-3- ("all T)- butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-phenoxybezl~y)-6-OXO-5H- dibenz [b,d)azepin-7-yl] (cyciobutylimethyl) (butyl) butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-methoxyphelyl)belzyl)-6- [b,dI azep'in-7-yI] (cyclobutyimethyl) -3- (butyl) -butanediamide; (2R,3S) N1-[6..7-dihydro-5-(3-(4-- trifluoromethyiphenyl) benzyl) dibenz fb,dlazepin-7-yll (cyciobutylmethyl) (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-S-(3-(4-methyiphenyl)benzyi)-6- azepin-7-yi] (cyciobutylmethyl) -3- (butyl) -butanediamide; (2R,3S) Ni-(6,7-dihydro-5-(3-(2,4-dichlorophel)belzyl)- d] azepin-7-yil 2 (cyclobutyimethyl) -3- (butyl) -butanediainide; (2R,3S) N1-[6,7-dihydro-5-(3-(3-chloro-4- filuorophenyi) benzyi) -6-oxo-5H-dibenz d) azepin-7-yl) -2- (cyciobutyimethyl) (butyl) -butanediamide (2R, 3S) Ni- r6,7-dihydro-5- (benzophenon-3-yl) dibenz fb,d~azepin-7-yl] (cyclobutylmethyl) (butyl)- butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2-naphthiyl)benzy)-6-oxo-5H- dibenz [b,d~azepin-7--yl] -2-(cyciobutyimethyl) (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-phenoxbezl~y)-6-oxo-5H- dibenz [b,dl azepin-7-yl] (cyclopentylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dihydr-o-5-(3-(4-methoxyphenyl)benzyl)-6- azepin-7-yi] (cyciopentyimethyl) -3- (propyl) -butanediamide; -289- (2R,3S) N1-[6,7-dihydro-5-(3-(4- trifluoromethyiphenyl) benzyl) dibenz[b,d)azepin-7-yl] (cyciopentylmethyl) -3- (propyl) -butanediamide; (2R,3S) N1-[6,7-dih 'dro-5-(3-(4-methy iphenyi)-binzyl)--6- azepin-7-yll -2-(cyclopentyimethyi) (propyl) -butanediaiide; (2R,3S) N1-[6,7-dihydro-5-(3-(2,4-dichlorophenyl)benzyl)- 6-oxo-SH-dibenz dl azepin-7-yll (cyclopentylmethyl) 3- (propyl) -butanediamide;- (2R, 3S) N1- 7-dihydro-5- -ch-loro-4- f luoropheny.) benzyl) -6-oxo-5H-dibenz d] azepin-7 -yi]j -2 (cyclopentyJlmethyl) (propyl) -butanediami-de; (2R,3S) Ni- 7-dihydro-5- (benzophenon3--y) -6-oxo-SH- dibenz[b,dlazepin-7-yl] (cyclopentylmethyl) -3- (propyl) -butanedjanide; (2R,3S) N1-[6,7-dihydro-5-(3-(2-naphthyl)benzyi)-6-oxo-5H- dibenz dlazepin-7-yl] (cyclopentylmethyl) -3- (propyl) -butanediamide; (2R, 3S) N1-[6,7-dihydro-5- (3-phenoxybenzyl)-6-oxo-5H- dibenz~fb, dlazepin-7-yl)1 (cyclopentyznethyl) -3 (ailyl) butanediamide; (2R,3S) Ni-[6,7-dihydro-5-(3-(4-methoxyphenyl)benzyl)-6- Ib, d]azepin-7-yl) (cyclopentyimethyl) -3- (allyl) -butanedjanide; (2R,3S) N1-[6,7-dihydro-5-(3-(4- trifluoro methyiphenyl) benzyl) dibenz[b,dlazepin-7-yl) -2-(cyclopentylmethyl)-3-(allyl) butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-methylphenyl)benzyl)-6- dl azepin-7-yl] (cyclopentyimethyl) -3- (allyl) -butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(2,4-dichlorphi-eny!j-be6nzyl)- d]azepin-7-yl] (cyclopentylmethyl) 3- (ailyl) -butanediamide; (2R,3S) N1-[6,7-dihydlro-5-(3-(3-chloro-4- fluorophenyl )benzyl) -6-oxo-5H-dibenz d] azepin-7-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide; -290- (2R,3S) Ni-[6,7-dihydro-5-(benzophelof-3-yl)-6-oxo-5H- dibenz (b,d~azepin-7-yl) (cycJlopentyimethyl) (allyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(2-laphthyl)beflzyl)-6-oxo-5H- dibenz[b,d~azepin-7-yl)-2-(cyclopefltylmethy l)-3--(allyl)-' butanediamide; (2R,3S) N1-116,7-dihydro-5-(3-pheloxybezl~y)--6-oxo-5H- dibenz [b,dlaz.!pin-7-yl] (cyclopentylmethyl) (butyl) butanediamide; (2R,3S) N1-(6,7-dihydro-5-(3-(4-methoxyph~fly1y)bel'zyl)-6- jb, dlazepin-7-yil (cyclopentylmethyl) -3- (butyl) -butanedianide; (2R,3S) N1-[6,7-dihydro-5-(3-(4- trifluoromethyiphenyl) benzyi) dibenz[b,dlazepin-7-yil (cyclopentylmethyl) (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(3-(4-methylphenyl)benzyl)-6- [b,djazepin-7-yl] (cyclopentylmethyl) -3- (butyl) -butanedianide; (2R,3S) N1-(6,7-dihydro-5-(3-(2,4-di chlorophelyl)belzyl)'- ji, -I]azepin-7-yl] (cyclopentylmethyl) 3- (butyl) -butanediamide; (2R, 3S) Ni- 7-dihydro-5- (3-chloto-4- fluorophenyl) benzy.) -6-oxo-5H-dibenz azepin-7-yl] -2- (cyclopentylmethyl) (butyl) -butanediaiide;- (2R,3S) Ni- [6,7-dihydro-5- (benzophenon-3-yl) -6-oxo-SH- dibenz~b,d]azepin-7-yll (cyclopentylmethyl) (butyl) butanediamide; and (2R,3S) N1-[6,7-dihydro-5-(3-(2-naphthyl)benzyl)-6-oxo-5H- dibenzfb,dlazepin-7-yl] (cyclopentylmethyl) (butyl) butanediaiuide; (2R,3S) Ni-f 6,7-dihydro-5-(benzyl)-6-oxo-5H- dibenz azepin-7-yl (2-methyipropyl) (propyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(phenethyl)-6-oxo-5H- dibenz (b,dljazepin-7-yil (2-methyipropyl) (propyl) butanediarnide; -291- (2R,3S) N1-[6,7-dihydro-5-( (4-f luorophenyl)methyl)-6-oxo- dJazepin-7-yiJ (2-methyipropyl) -3- (propyl) -butanediamide; (2R,3S) N1-(6,7-dihydro-5-(cyclopropylmethyl)6oxoSH- dibenz [b,dlazepin-7-yl] (2-methyipr opyl) (repl butanediaiide; (2R,3S) Nl-[6,7-dihydro-5-(cycobutynethy)6oxo5H- dibenz [b,dlazepin-7-yl] (2-iethyipropyl) (propyl) butanediamide; (2R,3S) N1-[6,7-dihydro--(cycopentymethy)-6oxo5H- dibenz dJazepin-7-yl] (2-mepthyipropyl) -3-.(propyl) butanedianide; (2R,3S) Nl-[6, 7 -dihydro-5-(cycohexymy1). dibenz [b,d]azepin-7-yl] -2-'(2-met hylpr opl) (propyl) butanediamide; (2R,3S) Ni- [6,7-dihydro-5-(cycopropyethy)6..oxo.5H- dibenz (b,d~azepin-7-yl] (2-methyipropyl) (propyl) butanediamide; (2R,3S) Ni- [6,7-dihydro-5-(cyclobutyiethyl) dibenz[b,dlazepin-7-yl] -2-(2-methylpropyi)-3- (propyl) butanediamide; -(2R,3S) Ni- 7-dihydro-5- (cyclopenty~ethyl) dibenz d]azepin-7-yl] (2-methylpropyl)-3- (propyl)-' butanediamide; (2R,3S) N1-[6,7-dihydro-5-(cycohexyethy)6 dibenz [b,dlazepin-7-yl 2- (2-methyipropyl) -3-(propyl)- butanediamide; (2R,3S) N1-[6,7-d ihydro-5-(benzyl)-6-oxo-5H- dibenz d] azepin-7-yl] (2-nethyipropyl) (allyl) -butanediamide; (2R,3S) N1-[6,7-dihydro-5-(phenehy)6-oxo5H- dibenz [b,dlazepin-7-yl] (2-methyipropyl) (ailyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-( 4 -fluorophenyi)metl)-6-oxo. 5H-dibenz[b~dlazepin-7-yl2(2methypropy)3-(a-llyl)- butanediamide; -292- (2R,3S) Ni-[6, 7 -dihydro-5-(cyclopropylmethyl)- 6 -x-H dibenz~b,d)azepin7yl]-2(2-methyipropyl)> -(ailyl)- butanedafide; (2R,3S) N1-[6,7-dihYdro-5-(cyclobutylmethy)60oxo 5 H dibenzlb,dazepin- 7 -y 1 (2-methy1propyl)- 3 -(allyl)- butanedamfide; (2R,3S) Ni-[ 6 ,7-dihydro-5(cyclopent yi~ethyl)G6ox-H dibenzb,dazepi7y12(methypropyl) 3 (lyl)- butanedamride; (2R,3S) Nl[,-iyr--ccohxlehl--x-H dibenz b, d azepif7-yll2(2methypropyl).- 3 (alyl) butanedamfide; (2R,3S) Ni-[ 6 ,7-dihydro-5-(cycopropylethy)G6oxo-5H dibenz d]azepin- 7 -yi] (2-methYiproPYl) (ailyl) butanediamfide; (2R,3S) Ni-[ 6 7 -dihydro5-(cycobutyethy) 6 dibenz [b,dlazepil- 7 -Y]l (2-methYlpropyi)- 3 (allyl) but anediamide; (2R,3S) Ni- 7-dihydro-5- dibenz[b,d]azepifl- 7 Y 1 (2-methyiPropyl) (allyl) butanediamide; (2R,3S) Nl[,-iyr--ccoeyehl--x-H dibenz dl azepin-7-yl) (2-methyipropyl) (ailyl).-.. butanediatnide; (2R,3S) Nl-(6,7-dihydro5(benzy)6oxo-5H dibenz dl azepin- 7 (2-methYipropYl) (butyl) but anediainide; (2R,3S) Ni- 7-dihydro-5- (phenethYl) dibenz d) azepin- 7 -yl-i (2-methyipropYl) (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-( (4-fluorophefl)methyl)- 6 -oxo- d azepi- 7 -yll -2 (2 -methyipropyl) -3 (butyl) but anediamide; (2R, 3S) Ni- 7-dihydro-5- (cyclopropYlmethYl) dibenz[b,dlazepif7yl)2-(2-ethylpropyl)-3(butyl)- butanediamide; -293- (2R,3S) Nl-[6,7-dihydro-5-(cyciobutylmethyl)-6-oxo-5H- dibenz(b,dlazepin-7-yl] (2-methyipropyl) (butyl) butanediamide; (2R,3S) N1-[6,7-dihydro-5-(cyciopentyimethyl)-6-oxo-SH- dibenz d]azepin-7-yl]I-2-.(2-methylpropyi) (butyl) butanediamide; (2R, 3S) Ni- 7-dihydro-5- (cyclohexyixnwthy1) dibenz azepin-7-yl] (2-methyipropyl) (butyl) butanediamide; (2R,3S) Ni- [6,7-dihydro-5- (cyciopropylethyl) diberiz~b,dlazepin-7-ylj (2-ethylpropyi)-3-.(butyl)-.. butanediamide; (2R,3S) N1-[6,7-dihydro-5-(cyciobutyiethyl.)-6-oxo-5H- dibenz(b,dlazepin-7-yiI-2-(2-methylprepy-l)-3.-(butyl)- butanedianide; (2R, 3S) Ni- [6,7-dihydro-5- (cyclopentylethyl) dibenz[b,d~azepin-7-yl) -2-(2-methylpropyl) (butyl) butanediamide; and (2R,3S) Ni-[6,7-dihydro-5-(cyclohexylethyl)-.6-oxo-5H- dibenz[b,d]azepin-7-yl) -2-(2-methylpropyi) (butyl) butanediainide.
17. A compound according to Claim 1 selected from: (2R,3S) Ni-[l,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo- 5- (phenyl) 5-benzodiazepin-3-yi] (2- niethyipropyl) (propyl) -butanedianide; (2R,3S) Ni-[i,3,4,5-tetrahydro-1-(3-(4- methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -yi -2 (2 -methyipropyl) -3 (propyl) butanediainide; (2R,3S) N-[1,3,4,5-tetrahydro-i-(3-(4- trifiuoromethylphenyi)benzyi) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -2 (2 -methylpropy1 prcy-t-- but anediantide; (2R,3S) N-[1,3,4,5-tetrahydro-i-(3-(4- methylphenyl)benzyi) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yi]-2- (2-methyipropyl) (propyl) but anediainide; -294- (2R,3S) N1-[1,3,4, 5-tetrahydro-l-( 3 2 4 dichlorophenyl)belzyl) -2-oxo-5- (phenyl) -2H-1, berzodiazepi->Yl] (2-methyipropyl) (propyl) butanedianide; (2R,3S) Nl-[l,3,4,5-tetrahydro-li3-(3-chloro- 4 fluorophenyl1)belzyl) -2-oxo--5- (phenyl) benzodiazepifl- 3 yl 1 (2-mqethyipropyl) (propyl) butanedianide; (2R,3S) Nl-[l,3,4,5tetrahydo-lbenzophenon 3 yl)>:f2oxo- 5- (phenyl)-2H-1, 5-benzodiazepif-3-yl]P 2 inethyipropyl) -3 (propyl) -butanedamride; (2R,3S) Nl[,,,-erhdol(-2npty~e~y)2 (phenyl) -2H-1, 5-benzodiazepif- 3 -Ylli- 21 2 methyipropyl) (propyl) -butanediamide;.. (2R,3S) Nl-[l,3,4,5-tetrahydro-l-(3-pheloxybelzyl)- 2 -oxo- (phenyl) -2H-1, 5-benzodiazepifl- 3 -Y 1 (2- methyipropyl) (allyl) -butanediamide; methoxyphelyl)belzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepifl-3-yll (2-methylproPYl) (ailyl) butanediamide; trifluoromethylphelYl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepil-3-y-] (2-methyipropYl) (allyl) butanediamide; methylphenyl)belzyl) -2-oxo--5- (phenyl) -2H-1, benzodiazePifl-3-Yl) (2-methyipropYl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-l-( 3 2 4 dichlorophenyl)belzyl) -2-oxo-5- (phenyl) -2H1{-,5- benzodiazepin-3-Yl] (2-methyipropYl) (allyl) butanediamide; (2R,3S) N1lI?1,3,4,5-tetrahydro-1-(3-( 3 -chloro- 4 fluorophenyl)belzyl) -2-6xo-5- (phenyl) -2H-1, benzodiazepifl- 3 -Yl] (2-methyJlpropyl) (allyl) butanedianide; -295- (2R,3S) N1-[1,3,4,5- tetrahydro-1,-(3-(2-naphthyl)benzyl)-2- (phenyl) -2H-1, 5-benzodiazepin-3-yl] inethyipropyl) (allyl) -butanedianide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo- 5-(phenyl)-2H-1,5-benzodiazepii--3-yl]-2--(2- methyipropyl) (butyl) -butanediamide;- (2R,3S) N1-[1,3..4,5-tetrahydro-1-(3-(4- methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-ruethyipropyl) -3-(bftyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahyfro-1-(3-(4.- trifluoroniethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1,5- benzodiazepin-3-yl] (2-rnethylpropyl) (butyl) butanedianide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4-- methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-niethylpropyl) (butyl) butanediamide; (2R,3S) N-[1,3..4,5-tetrahydro-1-(3-(2,4- dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (2-rnethylpropyl) (butyl) butanediaxnide; (2R,3S) N-f1,3,4,5-tetrahydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin,-3-yl-)-2- (2-inethyipropyl) -3-'(butyl) butanediaride; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(benzophenon-3-yl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2- methyipropyl) (butyl).-butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2-naphthyl)benzyl)-2. (phenyl)-2H-1, 5-benzodiazepin-3-yl] (2- methyipropyl) (butyl) -butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro--(3-sh-4zib5tbe~'F§oz (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (propyl) -butanedjinide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- -2H-1, -296- benzodiazepin-3-yl] (cyclopropylmfethyl) (propyl) butanediamide; (2R,3S) N-[13,4,5-tetrahydro-1-(3-(4- trif luoromethylphenyl)belzyl) -2-oxo-5- (pheniyl) -2H-1, benzodiazepin-3--yl 1-2- (cy clopr-opylmethYl).-3-- (.1ropyl).- butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro.-l-(3-(4- methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin- 3-yl 1 -2 (cyclopropylmethyl) -3 (propyl) butanediamide; (2R,.3S) N1-tl,3,4,5-tetrahydr-1-(3-(2, 4 dichlorophenyl) benzyl) -2-oxo-5- (phelyl) -2H-1, benzodiazepin-3-yl] (cycloprop-ylmethyl)-3- (propyl) butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-(3-(3-7chloro- 4 fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl]
72- (cyclopropylmethyl) (propyl) butanediamide; (2R,3S) N1-t1,3,4,5-tetrahydro--(belzophelof-3-y1)--2-O-o 5- (phenyl) -2H-1, 5-benzodiazepin-3-y1] -2- (cyclopropylmethyl) -3 (propyl) -butanediamide; (2R,3S) Nl-[il,3,4,5-tetrahydro-l-(3-(2-flaphthyl)beflY)-2- (phenyl) -2H-1, 5-benzodiazepii-3--yl)-2- (cyclopropylmethyl) (propyl) -butanediiamide; (2R,3S) Nl-[1,3,4,5-tetrahydro--(3-pheloxybel)-2-oxo- (phenyl) -21i-i, 5-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -yl] (cyclopropylmethyl) (allyl) butanediamide; (2R,3S) Ni-[1,3,4,5-tetrahydro-1-(3-(4- trifluoromethyiphenyl )benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (allyl1) butanediamide; (2R,3S) Nl-fl,3,4,5-tetrahydro-l-(3-(4- rnethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1,5- -297- benzodiazepin-3-yli]-2- (cyciopropylmethyl) (ailyl) butariediarnide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2,4- dichiorophenyl)benzyl) -2-oxo-5- (phenyl).-2H-1, benzodiazepin-3-yi] -2'-(cyclopropyliethyl) (allyl) butanediainide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(3-chioro-4- fluorophenyl) benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl)-3-4-aliyi) butanediaxnide; (2R, 3S) Ni- 5-tetraLhydro-.- (benzophenon-3-yl) -2-oxo- (phenyl) -2H-1,5-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide; (2R,3S) Nl-[1,3,4,S-tetrahydro-1-(3-(2-napkhthyi)benzy1)-2- oxo- 5- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopropylmethyl) (allyl) -butanediamide;- (2R,3S) N1-(1,3,4,5-tetrahydro--(3-phenoxybeizyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopropylnethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyciopropyimethyl) (butyl) butanediamide;- (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- trifiuoromethylphenyi)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopropylmethyl) (butyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- znethyiphenyl)benzyl) -2-oxco-5- (phenyl) -2H-1, benzodiazepin-3-yl]-2- (cyciopropylmethyl) (butyl) butanediamide; (2R,3S) N1-II1,3,4,5-tetrahydro-1-(3-(2,4- dichi~orophenyl) benzyl) -2 -oxo-5- (pheny 2ji-1,iL., benzodiazepin-3-yl] (cyclopropyimethyl) -3-(butyl) butanedianide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(3-chioro-4- f luorophenyl) benzyl) 2-oxo- 5- (phenyl) -2H- 1, 5 -298- benzodiazepin-3-YlI] -2 (cyclopropylmethyl) 3- (butyl) butanedianide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(belzophelof- 3 -yl)- 2 -oxo- (phenyl) -2H-1,5-benzodiazepil-3-y1] -2- (cyclopropylmfethYl) (butyl) -butanedianide; (2R,3S) Nl-f1,3,4,5-tetrahydro-1-(3-(2-laphthyl)berlzyl)-2- (phenyl) -2H-1, 5-benzodiazepil-3-yl]-2- (cyclopropylmethYl) (butyl) -butanediamide; (2R,3S) N1lII1,3,4,5-tetrahydro1-(3-pheloxybeflzyl)- 2 -oxo- 5- (phenyl) -2H-1, 5-benzodiazepil-3-Y1I -2- (cyc lobutylrnethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-j 3 4 methoxyphenyl)beizyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepil-3 -Yl] -2 (cyclobutylmethyl) -3 (propyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-li(3-4- (phenyl) -2H-1, benzodiazepin-3 -Yl] -2 (cyclobutylmethyl) -3 (propyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahYdro-1-(3-(4- ~methyiphenyl benzyl) 2-oxo- 5- (phenyl) -2H- 1, 5 benzodiazepin-3-yl]I 2- (cyclobutylmethyl) -3 (propyl) butanediamide; dichlorophenyl)befzl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3 -yl]1 -2 (cyclobutylmethyl) (propyl)- butanediaxnide; (2R,3S) N1-[1,3,4,5-tetrahydro-l-(3-(3-chloro- 4 f luorophenyl) belzyl) 2-oxo- 5- (phenyl) -2H- 1, 5 benzodiazepin- 3-yl) 2- (cycl1obutylmethyl) 3- (propyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-libelzophelofl3-yl)- 2 -oxo- (phenyl) -2H-1, 5-benzodiazepin-3-y1] -2- (cyclobutylmethyl) (propyl) -butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro--(3-(2-laphthyl)bel)- 2 (phenyl) -2H-1, 5-benzodiazepin-3-yl]i-2- (cyclobutylmethyl) (propyl) -butanediamide; -299- (2R..3S) N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclobutyirnethyl) (allyl) -butanediamide;. (2R,3S) N1-[1..3,4,5-tetrahydro-1-(3-(4- methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclobutylniethy(l) (allyl) butanediamide; (2R,3S) N1-[1,3,4..5-tetrahydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-5- (pheny1)-2H benzodiazepin-3-yl] (cyclobutylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- methylphenyl)benzyl) -2-OXO-75- (phenyl).-2H-1, benzodiazepin-3-yl) (cyclobutylmety4. 3- (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2,4- dichiorophenyl) benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-y.]-2- (cyclobutylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(3-chloro-4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclobutylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(benzophenon-3-yl)-2-oxo- 5- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclobutylinethyl) (allyl) -butanediamide; (2R,3S) N1-(1,3,4,5-tetraLhydro-1-(3-(2-naphthyl)benzyl)-2- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclobutylinethyl) (allyl) -butanedianide; (2R, 3S) Nl-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclobutylmethyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro--(3-(.4, -L- xethoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-ylj (cyclobutylmethyl) (butyl) butanedianide; trifluorornethyiphenyl )benzyl) -2-oxo-5- (phenyl) -2Hi-1, -3 00- benzodiazepin-3-yl] -2-(cyclobutylmethyl) (butyl)- butanediamide; (2R..3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- methyjlphenyl) benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclobutylmethyl) (butyl) butanedianide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2,4-- dichJlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1,5- benzodiazepin-3-y.]-2- (cyclobutylmethyl) (butyl) butanediainide; (2R,3S) Nl-[l,3,4,5-tetrahylro-1-(3-.(-3-chloro-4:- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl]-2- (cyclobutylmethyl) (butyI)-Z butanediamide; (2R,3S) Nl-fl, 3 ,4,5-tetrahydro--benzoph eno3 2oxo. (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclobutylxnethyl) (butyl) -butanediamide; (2R,3S) Nl-[lI 3 4 ,5-tetrahydo--(3-(2-naphthy)benzy).2 (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclobutylxnethyl) (butyl) -butanediamide; (2R,3S) Nl-[l,3,4,5-tetrahydro--(3-phenoxybenzyl)2oxo- (phenyl) -2H-1, 5-benzodiazepin-3-ylI -2- (cyclopentylmethyl) (propyl) -butanedianide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-(3-(4. rethoxyphenyl)benzyl) -2-oxo-5-(phenyl)-2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (propyl) butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(3-(4- trifluoromethylphenyljbenzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (propyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro--(3-(4- methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (propyl) butanedianide; (2R,3S) N1-t1,3,4,5-tetrahydro-1-(3-(2,4- dichlorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, -301- benzodiazepii-3-yl] (cyclopentylmethyl) (propyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(.3-chloro-r4- fluorophenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-ylI (cyclopentylmethy.) (propy.) biitanediamide; (2R,3S) Nl[,,,-erhdo1:-(ezpeot.3y)2oo (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (propyl) -butanediamride; (2R,3S). N1-[13,4,5-tetrahydro-1-(3-(2-naphthyl)benzyl)-2- oxo-5-(phenyl)-2H-1,5-benzodiazepin-3-V1]=2- (cyclopentylmethyl) (propyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo. (phenyl) -2H-1, 5-benzodiazepin-3-y (cyclopentyirnethyl) (allyl) -butanedianide; (2R.,3S) N1-(1,3,4,5-tetrahydro-1-(3-(4- methoxyphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-ylJ (cyclopentylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(4- trifluoromethylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylnethyl) (allyl) butanediamide; (2R,3S) N1-I?1,3,4,5-tetrahydro-1-(3-(4- methylphenyl)benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (allyl) butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(3-(2,4- (phenyl) -2H-1, benzodiazepin-3-yl] (cyclopentylmethyl) (allyl')- butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(3-(3-chloro-4- fluorophenyl )benzyl) -2-oxo-5- (phenylt'-2it-1, _lw' benzodiazepin-3-yl] (cyclopentylmethyl) (allyl) butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-l-(benzopheno-n-3-yl)-2 oxo.. (phenyl) -2H-1, 5-benzodiazepin-3-yl] -2- (cyclopentylmethyl) (allyl) -butanediamide;- -302- (2R,3S) Nl-(l, 3 4 ,5-tetrahydrol(3-(2flaphthYl).benzyl)- 2 (phenyl) -2H-1, 5-benzodiazepifl-3-Yl1 -2- (cyclopentylnlethYl) (ally 1 -butanedianide; (2R,3S) Nl-[1,3,4,5-tetrahydro1-(3-phenoxcybenzy.)- 2 -oxo- 5- (pheriyl) -211-1, 5-benzodiaZePil- 3 -Yl) (cyclopentYlmethYl) (butyl) -butanedamfide,- methoxyphelYl)belzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepil- 3 -yl 1 -2 (cyclopentYlmethYl) -3 (butyl) butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-i( 3 4 trifluoromethYlphelyl)belzYl) -2-oxo--5- (phenyl) benzodiazepifl-3-yl) (cyclopentylfethYl) (butyl):- butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-l-( 3 4 methylphenYl)belzyl) -2-oxo-5- (phenyl) -2H11-1,5- benzodiazepifl- 3 Yl] (cyclopenty~lmethyl) (butyl) butanediamide; (2R,3S) N1-E1,3,4, 5-tetrahydro-1-( 3 2 4 dichiorophel) benzyl) -2-oxo-5- (phenyl) -2H-1, benzodiazepifl- 3 -Yl -2 (cyclopentYJlmethyl) -3 (butyl) butanedjanide; (2R,3S) Nl[,,,-erhdo--(-3cl*r 4 fJluorophenyl)beflzyl) -2-oxo-5- (phenyl) -211-1,5- benzodiazepifl- 3Y -2 (cyclopentYlmethYl) 3- (butyl) butanediamide; (2R,3S) Nl-[1,3,4,5-tetrahydro-1-(beflzophenon- 3 yl) 2 oxo- (phenyl) -211-1, 5-benzodiazepil- 3 -Yl) -2- (cyclopentyJlmethy1) (butyl) -butanediamide; and (2R,3S) Nl-[l, 3 ,4,5-tetrhydro-i3(2naphthyl)benzyl)- 2 (phenyl) -2H1-1, 5-benzodiazepil- 3 -yl] -2- (cyclopentylmethyl) (butyl) -butanediamide; (2R,3S) N1-E1,3,4,5tetrahydro1l(bnzyl)- 2 (phenyl) -2H-1, 5-benzodiazepil- 3 -YlI (2 -methylpropyl) 3- (propyl) -butanedianide; (2R,3S) Nl-[1,3,4,5-tetrahydrO'I-phenethy) 2 oxo- (phenyl) -2H1-1, 5 -benzodiazePifl- 3 Yl 1 -2 (2 -methyiPropyl) 3- (propyl) -butanediamide; -3 03- (2R,3S) N1-[1,3,4,5-tetrahydro-l-((4-fiuorophenyl)-methyl)- (phenyl) -2H-1, 5-benzodiazepin-3-yi] methyipropyl) (propyl) -butanediamide; (2R,3S) N1-[1,3.,4,5-tetrahydro-1-(cyclopropylmethyl)-2- oxo-5- (phenyl) -2H-1, 5-benzociazep-in--3-yl] methyipropyl) (propyl) -butanedianide; (2R,3S) N1-(1,3,4,5-tetrahydro-i-(cyclobutylmethyl)-2-oxo-- (phenyl) -2H-1, 5-benzodiazepin-3-ylI (2- methyipropyl) (p ropyl) -butanediamide; (2R,3S) Ni- 5-tetrahydro-1- (cyciopentylmethyl) -2- (phenyl) -2H-1, 5-benzod-iazep-in-3,--yi]--2-(2- methyipropyl) (propyl) -butanediamide; (2R,3S) Ni-[1,3,4,5-tetrahydro-1-(cyclohexyliethyl)-2-oxo- (phenyl) -2H-1 ,5-benzodiazepin-3-yl--2--(2- methyipropyl) (propyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cycopropylethy)-2-oxo- (phenyl) -2H-1, S-benzodiazepin-3-yl] (2- methyipropyl) (propyl) -butanediamide; (2R,35) Ni- 5-tetrahydro-1- (cyclobutylethyl) -2-oxo- 5- (phenyl) -2H-1, 5-benzodiazepin-3-yi] (2- methyipropyl) (propyl) -butanediamide; (2R,3S) Ni-[1,3,4,5-tetrahydro-1-(cyclopentylethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] methyipropyl) (propyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyciohexylethyl)-2-oxo'- (phenyl) -2H-1, 5-benzodiazepin-3--yi] (2- methyipropyl) (propyl) -butanediamide; (2R,3S) Ni-[1,3,4,5-tetrahydro-1-(benzyl)-2-oxo-5- (phenyl) -2H-1, 5-benzodiazepin-3 -yi -2 (2 -methyipropyl) 3- (ailyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(phenethyi)-2-oxo-5- (phenyl) -2H-1, 5-benzodiazepin-3-yll (2-methyipropyl) 3-(ailyl)-butanediamide; (2R,35) N1-(1,3,4,5-tetrahydro-1-( (4-fiuorophenyi)methyi)- 2-oxo-5- (phenyl) -2H-1, 5-benzodiazepin-3-yi] (2- iethyipropyl) (allyl) -butanediamide; -3 04- (2R,3S) N1-(1,3,4,5-tetrahydro-1-(cyclopropylmethyl)-2- (phenyl) -2H-1,5-benzodiazepin-3-y1I (2- methyipropyl) (allyl) -butanediamTide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(cyclobutylmethyl)-2-oxo- 5- (phenyl)-2H-1,5-benzodiazepin-3-yl)-2-(2- methyipropyl) (allyl) -butanedanide;.' (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclopentylmethyl)-2- oxo-*3- (phenyl) -2H-1,5-benzodiazepin.-3-yl] (2- methyipropyl) (allyl) -butanediaride; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cylohexylmfethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3- yl1]-2- (2- methylpropyl) -3 -(allyl) -butanedianide;- (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclopropylethyl)-2-*OXO- (phenyl) -2H-i, 5-benzodiazepin-3-yl] (2- methyipropyl) (allyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclobutylethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl) (2- methyipropyl) (allyl) -butanedianide; (2R,3S) Ni- 5-tetrahydro-1- (cyclopentyle thyl) -2-oxo- 5- (phenyl) -2H-1,5-benzodiazepin-3-ylJ (2- methyp. pyl) (allyl) -butanediamide; (2R,3S) N1-(1,3,4,5-tetrahydro-1-(cyclohexylethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2- methyipropyl) (allyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(benzyl)-2-ox-o-5- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(phenethyl)-2-oxo-5- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2-methyipropyl) 3- (butyl) -butanediamide; (2R,3S) N-[1,3,4,5-tetrahydro-1-( (4-fJ.uoropheniyl)methyl)- (phenyl) -2H-1, 5-benzodiazepin-3-yl) (2- methyipropyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclopropylmethyl)-2- oxo-5- (phenyl) -2H-1,5-benzodiazepin-3-ylJ (2- methyipropyl) (butyl) -butanediamide;. -3 (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclobutylnethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] methyipropyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclopentylmethyl)-2- oxo-5-(phenyl)-2H-1,5-benzodiazepin-3-yl]-2-(2- inethyipropyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro--(cyclohexylrnethyl)-2-oxo- (phenyl) -2H-1, 5-benzodiazepin-3-yl] methyipropyl) (butyl) -butanediamide; (2R,3S) Ni-[1,3,4,5-tetrahydro-1-.(cyciopropylethyl)-2-oxo- (phenyl) -2H-1, 5-beiz'odiazepin-3-yiJ methyipropyl) (butyl) -butanediamide; (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclobutyiethyl)-2-oxo- (pheniyl) -2H-1, 5-benzodiazepin-3-yli-2_j2- inethyipropyl) (butyl) -butanediamide; (2R,3S) Ni- 5-tetrahydro-1- (cyclopentylethyl) -2-oxo:- (phenyl) -2H-1, 5-benzodiazepin-3-yl] (2- methyipropyl) (butyl) -butanediamide; and (2R,3S) N1-[1,3,4,5-tetrahydro-1-(cyclohexylethyl)- 2-oxo- 5- (phenyl) -2H-1, 5-benzodiazepin-3-yl]-2- (2- methyipropyl) (butyl) -butanediamide. 18. A compound according to Claim 1 selected from: (2R,3S) Ni-l(3S)-hexahydro-i-(3,3-diphenylpropyl)-2-oxo- 1H-azepin-3-yl] -N4- (hydroxy) (2-methyipropyl) -3- (propyl) -butanedianide; (2R,3S) Ni-I (3S) -hexahydro-1- (3-phenoxybenzyi) -2-oxo-1H- azepin-3-yl] -N4- (hydroxy) (2-iethyipropyl) (propyl) butanediamide; (2R,3S) Ni-I (3S)-hexahydro-1-(phenyl)-2-oxo-1H-azepin-3- yl] -N4- (hydroxy) (2-methylpropyl) (propyl) butanediamide; (2R,3S) Ni-I (3S)-hexahydro-1-(3-phenxyepizyl) -;.oo-1H- azepin-3 -yl -N4 (methyl) -2 (2 -methylpropyl) z:3 (propyl) butanediamide; (2R,3S) Ni-I (3S)-hexahydro-1-(3-phenoxybenzyi)-2-oxo-iH- azepin-3-yi] -N4- (methoxy) -N4- (methyl) (2- methyipropyl) (propyl) -butanediamide; -3 06- (2R,3S) Nl-[ 3 S)-hexahydro-li3-phenoxybenzyl) 2 oxo-lH- azepin-3-yl] -N4- (methoxy) (2-methyipropyl) (propyl) butanedamfide; (2R,3S) Nl-I(3S)hexahydro1l(3-phenoxybenzyl) -2-oxo-1H- azepin- 3 -ylJ -N4- (amino) (2-methyiproPyl) (p?opyil)- butanedialnide; (2R,3S) N1-[ 3 S)-hexahydro-1(3-phenoxcybenzyl) -2-oxo-1H- azepifl- 3 -N4- (hydroxy) (2-methyipropyl) (ally1) butanediamide; (2R,3S) N1-( (3S)-hexahydro-l-( 3 2 4 dichioroPhelYl) 1erizyl)'-2-oxo-1H-azepinl 3 -Yl] -N4- (hydroxy) (2-methyiPropyl) (propyl) -butan'e'da'lide; (2R,3S) Ni-[( 3 S)-hexahydro-i3-(4 fuorophenyl)belzyl)- 2 oxo-lH-azepifl 3 -Yl] -N4- (hydroxy) (2-methyiproPYl) -3- (propyl) -butanediamide; (2R,3S) Ni-l( 3 S)-hexahydro-li3(4methylphenyl)benzyl)- 2 oxo-lH-azepifl 3 -Yl) -N4- (hydroxy) (2-methyipropYl) -3- (propyl) -butanediamide; (2R,3S) Ni-l( 3 S)-hexahydo-li3-4methoyphenyl)benzyl)- 2-oxo-1H-azepifl3-yl] -N4- (hydroxy) (2-methyiproPYl) -3- (propyl) -butanediamide, (2R,3S) Ni-l( 3 S)-hexahyro-.1i3-(3methylphenyl)benzyl)- 2 oxo-1H-azepil-3-Yl) -N4- (hydroxy) (2-methyiPropyl) -3- (propyl) -butanediamide; (2R,3S) Ni-[l(3S)-hexahydro-1-(3-(3"chloro' 4 fluorophelyl)beflzYl) -2-oxo-1H-azepif 3 yl (hydroxy) 2- (2-methyipropYl) (propyl) -butanediamide; (2R,3S) Ni-l(3S)-hexahydro-1-( 3 4 trifluoromethYlphelYl) benzyl) -2-oxo-1H-azePil- 3 -yl] -N4- (hydroxy) (2-methylprOpYl) (propyl) -butanediamide; (2R,3S) Ni-l( 3 S)-hexahydro-l1(33methoyphenyl)benzyl)- 2-oxo-1H-azepifl- 3 Yl] -N4- (hydroxy) (2-methyiPropyl) -3- (propyl) -butanedia1Uide (2R,3S) Ni-l( 3 S)-hexahydro-l-(33-fluorophenyl)benzyl)- 2 oxo-l1{-azepin-3-yl] -N4- (hydroxy) (2-methyiProPY)-) -3- (propyl) -butanediamide; -3 07- (2R,3S) Ni-[( 3 S)-hexahydro-1-(3-(2-methoxyphenyl)benzyl)- 2 -oxo-1H-azepin-3-yl]-N4-(hydroxy)-2-(2-methyipropyl)-3- (propyl)-butanediamide; (2R,3S) Ni-[( 3 )-hexahydro-l-(3-(2-naphthyl)benzylenzyl) 2 iH-azepin-3-yl]-N4-(hydroxy)-2-(2-methyipropyl)-3- (propyl)-butanediamide; (2R,3S) Ni-[( 3 S)-hexahydro--(3-phenoxybenzyl)-2 -oxo-1H- azepin-3-yl]-N4-(butyl)-2-(2-methyipropyl)-3-(propyl)- butanediamide; (2R, 3S) Ni-f (3S) -hexahydro-1- (3-phenoxybenzyl) -2-oxo-1H- azepin-3-yl I -N4- (2-f urylmethyl) (2-methyipropyl) -3- (propyl)-butanediamide; (2R,3S) Ni-[( 3 S)-hexahydro-l-(3-phenoxybenzy1)-2-oxo-lH,- azepin-3-ylJ-N4-(cyclopentyl)-2-(2-metlytpropyl)-3- (propyl) -butanediamide; and (2R,3S) Ni- (3S) -hexahydro-1- 3 -phenoxybenzyl). 2 oxo -lH- azepin-3-yl]-N4-(cinnayl)-2-(2-methylpropyl)-3- (propyl)-butanediamide. 19. A pharmaceutical composition comprising a compound according to one of Claims 1- 18 and a pharmaceutically acceptable carrier. A method for the treatment of neurological disorders associated with A-amyloid. production comprising administering to a host in need of such treatment.a therapeutically effective amount of a compound according to one of Claims 1- 18. 21. .A method for the treatment of Alzheimers Disease associated with P-amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound according to-one of 4aixis 18 22. A method for the treatment of neurological disorders associated with 0-amyloid production comprising administering to a host in need of such treatment a therapeutically-'_ -308- effective amount of a metalloprotease inhibitor which inhibits y-secretase activity. 23. The method of Claim 22, wherein the metalloprotease inhibitor is a hydroxamic acid. 24. The method of Claim 22, wherein the metalloprotease inhibitor is a hydroxamic acid with an IC5o value of less than 10 tM in the Ap immunoprecipitation assay. A method for inhibiting y-secretase activity comprising administering to a host in need of such inhibition a therapeutically effective amount of a compound according to one of Claims 1 to 18 that inhibits y-secretase activity. Dated this 2 3 rd day of April, 2003 DU PONT PHARMACEUTICALS COMPANY By their Patent Attorneys: CAL INAN LAWRIE 309 23/04/03.swl3348spa,309
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003203805A AU2003203805B8 (en) | 1998-08-07 | 2003-04-23 | Succinoylamino lactams as inhibitors of ABeta protein production |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/095698 | 1998-08-07 | ||
| US60/113558 | 1998-12-24 | ||
| US60/120227 | 1999-02-15 | ||
| US09/370089 | 1999-08-06 | ||
| AU53378/99A AU756830B2 (en) | 1998-08-07 | 1999-08-07 | Succinoylamino lactams as inhibitors of Abeta protein production |
| AU2003203805A AU2003203805B8 (en) | 1998-08-07 | 2003-04-23 | Succinoylamino lactams as inhibitors of ABeta protein production |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU53378/99A Division AU756830B2 (en) | 1998-08-07 | 1999-08-07 | Succinoylamino lactams as inhibitors of Abeta protein production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2003203805A1 true AU2003203805A1 (en) | 2003-06-12 |
| AU2003203805B2 AU2003203805B2 (en) | 2007-01-04 |
| AU2003203805B8 AU2003203805B8 (en) | 2007-02-15 |
Family
ID=38121675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003203805A Ceased AU2003203805B8 (en) | 1998-08-07 | 2003-04-23 | Succinoylamino lactams as inhibitors of ABeta protein production |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003203805B8 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
-
2003
- 2003-04-23 AU AU2003203805A patent/AU2003203805B8/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003203805B2 (en) | 2007-01-04 |
| AU2003203805B8 (en) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU756830B2 (en) | Succinoylamino lactams as inhibitors of Abeta protein production | |
| US7053084B1 (en) | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | |
| US6632812B2 (en) | Substituted lactams as inhibitors of Aβ protein production | |
| US7507815B2 (en) | Succinoylamino lactams as inhibitors of a-β protein production | |
| AU783914B2 (en) | Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production | |
| AU2003203805A1 (en) | Succinoylamino lactams as inhibitors of ABeta protein production | |
| US20100048541A1 (en) | Substituted lactams as inhibitors of abeta protein production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: BRISTOL-MYERS SQUIBB PHARMA COMPANY Free format text: FORMER NAME: DU PONT PHARMACEUTICALS COMPANY |
|
| TH | Corrigenda |
Free format text: IN VOL 21, NO 1, PAGE(S) 107 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME BRISTOL-MYERS SQUIBB PHARMA COMPANY, APPLICATION NO. 2003203805, UNDER INID (72) CORRECT THE CO-INVENTOR NAME TO READ THOMPSON, LORIN ANDREW |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |